0001739104-20-000023.txt : 20201106 0001739104-20-000023.hdr.sgml : 20201106 20201106161202 ACCESSION NUMBER: 0001739104-20-000023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201106 DATE AS OF CHANGE: 20201106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 201294538 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 10-Q 1 elan-20200930.htm 10-Q elan-20200930
false2020Q30001739104--12-31us-gaap:AccountingStandardsUpdate201613Memberus-gaap:AccountingStandardsUpdate201613Member1.5625P7YP5YP5Y100017391042020-01-012020-09-300001739104elan:CommonStockNoParValueMember2020-01-012020-09-300001739104elan:A500TangibleEquityUnitsMember2020-01-012020-09-30xbrli:shares00017391042020-11-02iso4217:USD00017391042020-07-012020-09-3000017391042019-07-012019-09-3000017391042019-01-012019-09-300001739104us-gaap:RetainedEarningsMember2020-07-012020-09-30iso4217:USDxbrli:shares00017391042020-09-3000017391042019-12-310001739104us-gaap:CommonStockMember2018-12-310001739104us-gaap:AdditionalPaidInCapitalMember2018-12-310001739104us-gaap:RetainedEarningsMember2018-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-3100017391042018-12-310001739104us-gaap:RetainedEarningsMember2019-01-012019-03-3100017391042019-01-012019-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001739104us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001739104us-gaap:CommonStockMember2019-01-012019-03-310001739104us-gaap:CommonStockMember2019-03-310001739104us-gaap:AdditionalPaidInCapitalMember2019-03-310001739104us-gaap:RetainedEarningsMember2019-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-3100017391042019-03-310001739104us-gaap:RetainedEarningsMember2019-04-012019-06-3000017391042019-04-012019-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-04-012019-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-04-012019-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300001739104us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300001739104us-gaap:CommonStockMember2019-06-300001739104us-gaap:AdditionalPaidInCapitalMember2019-06-300001739104us-gaap:RetainedEarningsMember2019-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-3000017391042019-06-300001739104us-gaap:RetainedEarningsMember2019-07-012019-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-07-012019-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-07-012019-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001739104us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001739104us-gaap:CommonStockMemberelan:AratanaTherapeuticsInc.Member2019-07-012019-09-300001739104us-gaap:AdditionalPaidInCapitalMemberelan:AratanaTherapeuticsInc.Member2019-07-012019-09-300001739104elan:AratanaTherapeuticsInc.Member2019-07-012019-09-300001739104us-gaap:CommonStockMember2019-09-300001739104us-gaap:AdditionalPaidInCapitalMember2019-09-300001739104us-gaap:RetainedEarningsMember2019-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-3000017391042019-09-300001739104us-gaap:CommonStockMember2019-12-310001739104us-gaap:AdditionalPaidInCapitalMember2019-12-310001739104us-gaap:RetainedEarningsMember2019-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001739104us-gaap:RetainedEarningsMember2020-01-012020-03-3100017391042020-01-012020-03-3100017391042019-01-012019-12-310001739104srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-12-310001739104srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001739104us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001739104us-gaap:CommonStockMember2020-01-012020-03-310001739104us-gaap:CommonStockMember2020-03-310001739104us-gaap:AdditionalPaidInCapitalMember2020-03-310001739104us-gaap:RetainedEarningsMember2020-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100017391042020-03-310001739104us-gaap:RetainedEarningsMember2020-04-012020-06-3000017391042020-04-012020-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-04-012020-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-04-012020-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-04-012020-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001739104us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001739104us-gaap:CommonStockMember2020-04-012020-06-300001739104us-gaap:CommonStockMember2020-06-300001739104us-gaap:AdditionalPaidInCapitalMember2020-06-300001739104us-gaap:RetainedEarningsMember2020-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000017391042020-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012020-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012020-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001739104us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001739104us-gaap:CommonStockMember2020-07-012020-09-300001739104elan:BayerAnimalBusinessMemberus-gaap:CommonStockMember2020-07-012020-09-300001739104us-gaap:AdditionalPaidInCapitalMemberelan:BayerAnimalBusinessMember2020-07-012020-09-300001739104elan:BayerAnimalBusinessMember2020-07-012020-09-300001739104us-gaap:CommonStockMember2020-09-300001739104us-gaap:AdditionalPaidInCapitalMember2020-09-300001739104us-gaap:RetainedEarningsMember2020-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-30elan:brandelan:country0001739104us-gaap:IPOMember2018-09-242018-09-24xbrli:pure0001739104us-gaap:IPOMember2018-09-240001739104elan:BayerAnimalBusinessMember2020-08-012020-08-010001739104us-gaap:SeniorNotesMember2018-09-240001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2018-09-240001739104elan:TermCreditFacilityMemberus-gaap:LineOfCreditMember2018-09-240001739104country:USelan:ContractWithCustomerLiabilityMemberus-gaap:GeographicConcentrationRiskMember2020-01-012020-09-300001739104country:USelan:ContractWithCustomerLiabilityMemberus-gaap:GeographicConcentrationRiskMember2019-01-012019-09-300001739104elan:ContractWithCustomerLiabilityMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2020-01-012020-09-300001739104elan:ContractWithCustomerLiabilityMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2019-01-012019-09-300001739104us-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2020-07-012020-09-300001739104us-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2019-07-012019-09-300001739104us-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2020-01-012020-09-300001739104us-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2019-01-012019-09-300001739104elan:PetHealthDiseasePreventionMember2020-07-012020-09-300001739104elan:PetHealthDiseasePreventionMember2019-07-012019-09-300001739104elan:PetHealthDiseasePreventionMember2020-01-012020-09-300001739104elan:PetHealthDiseasePreventionMember2019-01-012019-09-300001739104elan:PetHealthTherapeuticsMember2020-07-012020-09-300001739104elan:PetHealthTherapeuticsMember2019-07-012019-09-300001739104elan:PetHealthTherapeuticsMember2020-01-012020-09-300001739104elan:PetHealthTherapeuticsMember2019-01-012019-09-300001739104elan:FarmAnimalFutureProteinAndHealthMember2020-07-012020-09-300001739104elan:FarmAnimalFutureProteinAndHealthMember2019-07-012019-09-300001739104elan:FarmAnimalFutureProteinAndHealthMember2020-01-012020-09-300001739104elan:FarmAnimalFutureProteinAndHealthMember2019-01-012019-09-300001739104elan:FarmAnimalRuminantsAndSwineMember2020-07-012020-09-300001739104elan:FarmAnimalRuminantsAndSwineMember2019-07-012019-09-300001739104elan:FarmAnimalRuminantsAndSwineMember2020-01-012020-09-300001739104elan:FarmAnimalRuminantsAndSwineMember2019-01-012019-09-300001739104elan:ContractManufacturingMember2020-07-012020-09-300001739104elan:ContractManufacturingMember2019-07-012019-09-300001739104elan:ContractManufacturingMember2020-01-012020-09-300001739104elan:ContractManufacturingMember2019-01-012019-09-300001739104elan:BayerAnimalBusinessMember2020-08-010001739104elan:BayerAnimalBusinessMember2019-07-012019-09-300001739104elan:BayerAnimalBusinessMember2020-01-012020-09-300001739104elan:BayerAnimalBusinessMember2019-01-012019-09-300001739104elan:BayerAnimalBusinessMemberus-gaap:InProcessResearchAndDevelopmentMember2020-08-010001739104us-gaap:MarketingRelatedIntangibleAssetsMemberelan:BayerAnimalBusinessMember2020-08-010001739104elan:FinishedGoodsMemberelan:BayerAnimalBusinessMember2020-08-010001739104elan:InProcessMemberelan:BayerAnimalBusinessMember2020-08-010001739104us-gaap:PublicUtilitiesInventoryRawMaterialsMemberelan:BayerAnimalBusinessMember2020-08-010001739104us-gaap:MarketingRelatedIntangibleAssetsMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:RightsToTheProfenderAndDrontalProductFamiliesMember2020-08-010001739104us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:RightsToTheProfenderAndDrontalProductFamiliesMember2020-08-010001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:InventoriesMemberelan:RightsToTheProfenderAndDrontalProductFamiliesMember2020-08-010001739104elan:OsurniaMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-07-012020-09-300001739104elan:OsurniaMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:VecoxanMember2020-01-012020-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:VecoxanMember2020-07-012020-09-300001739104elan:CapstarMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-07-012020-09-300001739104elan:CapstarMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-09-300001739104elan:DrontalAndProfenderMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-09-300001739104elan:DrontalAndProfenderMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-07-012020-09-300001739104elan:OtherImmaterialDivestituresMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-09-300001739104elan:OtherImmaterialDivestituresMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-07-012020-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-07-012020-09-300001739104elan:WorldwideRightsToOsurniaUSRightsToCapstarAndWorldwideRightsToVecoxanMemberus-gaap:MarketingRelatedIntangibleAssetsMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-07-310001739104elan:WorldwideRightsToOsurniaUSRightsToCapstarAndWorldwideRightsToVecoxanMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:InventoriesMember2020-07-310001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:RightsToTheProfenderAndDrontalProductFamiliesMember2020-08-032020-08-030001739104us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:RightsToTheProfenderAndDrontalProductFamiliesMember2020-08-032020-08-030001739104us-gaap:MarketingRelatedIntangibleAssetsMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:RightsToTheProfenderAndDrontalProductFamiliesMember2020-08-030001739104us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:RightsToTheProfenderAndDrontalProductFamiliesMember2020-08-030001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:InventoriesMemberelan:RightsToTheProfenderAndDrontalProductFamiliesMember2020-08-030001739104us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberelan:WorldwideRightsToOsurniaAndUSRightsToCapstarMember2019-12-310001739104elan:AratanaTherapeuticsInc.Member2019-07-182019-07-180001739104elan:AratanaTherapeuticsInc.Member2019-07-180001739104elan:GalliprantMember2019-07-180001739104elan:GalliprantMember2019-01-012019-12-310001739104us-gaap:InProcessResearchAndDevelopmentMemberelan:AratanaTherapeuticsInc.Member2019-07-180001739104us-gaap:MarketingRelatedIntangibleAssetsMemberelan:AratanaTherapeuticsInc.Member2019-07-180001739104us-gaap:OtherIntangibleAssetsMemberelan:AratanaTherapeuticsInc.Member2019-07-180001739104elan:AratanaTherapeuticsInc.Member2020-01-012020-09-300001739104elan:AratanaTherapeuticsInc.Member2019-01-012019-12-310001739104elan:PrevtecMicrobiaInc.Member2019-07-312019-07-310001739104elan:PrevtecMicrobiaInc.Member2019-07-310001739104us-gaap:InProcessResearchAndDevelopmentMemberelan:PrevtecMicrobiaInc.Member2019-07-310001739104us-gaap:MarketingRelatedIntangibleAssetsMemberelan:PrevtecMicrobiaInc.Member2019-07-310001739104elan:PrevtecMicrobiaInc.Memberus-gaap:OtherIntangibleAssetsMember2019-07-31elan:position0001739104elan:BayerAnimalBusinessMember2020-01-012020-09-300001739104elan:BayerAnimalBusinessMembersrt:MinimumMember2020-09-300001739104srt:MaximumMemberelan:BayerAnimalBusinessMember2020-09-300001739104us-gaap:FacilityClosingMember2018-12-310001739104us-gaap:EmployeeSeveranceMember2018-12-310001739104us-gaap:FacilityClosingMember2019-01-012019-09-300001739104us-gaap:EmployeeSeveranceMember2019-01-012019-09-300001739104us-gaap:FacilityClosingMember2019-09-300001739104us-gaap:EmployeeSeveranceMember2019-09-300001739104us-gaap:FacilityClosingMember2019-12-310001739104us-gaap:EmployeeSeveranceMember2019-12-310001739104us-gaap:FacilityClosingMember2020-01-012020-09-300001739104us-gaap:EmployeeSeveranceMember2020-01-012020-09-300001739104us-gaap:FacilityClosingMember2020-09-300001739104us-gaap:EmployeeSeveranceMember2020-09-300001739104elan:CommonStockOfferingMember2020-01-222020-01-220001739104elan:CommonStockOfferingMember2020-01-220001739104us-gaap:OverAllotmentOptionMember2020-01-222020-01-2200017391042020-01-232020-01-230001739104elan:TangibleEquityUnitMember2020-01-222020-01-220001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2020-01-220001739104elan:TangibleEquityUnitMember2020-01-220001739104elan:TangibleEquityUnitEquityComponentMember2020-01-220001739104elan:TangibleEquityUnitDebtComponentMember2020-01-220001739104elan:TangibleEquityUnitEquityComponentMember2020-01-222020-01-220001739104elan:TangibleEquityUnitDebtComponentMember2020-01-222020-01-220001739104elan:A275SeniorAmortizingNotesMemberus-gaap:SeniorNotesMember2020-01-220001739104elan:A275SeniorAmortizingNotesMemberus-gaap:SeniorNotesMember2020-01-222020-01-220001739104elan:TangibleEquityUnitMember2020-01-22elan:trading_day0001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2020-01-222020-01-220001739104srt:MaximumMemberelan:TangibleEquityUnitMember2020-01-220001739104elan:TangibleEquityUnitMembersrt:MinimumMember2020-01-220001739104elan:TermBLoanFacilityMemberus-gaap:LineOfCreditMember2020-09-300001739104elan:TermBLoanFacilityMemberus-gaap:LineOfCreditMember2019-12-310001739104elan:TermCreditFacilityMemberus-gaap:LineOfCreditMember2020-09-300001739104elan:TermCreditFacilityMemberus-gaap:LineOfCreditMember2019-12-310001739104elan:A3.912SeniorNotesDue2021Memberus-gaap:SeniorNotesMember2020-09-300001739104elan:A3.912SeniorNotesDue2021Memberus-gaap:SeniorNotesMember2019-12-310001739104elan:A4.272SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2020-09-300001739104elan:A4.272SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2019-12-310001739104elan:A4.9SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2020-09-300001739104elan:A4.9SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2019-12-310001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2020-09-300001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2019-12-310001739104us-gaap:NotesPayableOtherPayablesMember2020-09-300001739104us-gaap:NotesPayableOtherPayablesMember2019-12-310001739104elan:BayerAnimalBusinessMemberelan:TermBLoanFacilityMemberus-gaap:LineOfCreditMember2020-08-010001739104elan:BayerAnimalBusinessMemberelan:TermBLoanFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMember2020-08-012020-08-010001739104elan:BayerAnimalBusinessMemberelan:TermBLoanFacilityMemberus-gaap:LineOfCreditMember2020-08-012020-08-010001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-08-010001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-08-012020-08-010001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMembersrt:MinimumMember2020-08-012020-08-010001739104srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMember2020-08-012020-08-010001739104us-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-10-012020-10-3100017391042020-08-012020-08-01elan:numberOfCovenants0001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-09-300001739104elan:TermCreditFacilityMemberus-gaap:LineOfCreditMember2020-01-312020-01-310001739104elan:TermBLoanFacilityMemberus-gaap:LineOfCreditMember2020-09-252020-09-250001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2020-01-012020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-09-300001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-09-300001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeContractMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-09-300001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2019-12-310001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2019-12-310001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeContractMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2019-12-310001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2019-12-310001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2019-12-310001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310001739104elan:PrevtecMicrobiaInc.Member2020-01-012020-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2019-12-310001739104us-gaap:ForeignExchangeContractMemberus-gaap:OtherOperatingIncomeExpenseMemberus-gaap:NondesignatedMember2020-07-012020-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:OtherOperatingIncomeExpenseMemberus-gaap:NondesignatedMember2019-07-012019-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:OtherOperatingIncomeExpenseMemberus-gaap:NondesignatedMember2020-01-012020-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:OtherOperatingIncomeExpenseMemberus-gaap:NondesignatedMember2019-01-012019-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2018-10-012018-10-31iso4217:CHF0001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2018-10-310001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-01-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2020-07-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2019-07-012019-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2020-01-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2019-01-012019-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-07-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2019-07-012019-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2019-01-012019-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMember2020-03-3100017391042020-06-262020-06-2600017391042020-06-260001739104elan:NovartisAnimalHealthMember2020-07-012020-09-300001739104us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberelan:CustomerAMember2020-07-012020-09-300001739104us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberelan:CustomerAMember2019-07-012019-09-300001739104us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberelan:CustomerAMember2020-01-012020-09-300001739104us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberelan:CustomerAMember2019-01-012019-09-300001739104us-gaap:ProductMember2020-09-300001739104us-gaap:ProductMember2019-12-310001739104country:US2020-07-012020-09-300001739104country:US2019-07-012019-09-300001739104country:US2020-01-012020-09-300001739104country:US2019-01-012019-09-300001739104us-gaap:NonUsMember2020-07-012020-09-300001739104us-gaap:NonUsMember2019-07-012019-09-300001739104us-gaap:NonUsMember2020-01-012020-09-300001739104us-gaap:NonUsMember2019-01-012019-09-300001739104country:US2020-09-300001739104country:US2019-12-310001739104country:DE2020-09-300001739104country:DE2019-12-310001739104country:GB2020-09-300001739104country:GB2019-12-310001739104elan:OtherForeignCountriesNotSeparatelyDisclosedMember2020-09-300001739104elan:OtherForeignCountriesNotSeparatelyDisclosedMember2019-12-31elan:segment0001739104elan:CommonStockOfferingMember2020-07-012020-09-300001739104elan:CommonStockOfferingMember2020-01-012020-09-300001739104elan:TangibleEquityUnitMember2020-01-012020-09-300001739104elan:TangibleEquityUnitMember2020-07-012020-09-300001739104elan:BayerAnimalBusinessMember2020-09-300001739104srt:AffiliatedEntityMember2020-09-300001739104srt:AffiliatedEntityMemberelan:LeasesMember2020-09-300001739104elan:TransitionalServicesAgreementMembersrt:AffiliatedEntityMember2020-09-300001739104elan:LocalCountryAssetPurchasesMembersrt:AffiliatedEntityMember2020-09-300001739104elan:OtherRelatedPartyActivitiesMembersrt:AffiliatedEntityMember2020-09-300001739104elan:TransitionalServicesAgreementMemberus-gaap:MajorityShareholderMember2020-09-300001739104elan:TransitionalServicesAgreementMemberus-gaap:MajorityShareholderMember2019-12-310001739104elan:OtherRelatedPartyActivitiesMemberus-gaap:MajorityShareholderMember2020-09-300001739104elan:OtherRelatedPartyActivitiesMemberus-gaap:MajorityShareholderMember2019-12-310001739104elan:LocalCountryAssetPurchasesMemberus-gaap:MajorityShareholderMember2020-09-300001739104elan:LocalCountryAssetPurchasesMemberus-gaap:MajorityShareholderMember2019-12-310001739104us-gaap:MajorityShareholderMember2020-09-300001739104us-gaap:MajorityShareholderMember2019-12-310001739104elan:TransitionalServicesAgreementMemberus-gaap:MajorityShareholderMember2020-01-012020-09-300001739104us-gaap:MajorityShareholderMember2019-01-012019-09-30




SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☒ Quarterly Report Under Section 13 or 15(d) of the
Securities Exchange Act of 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020
OR
☐ Transition Report Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934
COMMISSION FILE NUMBER 001-38661
Elanco Animal Health Incorporated
(Exact name of Registrant as specified in its charter)
INDIANA
 82-5497352
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2500 INNOVATION WAY, GREENFIELD, INDIANA 46140
(Address of principal executive offices)
Registrant’s telephone number, including area code (877) 352-6261
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, no par valueELANNew York Stock Exchange
5.00% Tangible Equity UnitsELATNew York Stock Exchange
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
The number of shares of common stock outstanding as of November 2, 2020 were 471,915,051





Elanco Animal Health Incorporated
Form 10-Q
For the Quarter Ended September 30, 2020
Table of Contents
Page
PART I. Financial Information
Item 1.
Financial Statements
Condensed Consolidated Statements of Operations (Unaudited)
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Statements of Equity (Unaudited)
Condensed Consolidated Statements of Cash Flows (Unaudited)
Notes to Condensed Consolidated Financial Statements (Unaudited)
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Overview
Results of Operations
Summary of Changes
Liquidity and Capital Resources
Contractual Obligations
Item 3.Quantitative and Qualitative Disclosures About Market Risk
Item 4.Controls and Procedures
PART II. Other Information
Item 1.
Legal Proceedings
Item 1A.
Risk Factors
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.Defaults Upon Senior Securities
Item 4.Mine Safety Disclosures
Item 5.Other Information
Item 6.
Exhibits
Signatures





Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of the federal securities laws. This quarterly report contains forward-looking statements, including, without limitation, statements concerning the impact on our business caused by the integration of the animal health business of Bayer Aktiengesellschaft (Bayer), expected synergies and cost savings, product launches, reduction of debt, independent company stand-up costs and timing, expectations relating to sustainability commitments, the coronavirus (COVID-19) global pandemic, 2020 fourth quarter outlook, our expected compliance with debt covenants, our industry and our operations, performance and financial condition, and including in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national, or global political, economic, business, competitive, market, and regulatory conditions, including but not limited to the following:

•heightened competition, including from innovation or generics;
•the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;
•changes in regulatory restrictions on the use of antibiotics in farm animals;
•the impact on our operations, the supply chain, customer demand, and our liquidity as a result of the COVID-19 global health pandemic;
•our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;
•an outbreak of infectious disease carried by food animals;
•the success of our research and development (R&D) and licensing efforts;
•our ability to successfully integrate the businesses we acquire, including the animal health business of Bayer (Bayer Animal Health);
•the impact of the COVID-19 global health pandemic on our ability to achieve the anticipated revenue, earnings, accretion and other benefits associated with the acquisition of Bayer Animal Health;
•misuse, off-label or counterfeiting use of our products;
•unanticipated safety, quality or efficacy concerns associated with our products;
•the impact of weather conditions and the availability of natural resources;
•disruption in our supply chain due to manufacturing issues experienced by our contract manufacturers;
•consolidation of our customers and distributors;
•the impact of increased or decreased sales to our channel distributors resulting in higher or lower inventory levels held by them in advance of or trailing actual customer demand, which could lead to variations in quarterly revenue results;
•risks related to our presence in emerging markets;
•changes in United States (U.S.) foreign trade policy, imposition of tariffs or trade disputes;
•the impact of global macroeconomic conditions; and
•the effect on our business resulting from our separation from Eli Lilly and Company (Lilly), including the various costs associated with transition to a standalone entity, including the ability to stand up our enterprise resource planning (ERP) system and other information technology systems.
3



See “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) and Item 1A, "Risk Factors," of Part II of our Quarterly Report on Form 10-Q for the periods ended June 30, 2020 and March 31, 2020 and Part II of this Quarterly Report on Form 10-Q, for a further description of these and other factors. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. For the reasons described above, we caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this quarterly report. Any forward-looking statement made by us in this quarterly report speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should be viewed as historical data.
4



PART I. Financial Information
Item 1. Financial Statements
Elanco Animal Health Incorporated
Condensed Consolidated Statements of Operations (Unaudited)
(Dollars and shares in millions, except per-share data)
 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Revenue$889.6 $771.3 $2,133.6 $2,284.0 
Costs, expenses and other:
Cost of sales441.8 360.4 1,070.4 1,060.2 
Research and development88.1 69.9 214.3 202.8 
Marketing, selling and administrative277.7 192.3 622.5 574.3 
Amortization of intangible assets
95.6 50.7 196.2 149.0 
Asset impairment, restructuring and other special charges (Note 7)
262.2 77.2 456.4 133.9 
Interest expense, net of capitalized interest (Note 10)48.1 18.7 89.4 60.2 
Other–net, (income) expense(114.9)14.6 (161.7)21.1 
1,098.6 783.8 2,487.5 2,201.5 
Income (loss) before income taxes(209.0)(12.5)(353.9)82.5 
Income tax (benefit) expense(74.0)(22.5)(116.6)5.1 
Net income (loss)$(135.0)$10.0 $(237.3)$77.4 
Earnings (loss) per share:
Basic $(0.29)$0.03 $(0.56)$0.21 
Diluted$(0.29)$0.03 $(0.56)$0.21 
Weighted average shares outstanding:
Basic462.4 371.6 426.5 367.7 
Diluted462.4 373.2 426.5 368.7 
See notes to condensed consolidated financial statements.
5



Elanco Animal Health Incorporated
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
(Dollars in millions)
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Net income (loss)$(135.0)$10.0 $(237.3)$77.4 
Other comprehensive income (loss):
Unrealized loss on derivatives for cash flow hedges, net of taxes(7.5)— (67.4)— 
Foreign currency translation101.2 (58.9)121.5 (53.7)
Defined benefit pension and retiree health benefit plans, net of taxes(0.7)21.2 (2.2)23.4 
Other comprehensive income (loss), net of tax93.0 (37.7)51.9 (30.3)
Comprehensive income (loss)$(42.0)$(27.7)$(185.4)$47.1 
See notes to condensed consolidated financial statements.

6



Elanco Animal Health Incorporated
Condensed Consolidated Balance Sheets
(Dollars in millions)
September 30,
2020		December 31, 2019
(Unaudited)
Assets 
Current Assets
Cash and cash equivalents$659.9 $334.0 
Accounts receivable, net of allowances of $8.8 (2020) and $6.2 (2019)
762.3 816.9 
Other receivables70.8 73.0 
Inventories (Note 8)1,597.1 1,050.7 
Prepaid expenses and other180.6 87.4 
Restricted cash (Note 17)10.7 11.1 
Total current assets3,281.4 2,373.1 
Noncurrent Assets
Goodwill (Note 6)6,434.7 2,989.6 
Other intangibles, net (Note 6)5,785.6 2,482.8 
Other noncurrent assets492.8 185.0 
Property and equipment, net of accumulated depreciation of $982.7 (2020) and $930.5 (2019)
1,242.5 955.3 
Total assets$17,237.0 $8,985.8 
Liabilities and Equity
Current Liabilities
Accounts payable$355.9 $222.6 
Employee compensation139.9 99.6 
Sales rebates and discounts278.6 211.0 
Current portion of long-term debt (Note 10)553.6 24.5 
Other current liabilities531.9 244.4 
Payable to Lilly (Note 17)11.3 16.4 
Total current liabilities1,871.2 818.5 
Noncurrent Liabilities
Long-term debt (Note 10)5,586.5 2,330.5 
Accrued retirement benefits 299.1 82.5 
Deferred taxes823.1 100.8 
Other noncurrent liabilities312.9 106.6 
Total liabilities8,892.8 3,438.9 
Commitments and Contingencies (Note 14)— — 
Equity
Preferred stock, no par value, 1,000,000,000 shares authorized; none issued
— — 
Common stock, no par value, 5,000,000,000 shares authorized, 471,879,904 and 373,011,513 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively
— — 
Additional paid-in capital8,620.4 5,636.3 
Retained earnings (accumulated deficit)(154.4)84.3 
Accumulated other comprehensive loss(121.8)(173.7)
Total equity8,344.2 5,546.9 
Total liabilities and equity$17,237.0 $8,985.8 

See notes to condensed consolidated financial statements.
7



Elanco Animal Health Incorporated
Condensed Consolidated Statements of Equity (Unaudited)
(Dollars and shares in millions)

Common StockAccumulated Other Comprehensive Income (Loss)
SharesAmountAdditional Paid-in CapitalRetained Earnings (Accumulated Deficit)Cash Flow Hedge Gain (Loss)Foreign Currency TranslationDefined Benefit Pension and Retiree Health Benefit PlansTotalTotal Equity
December 31, 2018365.6 $— $5,403.3 $16.4 $— $(218.2)$(4.0)$(222.2)$5,197.5 
Net income— — — 31.5 — — — — 31.5 
Other comprehensive income (loss), net of tax— — — — — (30.2)2.0 (28.2)(28.2)
Separation activities(1)
— — (7.0)— — — — — (7.0)
Stock compensation— — 2.4 — — — — — 2.4 
Issuance of stock under employee stock plans, net0.1 — — — — — — — — 
March 31, 2019365.7 — 5,398.7 47.9 — (248.4)(2.0)(250.4)5,196.2 
Net income— — — 35.9 — — — — 35.9 
Other comprehensive income, net of tax— — — — — 35.4 0.2 35.6 35.6 
Separation activities(1)
— — (18.4)— — — — — (18.4)
Stock compensation— — 14.3 — — — — — 14.3 
Other— — 1.9 — — — — — 1.9 
June 30, 2019365.7 — 5,396.5 83.8 — (213.0)(1.8)(214.8)5,265.5 
Net income— — — 10.0 — — — — 10.0 
Other comprehensive income (loss), net of tax— — — — — (58.9)21.2 (37.7)(37.7)
Separation activities(1)
— — (3.0)— — — — — (3.0)
Stock compensation— — 11.3 — — — — — 11.3 
Issuances of stock in connection with Aratana acquisition:(2)
Issuance to Aratana shareholders for acquisition7.2 — 238.0 — — — — — 238.0 
Accelerated vesting of equity awards0.1 — 3.6 — — — — — 3.6 
September 30, 2019373.0 $— $5,646.4 $93.8 $— $(271.9)$19.4 $(252.5)$5,487.7 

(1) See Note 17: Related Party Agreements and Transactions for further discussion.
(2) See Note 6: Acquisitions and Divestitures for further discussion.













8



Elanco Animal Health Incorporated
Condensed Consolidated Statements of Equity (Unaudited), Continued
(Dollars and shares in millions)

Common StockAccumulated Other Comprehensive Income (Loss)
SharesAmountAdditional Paid-in CapitalRetained Earnings (Accumulated Deficit)Cash Flow Hedge Gain (Loss)Foreign Currency TranslationDefined Benefit Pension and Retiree Health Benefit PlansTotalTotal Equity
December 31, 2019373.0 $— $5,636.3 $84.3 $— $(198.4)$24.7 $(173.7)$5,546.9 
Net loss— — — (49.1)— — — — (49.1)
Adoption of Accounting Standards Update 2016-13(1)
— — — (1.4)— — — — (1.4)
Other comprehensive loss, net of tax— — — — (39.2)(29.3)(0.4)(68.9)(68.9)
Separation activities(2)
— — 15.8 — — — — — 15.8 
Stock compensation — — 11.1 — — — — — 11.1 
Issuance of stock under employee stock plans, net0.8 — (12.8)— — — — — (12.8)
Issuance of common stock, net of issuance costs(3)
25.0 — 767.5 — — — — — 767.5 
Issuance of tangible equity units, net of issuance costs(3)
— — 452.4 — — — — — 452.4 
March 31, 2020398.8 — 6,870.3 33.8 (39.2)(227.7)24.3 (242.6)6,661.5 
Net loss— — — (53.2)— — — — (53.2)
Other comprehensive income (loss), net of tax— — — — (20.7)49.6 (1.1)27.8 27.8 
Separation activities (2)
— — 8.8 — — — — — 8.8 
Stock compensation— — 8.3 — — — — — 8.3 
Issuance of stock under employee stock plans, net0.1 — (1.0)— — — — — (1.0)
Other— — (0.3)— — — — (0.3)
June 30, 2020398.9 — 6,886.1 (19.4)(59.9)(178.1)23.2 (214.8)6,651.9 
Net loss— — — (135.0)— — — — (135.0)
Other comprehensive income (loss), net of tax— — — — (7.5)101.2 (0.7)93.0 93.0 
Stock compensation— — 11.7 — — — — — 11.7 
Issuance of stock under employee stock plans, net0.1 — (0.2)— — — — — (0.2)
Issuance of stock to Bayer for acquisition, net of issuance costs (4)
72.9 — 1,722.8 — — — — — 1,722.8 
September 30, 2020471.9 $— $8,620.4 $(154.4)$(67.4)$(76.9)$22.5 $(121.8)$8,344.2 
(1) See Note 4: Implementation of New Financial Accounting Pronouncements for further discussion.
(2) See Note 17: Related Party Agreements and Transactions for further discussion.
(3) See Note 9: Equity for further discussion.
(4) See Note 6: Acquisitions and Divestitures for further discussion.

See notes to condensed consolidated financial statements.
9



Elanco Animal Health Incorporated
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
Nine Months Ended
September 30,
 20202019
Cash Flows from Operating Activities
Net income (loss)$(237.3)$77.4 
Adjustments to reconcile net income (loss) to cash flows from operating activities:
Depreciation and amortization294.7 231.1 
Change in deferred income taxes(159.8)14.9 
Stock-based compensation expense31.1 36.7 
Asset impairment charges4.7 24.7 
Gain on sale of assets(51.3)— 
Gain on divestitures (Note 6)(169.7)— 
Changes in operating assets and liabilities, net of acquisitions
290.9 (267.0)
Other non-cash operating activities, net48.6 (20.0)
Net Cash Provided by Operating Activities51.9 97.8 
Cash Flows from Investing Activities
Net proceeds from sale (purchases) of property and equipment(16.2)(49.8)
Cash paid for acquisitions, net of cash acquired (Note 6)(5,001.3)(32.8)
Proceeds from settlement of net investment hedges (Note 11)32.7 — 
Divestiture proceeds (Note 6)434.7 — 
Purchases of software(147.8)(36.2)
Other investing activities, net(8.0)(41.7)
Net Cash Used for Investing Activities(4,705.9)(160.5)
Cash Flows from Financing Activities
Repayments of borrowings (Note 10)(684.2)(115.0)
Proceeds from issuance of long-term debt (Note 10)4,554.2 — 
Proceeds from issuance of common stock and tangible equity units (Note 9)1,219.9 — 
Debt issuance costs(102.5)— 
Consideration paid to Lilly in connection with the Separation (Note 1)— (191.6)
Other net financing transactions with Lilly — 6.3 
Other financing activities, net(15.2)1.7 
Net Cash Provided by (Used for) Financing Activities4,972.2 (298.6)
Effect of exchange rate changes on cash and cash equivalents7.3 4.1 
Net increase (decrease) in cash, cash equivalents and restricted cash325.5 (357.2)
Cash, cash equivalents and restricted cash at January 1345.1 677.5 
Cash, cash equivalents and restricted cash at September 30$670.6 $320.3 

September 30,
20202019
Cash and cash equivalents$659.9 $309.2 
Restricted cash (Note 17)10.7 11.1 
Cash, cash equivalents and restricted cash at September 30$670.6 $320.3 
See notes to condensed consolidated financial statements.
10



Elanco Animal Health Incorporated
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Tables present dollars in millions, except per-share data)

Note 1. Nature of Business and Organization

Nature of Business

Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us or our) was formed as a wholly-owned subsidiary of Eli Lilly and Company (Lilly). Elanco is a global animal health company that innovates, develops, manufactures and markets products for pets and farm animals. We offer a diverse portfolio of approximately 190 brands to veterinarians and farm animal producers in more than 90 countries.

Organization

Elanco Parent was formed in May 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.

On September 24, 2018, Elanco Parent completed an initial public offering (IPO) resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares), which represented 19.8% of the outstanding shares, at $24 per share resulting in total net proceeds, after underwriting discounts and commissions, of $1.7 billion.  In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business. In exchange, Elanco Parent has paid to Lilly approximately $4.2 billion, which included the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 10: Debt). These transactions are collectively referred to herein as the Separation.

On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. The disposition of Elanco shares was completed on March 11, 2019, and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco.

On August 1, 2020, we completed the previously announced acquisition of Bayer Animal Health, for payment of $5.2 billion in cash, subject to customary post-closing adjustments, and approximately 72.9 million shares of Elanco common stock. See Note 6: Acquisitions and Divestitures for additional information.

Note 2. Basis of Presentation and Summary of Significant Accounting Policies

We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The accounts of all wholly owned and controlled subsidiaries are included in the condensed consolidated financial statements and all intercompany balances and transactions have been eliminated.

Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with current presentation.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020.

11



Our income taxes in 2019 and thereafter reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return with Lilly until full separation. The income tax amounts in the financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions.

The significant accounting policies set forth in Note 4 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to the adoption of the standards that were effective January 1, 2020 as described in Note 4: Implementation of New Financial Accounting Pronouncements.

Note 3. Impact of Separation

In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement, a tax matters agreement and the transitional services agreement (TSA).

In addition to the agreements referenced above, we entered into several other related party transactions with Lilly before and at the time of the Separation. For additional information regarding our ongoing agreements, as well as certain activities while Lilly was a related party, see Note 17: Related Party Agreements and Transactions.

Note 4. Implementation of New Financial Accounting Pronouncements

The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables.
We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements.
Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract
This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements.

12



The following table provides a brief description of accounting standards applicable to us that have not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.We are currently evaluating the effect of this standard on our consolidated financial statements.
Accounting Standards Update 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting
This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements.

Note 5. Revenue

Our sales rebates are based on specific agreements and the majority relate to sales in the U.S. As of September 30, 2020 and 2019, the liability for sales rebates in the U.S. represents approximately 54% and 71%, respectively, of our total liability with the next largest country representing approximately 12% and 6%, respectively, of our total liability.

The following table summarizes the activity in the sales rebates liability in the U.S.:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Beginning balance$122.0 $132.1 $150.4 $118.5 
Bayer Animal Health at acquisition20.8 — 20.8 — 
Reduction of revenue86.4 75.9 212.0 222.2 
Payments(78.6)(78.9)(232.6)(211.6)
Ending balance$150.6 $129.1 $150.6 $129.1 

Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2020 and 2019 for product shipped in previous periods were not material.

Product returns in the U.S. were approximately 0.1% and less than 0.1% of net revenue for the three months ended September 30, 2020 and 2019, respectively and approximately 1.2% and 0.1% of net revenue for the nine months ended September 30, 2020 and 2019, respectively.

13



Disaggregation of Revenue

The following table summarizes our revenue disaggregated by product category:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Pet Health Disease Prevention$297.0 $207.6 $613.6 $616.9 
Pet Health Therapeutics103.3 87.6 247.1 252.4 
Farm Animal Future Protein & Health180.9 191.5 518.8 534.5 
Farm Animal Ruminants & Swine292.3 266.2 703.1 811.8 
Contract Manufacturing (1)
16.1 18.4 51.0 68.4 
Revenue$889.6 $771.3 $2,133.6 $2,284.0 
(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. This category was previously called Strategic Exits.


Note 6. Acquisitions and Divestitures

During 2020, we completed the acquisition of Bayer Animal Health. During 2019, we completed the acquisitions of all outstanding shares of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec). These transactions were accounted for as business combinations under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our condensed consolidated financial statements from the dates of acquisition.

Bayer Animal Health Acquisition

On August 1, 2020, we completed our previously announced acquisition of Bayer Animal Health in a cash and stock transaction. Bayer Animal Health is a provider of products intended to improve the health and well-being of pets and farm animals. The acquisition expands our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our existing product portfolio and pipeline are enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure while expanding our direct to retailer/e-commerce presence.

Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows:

Cash consideration$5,170.1 
Fair value of Elanco common stock (1)
1,723.7 
Fair value of total consideration transferred (2)
$6,893.8 

(1)Represents the acquisition date fair value of 72.9 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).
(2)The purchase price is preliminary and subject to working capital and customary purchase price adjustments.

We recognized transaction costs related to the acquisition of Bayer Animal Health of $90.7 million and $17.4 million for the three months ended September 30, 2020 and 2019, respectively, and $212.3 million and $21.4 million for the nine months ended September 30, 2020 and 2019, respectively. These costs were associated with legal and professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.

14



The amount of revenues attributable to Bayer Animal Health included in our condensed consolidated statements of operations since the date of acquisition for the three and nine months ended September 30, 2020 is $195.6 million. Based on our current operational structure, we did not record standalone costs for Bayer Animal Health after the date of the acquisition. As a result, we are unable to accurately determine earnings or loss attributable to Bayer Animal Health since the date of acquisition.

The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2020. The purchase price allocation is preliminary and subject to change, including the valuation of inventories, property and equipment, intangible assets, income taxes and goodwill, among other items. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. Finalization of the valuation during the measurement period could result in a change in the amounts recorded for the acquisition date fair value.

The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 1, 2020
Cash and cash equivalents$168.8 
Accounts receivable9.7 
Inventories513.9 
Prepaid expenses and other current assets57.9 
Property and equipment299.6 
Intangible assets:
Acquired in-process research and development 240.0 
Marketed products3,220.0 
Assets held for sale146.9 
Accounts payable and accrued liabilities(172.8)
Accrued retirement benefits(209.6)
Other noncurrent assets and liabilities - net (707.9)
Total identifiable net assets3,566.5 
Goodwill3,327.3 
Total consideration transferred$6,893.8 

Inventories comprised of $359.6 million, $28.2 million, $126.1 million in finished products, work in process, and raw materials, respectively. The preliminary estimate of fair value of finished products was determined based on net realizable value adjusted for the costs to complete the sales process, a reasonable profit allowance from the sales process, and estimated holding costs. The preliminary estimate of fair value of work in process was determined based on net realizable value adjusted for costs to complete the manufacturing process, costs of the sales process, a reasonable profit allowance for the remaining manufacturing and sales process effort, and an estimate of holding costs. The fair value of raw materials was determined to approximate book value. The fair value step-up adjustment to inventories of $166.8 million is being amortized to cost of sales when the inventory is sold to customers, which is expected to be within less than one year from the acquisition date.

Property and equipment is mostly composed of land, buildings, equipment (including machinery, furniture and fixtures, and computer equipment), and construction in progress. The fair value of property and equipment was determined to approximate net book value at the time of the acquisition based on the information currently available and pending finalization of our fair value assessment.

Intangible assets relate to $240.0 million of in-process research and development (IPR&D) and $3,220.0 million of marketed products. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 12 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the "income approach," which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would




generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors. The fair value of intangible assets as of September 30, 2020 is based on preliminary assumptions which are subject to change as we complete our valuation procedures.
    
Assets held for sale include $135.0 million of marketed products rights, $7.3 million of IPR&D and $4.6 million of inventory related to the divestitures of Drontal™, Profender™ and other products. See the Divestitures section below for more information.

Accrued retirement benefits primarily relate to certain Bayer Animal Health international subsidiaries that have underfunded defined benefit pension plans. We have recorded the fair value of these plans using assumptions and accounting policies similar to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019. Upon acquisition, the excess of projected benefit obligation over the plan assets was recognized as a liability and previously existing deferred actuarial gains and losses and unrecognized service costs or benefits were eliminated. The resulting incremental net pension expense from the acquired plans was immaterial for the three months ended September 30, 2020.

The goodwill recognized from this acquisition represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies and cost savings from the creation of a single combined global organization. The majority of goodwill associated with this acquisition is not deductible for tax purposes.

The following table summarizes the changes in the carrying amount of goodwill during the period:

Balance as of December 31, 2019$2,989.6 
Aratana measurement period adjustments19.9 
Additions related to the Bayer Animal Health acquisition3,327.3 
Foreign currency translation adjustments97.9 
Balance as of September 30, 2020$6,434.7 

Goodwill is reviewed for impairment at least annually and when certain impairment indicators are present. As of September 30, 2020, there were no goodwill impairment losses.

Pro forma financial information (unaudited)

The following table presents the estimated unaudited pro forma combined results of Elanco, Bayer Animal Health and Aratana for the three and nine months ended September 30, 2020 and 2019 as if the acquisitions had occurred on January 1, 2019:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenues$1,072.6 $1,111.2 $3,318.3 $3,553.7 
Loss before income taxes
(222.8)(144.0)(382.1)(29.2)

The supplemental pro forma financial information has been prepared using the acquisition method of accounting and is based on the historical financial information of Elanco, Bayer Animal Health and Aratana. The supplemental pro forma financial information does not necessarily represent what the combined companies' revenue or results of operations would have been had the acquisitions been completed on January 1, 2019, nor is it intended to be a projection of future operating results of the combined company. It also does not reflect any operating efficiencies or potential cost savings that might be achieved from synergies of combining Elanco, Bayer Animal Health and Aratana.





The unaudited supplemental pro forma financial information reflects primarily pro forma adjustments related to divestitures, fair value estimates for intangibles and inventory, and interest expense and amortization of debt issuance costs for the debt issuance to finance the acquisition of Bayer Animal Health. The unaudited supplemental pro forma financial information includes transaction charges associated with the acquisition. There are no material, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported pro forma revenue and loss before income taxes.

Divestitures

In order to secure the necessary regulatory clearances for the acquisition of Bayer Animal Health, we signed agreements to divest the rights to manufacture and commercialize certain products. The following table summarizes the financial impact of the material divestitures completed during the third quarter of 2020, the pre-tax gains and losses on which are included in other - net, (income) expense in the condensed consolidated statement of operations.

Three and Nine Months Ended September 30, 2020
Gross Cash ProceedsPre-tax Gain
Osurnia™ $140.5 $93.1 
Vecoxan™ 55.1 37.1 
Capstar™ 95.9 25.5 
Drontal and Profender™
140.6 — 
Other immaterial divestitures2.6 0.7 
Total (1)
$434.7 $156.4 
(1) Pre-tax gain is net of transaction costs of $13.3 million.

We determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results.

Elanco product divestitures

In January 2020, we signed agreements to divest the worldwide rights to Osurnia and the U.S. rights to Capstar, and in February 2020, we signed an agreement to divest the worldwide rights to Vecoxan. The carrying value of the divested assets consisted of $114.1 million of marketed product rights and $7.9 million of inventory. In July 2020, we completed these sales, along with certain other immaterial divestitures. The transactions were accounted for as asset divestitures.

Bayer Animal Health product divestitures

To allow the Bayer Animal Health acquisition to close on a timely basis, we signed agreements to divest the rights to the Drontal and Profender product families within the United Kingdom and European Economic Area as well as other IPR&D. We completed the transactions, which were accounted for as asset divestitures, on August 3, 2020. Drontal, Profender, and the IPR&D were acquired as part of the Bayer Animal Health acquisition. The related assets were classified as held for sale on the balance sheet as of the acquisition date and measured at fair value at the time of the acquisition; therefore, no gains were recognized on the sales. A loss of $7.3 million was recorded on the sale of IPR&D as recognition of the potential income from the divestiture was constrained by revenue accounting standards. The estimated fair value of the divested assets consisted of $135.0 million of marketed product rights, $7.3 million of IPR&D, and $3.6 million of inventory.

There are additional marketed and pipeline products that we are required to dispose of in order to comply with regulatory requirements. These divestitures are not expected to have a material effect on our operations, cash flows or financial position.





Assets Held For Sale

The related assets for the Osurnia and Capstar divestitures met the assets held for sale criteria as of December 31, 2019. No adjustments were required to record the assets at the lower of their carrying amounts or fair values less costs to sell on the consolidated balance sheet. Assets and liabilities considered held for sale in connection with the divestitures were included in the respective line items on the consolidated balance sheet as follows:
December 31, 2019
Inventories$10.6 
Other intangibles, net61.2 
Property and equipment, net0.2 
Total assets held for sale$72.0 
Deferred taxes$(1.4)
Total liabilities held for sale$(1.4)

Other intangibles, net classified as held for sale primarily consisted of marketed products.

2019 Acquisitions

Aratana Therapeutics, Inc.

On July 18, 2019, we acquired Aratana, a pet therapeutics company focused on innovative therapies for dogs and cats, for stock and cash-based contingent value rights. Aratana is the creator of the canine osteoarthritis medicine, Galliprant™, the rights to which we acquired in 2016. The acquisition enhances our presence in the areas of appetite stimulants in dogs, pain relief in dogs and cats, and treatments of other conditions in the U.S. and internationally. In connection with the acquisition, we issued approximately 7.2 million shares with a value of $238.0 million to Aratana shareholders, based on our stock price on the last trading day immediately prior to the closing date. The purchase consideration also included up to $12 million in contingent value rights, which represent the rights of Aratana shareholders to receive a contingent payment of $0.25 per share in cash upon the achievement of a specified milestone as outlined in the merger agreement. We calculated an immaterial fair value for the contingent value rights using the Monte Carlo simulation model.

Contingent consideration liabilities that we previously recorded for future royalty and milestone payments in relation to the 2016 acquisition of rights to Galliprant were settled upon the closing of our acquisition of Aratana. The liabilities were valued at $84.7 million as of the acquisition date using the Monte Carlo simulation model. The resulting $7.5 million loss upon settlement was recorded in other - net, (income) expense in the consolidated and combined statement of operations for the year ended December 31, 2019.





The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 18, 2019
Cash and cash equivalents$26.4 
Inventories10.3 
Acquired in-process research and development 31.9 
Marketed products (1)
36.7 
Other intangible assets (1)
13.2 
Other assets and liabilities - net 4.1 
Total identifiable net assets122.6 
Goodwill (2)
30.7 
Settlement of existing contingent consideration liabilities84.7 
Total consideration transferred$238.0 
(1)These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.
(2)The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.

The accounting for this acquisition is complete. A $19.1 million measurement period adjustment was recorded to establish a deferred tax liability for the preexisting Galliprant contingent consideration liability during the nine months ended September 30, 2020.

We issued 0.1 million shares and recorded $3.6 million of stock-based compensation expense for the vesting of Aratana equity awards that was accelerated upon the closing of the acquisition during 2019.

Prevtec Microbia Inc.

On July 31, 2019, we acquired Prevtec in a cash transaction for approximately $60.3 million, inclusive of certain post-closing adjustments. Prevtec is a Canadian biotechnology company specializing in the development of vaccines intended to help prevent bacterial diseases in farm animals. The acquisition allows us to expand on our previous distribution arrangement for Coliprotec™ and is consistent with our efforts to explore innovative antibiotic alternatives.

The purchase consideration included up to $16.3 million in additional cash consideration, contingent upon the achievement of specific sales milestones by December 31, 2021. We recorded a $4.7 million liability on the condensed consolidated balance sheet as of the acquisition date based on the fair value of the contingent consideration as calculated using the Monte Carlo simulation model.

A previously existing $0.7 million receivable owed from Prevtec to Elanco Animal Health UK Limited was settled upon the closing of our acquisition of Prevtec. The resulting immaterial gain upon settlement was recorded in other - net, (income) expense in the consolidated and combined statement of operations for the year ended December 31, 2019.





The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 31, 2019
Cash and cash equivalents$0.9 
Property and equipment0.5 
Acquired in-process research and development 2.8 
Marketed products (1)
58.9 
Other intangible assets1.1 
Other assets and liabilities - net(9.3)
Total identifiable net assets54.9 
Goodwill (2)
10.1 
Total consideration transferred$65.0 
(1)These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.
(2)The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.

The accounting for this acquisition is complete. An immaterial measurement period adjustment to deferred taxes was recorded during the nine months ended September 30, 2020.


Note 7. Asset Impairment, Restructuring and Other Special Charges

In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.

For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.





Components of asset impairment, restructuring and other special charges are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Restructuring charges:
Severance and other costs (1) (2)
$130.2 $10.4 $131.2 $9.6 
Facility exit costs— — 0.7 — 
Acquisition related charges:
Transaction and integration costs (3)
131.1 46.1 318.5 99.6 
Non-cash and other items:
Asset impairment (4) (5)
— 10.2 3.5 14.2 
Asset write-down (6)
0.9 10.5 3.2 10.5 
Gain on sale of fixed assets (7)
— — (3.8)— 
Settlements and other (8)
— — 3.1 
Total expense$262.2 $77.2 $456.4 $133.9 

(1)For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program initiated following the acquisition of Bayer Animal Health. See below for further details.
(2)For the three and nine months ended September 30, 2019, these charges primarily related to a restructuring program initiated in 2019 to reduce costs and support margin expansion by eliminating certain positions across multiple locations and functions, including exiting research and development (R&D) operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England.
(3)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisition of Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly.
(4)Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an in-process research and development asset resulting from a reassessment of geographic viability.
(5)Asset impairment charges for the three and nine months ended September 30, 2019 related to an adjustment to fair value of intangible assets that were subject to product rationalization.
(6)Asset write-down expenses for the three and nine months ended September 30, 2020 and 2019 resulted from adjustments recorded to write assets classified as held and used down to their current fair value. Included are charges related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.
(7)Represents a gain on the disposal from the sale of an R&D facility in Prince Edward Island, Canada, which was written down during the three months ended September 30, 2019 as part of the announced 2019 program to streamline operations.
(8)Charge primarily relates to a non-recurring litigation settlement for a matter that originated prior to the Separation.

Following the closing of the Bayer Animal Health acquisition, we implemented a restructuring program designed to reduce duplication, drive efficiency and optimize our footprint in key geographies. As part of the restructuring plan, we intend to eliminate approximately 900 positions across 40 countries, primarily in the commercial and marketing functions, but also in the R&D, manufacturing and quality, and back office support functions. The proposed initiative is expected to lead to total restructuring charges of approximately $190 million to $210 million through 2021, consisting primarily of severance.

21



The following table summarizes the activity in our reserves established in connection with restructuring activities:
Facility exit costs SeveranceTotal
Balance at December 31, 2018$9.3 $35.1 $44.4 
Charges20.7 20.0 40.7 
Reserve adjustments— (10.2)(10.2)
Cash paid(2.0)(18.8)(20.8)
Balance at September 30, 2019$28.0 $26.1 $54.1 
Balance at December 31, 2019$5.4 $15.5 $20.9 
Charges0.7 131.9 132.6 
Reserve adjustments— (0.8)(0.8)
Cash paid(1.2)(15.0)(16.2)
Balance at September 30, 2020$4.9 $131.6 $136.5 

These reserves are included in other current liabilities on the consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.

Note 8. Inventories

We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method.

Inventories consisted of the following:
September 30, 2020December 31, 2019
Finished products$797.1 $402.9 
Work in process664.1 603.2 
Raw materials and supplies167.0 83.9 
Total1,628.2 1,090.0 
Decrease to LIFO cost(31.1)(39.3)
Inventories$1,597.1 $1,050.7 

Note 9. Equity

Common Stock Offering

On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 22.7 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2.3 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25.0 million shares of our common stock for $767.5 million, after issuance costs.

Tangible Equity Unit (TEU) Offering

On January 22, 2020, we also completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528.5 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification.

22



The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in long-term debt on the consolidated balance sheet, with payments expected in the next twelve months reflected in current portion of long-term debt. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.

The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$470.8 $79.2 $550.0 
Less: Issuance costs18.4 3.1 21.5 
Net proceeds$452.4 $76.1 $528.5 

The senior amortizing notes have an aggregate principal amount of $79.2 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we will pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate will be equivalent to 5.00% per year with respect to the $50 stated amount per TEU.

Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)

The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14.3 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period.

23



Note 10. Debt

Long-term debt consisted of the following:
September 30, 2020December 31, 2019
Term loan B credit facility$4,175.0 $— 
Term credit facility— 371.4 
3.912% Senior Notes due 2021
500.0 500.0 
4.272% Senior Notes due 2023
750.0 750.0 
4.900% Senior Notes due 2028
750.0 750.0 
TEU amortizing notes66.2 — 
Other obligations0.4 0.4 
Unamortized debt issuance costs(101.5)(16.8)
Total debt6,140.1 2,355.0 
Less current portion of long-term debt553.6 24.5 
Total long-term debt$5,586.5 $2,330.5 
Maturities on long-term debt consisted of the following:

As of September 30, 2020 and for period/years ending December 31
Fourth quarter of 2020$16.8 
2021567.6 
202268.0 
2023797.5 
202440.3 
202539.9 
Thereafter4,711.1 
Total obligations and commitments6,241.2 
Unamortized debt issuance costs and other obligations(101.1)
Total debt$6,140.1 

New Credit Facility

In connection with the acquisition of Bayer Animal Health, on August 1, 2020, we executed our previously announced borrowing of $4,275.0 million under a term loan B credit facility, of which $4,175.0 million was outstanding as of September 30, 2020. The term loan B facility bears interest at a floating rate of LIBOR plus 175 basis points over a seven-year term.

Simultaneously, we entered into a revolving credit facility providing up to $750.0 million and maturing over a five-year term. The revolving credit facility bears interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on our corporate family rating or corporate credit rating. On August 1, 2020, we drew down $200.0 million on the revolving credit facility to fund local country asset purchases in connection with our acquisition of Bayer Animal Health subsidiaries and subsequently repaid the amount in full later that month. As a result, we capitalized approximately $9.2 million of debt issuance costs in other noncurrent assets on the condensed consolidated balance sheet. In October 2020, we drew down $250.0 million on the revolving credit facility to fund local country asset purchases in connection with our acquisition of Bayer Animal Health subsidiaries. Pursuant to the stock and asset purchase agreement, Bayer is to reimburse us for these purchases. See Note 17: Related Party Agreements and Transactions for further discussion.

We have capitalized deferred financing costs of approximately $90.2 million, consisting of legal, accounting and other fees relating to our new credit facility. Deferred financing costs are recorded as a contra-liability and presented
24



net against long-term debt on the condensed consolidated balance sheet. Upon closing the acquisition of Bayer Animal Health on August 1, 2020, we terminated our unused commitments and incurred approximately $13.8 million in fees, which are included in other - net, (income) expense in the condensed consolidated statement of operations.

Proceeds from the equity and debt activities were used to finance the cash portion of our acquisition of Bayer Animal Health and to pay related fees and expenses (see Note 6: Acquisitions and Divestitures for further discussion). Subsequent to these borrowings, we have terminated all unused commitments to our lenders.

These senior secured first lien credit facilities are secured by a significant portion of our assets. They include two financial maintenance covenants which are solely for the benefit of lenders under the revolving credit facility. There are no financial maintenance covenants for the benefit of the term loan B facility. The lenders under the term loan B facility have no enforcement rights with respect to the financial maintenance covenants for the revolving credit facility.

The first financial maintenance covenant for the revolving credit facility requires us to maintain a net total leverage ratio level (which is not subject to step-downs) as of the end of each quarter, beginning with the fiscal quarter ending September 30, 2020. The required level of this covenant is based on closing date pro forma net leverage and pro forma adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) not exceeding 7.71 to 1.00 of our pro forma adjusted EBITDA for the four fiscal quarters ended September 30, 2020.

The second financial maintenance covenant for the revolving credit facility requires us to maintain a ratio of pro forma adjusted EBITDA to cash interest expense of no less than 2.00 to 1.00, tested as of the end of each fiscal quarter, beginning with the fiscal quarter ended September 30, 2020. We were in compliance with all covenants under the credit facility as of September 30, 2020.

Debt Extinguishment

On January 31, 2020, we repaid indebtedness outstanding under our existing term loan facility. We paid $372.4 million in cash, composed of $371.4 million of principal and $1.0 million of accrued interest, resulting in a debt extinguishment loss of $0.8 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statement of operations for the nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs.

On September 25, 2020, we made a repayment of principal of $100.0 million on the indebtedness outstanding under our new term loan B facility. The repayment was accounted for as a partial debt extinguishment and resulted in a debt extinguishment loss of $2.1 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statement of operations for the three and nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs.

TEU Amortizing Notes

On January 22, 2020, we issued $550 million in TEUs. We offered 11 million, 5.00% TEUs at the stated amount of $50 per unit, comprised of prepaid stock purchase contracts and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $528.5 million was received, comprised of $452.4 million of prepaid stock purchase contracts and $76.1 million of senior amortizing notes, net of issuance costs. We paid $14.1 million representing partial payment of principal and interest on the TEU amortizing notes during the nine months ended September 30, 2020. See Note 9: Equity for further information.

Note 11. Financial Instruments and Fair Value

Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.

A large portion of our cash is held in a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.
25




As of September 30, 2020 and December 31, 2019, we had $21.7 million and $18.8 million, respectively, primarily related to equity method investments included in other noncurrent assets on our condensed consolidated balance sheet.

The following table summarizes the fair value information at September 30, 2020 and December 31, 2019 for foreign exchange contract assets (liabilities), contingent consideration liabilities, net investment hedge assets (liabilities) and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2020
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$10.7 $— $10.7 $— $10.7 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(7.6)— (7.6)— (7.6)
Other noncurrent liabilities - contingent consideration(2.6)— — (2.6)(2.6)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges(87.0)— (87.0)— (87.0)
Long-term debt - senior notes(2,000.0)— (2,186.7)— (2,186.7)
TEU amortizing note (1)
(66.2)— (66.2)— (66.2)
Term loan B(4,175.0)— (4,068.0)— (4,068.0)
December 31, 2019
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$0.8 $— $0.8 $— $0.8 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(1.1)— (1.1)— (1.1)
Other noncurrent liabilities - contingent consideration(4.7)— — (4.7)(4.7)
Other noncurrent assets - cross currency interest rate contracts designated as net investment hedges2.3 — 2.3 — 2.3 
Long-term debt - senior notes(2,000.0)— (2,120.6)— (2,120.6)
Long-term debt - term credit facility (1)
(371.4)— (371.4)— (371.4)

(1)We consider the carrying value to be representative of its fair value.

We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities.

26



Contingent consideration liabilities as of September 30, 2020 and December 31, 2019 related to contingent consideration associated with the acquisitions of Aratana and Prevtec during 2019. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16.3 million contingent upon the achievement of specific Coliprotec sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility. During the nine months ended September 30, 2020, primarily as a result of a decrease in forecasted revenues related to Coliprotec, we decreased the fair value of the contingent consideration liability associated with the Prevtec acquisition by $2.1 million, and recognized the gain in other – net, (income) expense in the condensed consolidated statement of operations. See Note 6: Acquisitions and Divestitures for further discussion.

Derivative Instruments and Hedging Activities

We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures.

Derivatives Not Designated as Hedges

We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the British pound, Canadian dollar, Euro, Japanese yen, Swiss franc (CHF), and Chinese renminbi. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other – net, (income) expense in the condensed consolidated income statement. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2020 and December 31, 2019, we had outstanding foreign exchange contracts with aggregate notional amounts of $1,496.9 million and $861.2 million, respectively.

The amount of net gain/(loss) on derivative instruments not designated as hedging instruments, recorded in other - net, (income) expense are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Foreign exchange forward contracts (1)
$(2.3)$10.1 $19.4 $8.8 

(1)These amounts were substantially offset in other – net, (income) expense by the effect of changing exchange rates on the underlying foreign currency exposures.

Derivatives Designated as Hedges

In October 2018, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a five-year cross-currency fixed interest rate swap with a 750 million CHF notional amount, which was designated as a net investment hedge (NIH) against CHF denominated assets (the fair value of which was estimated based on quoted market values of similar hedges and was classified as Level 2). During the nine months ended September 30, 2020, we fully liquidated our cross currency interest rate swaps for a cash benefit of $35.1 million (including $2.4 million in interest). Notwithstanding settlement, gains and losses within accumulated other comprehensive loss will remain in accumulated other comprehensive loss until either the sale or substantial liquidation of the hedged subsidiary.


27



Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cross-currency interest rate swap contracts$— $6.2 $6.2 $18.4 

Over the life of the derivative, gains or losses due to spot rate fluctuations were recorded in cumulative translation adjustment in other comprehensive income. The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cross-currency interest rate swap contracts$— $18.5 $24.0 $23.9 


Separately, in March 2020, as a means of mitigating variability in cash flows associated with the anticipated term loan B issuance, we executed forward-starting interest rate swaps with a $4.05 billion notional amount, which are designated as cash flow hedges and have settlement dates ranging between 2022 and 2025. These instruments effectively convert floating-rate debt to fixed-rate debt. The cash flow hedges are recorded at fair value on our condensed consolidated balance sheet, while changes in the fair value of the hedge are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Amounts recorded in accumulated other comprehensive income (loss) will be recognized in earnings in interest expense, net of capitalized interest when the hedged transaction affects earnings (i.e., when interest payments are accrued on the term loan B). During the three and nine months ended September 30, 2020, we recorded a loss of $7.5 million (net of tax benefit of $2.2 million) and $67.4 million (net of tax benefit of $19.6 million), respectively, on the cash flow hedges in other comprehensive income (loss). Over the next 12 months we expect to reclassify $28.0 million from accumulated other comprehensive loss to interest expense, net of capitalized interest due to the amortization of net losses on the interest rate swaps.

Note 12. Leases

Australia Sale-Leaseback

On June 26, 2020, our wholly-owned subsidiary, Elanco Australasia PTY LTD, sold land and an R&D facility located in New South Wales, Australia, for aggregate proceeds of $55.1 million, and leased the property back for an initial term of 15 years through a sale-leaseback transaction. Under the terms of the purchase and sale agreement, we determined that control of the assets was relinquished to the buyer-lessor. Therefore, we recognized a pre-tax gain on the sale of $45.6 million in other - net, (income) expense in the condensed consolidated statement of operations during the nine months ended September 30, 2020. Operating lease right-of-use assets and liabilities include the present value of $27.8 million for the associated lease payments, which are presented in other noncurrent assets and other noncurrent liabilities and other current liabilities on the condensed consolidated balance sheet.

Note 13. Income Taxes


Provision for Taxes on IncomeThree Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Income tax (benefit) expense$(74.0)$(22.5)$(116.6)$5.1 
Effective tax rate35.4 %179.7 %32.9 %6.2 %

Our income taxes for the nine months ended September 30, 2019 and 2020, respectively, reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return until full separation. In the jurisdictions in which we were included in a combined tax return, our income taxes were
28



determined based on the tax matters agreement between us and Lilly. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns.

In 2017, the U.S. enacted the Tax Cuts and Jobs Act (2017 Tax Act), which significantly revised U.S. tax law. Guidance related to the 2017 Tax Act, including Notices, Proposed Regulations, and Final Regulations, has been issued, and we expect additional guidance will be issued in 2020. This additional guidance could materially impact our assumptions and estimates used to record our U.S. federal and state income tax expense resulting from the 2017 Tax Act.

We are included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. During the fourth quarter of 2019, the IRS began its examination of tax years 2016 - 2018. Because the examination is still in the early stages of information gathering, the resolution of the audit will likely extend beyond the next 12 months.

For the three and nine months ended September 30, 2020, we recognized $74.0 million and $116.6 million, respectively, of income tax benefit. For the three and nine months ended September 30, 2020, our effective tax rate of 35.4% and 32.9%, respectively, differs from the statutory income tax rate primarily due to the release of foreign valuation allowances as a result of gains on divestitures. Additionally, the state tax benefit is a result of U.S. pre-tax losses and the foreign tax benefit is due to losses in jurisdictions with tax rates higher than U.S. statutory rates.

For the three and nine months ended September 30, 2019, we recognized a tax benefit of $22.5 million and incurred $5.1 million of income tax expense, respectively. For the three and nine months ended September 30, 2019, our effective tax rate differs from the statutory income tax rate primarily due to a discrete tax benefit from the resolution of a Brazil tax audit in addition to the impact of lower pre-tax earnings largely due to restructuring charges. Tax reserves had been established in the 2015 acquisition of Novartis Animal Health (Novartis) and were partially covered by an indemnity. The favorable resolution of the Brazil tax audit resulted in an income tax benefit of approximately $14 million in the third quarter of 2019.

Note 14. Commitments and Contingencies

Legal Matters

On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco, Jeffrey Simmons and Todd Young. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between January 10, 2020 and May 6, 2020. On September 3, 2020, the Court appointed a lead plaintiff. The deadline for the lead plaintiff to file an amended complaint is November 9, 2020. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

On October 16, 2020, a shareholder class action lawsuit captioned Safron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3/ASR dated January 21, 2020 and accompanying prospectus on Form 424B5 issued in connection with Elanco’s secondary public offering that closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities pursuant to the secondary public offering. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

29



We are party to various other legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. We accrue for certain liability claims to the extent that it is probable we will incur a loss and we can formulate a reasonable estimate of the costs. As of September 30, 2020 and December 31, 2019, we had no material liabilities established related to litigation as there were no significant claims which were probable and estimable. We have not historically had any significant litigation expense and are not currently subject to a significant claim other than the lawsuits noted above.

Note 15. Geographic Information

We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both farm animals and pets. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant cost/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results. We are currently in the process of reviewing our operating segments as a result of potential changes to our operational structure due to the acquisition of Bayer Animal Health.

Our products include Rumensin™, Optaflexx™, Denagard™, Tylan™, Maxiban™, Baycox™, Cydectin™ and other products for livestock and poultry, as well as Trifexis™, Interceptor™, Comfortis™, Galliprant, Seresto™, Advantage™, Advantix™, Advocate™ (collectively referred to as the Advantage Family) and other products for pets.

We have a single customer that accounted for 11.7% and 15.9% of revenue for the three months ended September 30, 2020 and 2019, respectively, and for 11.9% and 13.4% of revenue for the nine months ended September 30, 2020 and 2019, respectively. The product sales resulted in accounts receivable with this customer of $78.1 million and $90.5 million as of September 30, 2020 and December 31, 2019, respectively.

We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

Selected geographic area information was as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenue—to unaffiliated customers (1)
United States$421.5 $388.2 $969.5 $1,167.1 
International468.1 383.1 1,164.1 1,116.9 
Revenue$889.6 $771.3 $2,133.6 $2,284.0 

30



September 30, 2020December 31, 2019
Long-lived assets (2)
United States$942.6 $709.8 
Germany243.7 39.7 
United Kingdom206.3 192.6 
Other foreign countries273.1 205.0 
Long-lived assets$1,665.7 $1,147.1 
(1)Revenue is attributed to the countries based on the location of the customer.
(2)Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.

Note 16. Earnings Per Share

Basic Earnings Per Share

We compute basic earnings (loss) per share by dividing net earnings (loss) available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. For the three and nine months ended September 30, 2020, the weighted average number of common shares outstanding used to calculate basic earnings per share includes the impact of approximately 72.9 million shares of common stock issued to Bayer and its subsidiaries for the Bayer Animal Health acquisition. In addition, basic earnings per share reflects the impacts of 25.0 million shares and 14.3 million shares, respectively, issued in connection with our common stock and TEU issuances in the first quarter of 2020. See Note 6: Acquisitions and Divestitures and Note 9: Equity for further discussion.

Diluted Earnings Per Share

Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts. Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method.

Weighted average diluted shares outstanding included common stock equivalents of 1.5 million and 1.0 million for the three and nine months ended September 30, 2019, respectively.
Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. During the three and nine months ended September 30, 2020, we reported a net loss. Therefore, dilutive common shares are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share.

For the three and nine months ended September 30, 2019, approximately 0.1 million shares of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.

Note 17. Related Party Agreements and Transactions

Elanco Shares Held by Bayer

On August 1, 2020, we completed the acquisition of Bayer Animal Health, which included cash and Elanco stock consideration. Pursuant to the share and asset purchase agreement, Bayer has the right to sell such shares on or after November 1, 2020 through multiple registered offerings. Upon Bayer's written request, Elanco is obligated to use commercially reasonable efforts to file a shelf registration statement covering the resale by Bayer of its Elanco common stock. As of September 30, 2020, Bayer owns 72.9 million shares, or 15.5% of our outstanding common stock.
31




Transactions with Bayer Subsequent to the Acquisition of Bayer Animal Health

There were various transactions between us and Bayer during the period after the acquisition of Bayer Animal Health. The total net payable due to Bayer at September 30, 2020 was $9.8 million related to these transactions. We also have $60.0 million associated with lease agreements with Bayer recorded on our condensed consolidated balance sheet as of September 30, 2020. Further details regarding our ongoing relationship with Bayer are included below.

Transitional Services Agreements (TSA) and Reverse TSAs

To ensure business continuity after the acquisition of the Bayer Animal Health business, we entered into certain TSAs and reverse TSAs with Bayer. Under the TSAs, Bayer will provide us certain specified R&D services and back office support on a transitional basis, including among other things, logistical services, commercial operations support, and information systems. We will pay Bayer mutually agreed-upon fees for services provided under the TSAs, a majority of which are based on fixed hourly rates, and subject to a contractually agreed mark-up. We have recorded approximately $2.7 million of expense for the three and nine months ended September 30, 2020 related to these agreements.

The reverse TSAs are primarily comprised of contracts whereby we have agreed to provide Bayer certain R&D services on a transitional basis. During the three and nine months ended September 30, 2020, reverse TSA activity was immaterial.

Leases

We lease certain facilities and fleet vehicles from Bayer. Our operating lease right-of-use assets and liabilities include the present value of $60.0 million for the lease payments related to these leases, which are presented in other noncurrent assets and other noncurrent liabilities and other current liabilities on the condensed consolidated balance sheet.

Local Country Asset Purchases

For regulatory purposes in certain jurisdictions, consideration was required to be paid locally at closing in addition to amounts paid globally for the acquisition. Pursuant to the stock and asset purchase agreement, Bayer is to provide a refund for payment amounts duplicated in these regions. As of September 30, 2020, the local payment has not yet been made in China due to certain regulatory delays. Thus, as of September 30, 2020, we had a receivable from and payable to Bayer of $233.6 million and $233.6 million, respectively, recorded on a net basis on the condensed consolidated balance sheet.

Other Activities

We also entered into various other agreements with Bayer, including certain supply agreements and contract manufacturing and toll manufacturing agreements. These contracts are for activities in the normal course of business and are required to maintain and establish business relationships on a long-term basis.

In connection with the acquisition, we have an obligation to reimburse Bayer for certain costs they incurred on our behalf. Accordingly, we have recorded approximately $20.4 million in other current liabilities on the condensed consolidated balance sheet as of September 30, 2020 and within asset impairment, restructuring and other special charges in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 for amounts owed to Bayer.
32




Transactions with Lilly Subsequent to Separation and Related to the Separation

Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services were as follows:
September 30, 2020December 31, 2019
TSA$1.1 $10.5 
Other activities(1.7)(15.8)
Local country asset purchases(10.7)(11.1)
Total payable to Lilly$(11.3)$(16.4)

As described in Note 1, we completed an IPO in September 2018 and Lilly fully divested all ownership of Elanco in March 2019. In connection with the Separation, we entered into various agreements with Lilly related to the form of our separation and certain ongoing activities that will continue for a period of time. These included, among others, a master separation agreement (MSA), a TSA and a tax matters agreement. In addition, there was a portion of our operations for which the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries.

TSA

Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we are able to use Lilly Services for a fixed term established on a service-by-service basis. We pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which are based on Lilly's cost (including third-party costs) of providing the Lilly Services through March 31, 2021, and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2022. The fees under the TSA became payable for all periods beginning after October 1, 2018.

Separation Activities

Subsequent to our IPO, there continue to be transactions between us and Lilly related primarily to the completion of the local country asset purchases and finalization of assets and liabilities associated with the legal separation from Lilly, combined income tax returns and the impact of the tax matters agreement, historical Lilly retirement benefits, and centralized cash management. The most significant of these activities includes the finalization of the local country valuation of business and the resulting impact on deferred tax assets and the impact of combined tax returns.

Other Activities

We continue to share certain services and back office functions with Lilly, which in certain instances result in Lilly paying costs for Elanco (e.g., utilities, local country operating costs, etc.) that are then passed through to Elanco for reimbursement. These amounts are included in cash flows from operating activities in our consolidated statements of cash flows. In addition, we operate through a single treasury settlement process and prior to the local country asset purchases (as described below) continued to transact through Lilly's processes in certain instances. As a result of these activities, there were certain amounts of financing that occurred between Lilly and Elanco during the nine months ended September 30, 2019 and 2020. These amounts are included in cash flows from financing activities in our condensed consolidated statements of cash flows.

Local Country Asset Purchases

The legal transfer of certain of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. The related assets, liabilities, and results of operations have been reported in our condensed consolidated financial statements, as we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets under the terms of the MSA. We held restricted cash, and the associated payable to Lilly, at the date of Separation to fund the acquisition of these assets. As of September 30, 2020, the majority of these assets have been legally
33



acquired and the remainder are expected to be purchased during 2020. Restricted cash and Payable to Lilly of $10.7 million are recorded on the condensed consolidated balance sheet for the remainder of the assets expected to be purchased by the end of 2020.

Transactions with Lilly Prior to Full Separation

Prior to the IPO, we did not operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us. The impact on our historical combined financial statements includes the following:

Stock-based Compensation

Prior to full separation, our employees participated in Lilly stock-based compensation plans, the costs of which were allocated to us and recorded in cost of sales, research and development, and marketing, selling and administrative expenses in the condensed consolidated statements of operations. The costs of such plans related to our employees were $5.1 million for the nine months ended September 30, 2019.
34



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations
(Tables present dollars in millions, except per-share data)

Management’s discussion and analysis of financial condition and results of operations is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 1 of Part I of this Quarterly Report on Form 10-Q. Certain statements in this Item 2 of Part I of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements," Item 1A, "Risk Factors," of Part II of this Quarterly Report on Form 10-Q, and Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2019, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.

Overview

Founded in 1954 as part of Eli Lilly and Company (Lilly), Elanco is a premier animal health company that innovates, develops, manufactures and markets products for pets and farm animals. Headquartered in Greenfield, Indiana, we are the second largest animal health company in the world, with pro forma combined revenue of Elanco and Bayer Animal Health of approximately $4.7 billion for the year ended December 31, 2019. Excluding Bayer Animal Health, globally, we are #1 in medicinal feed additives, #2 in poultry, and #3 in other pharmaceuticals, which are mainly pet health therapeutics, measured by 2019 revenue, according to Vetnosis.

We have one of the broadest portfolios of pet parasiticides in the pet health sector. We offer a diverse portfolio of approximately 190 brands that make us a trusted partner to veterinarians and farm animal producers in more than 90 countries.

On September 24, 2018, we completed our initial public offering (IPO), pursuant to which we issued and sold 19.8% of our total outstanding shares. On September 20, 2018, our common stock began trading on the New York Stock Exchange (NYSE) under the symbol “ELAN.” On September 24, 2018, immediately preceding the completion of the IPO, Lilly transferred to us substantially all of its animal health businesses in exchange for (i) all of the net proceeds (approximately $1,659.7 million) we received from the sale of our common stock in the IPO, including the net proceeds we received as a result of the exercise in full of the underwriters’ option to purchase additional shares, (ii) all of the net proceeds (approximately $2,000 million) we received from the issuance of our senior notes; and (iii) all of the net proceeds ($498.6 million) we received from the entry into our term loan facility. In addition, immediately prior to the completion of the IPO, we entered into certain agreements with Lilly that provide a framework for our ongoing relationship with them.

On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. On that date, we filed a Registration Statement on Form S-4 with the SEC in connection with that exchange offer. The disposition of Elanco shares was completed on March 11, 2019, and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco.

On August 1, 2020, we completed the acquisition of Bayer Animal Health. The acquisition expands our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our existing product portfolio and pipeline are enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure. See Note 6: Acquisitions and Divestitures to the condensed consolidated financial statements for additional information on the acquisition. Subsequent to the acquisition date, our consolidated financial statements include the assets, liabilities, operating results and cash flows of Bayer Animal Health.


35



We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable and through pet companionship, helping pets live longer, healthier lives. During the third quarter of 2020, we renamed our four primary product categories by replacing "food animal" and "companion animal" with "farm animal" and "pet health," respectively, to better reflect the terminology used by our customers. We advance our vision by offering products in these four primary categories:

Pet Health Disease Prevention (PH Disease Prevention): We have one of the broadest parasiticide portfolios in the pet health sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. Our Seresto and Advantage Family products represent treatments for the elimination and prevention, respectively, of fleas and ticks. Combining our parasiticide portfolio with our vaccines presence, we are a leader in the U.S. in the disease prevention category based on share of revenue.
Pet Health Therapeutics (PH Therapeutics): We have a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. Pet owners are increasingly treating osteoarthritis in their pets, and our Galliprant™ product is one of the fastest growing osteoarthritis treatments in the U.S. We also have treatments for otitis (ear infections), as well as cardiovascular and dermatology indications.
Farm Animal Future Protein & Health (FA Future Protein & Health): Our portfolio in this category, which includes vaccines, nutritional enzymes and animal only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. We are focused on developing functional nutritional health products that promote farm animal health, including enzymes, probiotics and prebiotics. We are a leader in providing vaccines as alternatives to antibiotics to promote animal health based on share of revenue.
Farm Animal Ruminants & Swine (FA Ruminants & Swine): We have developed a range of farm animal products used extensively in ruminant (e.g., cattle, sheep and goats) and swine production.
A summary of our 2020 revenue and net income compared with the same period in 2019 is as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenue$889.6 $771.3 $2,133.6 $2,284.0 
Net income (loss)(135.0)10.0 (237.3)77.4 

Increases or decreases in inventory levels at our channel distributors can positively or negatively impact our quarterly and annual revenue results, leading to variations in quarterly revenues. This can be a result of various factors, such as end customer demand, new customer contracts, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics, payment terms we extend, which are subject to internal policies, and procedures and environmental factors beyond our control, including weather conditions and the COVID-19 global pandemic.

Key Trends and Conditions Affecting Our Results of Operations

Industry Trends

The animal health industry, which includes both farm animals and pets, is a growing industry that benefits billions of people worldwide.


36



As demand for animal protein grows, farm animal health is becoming increasingly important. We believe that factors influencing growth in demand for farm animal medicines and vaccines include:

•one in three people needing improved nutrition;
•increased global demand for protein, particularly poultry and aquaculture;
•natural resource constraints, such as scarcity of arable land, fresh water and increased competition for cultivated land, driving the need for more efficient food production;
•loss of productivity due to farm animal disease and death;
•increased focus on food safety and food security; and
•human population growth, increased standards of living, particularly in many emerging markets, and increased urbanization.

Growth in farm animal nutritional health products (enzymes, probiotics and prebiotics) is influenced, among other factors, by demand for antibiotic alternatives that can promote animal health and increase productivity.
We believe that factors influencing growth in demand for pet medicines and vaccines include:

•increased pet ownership globally;
•pets living longer; and
•increased pet spending as pets are viewed as members of the family by owners.

Factors Affecting Our Results of Operations

COVID-19 Pandemic

The outbreak of COVID-19 originating in Wuhan, China, in December 2019 has since rapidly increased its exposure globally. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. We continue to monitor the global outbreak of COVID-19 and are working with our customers, employees, suppliers and other stakeholders to mitigate the risks posed by its spread. The COVID-19 pandemic is affecting the economy in the United States and globally, and has had an effect on the operations of our company, vendors and suppliers, and supply of and demand for our products as follows:

Operations

As a result of the COVID-19 pandemic, governmental authorities have implemented and are continuing to implement numerous and constantly evolving measures to try to contain the virus, such as travel bans and restrictions, limits on gatherings, quarantines, shelter-in-place orders, site closures and business shutdowns. These measures have affected the ability of our employees, vendors, and suppliers to perform their respective responsibilities and obligations relative to the conduct of our business. We have important manufacturing operations worldwide that have been impacted by the outbreak. Measures requiring business shutdowns generally exclude certain essential services, and those essential services commonly include critical infrastructure and the businesses that support that critical infrastructure. Because the animal health industry has been designated an essential business, our manufacturing and research facilities remain operational, while our employees in other company functions are primarily working remotely. These measures have impacted and may further impact our workforce and operations, as well as those of our customers, vendors and suppliers.

Supply

In the third quarter, we have not experienced significant impacts or interruptions to our supply chain as a result of the COVID-19 pandemic. However, as the pandemic continues, we may face supply chain disruptions due to operational difficulties experienced by our suppliers in light of government-ordered restrictions and shelter-in-place mandates. Although we regularly monitor the financial health of companies in our supply chain, the financial hardship on our suppliers caused by the COVID-19 pandemic could cause a disruption in our ability to obtain raw materials or components required to manufacture our products, adversely affecting our operations. Freight processes relating to the shipment of our finished goods have been disrupted and have resulted in higher shipping
37



costs, which has negatively impacted our profitability.

Demand

The COVID-19 pandemic has adversely impacted global economic conditions. In particular, the COVID-19 pandemic has created near-term uncertainty for our channel distribution partners with respect to end customer demand and working capital. Based on these factors, in addition to a shift in tactics for demand generation with our distributors, in the first and second quarters of 2020, we reduced the amount of inventory held in the channel. We anticipate that decreases in end customer demand could impact our pet health business, primarily in clinically administered pharmaceutical products such as vaccines, and in international markets, as social distancing guidelines could decrease veterinary visits again in the future, reducing veterinary practice revenue and increasing working capital considerations for all parties in the value chain. If this occurs, even if we are able to increase sales in our direct to retailer and e-commerce channels, which have been important components of the Bayer Animal Health distribution model, these increases may not compensate for reduced sales through veterinary practices. Further, demand in our direct to retailer and e-commerce channels could be negatively impacted if global economic conditions do not improve.

In our farm animal business, demand has been negatively impacted by processing plant closures, a backlog of animals ready for processing and pressured producer economics, which has and could continue to impact demand for a number of our farm animal products. While the impact has been most significant for the U.S. livestock industry, the pressure has occurred globally and across species. As the pandemic has continued through the third quarter of 2020, our business has been affected by lower levels of demand in certain markets due to unfavorable macroeconomic conditions and reduced food service consumption trends. As a result, the industry has seen pressured prices and producer profitability across species, most notably in poultry and aqua. We anticipate that decreases in demand as compared to prior year will continue to occur, particularly in the farm animal business, throughout the rest of the year.

Our third party distributors may face difficulties maintaining operations and normal liquidity in light of government-mandated restrictions. Due to liquidity and working capital pressure caused by the COVID-19 pandemic, our distributors are managing inventory more tightly. In response to this along with a shift in tactics for demand generation with our distributors, we reduced channel inventory levels during the first half of 2020 as we tighten our approach across all facets of our distributor relationships. These actions have allowed us to improve working capital management, implement new compensation structures with our distributors and enable greater control of overall stock levels. We continue to monitor the impacts on our customers' liquidity and therefore our ability to collect on our accounts receivable. While our allowance on these receivables factors in expected credit losses, continued disruption and declines in the global economy could result in difficulties in our ability to collect, which we have not experienced on a material basis at this time. If significant issues with collections occur, material increases in our allowance for doubtful accounts may be required.

Our Acquisition of Bayer Animal Health

We have incurred and expect to continue to incur expenses in connection with our acquisition of Bayer Animal Health. In addition, we have incurred and expect to continue to incur costs related to the build out of processes and systems to support finance and global supply and logistics and to expand administrative functions, including, but not limited to, information technology, facilities management, distribution, human resources, and manufacturing, to replace services previously provided by the former parent company of Bayer Animal Health. We anticipate that these additional costs will be partially offset by expected synergies.

Product Development and New Product Launches

A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation, primarily in our three targeted growth categories of PH Disease Prevention, PH Therapeutics and FA Future Protein & Health. Since 2015, legacy Elanco has launched or acquired 14 new products, including the additions of Entyce™, Nocita™ and Tanovea™ in 2019 through acquisition and business development activities. Revenue from these products contributed $337.1 million to revenue for the nine months ended September 30, 2020. This excludes our most recent acquisition of Bayer Animal Health, which added approximately 65 products to the Elanco portfolio that contributed $195.6 million to revenue during the current quarter. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depends on both our pipeline of new products, including new products that we may develop through joint
38



ventures and products that we are able to obtain through license or acquisition, and the expansion of the use of our existing products. We believe we are an industry leader in animal health R&D, with a track record of product innovation, business development and commercialization.

Productivity

Our results during the periods presented have benefited from operational and productivity initiatives implemented following recent acquisitions and in response to changing market demand for antibiotics and other headwinds.

Prior to the acquisition of Bayer Animal Health, our acquisitions within the last six years added in the aggregate $1.4 billion in revenue, 4,600 full-time employees, 12 manufacturing and eight R&D sites. In addition, from 2015 to 2019, changing market demand for antibiotics and other headwinds, such as competition with generics and innovation, affected some of our highest gross margin products, resulting in a change to our product mix and driving operating margin lower. In response, we implemented a number of initiatives across the manufacturing, R&D and selling, general and administrative (SG&A) functions. Our manufacturing cost savings strategies included improving manufacturing processes and headcount through lean manufacturing (minimizing waste while maintaining productivity), closing of three manufacturing sites, consolidating our CMO network, strategically insourcing certain projects, and pursuing cost savings opportunities with respect to raw materials via a new procurement process. Additional cost savings resulted from reducing the number of R&D sites from 16 to nine, SG&A savings from sales force consolidation, and reducing discretionary and other general and administrative (G&A) operating expense.

The acquisition of Bayer Animal Health on August 1, 2020 added 3,900 full-time employees, eight manufacturing sites (subject to local country regulatory delays), four R&D sites and, based on historical revenues, is expected to add approximately $1.7 billion in annual revenues.

Foreign Exchange Rates

Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 90 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. During the nine months ended September 30, 2020 and 2019, approximately 52% and 43%, respectively, of our revenue was denominated in foreign currencies. As we operate in multiple foreign currencies, including the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, Chinese yuan, and other currencies, changes in those currencies relative to the U.S. dollar impact our revenue, cost of sales and expenses, and consequently, net income. These fluctuations may also affect the ability to buy and sell our products between markets impacted by significant exchange rate variances. Currency movements decreased revenue by 1% during the nine months ended September 30, 2020. Currency movements decreased revenue by 2% during the nine months ended September 30, 2019.

Our Relationship with Lilly and Additional Standalone Costs

We are currently investing in expanding our own administrative functions, including, but not limited to, information technology, facilities management, distribution, human resources, and manufacturing, to replace services previously provided by Lilly. Because of initial stand up costs and overlaps with services previously provided by Lilly, we have incurred and expect to continue to incur certain temporary, duplicative expenses in connection with the Separation. We have also incurred and expect to continue to incur costs related to the build out of processes and systems to support finance and global supply and logistics, among others. We currently estimate these costs taken together to be in a range from $280 million to $320 million, net of completed and potential real estate dispositions and employee benefit changes, of which a portion will be capitalized and the remainder will be expensed. The increase compared to the prior expected range of $240 million to $290 million primarily reflects higher costs to execute local country IT infrastructure deployment and transitions as a result of COVID-19 pandemic-related travel restrictions and protocols, as well as increased site cutover expenses and additional scope costs.

As a result of the IPO, we became subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and the Sarbanes-Oxley Act. We continue to establish and expand additional procedures and practices as a standalone public company. As a result, we continue to incur additional costs as a standalone public company compared to the prior period, including internal audit, external audit, investor relations, stock administration, stock exchange fees and regulatory compliance costs.

39



Asset Impairment, Restructuring and Other Special Charges

Our results have been impacted by asset impairment, restructuring and other special charges, including integration of acquired businesses, during the three and nine months ended September 30, 2020 and 2019. These charges primarily include severance costs resulting from actions taken to reduce our cost structure, asset impairment charges related to product rationalization and site closures, and charges and costs related to our integration efforts as a result of our acquired businesses and the acquisition of Bayer's animal health business, external costs directly related to acquiring businesses, including expenses for banking, legal, accounting, and other similar services, and costs to stand our organization up to be an independent company.

For more information on these charges, see Note 7: Asset Impairment, Restructuring and Other Special Charges in our condensed consolidated financial statements.

Results of Operations

The following discussion and analysis of our results of operations should be read along with our condensed consolidated financial statements and the notes thereto.
Three Months Ended September 30,Nine Months Ended September 30,
20202019% Change20202019% Change
Revenue $889.6 $771.3 15 %$2,133.6 $2,284.0 (7)%
Costs, expenses and other:
Cost of sales441.8 360.4 23 %1,070.4 1,060.2 1 %
% of revenue50 %47 %3 %50 %46 %4 %
Research and development88.1 69.9 26 %214.3 202.8 6 %
% of revenue10 %9 %1 %10 %9 %1 %
Marketing, selling and administrative277.7 192.3 44 %622.5 574.3 8 %
% of revenue31 %25 %6 %29 %25 %4 %
Amortization of intangible assets95.6 50.7 89 %196.2 149.0 32 %
% of revenue11 %7 %4 %9 %7 %3 %
Asset impairment, restructuring and other special charges262.2 77.2 240 %456.4 133.9 241 %
Interest expense, net of capitalized interest48.1 18.7 157 %89.4 60.2 49 %
Other - net, (income) expense(114.9)14.6 NM(161.7)21.1 NM
Income (loss) before income taxes(209.0)(12.5)NM(353.9)82.5 NM
% of revenue(23)%(2)%(21)%(17)%4 %(21)%
Income tax (benefit) expense(74.0)(22.5)NM(116.6)5.1 NM
Net income (loss)$(135.0)$10.0 NM$(237.3)$77.4 NM
Certain amounts and percentages may reflect rounding adjustments.
NM - Not meaningful

40



Revenue

On a global basis, our revenue within our product categories was as follows:
Three Months Ended September 30,Nine Months Ended September 30,
20202019% Change20202019% Change
PH Disease Prevention$297.0 $207.6 43 %$613.6 $616.9 (1)%
PH Therapeutics103.3 87.6 18 %247.1 252.4 (2)%
FA Future Protein & Health180.9 191.5 (6)%518.8 534.5 (3)%
FA Ruminants & Swine292.3 266.2 10 %703.1 811.8 (13)%
Subtotal873.5 752.9 16 %2,082.6 2,215.6 (6)%
Contract Manufacturing(1)
16.1 18.4 (13)%51.0 68.4 (25)%
Total$889.6 $771.3 15 %$2,133.6 $2,284.0 (7)%
(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. This category was previously called Strategic Exits.

Total revenue

Three months ended September 30, 2020 vs. three months ended September 30, 2019

Total revenue increased $118.3 million to $889.6 million comprised of $694.0 million from the legacy Elanco portfolio and $195.6 million from the legacy Bayer Animal Health portfolio. This 15% increase reflects a 14% increase in volume and a 2% increase in price, slightly offset by a less than 1% unfavorable impact from foreign exchange rates.

In summary, the total revenue increase was due primarily to:

•an increase in revenue of $89.7 million or 43% from PH Disease Prevention products, excluding the impact of foreign exchange rates;
•an increase in revenue of $15.1 million or 17% from PH Therapeutics products, excluding the impact of foreign exchange rates; and
•an increase in revenue of $28.1 million or 12% from FA Ruminants & Swine products, excluding the impact of foreign exchange rates;
partially offset by:
•a decrease in revenue of $9.1 million or 4% from FA Future Protein & Health products, excluding the impact of foreign exchange rates;
•a decrease in revenue of $1.9 million or 10% from Contract Manufacturing, excluding the impact of foreign exchange rates; and
•a decrease in revenue of $3.6 million due to the negative impact of foreign exchange rates.

The detailed change in revenue by product category was as follows:

•PH Disease Prevention revenue increased by $89.4 million or 43% for the quarter, driven by an increase in revenue as a result of the addition of Bayer Animal Health product revenue of $99.7 million in the quarter and to a lesser extent, price. The decline in the legacy Elanco business was driven by an unfavorable comparison to the prior year, which included an initial stocking for a new retail customer agreement and a full quarter of revenue for products that were divested during the third quarter of 2020, partially offset by price growth across the portfolio and higher volume from newer generation parasiticide products.
•PH Therapeutics revenue increased by $15.7 million or 18% for the quarter, due to the addition of Bayer Animal Health product revenue of $13.5 million in the quarter and to a lesser extent an increase in price. Growth in the legacy Elanco business was driven by price increases partially
41



offset by a small volume decrease across the portfolio. Increases were partially offset by an unfavorable comparison to the prior period which included an initial stocking for a new retail customer agreement and a full quarter of revenue for products that were divested during the third quarter of 2020.
•FA Future Protein & Health revenue decreased by $10.6 million or 6% for the quarter, driven by lower volume and, to a lesser extent, unfavorable impact from foreign exchange rates, partly offset by an increase in price and the addition of revenue from Bayer Animal Health products in the quarter totaling $15.9 million. Legacy Elanco revenue declined due to lower levels of demand in certain markets due to the negative impact of the COVID-19 pandemic on poultry and aqua consumption, production, and profitability as well as an unfavorable comparison to the prior period as a result of the sellout of the remaining inventory of a product that was phased out in China.
•FA Ruminants & Swine revenue increased by $26.1 million or 10% for the quarter, driven by $61.0 million from the addition of Bayer Animal Health products in the quarter, partially offset by an unfavorable impact from foreign exchange rates and price. In addition, revenue increased due to higher demand in China's swine market with favorable producer economics and positive efforts to repopulate herds impacted by African Swine Fever in 2019. We experienced lower levels of demand for legacy Elanco products due to the negative impact of the COVID-19 pandemic on global protein markets, generic competition, and an unfavorable comparison to the prior period as a result of lower sales from the commercial agreement for Posilac.
•Contract Manufacturing revenue decreased by $2.3 million to $16.1 million, and represented 2% of total revenue. Contract manufacturing revenue for the period includes $5.5 million resulting from the acquisition of Bayer Animal Health.

Nine months ended September 30, 2020 vs. nine months ended September 30, 2019

Total revenue decreased $150.4 million or 7%, reflecting a 7% decrease in volume and a 1% unfavorable impact from foreign exchange rates, partially offset by a 2% increase in price. Revenue attributable to the addition of Bayer Animal Health was $195.6 million.

In summary, the total revenue decrease was due primarily to:

•a decrease in revenue of $4.0 million or 1% from PH Therapeutics products, excluding the impact of foreign exchange rates;
•a decrease in revenue of $3.2 million or 1% from FA Future Protein & Health products, excluding the impact of foreign exchange rates;
•a decrease in revenue of $98.6 million or 12% from FA Ruminants & Swine products, excluding the impact of foreign exchange rates;
•a decrease in revenue of $16.0 million or 23% from Contract Manufacturing, excluding the impact of foreign exchange rates; and
•a decrease in revenue of $28.8 million due to the negative impact of foreign exchange rates;

partially offset by:

•an increase in revenue of $0.2 million or 0% from PH Disease Prevention products.

The detailed change in revenue by product category was as follows:

•PH Disease Prevention revenue decreased by $3.3 million or less than 1%, driven by decreased volume and to a lesser extent an unfavorable impact from foreign exchange rates, partially offset by an increase in price. The volume decline was the result of actions taken across brands to reduce channel inventory levels and decreased demand in veterinary products as a result of the COVID-19 pandemic, primarily in U.S. vaccines and international markets. In addition, revenue decreased due to an unfavorable comparison to the prior period which included an initial stocking for a new retail customer agreement and a full quarter of revenue for products that were divested during the third quarter of 2020. These decreases were partially offset by the addition of Bayer Animal Health
42



products totaling $99.7 million in revenue, including Seresto and the Advantage Family, increases in sales through alternative channels outside vet clinics, price increases across the portfolio, and increased demand for newer generation parasiticide products.
•PH Therapeutics revenue decreased by $5.3 million or 2%, driven by decreased volume and to a lesser extent an unfavorable impact from foreign exchange rates, partially offset by an increase in price. The volume decline was the result of actions taken across brands to reduce channel inventory levels and decreased demand in veterinary products as a result of the COVID-19 pandemic, primarily in veterinarian-administered products and international markets, In addition, the decrease is partially due to an unfavorable comparison to the prior period which included an initial stocking for a new retail customer agreement and a full quarter of revenue for products that were divested during the third quarter of 2020. The decreases are partially offset by revenue from Bayer Animal Health products as a result of the acquisition in the third quarter of 2020 totaling $13.5 million, price increases across the legacy Elanco portfolio and the inclusion of sales for Entyce and Nocita from the acquisition of Aratana beginning in the third quarter of 2019.

•FA Future Protein & Health revenue decreased by $15.7 million or 3%, driven primarily by decreased volume and an unfavorable impact from foreign exchange rates, partially offset by an increase in price. The decline in volume was driven by lower levels of demand in certain markets due to the negative impact of the COVID-19 pandemic on poultry and aqua consumption, production, and profitability as well as an unfavorable comparison to the prior period as a result of the sale of the remaining inventory of a product that was phased out in China. These decreases were partly offset by the addition of revenue of $15.9 million from Bayer Animal Health products in the third quarter of 2020.

•FA Ruminants & Swine revenue decreased by $108.7 million or 13%, driven by decreased volume and to a significantly lesser extent an unfavorable impact from foreign exchange rates. The volume decrease was driven by decreased demand due to the impact of the COVID-19 pandemic on global protein markets, primarily Optaflexx, and actions taken across brands to reduce channel inventory levels, primarily Rumensin. Additionally, volume was impacted by generic competition for Rumensin, trade pressure affecting Paylean, and an unfavorable comparison to the prior period as a result of lower sales from the commercial agreement for Posilac. These decreases were partially offset by the addition of Bayer Animal Health products totaling $61.0 million of revenue. Additionally, higher demand in China's swine market with favorable producer economics and positive efforts to repopulate herds impacted by African Swine Fever in 2019 was a partial offset to other revenue declines.

•Contract Manufacturing revenue decreased by $17.4 million to $51.0 million and represented 2% of total revenue. Contract manufacturing revenue for the period includes $5.5 million resulting from the acquisition of Bayer Animal Health.

Costs and Expenses and Other

Cost of sales

Three months ended September 30, 2020 vs. three months ended September 30, 2019

Cost of sales increased $81.4 million primarily due to higher revenue and the amortization of the fair value adjustment to inventory of approximately $33.1 million due to the acquisition of Bayer Animal Health. We continued to experience manufacturing productivity improvements during the quarter.

Cost of sales as a percent of revenues increased to 49.7% from 46.7%, primarily due to the amortization of the fair value adjustment to inventory of approximately $33.1 million due to the acquisition of Bayer Animal Health along with unfavorable product and geographic mix and unfavorable leverage of fixed manufacturing costs across a lower revenue base, partially offset by continued improvements in manufacturing productivity, increases in price, and the inclusion of Bayer Animal Health margins. Excluding the amortization of the inventory fair value adjustment, cost of sales would have been approximately 45.9% of revenue.

43



Nine months ended September 30, 2020 vs. nine months ended September 30, 2019

Cost of sales increased $10.2 million due primarily to manufacturing productivity improvements and decreased revenue, partially offset by the amortization of the fair value adjustment to inventory of approximately $33.1 million due to the acquisition of Bayer Animal Health.

Cost of sales as a percent of revenues increased to 50.2% from 46.4%, primarily due to the amortization of the fair value adjustment to inventory of approximately $33.1 million due to the acquisition of Bayer Animal Health along with unfavorable product and geographic mix, and unfavorable leverage of fixed manufacturing costs across a lower revenue base, partially offset by continued improvements in manufacturing productivity and increases in price. Excluding the amortization of the inventory fair value adjustment, cost of sales would have been approximately 48.6% of revenue.

Research and development

Three months ended September 30, 2020 vs. three months ended September 30, 2019

R&D expenses increased $18.2 million, primarily due to the acquisition of Bayer Animal Health.

Nine months ended September 30, 2020 vs. nine months ended September 30, 2019

R&D expenses increased $11.5 million, primarily due to the acquisition of Bayer Animal Health, partially offset by strong expense management and adjustments to variable pay.

Marketing, selling and administrative

Three months ended September 30, 2020 vs. three months ended September 30, 2019

Marketing, selling and administrative expenses increased $85.4 million, primarily due to the acquisition of Bayer Animal Health and a shift in certain marketing expenses from the second quarter to the third quarter of 2020, partially offset by disciplined cost management across the business as we have moved primarily to virtual operations due to the COVID-19 pandemic and adjustments to variable pay.

Nine months ended September 30, 2020 vs. nine months ended September 30, 2019

Marketing, selling and administrative expenses increased $48.2 million, primarily due to the acquisition of Bayer Animal Health and additional costs from acquired businesses in 2019, including Aratana and Prevtec, partially offset by disciplined cost management across the business as we have moved primarily to virtual operations due to the COVID-19 pandemic and adjustments to variable pay.

Amortization of intangible assets

Three months ended September 30, 2020 vs. three months ended September 30, 2019

Amortization of intangible assets increased $44.9 million, primarily due to the addition of amortization of intangible assets recorded from the acquisition of Bayer Animal Health during 2020.

Nine months ended September 30, 2020 vs. nine months ended September 30, 2019

Amortization of intangible assets increased $47.2 million, primarily due to the addition of amortization of intangible assets recorded from the acquisition of Bayer Animal Health during 2020.

Asset impairment, restructuring and other special charges

For additional information regarding our asset impairment, restructuring and other special charges, see Note 7: Asset Impairment, Restructuring and Other Special Charges to our condensed consolidated financial statements.

44



Three months ended September 30, 2020 vs. three months ended September 30, 2019

Asset impairment, restructuring and other special charges increased $185.0 million to $262.2 million from $77.2 million, primarily due to severance associated with a restructuring program announced during the three months ended September 30, 2020 as well as higher transaction costs directly related to business acquisitions, including the acquisition of the animal health business of Bayer, higher integration costs of acquisitions, and costs associated with the implementation of new systems, programs, and processes due to the Separation from Lilly and in connection with the acquisition of the animal health business of Bayer, as more fully described in Note 7.

Nine months ended September 30, 2020 vs. nine months ended September 30, 2019

Asset impairment, restructuring and other special charges increased $322.5 million to $456.4 million from $133.9 million, primarily due to severance associated with the restructuring program announced during the three months ended September 30, 2020 as well as higher transaction costs directly related to business acquisitions, including the acquisition of the animal health business of Bayer, higher integration costs of acquisitions, and costs associated with the implementation of new systems, programs, and processes due to the Separation from Lilly and in connection with the acquisition of the animal health business of Bayer, as more fully described in Note 7.

Interest expense, net of capitalized interest

Three months ended September 30, 2020 vs. three months ended September 30, 2019

Interest expense, net of capitalized interest, increased $29.4 million from $18.7 million to $48.1 million, primarily due to incremental interest and debt issuance costs associated with the term loan B used to finance the Bayer Animal Health acquisition, partially offset by gains from the net investment hedge recorded in the third quarter of 2019 that did not recur in the third quarter of 2020 due to its liquidation.

Nine months ended September 30, 2020 vs. nine months ended September 30, 2019

Interest expense, net of capitalized interest, increased $29.2 million from $60.2 million to $89.4 million, primarily due to incremental interest and debt issuance costs associated with the term loan B used to finance the Bayer Animal Health acquisition partially offset by a decrease related to the repayment of indebtedness outstanding under our existing term loan facility during the first quarter of 2020.

Other - net, (income) expense

Three months ended September 30, 2020 vs. three months ended September 30, 2019

Other - net, (income) expense changed by $129.5 million from expense of $14.6 million to income of $114.9 million, primarily as a result of gains recorded on the divestitures of certain products during the three months ended September 30, 2020. See Note 6: Acquisitions and Divestitures for further discussion.

Nine months ended September 30, 2020 vs. nine months ended September 30, 2019

Other - net, (income) expense changed by $182.8 million from expense of $21.1 million to income of $161.7 million, primarily as a result of gains recorded on the divestitures of certain products (see Note 6: Acquisitions and Divestitures for further discussion) as well as the gain on the sale of land and buildings in New South Wales, Australia (see Note 12: Leases for further discussion).

Income tax expense

Three months ended September 30, 2020 vs. three months ended September 30, 2019

Income tax benefit increased $51.5 million, primarily due to a higher pre-tax loss driven mainly by an increase in asset impairment, restructuring and other special charges, which included increased acquisition and integration costs. See Note 13: Income Taxes to our condensed consolidated financial statements.

45



Nine months ended September 30, 2020 vs. nine months ended September 30, 2019

Income tax benefit was $116.6 million during the nine months ended September 30, 2020 as compared to income tax expense of $5.1 million during the nine months ended September 30, 2019, as we generated a pre-tax loss in the current period as compared to pre-tax income in the comparative period in 2019. The pre-tax loss was driven mainly by a decrease in revenue and an increase in asset impairment, restructuring and other special charges, which included increased acquisition and integration costs. See Note 13: Income Taxes to our condensed consolidated financial statements.

Liquidity and Capital Resources

Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our credit facilities. As a significant portion of our business is conducted outside the U.S., we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, following U.S. tax reforms, the income taxes associated with transferring cash to the U.S. As our structure evolves as a standalone company, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.

Our principal liquidity needs going forward include funding existing marketed and pipeline products, capital expenditures, business development in our targeted areas, interest payments and payments on our amortizing notes. We believe our cash and cash equivalents on hand, our operating cash flows and our existing financing arrangements will be sufficient to support our cash needs for the foreseeable future, including for at least the next 12 months. Further, we believe we have sufficient cash flow and liquidity to meet our obligations and remain in compliance with our debt covenants.

Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As markets change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See Item 1A, "Risk Factors" for more information.

Cash Flows

The following table provides a summary of cash flows from operating, investing and financing activities for the periods presented:
Nine Months Ended September 30,$
Net cash provided by (used for):20202019Change
Operating activities$51.9 $97.8 $(45.9)
Investing activities(4,705.9)(160.5)(4,545.4)
Financing activities4,972.2 (298.6)5,270.8 
Effect of exchange-rate changes on cash and cash equivalents7.3 4.1 3.2 
Net increase (decrease) in cash, cash equivalents and restricted cash$325.5 $(357.2)$682.7 

Operating activities

Our cash provided by operating activities decreased by $45.9 million, from $97.8 million for the nine months ended September 30, 2019 to $51.9 million for the nine months ended September 30, 2020. The decrease in operating cash flows was primarily attributable to a decrease in net income, partially offset by decreases in accounts receivable and increases in accounts payable and other current liabilities. The COVID-19 global health pandemic and related economic downturn led to an increase in customer accounts receivable that were past due at the end of the first quarter of 2020; however, customer collections improved in the second and third quarters and payment terms decreased. In the past, we have extended our payment terms for distributors on occasion. Although we presently have no plans to do so in the future, it is possible that we will need to extend payment terms in certain situations as a result of the COVID-19 global health pandemic, competitive pressures and the need for certain inventory levels at our channel distributors to avoid supply disruptions. If so, such extensions of customer payment terms could result in additional uses of our cash flow.
46




Investing activities

Our cash used for investing activities increased by $4,545.4 million, to $4,705.9 million for the nine months ended September 30, 2020 compared to $160.5 million for the nine months ended September 30, 2019. The change was primarily driven by higher acquisition payments resulting from $5,170.1 million of cash consideration paid to acquire Bayer Animal Health offset by cash acquired of $168.8 million, partially offset by proceeds of $421.4 million and $32.7 million from product divestitures required to close the acquisition of Bayer Animal Health and the NIH settlement, respectively.

Financing activities

Our cash provided by financing activities was $4,972.2 million for the nine months ended September 30, 2020 as compared to cash used for financing activities of $298.6 million for the nine months ended September 30, 2019. Cash provided by financing activities during the nine months ended September 30, 2020 reflects proceeds from our borrowings under the term loan B and revolving credit facility and issuances of common stock and TEUs to finance the acquisition of Bayer Animal Health during the period, partially offset by the repayment of indebtedness outstanding under our existing and new credit facilities. Cash used for financing activities during the nine months ended September 30, 2019, reflected the impact of $185.3 million of net cash consideration to Lilly in connection with local country asset purchases and other financing activities related to the Separation.

Description of Indebtedness

For a complete description of our outstanding debt as of September 30, 2020 and December 31, 2019, see Note 10: Debt to our condensed consolidated financial statements.

In connection with the IPO and the acquisition of Bayer Animal Health, we incurred $2.5 billion and $4.2 billion, respectively, of long-term borrowings. We have estimated interest expense of approximately $210 million on an annual basis based on our borrowings as of September 30, 2020.

Critical Accounting Policies

The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. There are certain of our accounting policies that are considered critical, as these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments, often employing the use of estimates about the effects of matters that are inherently uncertain. Such policies are summarized in Item 7, "Management's Discussion & Analysis of Results of Financial Condition and Results of Operations," of our Annual Report on Form 10-K for the year ended December 31, 2019. There have been no significant changes in the application of our critical accounting policies during the nine months ended September 30, 2020.

Contractual Obligations

See Contractual Obligations included in Item 7, "Management's Discussion & Analysis of Results of Financial Condition and Results of Operations," of our Annual Report on Form 10-K for the year ended December 31, 2019.

Payments due under contractual obligations as presented in our Annual Report on Form 10-K for the year ended December 31, 2019 have been updated to include financing related to the acquisition of Bayer Animal Health, as follows:

Years
(Dollars in millions)
Total(1)
Fourth Quarter of 2020
1 - 3 Years
4 - 5 Years
More Than 5 Years
Long-term debt obligations, including interest payments(1)
$7,382.1 $66.3 $1,000.0 $1,892.1 $4,423.7 

(1)Our long-term debt obligations include both our expected principal and interest obligations and our interest rate swaps. We used current period assumptions for interest rates to compute expected interest payments on variable rate debt instruments and swaps.

47



Item 3. Quantitative and Qualitative Disclosures About Market Risk

Foreign Exchange Risk

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to net assets denominated in the British pound, Canadian dollar, Euro, Japanese yen, Swiss franc (CHF), and Chinese renminbi. As part of the TSA, Lilly maintained a foreign currency risk management program through a central shared entity, which entered into derivative contracts to hedge foreign currency risk associated with forecasted transactions for the entire company, including historically for our operations. Gains and losses on derivative contracts entered into by Lilly were previously allocated to our results to the extent they were to cover exposure related to our business and offset gains and losses on underlying foreign currency exposures. We implemented our own foreign currency risk management program and assumed all hedging activities in the second quarter of 2019.

We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables, receivables denominated in foreign currencies and purchases of local subsidiaries due to local regulations as a result of the acquisition of Bayer Animal Health. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates in future periods.

We estimate that a hypothetical 10% adverse movement in all foreign currency exchange rates related to the translation of the results of our foreign operations would decrease our net income by approximately $5.7 million for the nine months ended September 30, 2020.

Interest Risk

Borrowings under our new term loan facility are exposed to interest rate fluctuations based on LIBOR. As of September 30, 2020, we held certain interest rate swap agreements with a notional value of $4.05 billion that have the economic effect of modifying the variable-interest obligations associated with the new term loan Facility, so that a portion of the variable-rate interest payable becomes fixed. During the nine months ended September 30, 2020, we recorded a loss of $67.4 million, net of taxes on these interest rate swaps in other comprehensive loss. The loss is primarily attributable to market conditions resulting from the COVID-19 pandemic and the resulting cut to interest rates by the U.S. Federal Reserve in the first quarter of 2020. See Note 11: Financial Instruments and Fair Value for further information.

Recently Issued Accounting Pronouncements

For discussion of our new accounting standards, see Note 4: Implementation of New Financial Accounting Pronouncements to our condensed consolidated financial statements.

Item 4. Controls and Procedures

(a)Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized, and reported on a timely basis.

Our management, with the participation of Jeffrey N. Simmons, president and chief executive officer, and Todd S. Young, executive vice president and chief financial officer, evaluated our disclosure controls and procedures as of September 30, 2020. Based on this evaluation, the chief executive officer and the chief financial officer concluded that the disclosure controls and procedures are effective.

(b)Changes in Internal Controls. As of September 30, 2020, management is in the process of integrating the internal controls of the acquired Bayer Animal Health business into our existing operations as part of planned integration activities. During the third quarter of 2020, there were no changes in our internal control over financial
48



reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. Other Information

Item 1. Legal Proceedings

See Note 14: Commitments and Contingencies to our condensed consolidated financial statements for a summary of our legal proceedings.

Item 1A. Risk Factors

Other than the revisions set forth below, there have been no material changes from the risk factors disclosed in Part I of our Annual Report on Form 10-K for the year ended December 31, 2019.

We have identified the following additional risk factor which has been updated from the version presented in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020:

The COVID-19 pandemic has had, and is expected to continue to have, an adverse impact on our business, our future results of operations and our overall financial performance.

The COVID-19 pandemic has impacted and may further impact the United States and the broader economies of affected countries, including negatively impacting economic growth, the proper functioning of financial and capital markets, foreign currency exchange rates and interest rates. There continues to be uncertainty around its duration, ultimate impact and the timing of recovery. Therefore, the pandemic has led to extended disruptions, and could continue to result in further disruptions, of economic activity and the impact on our consolidated results of operations, financial position and cash flows could be material.

As a result of the adverse impact that the COVID-19 pandemic is having on our economy and the economies in the countries in which we operate, the pandemic may affect our operations, including our supply chain distribution systems, production levels and research and development activities. In addition, any preventive or protective actions that governments implement or that we adopt in response to the COVID-19 pandemic, such as travel restrictions, quarantines, limited operations of governmental agencies or site closures, may interfere with the ability of our employees, vendors, and suppliers to perform their respective responsibilities and obligations relative to the conduct of our business. In particular, as a result of the COVID-19 pandemic, in-person interactions by our customer-facing professionals could be suspended and certain vet clinics could limit such interactions, especially if the markets in which we operate experience a second wave of the COVID-19 pandemic. Our ability to market our products has been and may continue to be limited, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products. Additionally, government regulations that have been imposed in response to the COVID-19 pandemic may cause delays in the receipt of products, causing delays in our global supply chain, delaying the transportation of finished goods, disrupting our freight processes, which would result in higher shipping costs, and causing resources to be diverted that are necessary to administer certain of our products. In addition, some research and development projects could be impacted based on need for the reagents from suppliers and clinical trial activity requiring veterinary clinic access and support. Furthermore, social distancing guidelines could have an adverse impact on our research and development activities as our laboratories are not operating at full capacity.

Our customers, and therefore our business and revenues, are sensitive to negative changes in economic conditions. As a result, we have experienced declines in revenue in 2020, including in our pet health business as social distancing guidelines have decreased veterinary visits and have reduced veterinary practice spending. In addition, there have been a number of shutdowns of processing plants as a result of COVID-19 outbreaks within their operations, and there could be more of these shutdowns, which, in turn, have led and may lead to a further decrease in demand for our customers’ livestock. Such shutdowns could not only lead to a decrease in demand for our products, but could also significantly impact their ability to pay for our products. In addition, an effort by dairy farmers to decrease milk production could negatively impact demand for Rumensin. We expect the negative impacts of the COVID-19 pandemic on our revenue will continue until conditions relating to the overall impact of COVID-19 on all aspects of the economy and life in general improve.

49



The impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. Additionally, our suppliers and third party distributors may face difficulties maintaining operations and normal liquidity in light of government-mandated restrictions. Further, the resulting global economic downturn may negatively impact the ability of certain of our customers to make payments on a timely basis, adversely impacting our cash flows from operations. While our liquidity has not been significantly impacted by delayed collections thus far, we do not yet know the full extent of the impact of the COVID-19 pandemic and its resulting economic impact, which could have a material adverse effect on our liquidity, capital resources, operations and business.

We are also monitoring the impact of COVID-19 on our talent recruitment and retention efforts. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. The loss or limited availability of the services of one or more of our executive officers or other key personnel, or our inability to recruit and retain qualified executive officers or other key personnel in the future, could, at least temporarily, have a material adverse effect on our business, financial condition and results of operations. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including delays in the recruiting and hiring process as a result of the COVID-19 pandemic.

Our business, financial condition and results of operations could be materially adversely affected by unfavorable results in future employment litigation matters as result of COVID-19. Our employees may sue us due to possible exposure to COVID-19 while working at one of our facilities or sites. In addition, employees may challenge decisions to implement protective measures such as contact tracing on the basis of local privacy laws due to the increased collection of employee medical information. Litigation matters, regardless of their merits or their ultimate outcomes, are costly, divert management’s attention and may materially adversely affect our reputation and demand for our products. We cannot predict with certainty the eventual outcome of pending or future litigation matters. An adverse outcome of litigation or legal matters could result in us being responsible for paying significant damages. Any of these negative effects resulting from litigation matters could materially adversely affect our business, financial condition or results of operations. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019.

Business continuity of the Bayer Animal Health business may be disrupted if conflicts arise with Bayer under the TSA and other long-term agreements.

To ensure business continuity after the transfer of the Bayer Animal Health business, we entered into TSAs and other long-term agreements with Bayer. Bayer’s performance of its obligations under such long-term agreements is critical to our transition of the Bayer Animal Health business. Our inability to resolve conflicts with Bayer that may arise under those long-term agreements could compromise our ability to successfully integrate the Bayer Animal Health business. We may also encounter difficulties in securing another vendor to provide us with those same services, which could adversely affect our business, financial condition or results of operations.

The following risk factors have changed from the risk factors that were disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019:

An outbreak of infectious disease carried by farm animals could negatively affect the demand for, and sale and production of, our farm animal products.

Sales of our farm animal products could be materially adversely affected by the outbreak of disease or an outbreak carried by farm animals, which could lead to the widespread death or precautionary destruction of farm animals as well as the reduced consumption and demand for animal protein. In addition, outbreaks of disease carried by farm animals may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our farm animal products due to reduced herd or flock sizes.

In recent years, outbreaks of various diseases, including African Swine Fever, avian influenza, foot-and-mouth disease, bovine spongiform encephalopathy (otherwise known as BSE or “mad cow” disease) and porcine epidemic diarrhea virus (otherwise known as PEDV) have negatively impacted sales of our animal health products. The discovery of additional cases of any of these, or new, diseases may result in additional restrictions on animal protein, reduced herd or flock sizes, or reduced demand for animal protein, any of which may have a material adverse effect on our business, financial condition and results of operations. In addition, the outbreak of any highly
50



contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere.

We may be unable to integrate the Bayer Animal Health business successfully and realize the anticipated benefits of the Acquisition.

The successful integration of the Bayer Animal Health business and operations into those of our own and our ability to realize the expected synergies and benefits of the transaction is subject to a number of risks and uncertainties, many of which are outside of our control. We will also be required to devote significant management attention and resources to integrating business practices, cultures and operations of each business. The risks and uncertainties relating to integrating the two businesses and realizing the anticipated cost synergies include, among other things:

•the inability to achieve the anticipated revenue, earnings, accretion and other benefits due to the impact of the COVID-19 global health pandemic;

•the challenge of integrating complex organizations, systems, including the enterprise resource planning system upon which the Bayer Animal Health business is currently operating, operating procedures, compliance programs, technology, networks and other assets of the Bayer Animal Health business;

•the difficulties harmonizing differences in the business cultures of our company and the Bayer Animal Health business;

•the inability to combine successfully our respective businesses in a manner that permits us to achieve the cost savings, synergies and other anticipated benefits from the acquisition;

•the inability to minimize the diversion of management attention from ongoing business concerns during the process of integrating the Bayer Animal Health business into our businesses;

•the inability to resolve potential conflicts that may arise relating to customer, supplier and other important relationships of our business and the Bayer Animal Health business;

•the inability to transfer agreements relating to customers, suppliers and other important relationships of the Bayer Animal Health business;

•difficulties in retaining key management and other key employees;

•the challenge of managing the expanded operations of a significantly larger and more complex company and coordinating geographically separate organizations; and

•difficulties in fully exploring intellectual property licensed from Bayer in connection with the acquisition, given Bayer's rights as licensor of such intellectual property.

We have incurred substantial expenses to consummate and will continue to incur substantial expenses to integrate the acquisition but may not realize the anticipated cost synergies and other benefits to the extent expected, on the timeline expected, or at all. In addition, even if we are able to integrate the Bayer Animal Health business successfully, the anticipated benefits of the acquisition may not be realized fully, or at all, or may take longer to realize than expected. Moreover, competition in the animal health industry, including competition that has negatively impacted results in the pet health parasiticide market, may also cause us not to fully realize the anticipated benefits of the acquisition. Given the size and significance of the acquisition, we may encounter difficulties in the integration of the operations of the Bayer Animal Health business and may fail to realize the full benefits and synergies of the acquisition, which could adversely impact our business, results of operation and financial condition.

51



The illegal distribution and sale by third parties of counterfeit or illegally compounded versions of our products or of stolen, diverted or relabeled products could have a negative impact on our reputation and business.

Third parties may illegally distribute and sell counterfeit or illegally compounded versions of our products that do not meet the exacting standards of our development, manufacturing and distribution processes. Counterfeit or illegally compounded medicines pose a significant risk to animal health and safety because of the conditions under which they are manufactured and the lack of regulation of their contents. Counterfeit or illegally compounded products are frequently unsafe or ineffective and can be potentially life-threatening to animals. Our reputation and business could suffer harm as a result of counterfeit or illegally compounded products which are alleged to be equivalent and/or which are sold under our brand name. In addition, products stolen or unlawfully diverted from inventory, warehouses, plants or while in transit, which are not properly stored or which have an expired shelf life and which have been repackaged or relabeled and which are sold through unauthorized channels, could adversely impact animal health and safety, our reputation and our business. With the acquisition of the Bayer Animal Health business, we have now expanded our business more into direct to retailer and e-commerce channels in order to meet the pet owners where they want to purchase, which may increase the risk of counterfeiting of our products. Public loss of confidence in the integrity of vaccines and/or pharmaceutical products as a result of counterfeiting, illegal compounding or theft could have a material adverse effect on our business, financial condition and results of operations.

Breaches of our information technology systems or improper disclosure of confidential company or personal data, or a failure to comply with privacy laws, regulations and our contractual obligations concerning data privacy or the security of certain information could have a material adverse effect on our reputation and operations.

We rely on information technology systems to process, transmit and store electronic information in our day-to-day operations, including customer, employee and company data. The secure processing, maintenance and transmission of this information is critical to our operations. In addition, the legal environment surrounding information security, storage, use, processing, transmission, maintenance, disclosure and privacy is demanding with the frequent imposition of new and changing regulatory requirements.

We are generally dependent upon our technology systems to operate our business in normal periods, but in the wake of the COVID-19 global pandemic, we are increasingly dependent on our information technology systems as our office workers, who are working remotely, rely on third-party applications to host a greater number of video conferences and teleconferences, and are processing information through our network via their home networks, which may be less secure. As such, our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data and the ability of our employees to follow our cyber security policies and protocols, including, but not limited to, the use of VPN when remotely working on company matters, and other security protocols when using various video conferencing and teleconferencing applications, especially in light of the increased use of these tools due to the COVID-19 global pandemic.

We also store certain information with third parties, including the use of cloud technologies. Our information systems and those of our third-party vendors are subjected to computer viruses or other malicious codes, unauthorized access attempts, and cyber or phishing-attacks and also are vulnerable to an increasing threat of continually evolving cybersecurity risks and external hazards, as well as improper or inadvertent staff behavior, all of which could expose confidential company and personally identifiable information, as well as technology, networks, or infrastructure. Any such breach could compromise our networks, including a breach caused by a failure by our employees, working remotely or otherwise, to use such security policies and protocols, which could result in the loss of confidential company data, or an intrusion or business interruption by hackers that are able to access the company’s network or meetings taking place via video conferencing or teleconferencing, and the information stored or in the process of being transmitted or communicated could be accessed, publicly disclosed, lost or stolen. Any such loss or misappropriation of company data or other intrusion could cause a disruption of our operations and other negative consequences, such as increased costs for security measures or remediation costs, and diversion of management attention.

Any actual or perceived access, disclosure or other loss of information or any significant breakdown, intrusion, interruption, cyber-attack or corruption of customer, employee or company data or our failure to comply with federal, state, local and foreign privacy laws or contractual obligations with customers, vendors, payment processors and other third parties, could result in legal claims or proceedings, liability under laws or contracts that protect the privacy of personal information, regulatory penalties, disruption of our operations, and damage to our reputation, all
52



of which could materially adversely affect our business, revenue and competitive position. While we will continue to implement additional protective measures to reduce the risk of and detect cyber-incidents, cyber-attacks are becoming more sophisticated and frequent, and the techniques used in such attacks change rapidly. Our protective measures may not protect us against attacks and such attacks could have a significant impact on our business and reputation. In addition, due to a TSA with Lilly, we rely on Lilly for certain privacy, compliance, and security functions, and personnel, and may experience difficulties maintaining and implementing all policies and practices following completion of the TSA for these services.

We may incur substantial costs and receive adverse outcomes in litigation and other legal matters.

Our business, financial condition and results of operations could be materially adversely affected by unfavorable results in pending or future litigation matters. These matters may include, among other things, allegations of violation of U.S. and foreign competition law, labor laws, consumer protection laws and environmental laws and regulations, as well as claims or litigation relating to product liability, intellectual property, securities, breach of contract and tort. For example, we have recently had filed against us shareholder class action lawsuits that allege, in part, that we and certain of our executives made materially false and/or misleading statements and/or failed to disclose certain facts about our supply chain, inventory, revenue, projections and our relationships with third party distributors and revenue attributable to those distributors. We intend to vigorously defend the claims made in these lawsuits, however, the ultimate resolution cannot be predicted and the claims raised in these lawsuits may result in further legal matters or actions against us, including, but not limited to, government enforcement actions or additional private litigation. In addition, changes in the interpretations of laws and regulations to which we are subject, or in legal standards in one or more of the jurisdictions in which we operate, could increase our exposure to liability. For example, in the U.S., attempts have been made to allow damages for emotional distress and pain and suffering in connection with the loss of, or injury to, a companion animal. If such attempts were successful, our exposure with respect to product liability claims could increase materially.

Litigation matters, regardless of their merits or their ultimate outcomes, are costly, divert management’s attention and may materially adversely affect our reputation and demand for our products. We cannot predict with certainty the eventual outcome of pending or future litigation matters. An adverse outcome of litigation or legal matters could result in us being responsible for significant damages. Any of these negative effects resulting from litigation matters could materially adversely affect our business, financial condition and results of operations.
53



Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(none)

Item 3. Defaults Upon Senior Securities

(none)

Item 4. Mine Safety Disclosures

(none)

Item 5. Other Information

(none)
54



Item 6. Exhibits

The following exhibits are either filed or furnished herewith (as applicable) or, if so indicated, incorporated by reference to the documents indicated in parentheses, which have previously been filed or furnished with the Securities and Exchange Commission.
Exhibit NumberDescription
2.1 
10.1 
31.1 
31.2 
32 
101 Interactive Data Files
104 Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101)

55



Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
ELANCO ANIMAL HEALTH INCORPORATED
(Registrant)
Date:November 6, 2020/s/ Jeffrey N. Simmons
Jeffrey N. Simmons
President and Chief Executive Officer
Date:November 6, 2020/s/ Todd S. Young
Todd S. Young
Executive Vice President, Chief Financial Officer

56
 EX-31.1 2 ex311elanco-20200930xceoce.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATIONS
I, Jeffrey N. Simmons, certify that:
1.    I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date:November 6, 2020
By:/s/Jeffrey N. Simmons
 Jeffrey N. Simmons
 President and Chief Executive Officer


 EX-31.2 3 ex312elanco-20200930xcfoce.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATIONS
I, Todd S. Young, certify that:
1.    I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date:November 6, 2020
By:/s/Todd S. Young
 Todd S. Young
 Executive Vice President and Chief Financial Officer


 EX-32 4 ex32elanco-20200930xsectio.htm EX-32 Document

EXHIBIT 32
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Elanco Animal Health Incorporated, an Indiana corporation (the “Company”), does hereby certify that, to the best of their knowledge:
The Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:November 6, 2020/s/Jeffrey N. Simmons
 Jeffrey N. Simmons
 President and Chief Executive Officer
 
Date:November 6, 2020/s/Todd S. Young
 Todd S. Young
 Executive Vice President and Chief Financial Officer


 EX-101.SCH 5 elan-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Nature of Business and Organization link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Nature of Business and Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Impact of Separation link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Impact of Separation (Details) link:presentationLink link:calculationLink link:definitionLink 2107104 - Disclosure - Implementation of New Financial Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2110105 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2115106 - Disclosure - Acquisitions and Divestitures link:presentationLink link:calculationLink link:definitionLink 2316303 - Disclosure - Acquisitions and Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - Acquisitions and Divestitures - Purchase Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Acquisitions and Divestitures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Acquisitions and Divestitures - Carrying Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Acquisitions and Divestitures - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Acquisitions and Divestitures - Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 2423413 - Disclosure - Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2124107 - Disclosure - Asset Impairment, Restructuring and Other Special Charges link:presentationLink link:calculationLink link:definitionLink 2325304 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2427415 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 2129108 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2330305 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2431417 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2132109 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2333306 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2434418 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2435419 - Disclosure - Equity - Schedule of Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2136110 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2337307 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2438420 - Disclosure - Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2438420 - Disclosure - Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2440422 - Disclosure - Debt - Maturity of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2141111 - Disclosure - Financial Instruments and Fair Value link:presentationLink link:calculationLink link:definitionLink 2342308 - Disclosure - Financial Instruments and Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 2443423 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2444424 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details) link:presentationLink link:calculationLink link:definitionLink 2445425 - Disclosure - Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2146112 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2447426 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2148113 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2349309 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2450427 - Disclosure - Income Taxes - Provision for Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 2451428 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2152114 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2453429 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2154115 - Disclosure - Geographic Information link:presentationLink link:calculationLink link:definitionLink 2355310 - Disclosure - Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2456430 - Disclosure - Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2457431 - Disclosure - Geographic Information - Revenue by Selected Geographic Area Information (Details) link:presentationLink link:calculationLink link:definitionLink 2458432 - Disclosure - Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details) link:presentationLink link:calculationLink link:definitionLink 2159116 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2460433 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2161117 - Disclosure - Related Party Agreements and Transactions link:presentationLink link:calculationLink link:definitionLink 2362311 - Disclosure - Related Party Agreements and Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 2463434 - Disclosure - Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details) link:presentationLink link:calculationLink link:definitionLink 2464435 - Disclosure - Related Party Agreements and Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 elan-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 elan-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 elan-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Other Immaterial Divestitures Other Immaterial Divestitures [Member] Other Immaterial Divestitures Related Party [Axis] Related Party [Axis] Germany GERMANY Other net financing transactions with Lilly Proceeds From (Payments To) Transactions With Parent Proceeds From (Payments To) Transactions With Parent In-Process Research and Development In Process Research and Development [Member] Debt issuance costs Debt Issuance Costs, Noncurrent, Net Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Aratana measurement period adjustments Goodwill, Purchase Accounting Adjustments Mark-up rate Related Party Transaction, Mark-Up Rate Related Party Transaction, Mark-Up Rate Debt financing costs Debt Issuance Costs, Gross Range [Domain] Statistical Measurement [Domain] Liabilities and Equity Liabilities and Equity [Abstract] Credit Facility Credit facility Line of Credit [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Deferred taxes Deferred Income Tax Liabilities, Net Current Fiscal Year End Date Current Fiscal Year End Date Other intangibles, net (Note 6) Intangible Assets, Net (Excluding Goodwill) Term loan B credit facility Term B Loan Facility [Member] Term B Loan Facility Long-lived Assets by Selected Geographic Area Information Long-lived Assets by Geographic Areas [Table Text Block] Debt issuance costs Payments of Debt Issuance Costs Entity Address, Postal Zip Code Entity Address, Postal Zip Code Total current liabilities Liabilities, Current Severance and other costs Severance Costs Summary of Activity in Sales Rebates and Discounts Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Prepaid expenses and other Prepaid Expense and Other Assets, Current Variable Rate [Domain] Variable Rate [Domain] Variable Rate [Axis] Variable Rate [Axis] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and Contingencies (Note 14) Commitments and Contingencies Issuance of stock under employee stock plans, net Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Assets Assets [Abstract] Entity Shell Company Entity Shell Company Payable to Lilly (Note 17) Due to Related Parties, Current Cover [Abstract] Accounts payable Accounts Payable, Current Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Document Type Document Type 2023 Long-Term Debt, Maturity, Year Three Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Vecoxan Vecoxan [Member] Vecoxan Retained earnings (accumulated deficit) Decrease due to adoption Retained Earnings (Accumulated Deficit) Operating lease, right-of-use asset Operating Lease, Right-of-Use Asset Debt extinguishment loss Gain (Loss) on Extinguishment of Debt Unused commitment fee Debt Instrument, Unused Borrowing Capacity, Fee Average useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Issuance of common stock, net of issuance costs (in shares) Shares Issued, Shares, Share-based Payment Arrangement, Forfeited Fair value used in estimate Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Used In Estimate Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Used In Estimate Commitments and Contingencies Legal Matters and Contingencies [Text Block] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Customer [Axis] Customer [Axis] Product Return Concentration Risk Product Return Concentration Risk [Member] Product Return Concentration Risk [Member] Balance at beginning of period (in shares) Balance at end of period (in shares) Shares, Outstanding Preferred stock, no par value, 1,000,000,000 shares authorized; none issued Preferred Stock, Value, Issued Pet Health Disease Prevention Pet Health Disease Prevention [Member] Pet Health Disease Prevention [Member] Income Tax Income Tax, Policy [Policy Text Block] Hedging Designation [Domain] Hedging Designation [Domain] Contingent consideration Nonfinancial Liabilities Fair Value Disclosure Document Quarterly Report Document Quarterly Report Restructuring charges: Restructuring, Settlement and Impairment Provisions [Abstract] Other noncurrent liabilities Other Liabilities, Noncurrent Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other investing activities, net Payments for (Proceeds from) Other Investing Activities Stock compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Non-cash and other items: Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract] Inventories (Note 8) Inventories Inventory, Net Thereafter Long-Term Debt, Maturity, after Year Five Revenue Revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Worldwide rights to Osurnia and U.S. rights to Capstar Worldwide Rights To Osurnia And U.S. Rights To Capstar [Member] Worldwide Rights To Osurnia And U.S. Rights To Capstar Concentration risk (less than 0.1%) Concentration risk (as a percent) Concentration Risk, Percentage Entity File Number Entity File Number Business Acquisition [Axis] Business Acquisition [Axis] Geographical [Domain] Geographical [Domain] Inventory [Axis] Inventory [Axis] Statement [Line Items] Statement [Line Items] Issuance for acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Class of Stock [Domain] Class of Stock [Domain] Debt maturity term Debt Instrument, Term Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Document Fiscal Period Focus Document Fiscal Period Focus TSA TSA Transitional Services Agreement [Member] Transitional Services Agreement [Member] Transaction costs Business Combination, Acquisition Related Costs Statement [Table] Statement [Table] Type of Restructuring [Domain] Type of Restructuring [Domain] Range [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Payments Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts Repayments of borrowings (Note 10) Repayments of Long-term Lines of Credit Bayer Animal Business Bayer Animal Business [Member] Bayer Animal Business Number of countries expected to eliminate positions Restructuring And Related Cost, Number Of Countries Expected to Eliminate Positions Restructuring And Related Cost, Number Of Countries Expected to Eliminate Positions Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Business Combinations [Abstract] Consolidation Consolidation, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Number of shares issued (in shares) Number of shares sold in public offering Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Debt Debt Disclosure [Text Block] Term loan B Loans Payable, Fair Value Disclosure Goodwill [Roll Forward] Goodwill [Roll Forward] Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] 4.900% Senior Notes due 2028 4.9% Senior Notes Due 2028 [Member] 4.9% Senior Notes Due 2028 [Member] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Amendment Flag Amendment Flag Outstanding debt Long-term Line of Credit Debt repaid Repayments of Debt Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Related Party [Domain] Related Party [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Long Lived Assets Held-for-sale, Name [Domain] Long Lived Assets Held-for-sale, Name [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Cash Flow Hedge Gain (Loss) Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] United Kingdom UNITED KINGDOM Derivative Instrument [Axis] Derivative Instrument [Axis] Total payable to Lilly Receivable from, payable (to) related party Related Party Transaction, Due from (to) Related Party Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Net gain (loss) on derivative instruments Derivative, Gain (Loss) on Derivative, Net Other noncurrent liabilities Other Noncurrent Liabilities [Member] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Due from related party Due from Related Parties Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities Senior Notes Senior Notes [Member] Geographical [Axis] Geographical [Axis] Local Phone Number Local Phone Number Number of brands in diverse portfolio Number Of Brands In Entity's Portfolio Number Of Brands In Entity's Portfolio Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Loss before income taxes Business Acquisition, Pro Forma Net Income (Loss) 2024 Long-Term Debt, Maturity, Year Four Common stock equivalents included in weighted average diluted shares outstanding (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Lilly Majority Shareholder [Member] Income Statement Location [Axis] Income Statement Location [Axis] Other intangibles, net Disposal Group, Including Discontinued Operation, Intangible Assets Accounts receivable, net of allowances Accounts Receivable, Allowance for Credit Loss, Current Issuance for acquisition Stock Issued During Period, Value, Acquisitions Income Statement Location [Domain] Income Statement Location [Domain] Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Expected reclassification from accumulated other comprehensive loss Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Marketing, selling and administrative Selling, General and Administrative Expense Bayer Animal Health at acquisition Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Notional amount (USD, CHF) Derivative, Notional Amount Amortization of intangible assets Amortization of Intangible Assets Cross-currency fixed interest rate swap Foreign exchange contracts not designated as hedging instruments Foreign Exchange Contract [Member] Entity Current Reporting Status Entity Current Reporting Status Other noncurrent assets Other Assets, Noncurrent Geographic Information Segment Reporting Disclosure [Text Block] Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Amount offsetting interest expense Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Concentration Risk [Table] Concentration Risk [Table] Total assets Assets Related Party Agreements and Transactions Related Party Transactions Disclosure [Text Block] Net Revenue Revenue from Contract with Customer Benchmark [Member] Capstar Capstar [Member] Capstar Accounts payable and accrued liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Other Current Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Other Current Assets Acquired in-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Required ratio of pro forma adjusted EBITDA to cash interest expense (no less than) Required Ratio Of Pro Forma Adjusted EBITDA To Cash Interest Expense Required Ratio Of Pro Forma Adjusted EBITDA To Cash Interest Expense Disposal Group Classification [Axis] Disposal Group Classification [Axis] Long-lived assets Long-Lived Assets Facility exit costs Business Exit Costs Settlements and other Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Subsequent Event Type [Axis] Subsequent Event Type [Axis] Entity Small Business Entity Small Business Interest expense, net of capitalized interest (Note 10) Interest Expense Farm Animal Ruminants & Swine Farm Animal Ruminants And Swine [Member] Farm Animal Ruminants And Swine [Member] Acquisitions and Divestitures Mergers, Acquisitions and Dispositions Disclosures [Text Block] Total net proceeds, after underwriting discounts and commissions Proceeds after underwriting discounts and commissions Net proceeds Sale of Stock, Consideration Received on Transaction Other Stockholders' Equity, Other Depreciation and amortization Depreciation, Depletion and Amortization Entity Filer Category Entity Filer Category Interest percentage Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Provision for Taxes on Income Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Other intangible assets Other Intangible Assets [Member] Description of Accounting Standards Adopted and Not Yet Adopted Accounting Standards Update and Change in Accounting Principle [Table Text Block] Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Entity Address, City or Town Entity Address, City or Town Cross currency interest rate contracts designated as net investment hedges Cross Currency Interest Rate Contract [Member] Other noncurrent assets Other Noncurrent Assets [Member] Long-term debt - term credit facility Lines of Credit, Fair Value Disclosure Next Largest Country International Non-US [Member] Interest included in cash benefit Derivative Instruments, Liquidated For Cash Benefit, Interest, Amount Derivative Instruments, Liquidated For Cash Benefit, Interest, Amount 2022 Long-Term Debt, Maturity, Year Two Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Separation activities Stockholders' Equity, Separation Adjustments Stockholders' Equity, Separation Adjustments Reduction of revenue Contract with Customer, Liability, Revenue Recognized Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Osurnia Osurnia [Member] Osurnia Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Document Fiscal Year Focus Document Fiscal Year Focus Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Total Inventory, Gross Purchase Consideration Schedule of Business Acquisitions, by Acquisition [Table Text Block] Other liabilities due to affiliate Due To Affiliate, Other Liabilities, Current Due To Affiliate, Other Liabilities, Current Accelerated vesting of equity awards APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Accelerated Vesting APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Accelerated Vesting Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Quarterly cash installment per amortizing note Debt Instrument, Periodic Payment Per Amortizing Note Debt Instrument, Periodic Payment Per Amortizing Note Settlement of existing contingent consideration liabilities Payment for Contingent Consideration Liability, Investing Activities Changes in operating assets and liabilities, net of acquisitions Increase (Decrease) in Operating Capital Adjustments to reconcile net income (loss) to cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Equity method investments Equity Method Investments Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] TEU amortizing note Convertible Debt, Fair Value Disclosures Other foreign countries Other Foreign Countries Not Separately Disclosed [Member] Other Foreign Countries Not Separately Disclosed [Member] Senior Unsecured Revolving Credit Facility Revolving credit facility Revolving Credit Facility [Member] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development Research and Development Expense Term of contract Derivative, Term of Contract IPO IPO [Member] Transaction and integration costs Business Combination, Integration Related Costs Aratana Aratana Therapeutics, Inc. [Member] Aratana Therapeutics, Inc. [Member] Subsequent Event Subsequent Event [Member] Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Cash paid for acquisitions, net of cash acquired (Note 6) Payments to Acquire Businesses, Net of Cash Acquired Common stock, shares authorized (in shares) Common Stock, Shares Authorized Concentration Risk Type [Axis] Concentration Risk Type [Axis] Revenue by Selected Geographic Area Information Revenue from External Customers by Geographic Areas [Table Text Block] Business combination, inventories, step-up fair value adjustment Business Combination, Inventories, Step-Up Fair Value Adjustment Business Combination, Inventories, Step-Up Fair Value Adjustment Restructuring Plan [Domain] Restructuring Plan [Domain] Prevtec Prevtec Microbia, Inc. [Member] Prevtec Microbia, Inc. [Member] Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Fair Value Estimate of Fair Value Measurement [Member] Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Over-Allotment Option Over-Allotment Option [Member] 2.75% Senior Amortizing Notes 2.75% Senior Amortizing Notes [Member] 2.75% Senior Amortizing Notes Finite lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Defined benefit pension and retiree health benefit plans, net of taxes Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Assets held for sale Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Held For Sale Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Held For Sale First installment payment per amortizing note Debt Instrument, First Periodic Payment Per Amortizing Note Debt Instrument, First Periodic Payment Per Amortizing Note Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Unamortized debt issuance costs and other obligations Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Current Assets Assets, Current [Abstract] Rights To The Profender And Drontal Rights To The Profender And Drontal Product Families [Member] Rights To The Profender And Drontal Product Families Marketed products Marketing-Related Intangible Assets [Member] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2021 Long-Term Debt, Maturity, Year One Debt repaid, interest Repayments Of Long Term Debt, Accrued Interest Repayments Of Long Term Debt, Accrued Interest Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Number of countries in which entity operates (more than) Number of Countries in which Entity Operates Purchases of software Payments for Software Net proceeds from sale (purchases) of property and equipment Payments to Acquire Property, Plant, and Equipment Document Information [Line Items] Document Information [Line Items] Entity Tax Identification Number Entity Tax Identification Number Contingent consideration liability Business Combination, Contingent Consideration, Liability Implementation of New Financial Accounting Pronouncements Accounting Changes and Error Corrections [Text Block] Net Investment Hedging Net Investment Hedging [Member] Percentage of total outstanding shares Sale of Stock, Percentage of Ownership before Transaction 4.272% Senior Notes due 2023 4.272% Senior Notes Due 2023 [Member] 4.272% Senior Notes Due 2023 [Member] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Trading Symbol Trading Symbol Hedging Designation [Axis] Hedging Designation [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Proceeds from issuance of long-term debt (Note 10) Proceeds from Issuance of Senior Long-term Debt Other obligations Notes Payable, Other Payables [Member] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Volume weighted average stock price as of the last day of trading before the closing of the acquisition duration Business Combination, Volume Weighted Average Stock Price As Of Last Day Of Trading Before Closing Acquisition Duration Business Combination, Volume Weighted Average Stock Price As Of Last Day Of Trading Before Closing Acquisition Duration Fourth quarter of 2020 Long-Term Debt, Maturity, Remainder of Fiscal Year Other financing activities, net Proceeds from (Payments for) Other Financing Activities Designated as Hedging Instrument Designated as Hedging Instrument [Member] Common Stock Offering Common Stock Offering [Member] Common Stock Offering Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan [Member] Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan Total Charges Related to Asset Impairment, Restructuring and Other Special Charges Restructuring and Related Costs [Table Text Block] Additions related to the Bayer Animal Health acquisition Goodwill, Acquired During Period Reserve adjustments Restructuring Reserve, Accrual Adjustment Other noncurrent assets and liabilities - net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Noncurrent Assets And Other Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Noncurrent Assets And Other Liabilities, Net Inventories Inventories [Member] Acquisition related charges: Asset Impairment Charges [Abstract] Settlement rate Tangible Equity Unit, Settlement Rate Tangible Equity Unit, Settlement Rate Bayer Affiliated Entity [Member] Net proceeds Total debt Long-term Debt in Process in Process [Member] in Process Leases Lessee, Operating Leases [Text Block] Sale leaseback gain Sale and Leaseback Transaction, Gain (Loss), Net Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Partial payment on principal and interest Debt Instrument, Payment, Principal And Interest Debt Instrument, Payment, Principal And Interest Consideration paid to Lilly in connection with the Separation (Note 1) Payments Of Separation Related Costs, Financing Activities Payments Of Separation Related Costs, Financing Activities City Area Code City Area Code Galliprant Galliprant [Member] Galliprant Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of sales Cost of Goods and Services Sold Costs, expenses and other Costs and Expenses Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member] Proceeds from issuance of common stock and tangible equity units (Note 9) Gross proceeds Proceeds from Issuance or Sale of Equity Equity Components [Axis] Equity Components [Axis] Unrealized loss on derivatives for cash flow hedges, net of taxes Loss on cash flow hedge, net of tax benefit Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Title of 12(b) Security Title of 12(b) Security Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Gain, net of tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Summary of Fair Value Information Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Gain on sale of assets Gain (Loss) on Disposition of Other Assets United States United States UNITED STATES Financial Instruments and Fair Value Fair Value Disclosures [Text Block] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Impact of Separation Equity Stockholders' Equity Note Disclosure [Text Block] Customer [Domain] Customer [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Finished Products Finished Goods [Member] Finished Goods Concentration Risk [Line Items] Concentration Risk [Line Items] Debt Component Tangible Equity Unit, Debt Component [Member] Tangible Equity Unit, Debt Component Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) Applicable Market Value (usd per share) Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share Unamortized debt issuance costs Debt Issuance Costs, Net Loss upon settlement of contingent consideration liability Decrease of fair value of contingent consideration liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Asset Impairment, Restructuring and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Symmetrical collar (as a percent) Business Combination, Consideration Transferred, Symmetrical Collar Business Combination, Consideration Transferred, Symmetrical Collar Weighted average commons shares included in calculation of basic earnings per share (in shares) Weighted Average Number of Shares Issued, Basic Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Held for Sale Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Goodwill impairment Goodwill, Impairment Loss Accounts receivable, net of allowances of $8.8 (2020) and $6.2 (2019) Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Finished products Inventory, Finished Goods, Gross Other assets and liabilities - net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets And Other Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets And Other Liabilities, Net Balance at beginning of period Balance at end of period Restructuring Reserve Gain on sale of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Drontal and Profender Drontal and Profender [Member] Drontal and Profender Sale of Stock [Axis] Sale of Stock [Axis] Sale leaseback lease payments Operating Lease, Lease Income, Lease Payments Payments made to date Separation Related Costs, Financing Activities, Payments Made To Date Separation Related Costs, Financing Activities, Payments Made To Date Restructuring Type [Axis] Restructuring Type [Axis] Cash paid Payments for Restructuring Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Divestiture transaction costs Disposal Group, Including Discontinued Operation, Transaction Costs Disposal Group, Including Discontinued Operation, Transaction Costs Debt instrument, face amount Debt Instrument, Face Amount Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Sale leaseback initial lease term Lessor, Sales-type Lease, Term of Contract Decrease to LIFO cost Inventory, LIFO Reserve Settlement of accounts receivable Business Combination, Consideration Transferred, Settlement Of Accounts Receivable Business Combination, Consideration Transferred, Settlement Of Accounts Receivable Schedule of Goodwill Schedule of Goodwill [Table Text Block] Equity [Abstract] Equity [Abstract] Basis of Presentation and Summary of Significant Accounting Policies Basis of Accounting [Text Block] Pet Health Therapeutics Pet Health Therapeutics [Member] Pet Health Therapeutics [Member] Entity Central Index Key Entity Central Index Key Divested assets, fair value Divested Assets, Fair Value Divested Assets, Fair Value Sales rebates and discounts Contract with Customer, Liability, Current Entity Emerging Growth Company Entity Emerging Growth Company Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible List] Issuance of tangible equity units, net of issuance costs Tangible Equity Units Issued During Period, Value Tangible Equity Units Issued During Period, Value Other activities Other Related Party Activities [Member] Other Related Party Activities [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Credit Facility [Domain] Credit Facility [Domain] Derivative Contract [Domain] Derivative Contract [Domain] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Basic (usd per share) Earnings Per Share, Basic Number of operating segments Number of Operating Segments Local country asset purchases Local Country Asset Purchases [Member] Local Country Asset Purchases [Member] Other current liabilities Other Current Liabilities [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Accrued retirement benefits Liability, Defined Benefit Plan, Noncurrent Number of financial covenants Debt Instrument, Number Of Financial Covenants Debt Instrument, Number Of Financial Covenants Restructuring Plan [Axis] Restructuring Plan [Axis] Intangible assets: Intangible Assets, Gross (Excluding Goodwill) [Abstract] Debt repaid, principal Repayments of Long-term Debt Divestitures Activities Disposal Groups, Including Discontinued Operations [Table Text Block] Net Cash Provided by (Used for) Financing Activities Net Cash Provided by (Used in) Financing Activities Inventories Disposal Group, Including Discontinued Operation, Inventory Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Required ratio of pro forma net leverage and pro forma adjusted EBITDA Required Ratio Of Pro Forma Net Leverage And Pro Forma Adjusted EBITDA Required Ratio Of Pro Forma Net Leverage And Pro Forma Adjusted EBITDA Cost of stock-based compensation plans Share-based Payment Arrangement, Expense Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common stock, no par value, 5,000,000,000 shares authorized, 471,879,904 and 373,011,513 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively Common Stock, Value, Issued 3.912% Senior Notes due 2021 3.912% Senior Notes Due 2021 [Member] 3.912% Senior Notes Due 2021 [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Farm Animal Future Protein & Health Farm Animal Future Protein And Health [Member] Farm Animal Future Protein And Health [Member] Noncurrent Assets Assets, Noncurrent [Abstract] Restricted cash (Note 17) Restricted cash (Note 17) Restricted cash and payable Restricted Cash, Current Current portion of long-term debt (Note 10) Less current portion of long-term debt Long-term Debt, Current Maturities Price per share (usd per share) Offering price (usd per share) Sale of Stock, Price Per Share Volume weighted average price for thirty trading days (usd per share) Business Combination, Volume Weighted Average Price For 30 Trading Days Business Combination, Volume Weighted Average Price For 30 Trading Days Expected total restructuring charges Restructuring and Related Cost, Expected Cost Related Party Transaction [Axis] Related Party Transaction [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Common stock price (in dollars per share) Business Acquisition, Share Price Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Liabilities related to litigation Estimated Litigation Liability Operating lease liabilities Operating Lease, Liability Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Long-term debt (Note 10) Total long-term debt Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Interest Expense Interest Expense [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Total equity Balance at beginning of period Balance at end of period Stockholders' Equity Attributable to Parent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Raw Materials Raw Materials [Member] Fair value of total consideration transferred (2) Consideration paid for acquisition Business Combination, Consideration Transferred Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total liabilities and equity Liabilities and Equity Shares issued to previous shareholders upon closing (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Derivative assets (liabilities) Derivative Assets (Liabilities), at Fair Value, Net Tax benefit on loss on cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Employee compensation Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Measurement period adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Total consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Hedging Relationship [Axis] Hedging Relationship [Axis] Antidilutive shares not included in calculating diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Product Sales Product [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Equity Component [Domain] Equity Component [Domain] Entity Address, Address Line One Entity Address, Address Line One Property and equipment, net of accumulated depreciation of $982.7 (2020) and $930.5 (2019) Property, Plant and Equipment, Net Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Forward-starting interest rate contracts designated as cash flow hedges Interest Rate Contract [Member] Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Entity Address, State or Province Entity Address, State or Province Contingent payment (usd per share) Business Combination, Contingent Consideration, Amount Per Share Paid Upon Specified Merger Agreement Milestones Business Combination, Contingent Consideration, Amount Per Share Paid Upon Specified Merger Agreement Milestones Shares issued upon conversion of prepaid stock purchase contracts (in shares) Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion Other current liabilities Other Liabilities, Current LIBOR London Interbank Offered Rate (LIBOR) [Member] Inventories Inventory Disclosure [Text Block] Other comprehensive income (loss), net of tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax 5.00% Tangible Equity Units TEU amortizing notes TEUs 5.00% Tangible Equity Units [Member] 5.00% Tangible Equity Units Work in process Inventory, Work in Process, Gross Leases [Abstract] Leases [Abstract] Related party, accounts payable Accounts Payable, Related Parties, Current Long Lived Assets Held-for-sale by Asset Type [Axis] Long Lived Assets Held-for-sale by Asset Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Earnings (loss) per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Charges Restructuring Charges Property and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Gain on divestitures (Note 6) Gain (loss) on disposition of business Pre-tax Gain Gain (Loss) on Disposition of Business Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Equity Stockholders' Equity Attributable to Parent [Abstract] Deferred taxes Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities Entity Interactive Data Current Entity Interactive Data Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Other receivables Other Receivables, Net, Current Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] Sale leaseback proceeds Sale Leaseback Transaction, Net Proceeds Sale Leaseback Transaction, Net Proceeds Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accrued retirement benefits Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Employee-Related Liabilities, Current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Employee-Related Liabilities, Current Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Inventory [Domain] Inventory [Domain] Due to related party Due to Related Parties Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Geographic Concentration Risk Geographic Concentration Risk [Member] Senior Unsecured Term Credit Facility Term credit facility Term Loan Facility Term Credit Facility [Member] Term Credit Facility [Member] Leases Leases [Member] Leases Revenue Revenue Benchmark [Member] Other Operating Income (Expense) Other Operating Income (Expense) [Member] Interest rate on debt component Interest rate Debt Instrument, Interest Rate, Stated Percentage Expected number of positions eliminated Restructuring and Related Cost, Expected Number of Positions Eliminated Property and equipment, net of accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Amounts Due From/(Due To) Lilly and Allocations of Services Schedule of Related Party Transactions [Table Text Block] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash benefit for liquidation Derivative Instruments, Liquidated For Cash Benefit, Amount Derivative Instruments, Liquidated For Cash Benefit, Amount Other–net, (income) expense Nonoperating Income (Expense) Hedging Relationship [Domain] Hedging Relationship [Domain] Asset write-down Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Proceeds from settlement of net investment hedges (Note 11) Proceeds from Hedge, Investing Activities Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Costs, expenses and other: Costs and Expenses [Abstract] Ownership [Axis] Ownership [Axis] Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Contract Manufacturing Contract Manufacturing [Member] Contract Manufacturing [Member] Cash Flow Hedging Cash Flow Hedging [Member] Sale of Stock [Domain] Sale of Stock [Domain] Severance Employee Severance [Member] Common stock, no par value Common Stock, No Par Value [Member] Common Stock, No Par Value Ownership [Domain] Ownership [Domain] 2025 Long-Term Debt, Maturity, Year Five Carrying Amount Reported Value Measurement [Member] Revenue Revenue from Contract with Customer [Text Block] Nature of Business and Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Additional paid-in capital Additional Paid in Capital Class of Stock [Axis] Class of Stock [Axis] Income tax (benefit) expense Income tax (benefit) expense Income Tax Expense (Benefit) Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Diluted (usd per share) Earnings Per Share, Diluted Single Customer Customer A [Member] Customer A [Member] Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Cash paid in acquisition Cash consideration Payments to Acquire Businesses, Gross Asset impairment charges Asset Impairment Charges, Including Inventory Write-Down Asset Impairment Charges, Including Inventory Write-Down Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Tangible Equity Unit (TEU) Tangible Equity Unit [Member] Tangible Equity Unit Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Fair value of Elanco common stock Value of shares issued as consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Accelerated stock based compensation expense Share-based Payment Arrangement, Accelerated Cost Accelerated vesting of equity awards (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Accelerated Vesting Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Accelerated Vesting Long-term debt, gross Total obligations and commitments Long-term Debt, Gross Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Beginning balance Ending balance Contract with Customer, Liability Related Party Transaction [Domain] Related Party Transaction [Domain] Number of consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Contingent value rights included in purchase consideration Maximum aggregate contingent payment Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Revenues Business Acquisition, Pro Forma Revenue Change in deferred income taxes Deferred Income Tax Expense (Benefit) Asset impairment Impairment of Long-Lived Assets to be Disposed of Credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Prepaid expenses and other Prepaid Expenses and Other Current Assets [Member] Equity Component Tangible Equity Unit, Equity Component [Member] Tangible Equity Unit, Equity Component Maximum Maximum [Member] Security Exchange Name Security Exchange Name Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Raw materials and supplies Inventory, Raw Materials and Supplies, Gross Document Information [Table] Document Information [Table] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Measurement Basis [Axis] Measurement Basis [Axis] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Initial principal amount Debt Instrument, Initial Principal Amount Debt Instrument, Initial Principal Amount Net Gain/Loss on Derivative Instruments Offsetting Liabilities [Table Text Block] Noncurrent Liabilities Liabilities, Noncurrent [Abstract] Document Transition Report Document Transition Report Summary of Activity in Reserves Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Asset impairment, restructuring and other special charges (Note 7) Total expense Restructuring, Settlement and Impairment Provisions Less: Issuance costs Payment of Financing and Stock Issuance Costs Facility exit costs Facility Closing [Member] Contract With Customer Liability Contract With Customer, Liability [Member] Contract With Customer, Liability [Member] Earnings Per Share Earnings Per Share [Text Block] Long-term debt - senior notes Notes Payable, Fair Value Disclosure Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current Liabilities Liabilities, Current [Abstract] Recurring Fair Value, Recurring [Member] Income Tax Contingency [Table] Income Tax Contingency [Table] Drawdown Proceeds from Lines of Credit Implementation of New Financial Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Divestiture proceeds (Note 6) Gross Cash Proceeds Proceeds from Divestiture of Businesses and Interests in Affiliates Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Novartis Animal Health Novartis Animal Health [Member] Novartis Animal Health EX-101.PRE 9 elan-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 elan-20200930_htm.xml IDEA: XBRL DOCUMENT 0001739104 2020-01-01 2020-09-30 0001739104 elan:CommonStockNoParValueMember 2020-01-01 2020-09-30 0001739104 elan:A500TangibleEquityUnitsMember 2020-01-01 2020-09-30 0001739104 2020-11-02 0001739104 2020-07-01 2020-09-30 0001739104 2019-07-01 2019-09-30 0001739104 2019-01-01 2019-09-30 0001739104 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001739104 2020-09-30 0001739104 2019-12-31 0001739104 us-gaap:CommonStockMember 2018-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001739104 us-gaap:RetainedEarningsMember 2018-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001739104 2018-12-31 0001739104 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001739104 2019-01-01 2019-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001739104 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001739104 us-gaap:CommonStockMember 2019-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001739104 us-gaap:RetainedEarningsMember 2019-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001739104 2019-03-31 0001739104 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001739104 2019-04-01 2019-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-04-01 2019-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001739104 us-gaap:CommonStockMember 2019-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001739104 us-gaap:RetainedEarningsMember 2019-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001739104 2019-06-30 0001739104 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2019-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-07-01 2019-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001739104 elan:AratanaTherapeuticsInc.Member 2019-07-01 2019-09-30 0001739104 us-gaap:CommonStockMember 2019-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001739104 us-gaap:RetainedEarningsMember 2019-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001739104 2019-09-30 0001739104 us-gaap:CommonStockMember 2019-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001739104 us-gaap:RetainedEarningsMember 2019-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001739104 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001739104 2020-01-01 2020-03-31 0001739104 2019-01-01 2019-12-31 0001739104 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001739104 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001739104 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001739104 us-gaap:CommonStockMember 2020-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001739104 us-gaap:RetainedEarningsMember 2020-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001739104 2020-03-31 0001739104 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001739104 2020-04-01 2020-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-04-01 2020-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-01 2020-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-04-01 2020-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001739104 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001739104 us-gaap:CommonStockMember 2020-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001739104 us-gaap:RetainedEarningsMember 2020-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001739104 2020-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001739104 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001739104 elan:BayerAnimalBusinessMember us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001739104 elan:BayerAnimalBusinessMember us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001739104 elan:BayerAnimalBusinessMember 2020-07-01 2020-09-30 0001739104 us-gaap:CommonStockMember 2020-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001739104 us-gaap:RetainedEarningsMember 2020-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001739104 us-gaap:IPOMember 2018-09-24 2018-09-24 0001739104 us-gaap:IPOMember 2018-09-24 0001739104 elan:BayerAnimalBusinessMember 2020-08-01 2020-08-01 0001739104 us-gaap:SeniorNotesMember 2018-09-24 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-24 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-24 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0001739104 us-gaap:NonUsMember elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0001739104 us-gaap:NonUsMember elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2020-07-01 2020-09-30 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2019-07-01 2019-09-30 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2020-01-01 2020-09-30 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2019-01-01 2019-09-30 0001739104 elan:PetHealthDiseasePreventionMember 2020-07-01 2020-09-30 0001739104 elan:PetHealthDiseasePreventionMember 2019-07-01 2019-09-30 0001739104 elan:PetHealthDiseasePreventionMember 2020-01-01 2020-09-30 0001739104 elan:PetHealthDiseasePreventionMember 2019-01-01 2019-09-30 0001739104 elan:PetHealthTherapeuticsMember 2020-07-01 2020-09-30 0001739104 elan:PetHealthTherapeuticsMember 2019-07-01 2019-09-30 0001739104 elan:PetHealthTherapeuticsMember 2020-01-01 2020-09-30 0001739104 elan:PetHealthTherapeuticsMember 2019-01-01 2019-09-30 0001739104 elan:FarmAnimalFutureProteinAndHealthMember 2020-07-01 2020-09-30 0001739104 elan:FarmAnimalFutureProteinAndHealthMember 2019-07-01 2019-09-30 0001739104 elan:FarmAnimalFutureProteinAndHealthMember 2020-01-01 2020-09-30 0001739104 elan:FarmAnimalFutureProteinAndHealthMember 2019-01-01 2019-09-30 0001739104 elan:FarmAnimalRuminantsAndSwineMember 2020-07-01 2020-09-30 0001739104 elan:FarmAnimalRuminantsAndSwineMember 2019-07-01 2019-09-30 0001739104 elan:FarmAnimalRuminantsAndSwineMember 2020-01-01 2020-09-30 0001739104 elan:FarmAnimalRuminantsAndSwineMember 2019-01-01 2019-09-30 0001739104 elan:ContractManufacturingMember 2020-07-01 2020-09-30 0001739104 elan:ContractManufacturingMember 2019-07-01 2019-09-30 0001739104 elan:ContractManufacturingMember 2020-01-01 2020-09-30 0001739104 elan:ContractManufacturingMember 2019-01-01 2019-09-30 0001739104 elan:BayerAnimalBusinessMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember 2019-07-01 2019-09-30 0001739104 elan:BayerAnimalBusinessMember 2020-01-01 2020-09-30 0001739104 elan:BayerAnimalBusinessMember 2019-01-01 2019-09-30 0001739104 elan:BayerAnimalBusinessMember us-gaap:InProcessResearchAndDevelopmentMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember us-gaap:MarketingRelatedIntangibleAssetsMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember elan:FinishedGoodsMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember elan:InProcessMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2020-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:MarketingRelatedIntangibleAssetsMember 2020-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:InProcessResearchAndDevelopmentMember 2020-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:InventoriesMember 2020-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:OsurniaMember 2020-07-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:OsurniaMember 2020-01-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:VecoxanMember 2020-01-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:VecoxanMember 2020-07-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:CapstarMember 2020-07-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:CapstarMember 2020-01-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:DrontalAndProfenderMember 2020-01-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:DrontalAndProfenderMember 2020-07-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:OtherImmaterialDivestituresMember 2020-01-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:OtherImmaterialDivestituresMember 2020-07-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2020-01-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2020-07-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:WorldwideRightsToOsurniaUSRightsToCapstarAndWorldwideRightsToVecoxanMember us-gaap:MarketingRelatedIntangibleAssetsMember 2020-07-31 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:WorldwideRightsToOsurniaUSRightsToCapstarAndWorldwideRightsToVecoxanMember us-gaap:InventoriesMember 2020-07-31 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember 2020-08-03 2020-08-03 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:InProcessResearchAndDevelopmentMember 2020-08-03 2020-08-03 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:MarketingRelatedIntangibleAssetsMember 2020-08-03 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:InProcessResearchAndDevelopmentMember 2020-08-03 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:InventoriesMember 2020-08-03 0001739104 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember elan:WorldwideRightsToOsurniaAndUSRightsToCapstarMember 2019-12-31 0001739104 elan:AratanaTherapeuticsInc.Member 2019-07-18 2019-07-18 0001739104 elan:AratanaTherapeuticsInc.Member 2019-07-18 0001739104 elan:GalliprantMember 2019-07-18 0001739104 elan:GalliprantMember 2019-01-01 2019-12-31 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2019-07-18 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:MarketingRelatedIntangibleAssetsMember 2019-07-18 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:OtherIntangibleAssetsMember 2019-07-18 0001739104 elan:AratanaTherapeuticsInc.Member 2020-01-01 2020-09-30 0001739104 elan:AratanaTherapeuticsInc.Member 2019-01-01 2019-12-31 0001739104 elan:PrevtecMicrobiaInc.Member 2019-07-31 2019-07-31 0001739104 elan:PrevtecMicrobiaInc.Member 2019-07-31 0001739104 elan:PrevtecMicrobiaInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2019-07-31 0001739104 elan:PrevtecMicrobiaInc.Member us-gaap:MarketingRelatedIntangibleAssetsMember 2019-07-31 0001739104 elan:PrevtecMicrobiaInc.Member us-gaap:OtherIntangibleAssetsMember 2019-07-31 0001739104 elan:BayerAnimalBusinessMember 2020-01-01 2020-09-30 0001739104 srt:MinimumMember elan:BayerAnimalBusinessMember 2020-09-30 0001739104 srt:MaximumMember elan:BayerAnimalBusinessMember 2020-09-30 0001739104 us-gaap:FacilityClosingMember 2018-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2018-12-31 0001739104 us-gaap:FacilityClosingMember 2019-01-01 2019-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-09-30 0001739104 us-gaap:FacilityClosingMember 2019-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2019-09-30 0001739104 us-gaap:FacilityClosingMember 2019-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2019-12-31 0001739104 us-gaap:FacilityClosingMember 2020-01-01 2020-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0001739104 us-gaap:FacilityClosingMember 2020-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2020-09-30 0001739104 elan:CommonStockOfferingMember 2020-01-22 2020-01-22 0001739104 elan:CommonStockOfferingMember 2020-01-22 0001739104 us-gaap:OverAllotmentOptionMember 2020-01-22 2020-01-22 0001739104 2020-01-23 2020-01-23 0001739104 elan:TangibleEquityUnitMember 2020-01-22 2020-01-22 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2020-01-22 0001739104 elan:TangibleEquityUnitMember 2020-01-22 0001739104 elan:TangibleEquityUnitEquityComponentMember 2020-01-22 0001739104 elan:TangibleEquityUnitDebtComponentMember 2020-01-22 0001739104 elan:TangibleEquityUnitEquityComponentMember 2020-01-22 2020-01-22 0001739104 elan:TangibleEquityUnitDebtComponentMember 2020-01-22 2020-01-22 0001739104 elan:A275SeniorAmortizingNotesMember us-gaap:SeniorNotesMember 2020-01-22 0001739104 elan:A275SeniorAmortizingNotesMember us-gaap:SeniorNotesMember 2020-01-22 2020-01-22 0001739104 elan:TangibleEquityUnitMember 2020-01-22 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2020-01-22 2020-01-22 0001739104 srt:MaximumMember elan:TangibleEquityUnitMember 2020-01-22 0001739104 srt:MinimumMember elan:TangibleEquityUnitMember 2020-01-22 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2020-09-30 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2020-09-30 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2020-09-30 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2019-12-31 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2020-09-30 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2019-12-31 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2020-09-30 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2019-12-31 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2020-09-30 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2019-12-31 0001739104 us-gaap:NotesPayableOtherPayablesMember 2020-09-30 0001739104 us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0001739104 elan:BayerAnimalBusinessMember elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-08-01 2020-08-01 0001739104 elan:BayerAnimalBusinessMember elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2020-08-01 2020-08-01 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-08-01 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-08-01 2020-08-01 0001739104 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-08-01 2020-08-01 0001739104 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-08-01 2020-08-01 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2020-10-01 2020-10-31 0001739104 2020-08-01 2020-08-01 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-09-30 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2020-01-31 2020-01-31 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2020-09-25 2020-09-25 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2020-01-01 2020-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 elan:PrevtecMicrobiaInc.Member 2020-01-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherOperatingIncomeExpenseMember 2020-07-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherOperatingIncomeExpenseMember 2019-07-01 2019-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherOperatingIncomeExpenseMember 2020-01-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherOperatingIncomeExpenseMember 2019-01-01 2019-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-10-01 2018-10-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-10-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001739104 2020-06-26 2020-06-26 0001739104 2020-06-26 0001739104 elan:NovartisAnimalHealthMember 2020-07-01 2020-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001739104 us-gaap:ProductMember 2020-09-30 0001739104 us-gaap:ProductMember 2019-12-31 0001739104 country:US 2020-07-01 2020-09-30 0001739104 country:US 2019-07-01 2019-09-30 0001739104 country:US 2020-01-01 2020-09-30 0001739104 country:US 2019-01-01 2019-09-30 0001739104 us-gaap:NonUsMember 2020-07-01 2020-09-30 0001739104 us-gaap:NonUsMember 2019-07-01 2019-09-30 0001739104 us-gaap:NonUsMember 2020-01-01 2020-09-30 0001739104 us-gaap:NonUsMember 2019-01-01 2019-09-30 0001739104 country:US 2020-09-30 0001739104 country:US 2019-12-31 0001739104 country:DE 2020-09-30 0001739104 country:DE 2019-12-31 0001739104 country:GB 2020-09-30 0001739104 country:GB 2019-12-31 0001739104 elan:OtherForeignCountriesNotSeparatelyDisclosedMember 2020-09-30 0001739104 elan:OtherForeignCountriesNotSeparatelyDisclosedMember 2019-12-31 0001739104 elan:CommonStockOfferingMember 2020-07-01 2020-09-30 0001739104 elan:CommonStockOfferingMember 2020-01-01 2020-09-30 0001739104 elan:TangibleEquityUnitMember 2020-01-01 2020-09-30 0001739104 elan:TangibleEquityUnitMember 2020-07-01 2020-09-30 0001739104 elan:BayerAnimalBusinessMember 2020-09-30 0001739104 srt:AffiliatedEntityMember 2020-09-30 0001739104 elan:LeasesMember srt:AffiliatedEntityMember 2020-09-30 0001739104 elan:TransitionalServicesAgreementMember srt:AffiliatedEntityMember 2020-09-30 0001739104 elan:LocalCountryAssetPurchasesMember srt:AffiliatedEntityMember 2020-09-30 0001739104 elan:OtherRelatedPartyActivitiesMember srt:AffiliatedEntityMember 2020-09-30 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2020-09-30 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2019-12-31 0001739104 elan:OtherRelatedPartyActivitiesMember us-gaap:MajorityShareholderMember 2020-09-30 0001739104 elan:OtherRelatedPartyActivitiesMember us-gaap:MajorityShareholderMember 2019-12-31 0001739104 elan:LocalCountryAssetPurchasesMember us-gaap:MajorityShareholderMember 2020-09-30 0001739104 elan:LocalCountryAssetPurchasesMember us-gaap:MajorityShareholderMember 2019-12-31 0001739104 us-gaap:MajorityShareholderMember 2020-09-30 0001739104 us-gaap:MajorityShareholderMember 2019-12-31 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2020-01-01 2020-09-30 0001739104 us-gaap:MajorityShareholderMember 2019-01-01 2019-09-30 shares iso4217:USD iso4217:USD shares elan:brand elan:country pure elan:position elan:trading_day elan:numberOfCovenants iso4217:CHF elan:segment false 2020 Q3 0001739104 --12-31 us-gaap:AccountingStandardsUpdate201613Member us-gaap:AccountingStandardsUpdate201613Member 1.5625 P7Y P5Y P5Y 1 10-Q true 2020-09-30 false 001-38661 Elanco Animal Health Inc IN 82-5497352 2500 INNOVATION WAY GREENFIELD IN 46140 877 352-6261 Common stock, no par value ELAN NYSE 5.00% Tangible Equity Units ELAT NYSE Yes Yes Large Accelerated Filer false false false 471915051 889600000 771300000 2133600000 2284000000.0 441800000 360400000 1070400000 1060200000 88100000 69900000 214300000 202800000 277700000 192300000 622500000 574300000 95600000 50700000 196200000 149000000.0 262200000 77200000 456400000 133900000 48100000 18700000 89400000 60200000 114900000 -14600000 161700000 -21100000 1098600000 783800000 2487500000 2201500000 -209000000.0 -12500000 -353900000 82500000 -74000000.0 -22500000 -116600000 -116600000 5100000 -135000000.0 -135000000.0 10000000.0 -237300000 77400000 -0.29 0.03 -0.56 0.21 -0.29 0.03 -0.56 0.21 462400000 371600000 426500000 367700000 462400000 373200000 426500000 368700000 -135000000.0 10000000.0 -237300000 77400000 -7500000 0 -67400000 0 101200000 -58900000 121500000 -53700000 700000 -21200000 2200000 -23400000 93000000.0 -37700000 51900000 -30300000 -42000000.0 -27700000 -185400000 47100000 659900000 334000000.0 8800000 6200000 762300000 816900000 70800000 73000000.0 1597100000 1050700000 180600000 87400000 10700000 11100000 3281400000 2373100000 6434700000 2989600000 5785600000 2482800000 492800000 185000000.0 982700000 930500000 1242500000 955300000 17237000000.0 8985800000 355900000 222600000 139900000 99600000 278600000 211000000.0 553600000 24500000 531900000 244400000 11300000 16400000 1871200000 818500000 5586500000 2330500000 299100000 82500000 823100000 100800000 312900000 106600000 8892800000 3438900000 0 0 1000000000 1000000000 0 0 0 0 5000000000 5000000000 471879904 471879904 373011513 373011513 0 0 8620400000 5636300000 -154400000 84300000 -121800000 -173700000 8344200000 5546900000 17237000000.0 8985800000 365600000 0 5403300000 16400000 -218200000 -4000000.0 -222200000 5197500000 31500000 31500000 -30200000 2000000.0 -28200000 -28200000 -7000000.0 -7000000.0 2400000 2400000 100000 365700000 0 5398700000 47900000 -248400000 -2000000.0 -250400000 5196200000 35900000 35900000 35400000 200000 35600000 35600000 -18400000 -18400000 14300000 14300000 -1900000 -1900000 365700000 0 5396500000 83800000 -213000000.0 -1800000 -214800000 5265500000 10000000.0 10000000.0 -58900000 21200000 -37700000 -37700000 -3000000.0 -3000000.0 11300000 11300000 7200000 238000000.0 238000000.0 100000 3600000 3600000 373000000.0 0 5646400000 93800000 -271900000 19400000 -252500000 5487700000 373000000.0 0 5636300000 84300000 -198400000 24700000 -173700000 5546900000 -49100000 -49100000 -1400000 -1400000 -39200000 -29300000 -400000 -68900000 -68900000 15800000 15800000 11100000 11100000 800000 12800000 12800000 25000000.0 767500000 767500000 452400000 452400000 398800000 0 6870300000 33800000 -39200000 -227700000 24300000 -242600000 6661500000 -53200000 -53200000 -20700000 49600000 -1100000 27800000 27800000 8800000 8800000 8300000 8300000 100000 1000000.0 1000000.0 300000 300000 398900000 0 6886100000 -19400000 -59900000 -178100000 23200000 -214800000 6651900000 -135000000.0 -135000000.0 -135000000.0 -7500000 101200000 -700000 93000000.0 93000000.0 11700000 11700000 100000 200000 200000 72900000 1722800000 1722800000 471900000 0 8620400000 -154400000 -67400000 -76900000 22500000 -121800000 8344200000 -237300000 77400000 294700000 231100000 -159800000 14900000 31100000 36700000 4700000 24700000 51300000 0 169700000 0 -290900000 267000000.0 48600000 -20000000.0 51900000 97800000 16200000 49800000 5001300000 32800000 32700000 0 434700000 0 147800000 36200000 8000000.0 41700000 -4705900000 -160500000 684200000 115000000.0 4554200000 0 1219900000 0 102500000 0 0 191600000 0 6300000 -15200000 1700000 4972200000 -298600000 7300000 4100000 325500000 -357200000 345100000 677500000 670600000 320300000 659900000 309200000 10700000 11100000 670600000 320300000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. Nature of Business and Organization </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Business</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us or our) was formed as a wholly-owned subsidiary of Eli Lilly and Company (Lilly). Elanco is a global animal health company that innovates, develops, manufactures and markets products for pets and farm animals. We offer a diverse portfolio of approximately 190 brands to veterinarians and farm animal producers in more than 90 countries.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elanco Parent was formed in May 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 24, 2018, Elanco Parent completed an initial public offering (IPO) resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares), which represented 19.8% of the outstanding shares, at $24 per share resulting in total net proceeds, after underwriting discounts and commissions, of $1.7 billion.  In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business. In exchange, Elanco Parent has paid to Lilly approximately $4.2 billion, which included the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 10: Debt). These transactions are collectively referred to herein as the Separation. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. The disposition of Elanco shares was completed on March 11, 2019, and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2020, we completed the previously announced acquisition of Bayer Animal Health, for payment of $5.2 billion in cash, subject to customary post-closing adjustments, and approximately 72.9 million shares of Elanco common stock. See Note 6: Acquisitions and Divestitures for additional information.</span></div> 190 90 72300000 0.198 24 1700000000 4200000000 5200000000 72900000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. Basis of Presentation and Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The accounts of all wholly owned and controlled subsidiaries are included in the condensed consolidated financial statements and all intercompany balances and transactions have been eliminated. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with current presentation.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our income taxes in 2019 and thereafter reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return with Lilly until full separation. The income tax amounts in the financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The significant accounting policies set forth in Note 4 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to the adoption of the standards that were effective January 1, 2020 as described in Note 4: Implementation of New Financial Accounting Pronouncements.</span></div> We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The accounts of all wholly owned and controlled subsidiaries are included in the condensed consolidated financial statements and all intercompany balances and transactions have been eliminated. Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with current presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020. Our income taxes in 2019 and thereafter reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return with Lilly until full separation. The income tax amounts in the financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. Impact of Separation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement, a tax matters agreement and the transitional services agreement (TSA).</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the agreements referenced above, we entered into several other related party transactions with Lilly before and at the time of the Separation. For additional information regarding our ongoing agreements, as well as certain activities while Lilly was a related party, see Note 17: Related Party Agreements and Transactions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. Equity</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Offering</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 22.7 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2.3 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25.0 million shares of our common stock for $767.5 million, after issuance costs.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tangible Equity Unit (TEU) Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2020, we also completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528.5 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in long-term debt on the consolidated balance sheet, with payments expected in the next twelve months reflected in current portion of long-term debt. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per unit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The senior amortizing notes have an aggregate principal amount of $79.2 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we will pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate will be equivalent to 5.00% per year with respect to the $50 stated amount per TEU.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applicable Market Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Issued</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equal to or greater than $38.40</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3021 shares (minimum settlement rate)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than $38.40, but greater than $32.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 divided by applicable market value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to $32.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5625 (maximum settlement rate)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14.3 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period.</span></div> 2000000000.0 750000000.0 500000000.0 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. Implementation of New Financial Accounting Pronouncements </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5MWRmODhmZTA3ODQ2NjJhMGVlZTRlNmVmN2VjYmZkL3NlYzo3OTFkZjg4ZmUwNzg0NjYyYTBlZWU0ZTZlZjdlY2JmZF80OS9mcmFnOjI5MWViZTIwYWJlNTRlYTg4NWVjNzFkMDZiMTdiMjVkL3RhYmxlOjdmMDJlNmIyNzVmMDQ4NDlhMWY1ZDk3YmFjYjZhZDUyL3RhYmxlcmFuZ2U6N2YwMmU2YjI3NWYwNDg0OWExZjVkOTdiYWNiNmFkNTJfMS0wLTEtMS0wL3RleHRyZWdpb246ODlmZWE3OGJkODkwNDhiMGFkMTg0N2I4YmFkOTdlYThfNQ_5e17a61a-759c-4072-9beb-db523bc8ec8f">Accounting Standards Update 2016-13</span>, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements. </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2018-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements. </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of accounting standards applicable to us that have not yet been adopted:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating the effect of this standard on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements. </span></td></tr></table></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5MWRmODhmZTA3ODQ2NjJhMGVlZTRlNmVmN2VjYmZkL3NlYzo3OTFkZjg4ZmUwNzg0NjYyYTBlZWU0ZTZlZjdlY2JmZF80OS9mcmFnOjI5MWViZTIwYWJlNTRlYTg4NWVjNzFkMDZiMTdiMjVkL3RhYmxlOjdmMDJlNmIyNzVmMDQ4NDlhMWY1ZDk3YmFjYjZhZDUyL3RhYmxlcmFuZ2U6N2YwMmU2YjI3NWYwNDg0OWExZjVkOTdiYWNiNmFkNTJfMS0wLTEtMS0wL3RleHRyZWdpb246ODlmZWE3OGJkODkwNDhiMGFkMTg0N2I4YmFkOTdlYThfNQ_5e17a61a-759c-4072-9beb-db523bc8ec8f">Accounting Standards Update 2016-13</span>, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements. </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2018-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements. </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of accounting standards applicable to us that have not yet been adopted:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating the effect of this standard on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements. </span></td></tr></table></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5MWRmODhmZTA3ODQ2NjJhMGVlZTRlNmVmN2VjYmZkL3NlYzo3OTFkZjg4ZmUwNzg0NjYyYTBlZWU0ZTZlZjdlY2JmZF80OS9mcmFnOjI5MWViZTIwYWJlNTRlYTg4NWVjNzFkMDZiMTdiMjVkL3RhYmxlOjdmMDJlNmIyNzVmMDQ4NDlhMWY1ZDk3YmFjYjZhZDUyL3RhYmxlcmFuZ2U6N2YwMmU2YjI3NWYwNDg0OWExZjVkOTdiYWNiNmFkNTJfMS0wLTEtMS0wL3RleHRyZWdpb246ODlmZWE3OGJkODkwNDhiMGFkMTg0N2I4YmFkOTdlYThfNQ_5e17a61a-759c-4072-9beb-db523bc8ec8f">Accounting Standards Update 2016-13</span>, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements. </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2018-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements. </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of accounting standards applicable to us that have not yet been adopted:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating the effect of this standard on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements. </span></td></tr></table></div> -1400000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. Revenue </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales rebates are based on specific agreements and the majority relate to sales in the U.S. As of September 30, 2020 and 2019, the liability for sales rebates in the U.S. represents approximately 54% and 71%, respectively, of our total liability with the next largest country representing approximately 12% and 6%, respectively, of our total liability. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in the sales rebates liability in the U.S.: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer Animal Health at acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 6.75pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 6.75pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 6.75pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020 and 2019 for product shipped in previous periods were not material.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product returns in the U.S. were approximately 0.1% and less than 0.1% of net revenue for the three months ended September 30, 2020 and 2019, respectively and approximately 1.2% and 0.1% of net revenue for the nine months ended September 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue disaggregated by product category:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health Disease Prevention</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health Therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal Future Protein &amp; Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal Ruminants &amp; Swine</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Manufacturing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. This category was previously called Strategic Exits. 0.54 0.71 0.12 0.06 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in the sales rebates liability in the U.S.: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer Animal Health at acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 6.75pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 6.75pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 6.75pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 122000000.0 132100000 150400000 118500000 20800000 0 20800000 0 86400000 75900000 212000000.0 222200000 78600000 78900000 232600000 211600000 150600000 129100000 150600000 129100000 0.001 0.001 0.012 0.001 <div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue disaggregated by product category:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health Disease Prevention</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health Therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal Future Protein &amp; Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal Ruminants &amp; Swine</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Manufacturing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. This category was previously called Strategic Exits. 297000000.0 207600000 613600000 616900000 103300000 87600000 247100000 252400000 180900000 191500000 518800000 534500000 292300000 266200000 703100000 811800000 16100000 18400000 51000000.0 68400000 889600000 771300000 2133600000 2284000000.0 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. Acquisitions and Divestitures </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we completed the acquisition of Bayer Animal Health. During 2019, we completed the acquisitions of all outstanding shares of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec). These transactions were accounted for as business combinations under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our condensed consolidated financial statements from the dates of acquisition.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Animal Health Acquisition</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 1, 2020, we completed our previously announced acquisition of Bayer Animal Health in a cash and stock transaction. Bayer Animal Health is a provider of products intended to improve the health and well-being of pets and farm animals. The acquisition expands our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our existing product portfolio and pipeline are enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure while expanding our direct to retailer/e-commerce presence. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,170.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Elanco common stock </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of total consideration transferred </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Represents the acquisition date fair value of 72.9 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">The purchase price is preliminary and subject to working capital and customary purchase price adjustments. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized transaction costs related to the acquisition of Bayer Animal Health of $90.7 million and $17.4 million for the three months ended September 30, 2020 and 2019, respectively, and $212.3 million and $21.4 million for the nine months ended September 30, 2020 and 2019, respectively. These costs were associated with legal and professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenues attributable to Bayer Animal Health included in our condensed consolidated statements of operations since the date of acquisition for the three and nine months ended September 30, 2020 is $195.6 million. Based on our current operational structure, we did not record standalone costs for Bayer Animal Health after the date of the acquisition. As a result, we are unable to accurately determine earnings or loss attributable to Bayer Animal Health since the date of acquisition.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2020. The purchase price allocation is preliminary and subject to change, including the valuation of inventories, property and equipment, intangible assets, income taxes and goodwill, among other items. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. Finalization of the valuation during the measurement period could result in a change in the amounts recorded for the acquisition date fair value.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at August 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,220.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets and liabilities - net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprised of $359.6 million, $28.2 million, $126.1 million in finished products, work in process, and raw materials, respectively. The preliminary estimate of fair value of finished products was determined based on net realizable value adjusted for the costs to complete the sales process, a reasonable profit allowance from the sales process, and estimated holding costs. The preliminary estimate of fair value of work in process was determined based on net realizable value adjusted for costs to complete the manufacturing process, costs of the sales process, a reasonable profit allowance for the remaining manufacturing and sales process effort, and an estimate of holding costs. The fair value of raw materials was determined to approximate book value. The fair value step-up adjustment to inventories of $166.8 million is being amortized to cost of sales when the inventory is sold to customers, which is expected to be within less than one year from the acquisition date.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is mostly composed of land, buildings, equipment (including machinery, furniture and fixtures, and computer equipment), and construction in progress. The fair value of property and equipment was determined to approximate net book value at the time of the acquisition based on the information currently available and pending finalization of our fair value assessment. </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets relate to $240.0 million of in-process research and development (IPR&amp;D) and $3,220.0 million of marketed products. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 12 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the "income approach," which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&amp;D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors. The fair value of intangible assets as of September 30, 2020 is based on preliminary assumptions which are subject to change as we complete our valuation procedures.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets held for sale include $135.0 million of marketed products rights, $7.3 million of IPR&amp;D and $4.6 million of inventory related to the divestitures of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Drontal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">™, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Profender</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">™ and other products. See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Divestitures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> section below for more information. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued retirement benefits primarily relate to certain Bayer Animal Health international subsidiaries that have underfunded defined benefit pension plans. We have recorded the fair value of these plans using assumptions and accounting policies similar to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019. Upon acquisition, the excess of projected benefit obligation over the plan assets was recognized as a liability and previously existing deferred actuarial gains and losses and unrecognized service costs or benefits were eliminated. The resulting incremental net pension expense from the acquired plans was immaterial for the three months ended September 30, 2020. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies and cost savings from the creation of a single combined global organization. The majority of goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill during the period:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aratana measurement period adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to the Bayer Animal Health acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually and when certain impairment indicators are present. As of September 30, 2020, there were no goodwill impairment losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro forma financial information (unaudited)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated unaudited pro forma combined results of Elanco, Bayer Animal Health and Aratana for the three and nine months ended September 30, 2020 and 2019 as if the acquisitions had occurred on January 1, 2019:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,318.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental pro forma financial information has been prepared using the acquisition method of accounting and is based on the historical financial information of Elanco, Bayer Animal Health and Aratana. The supplemental pro forma financial information does not necessarily represent what the combined companies' revenue or results of operations would have been had the acquisitions been completed on January 1, 2019, nor is it intended to be a projection of future operating results of the combined company. It also does not reflect any operating efficiencies or potential cost savings that might be achieved from synergies of combining Elanco, Bayer Animal Health and Aratana.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited supplemental pro forma financial information reflects primarily pro forma adjustments related to divestitures, fair value estimates for intangibles and inventory, and interest expense and amortization of debt issuance costs for the debt issuance to finance the acquisition of Bayer Animal Health. The unaudited supplemental pro forma financial information includes transaction charges associated with the acquisition. There are no material, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported pro forma revenue and loss before income taxes.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure the necessary regulatory clearances for the acquisition of Bayer Animal Health, we signed agreements to divest the rights to manufacture and commercialize certain products. The following table summarizes the financial impact of the material divestitures completed during the third quarter of 2020, the pre-tax gains and losses on which are included in other - net, (income) expense in the condensed consolidated statement of operations.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three and Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Cash Proceeds</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax Gain</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Osurnia™ </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Vecoxan™ </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Capstar™ </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Drontal </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Profender™</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other immaterial divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-tax gain is net of transaction costs of $13.3 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elanco product divestitures</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we signed agreements to divest the worldwide rights to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Osurnia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the U.S. rights to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capstar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and in February 2020, we signed an agreement to divest the worldwide rights to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vecoxan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The carrying value of the divested assets consisted of $114.1 million of marketed product rights and $7.9 million of inventory. In July 2020, we completed these sales,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">along with certain other immaterial divestitures. The transactions were accounted for as asset divestitures. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer Animal Health product divestitures</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To allow the Bayer Animal Health acquisition to close on a timely basis, we signed agreements to divest the rights to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drontal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profender </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product families within the United Kingdom and European Economic Area as well as other IPR&amp;D. We completed the transactions, which were accounted for as asset divestitures, on August 3, 2020. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drontal, Profender,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were acquired as part of the Bayer Animal Health acquisition. The related assets were classified as held for sale on the balance sheet as of the acquisition date and measured at fair value at the time of the acquisition; therefore, no gains were recognized on the sales. A loss of $7.3 million was recorded on the sale of IPR&amp;D as recognition of the potential income from the divestiture was constrained by revenue accounting standards. The estimated fair value of the divested assets consisted of $135.0 million of marketed product rights, $7.3 million of IPR&amp;D, and $3.6 million of inventory.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are additional marketed and pipeline products that we are required to dispose of in order to comply with regulatory requirements. These divestitures are not expected to have a material effect on our operations, cash flows or financial position.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related assets for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Osurnia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capstar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> divestitures met the assets held for sale criteria as of December 31, 2019. No adjustments were required to record the assets at the lower of their carrying amounts or fair values less costs to sell on the consolidated balance sheet. Assets and liabilities considered held for sale in connection with the divestitures were included in the respective line items on the consolidated balance sheet as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles, net classified as held for sale primarily consisted of marketed products. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Acquisitions</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aratana Therapeutics, Inc. </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 18, 2019, we acquired Aratana, a pet therapeutics company focused on innovative therapies for dogs and cats, for stock and cash-based contingent value rights. Aratana is the creator of the canine osteoarthritis medicine,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Galliprant™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the rights to which we acquired in 2016. The acquisition enhances our presence in the areas of appetite stimulants in dogs, pain relief in dogs and cats, and treatments of other conditions in the U.S. and internationally. In connection with the acquisition, we issued approximately 7.2 million shares with a value of $238.0 million to Aratana shareholders, based on our stock price on the last trading day immediately prior to the closing date. The purchase consideration also included up to $12 million in contingent value rights, which represent the rights of Aratana shareholders to receive a contingent payment of $0.25 per share in cash upon the achievement of a specified milestone as outlined in the merger agreement. We calculated an immaterial fair value for the contingent value rights using the Monte Carlo simulation model.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration liabilities that we previously recorded for future royalty and milestone payments in relation to the 2016 acquisition of rights to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Galliprant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were settled upon the closing of our acquisition of Aratana.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The liabilities were valued at $84.7 million as of the acquisition date using the Monte Carlo simulation model.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The resulting $7.5 million loss upon settlement was recorded in other - net, (income) expense in the consolidated and combined statement of operations for the year ended December 31, 2019.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at July 18, 2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of existing contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accounting for this acquisition is complete. A $19.1 million measurement period adjustment was recorded to establish a deferred tax liability for the preexisting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Galliprant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> contingent consideration liability during the nine months ended September 30, 2020. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued 0.1 million shares and recorded $3.6 million of stock-based compensation expense for the vesting of Aratana equity awards that was accelerated upon the closing of the acquisition during 2019.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevtec Microbia Inc. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2019, we acquired Prevtec in a cash transaction for approximately $60.3 million, inclusive of certain post-closing adjustments. Prevtec is a Canadian biotechnology company specializing in the development of vaccines intended to help prevent bacterial diseases in farm animals. The acquisition allows us to expand on our previous distribution arrangement for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coliprotec™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and is consistent with our efforts to explore innovative antibiotic alternatives.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase consideration included up to $16.3 million in additional cash consideration, contingent upon the achievement of specific sales milestones by December 31, 2021. We recorded a $4.7 million liability on the condensed consolidated balance sheet as of the acquisition date based on the fair value of the contingent consideration as calculated using the Monte Carlo simulation model.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A previously existing $0.7 million receivable owed from Prevtec to Elanco Animal Health UK Limited was settled upon the closing of our acquisition of Prevtec.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The resulting immaterial gain upon settlement was recorded in other - net, (income) expense in the consolidated and combined statement of operations for the year ended December 31, 2019.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at July 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.</span></div>The accounting for this acquisition is complete. An immaterial measurement period adjustment to deferred taxes was recorded during the nine months ended September 30, 2020. <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,170.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Elanco common stock </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of total consideration transferred </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Represents the acquisition date fair value of 72.9 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).</span></div>(2)The purchase price is preliminary and subject to working capital and customary purchase price adjustments. 5170100000 1723700000 6893800000 72900000 23.64 2300000000 P20D 0.075 2300000000 33.60 90700000 17400000 212300000 21400000 195600000 195600000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at August 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,220.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets and liabilities - net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at July 18, 2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of existing contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at July 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.</span></div> 168800000 9700000 513900000 57900000 299600000 240000000.0 3220000000.0 146900000 172800000 209600000 707900000 3566500000 3327300000 6893800000 359600000 28200000 126100000 166800000 240000000.0 3220000000.0 P12Y 135000000.0 7300000 4600000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill during the period:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aratana measurement period adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to the Bayer Animal Health acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2989600000 19900000 3327300000 97900000 6434700000 0 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated unaudited pro forma combined results of Elanco, Bayer Animal Health and Aratana for the three and nine months ended September 30, 2020 and 2019 as if the acquisitions had occurred on January 1, 2019:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,318.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1072600000 1111200000 3318300000 3553700000 -222800000 -144000000.0 -382100000 -29200000 The following table summarizes the financial impact of the material divestitures completed during the third quarter of 2020, the pre-tax gains and losses on which are included in other - net, (income) expense in the condensed consolidated statement of operations.<div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three and Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Cash Proceeds</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax Gain</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Osurnia™ </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Vecoxan™ </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Capstar™ </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Drontal </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Profender™</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other immaterial divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-tax gain is net of transaction costs of $13.3 million.</span></div>Assets and liabilities considered held for sale in connection with the divestitures were included in the respective line items on the consolidated balance sheet as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 140500000 140500000 93100000 93100000 55100000 55100000 37100000 37100000 95900000 95900000 25500000 25500000 140600000 140600000 0 0 2600000 2600000 700000 700000 434700000 434700000 156400000 156400000 13300000 13300000 114100000 7900000 0 7300000 135000000.0 7300000 3600000 10600000 61200000 200000 72000000.0 1400000 1400000 7200000 238000000.0 12000000 0.25 84700000 -7500000 26400000 10300000 31900000 36700000 13200000 4100000 122600000 30700000 84700000 238000000.0 P12Y6M 19100000 100000 3600000 60300000 16300000 4700000 700000 900000 500000 2800000 58900000 1100000 -9300000 54900000 10100000 65000000.0 P10Y <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. Asset Impairment, Restructuring and Other Special Charges </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Components of asset impairment, restructuring and other special charges are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring charges: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility exit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisition related charges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction and integration costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash and other items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4) (5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-down</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of fixed assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program initiated following the acquisition of Bayer Animal Health. See below for further details. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For the three and nine months ended September 30, 2019, these charges primarily related to a restructuring program initiated in 2019 to reduce costs and support margin expansion by eliminating certain positions across multiple locations and functions, including exiting research and development (R&amp;D) operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisition of Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an in-process research and development asset resulting from a reassessment of geographic viability. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset impairment charges for the three and nine months ended September 30, 2019 related to an adjustment to fair value of intangible assets that were subject to product rationalization.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset write-down expenses for the three and nine months ended September 30, 2020 and 2019 resulted from adjustments recorded to write assets classified as held and used down to their current fair value. Included are charges related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Represents a gain on the disposal from the sale of an R&amp;D facility in Prince Edward Island, Canada, which was written down during the three months ended September 30, 2019 as part of the announced 2019 program to streamline operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Charge primarily relates to a non-recurring litigation settlement for a matter that originated prior to the Separation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the Bayer Animal Health acquisition, we implemented a restructuring program designed to reduce duplication, drive efficiency and optimize our footprint in key geographies. As part of the restructuring plan, we intend to eliminate approximately 900 positions across 40 countries, primarily in the commercial and marketing functions, but also in the R&amp;D, manufacturing and quality, and back office support functions. The proposed initiative is expected to lead to total restructuring charges of approximately $190 million to $210 million through 2021, consisting primarily of severance. </span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our reserves established in connection with restructuring activities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility exit costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are included in other current liabilities on the consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.</span></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Components of asset impairment, restructuring and other special charges are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring charges: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility exit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisition related charges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction and integration costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash and other items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4) (5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-down</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of fixed assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program initiated following the acquisition of Bayer Animal Health. See below for further details. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For the three and nine months ended September 30, 2019, these charges primarily related to a restructuring program initiated in 2019 to reduce costs and support margin expansion by eliminating certain positions across multiple locations and functions, including exiting research and development (R&amp;D) operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisition of Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an in-process research and development asset resulting from a reassessment of geographic viability. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset impairment charges for the three and nine months ended September 30, 2019 related to an adjustment to fair value of intangible assets that were subject to product rationalization.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset write-down expenses for the three and nine months ended September 30, 2020 and 2019 resulted from adjustments recorded to write assets classified as held and used down to their current fair value. Included are charges related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Represents a gain on the disposal from the sale of an R&amp;D facility in Prince Edward Island, Canada, which was written down during the three months ended September 30, 2019 as part of the announced 2019 program to streamline operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Charge primarily relates to a non-recurring litigation settlement for a matter that originated prior to the Separation.</span></div> 130200000 10400000 131200000 9600000 0 0 700000 0 131100000 46100000 318500000 99600000 0 10200000 3500000 14200000 900000 10500000 3200000 10500000 0 0 3800000 0 0 0 -3100000 262200000 77200000 456400000 133900000 900 40 190000000 210000000 <div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our reserves established in connection with restructuring activities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility exit costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9300000 35100000 44400000 20700000 20000000.0 40700000 0 -10200000 -10200000 2000000.0 18800000 20800000 28000000.0 26100000 54100000 5400000 15500000 20900000 700000 131900000 132600000 0 -800000 -800000 1200000 15000000.0 16200000 4900000 131600000 136500000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. Inventories </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 797100000 402900000 664100000 603200000 167000000.0 83900000 1628200000 1090000000.0 31100000 39300000 1597100000 1050700000 22700000 32.00 2300000 25000000.0 767500000 11000000 0.0500 528500000 50 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per unit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applicable Market Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Issued</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equal to or greater than $38.40</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3021 shares (minimum settlement rate)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than $38.40, but greater than $32.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 divided by applicable market value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to $32.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5625 (maximum settlement rate)</span></div></td></tr></table></div> 42.80 7.20 50.00 470800000 79200000 550000000.0 18400000 3100000 21500000 452400000 76100000 528500000 79200000 0.0275 0.6250 7.2007 0.6528 0.0500 50 20 38.40 1.3021 38.40 32.00 50 32.00 1.5625 14300000 17200000 14300000 32.00 38.40 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. Debt </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan B credit facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,175.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.912% Senior Notes due 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.272% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.900% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU amortizing notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,140.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,586.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities on long-term debt consisted of the following:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2020 and for period/years ending December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter of 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,711.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total obligations and commitments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,241.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs and other obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,140.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Credit Facility</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Bayer Animal Health, on August 1, 2020, we executed our previously announced borrowing of $4,275.0 million under a term loan B credit facility, of which $4,175.0 million was outstanding as of September 30, 2020. The term loan B facility bears interest at a floating rate of LIBOR plus 175 basis points over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5MWRmODhmZTA3ODQ2NjJhMGVlZTRlNmVmN2VjYmZkL3NlYzo3OTFkZjg4ZmUwNzg0NjYyYTBlZWU0ZTZlZjdlY2JmZF83MC9mcmFnOmM4NDBhYTE3NjE3MjRlM2VhMjUzYzgwZTZkMjFlNzE0L3RleHRyZWdpb246Yzg0MGFhMTc2MTcyNGUzZWEyNTNjODBlNmQyMWU3MTRfNzE0NjgyNTU5OTg2MA_c13b7395-f18d-4fd1-a0f5-82612c33d58c">seven</span>-year term. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneously, we entered into a revolving credit facility providing up to $750.0 million and maturing over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5MWRmODhmZTA3ODQ2NjJhMGVlZTRlNmVmN2VjYmZkL3NlYzo3OTFkZjg4ZmUwNzg0NjYyYTBlZWU0ZTZlZjdlY2JmZF83MC9mcmFnOmM4NDBhYTE3NjE3MjRlM2VhMjUzYzgwZTZkMjFlNzE0L3RleHRyZWdpb246Yzg0MGFhMTc2MTcyNGUzZWEyNTNjODBlNmQyMWU3MTRfMjE5OTAyMzI3NDk3MQ_26435ae9-7a4e-4d11-856a-d4094df7259e">five</span>-year term. The revolving credit facility bears interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on our corporate family rating or corporate credit rating. On August 1, 2020, we drew down $200.0 million on the revolving credit facility to fund local country asset purchases in connection with our acquisition of Bayer Animal Health subsidiaries and subsequently repaid the amount in full later that month. As a result, we capitalized approximately $9.2 million of debt issuance costs in other noncurrent assets on the condensed consolidated balance sheet. In October 2020, we drew down $250.0 million on the revolving credit facility to fund local country asset purchases in connection with our acquisition of Bayer Animal Health subsidiaries. Pursuant to the stock and asset purchase agreement, Bayer is to reimburse us for these purchases. See Note 17: Related Party Agreements and Transactions for further discussion.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have capitalized deferred financing costs of approximately $90.2 million, consisting of legal, accounting and other fees relating to our new credit facility. Deferred financing costs are recorded as a contra-liability and presented </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net against long-term debt on the condensed consolidated balance sheet. Upon closing the acquisition of Bayer Animal Health on August 1, 2020, we terminated our unused commitments and incurred approximately $13.8 million in fees, which are included in other - net, (income) expense in the condensed consolidated statement of operations.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the equity and debt activities were used to finance the cash portion of our acquisition of Bayer Animal Health and to pay related fees and expenses (see Note 6: Acquisitions and Divestitures for further discussion). Subsequent to these borrowings, we have terminated all unused commitments to our lenders.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> These senior secured first lien credit facilities are secured by a significant portion of our assets. They include two financial maintenance covenants which are solely for the benefit of lenders under the revolving credit facility. There are no financial maintenance covenants for the benefit of the term loan B facility. The lenders under the term loan B facility have no enforcement rights with respect to the financial maintenance covenants for the revolving credit facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first financial maintenance covenant for the revolving credit facility requires us to maintain a net total leverage ratio level (which is not subject to step-downs) as of the end of each quarter, beginning with the fiscal quarter ending September 30, 2020. The required level of this covenant is based on closing date pro forma net leverage and pro forma adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) not exceeding 7.71 to 1.00 of our pro forma adjusted EBITDA for the four fiscal quarters ended September 30, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second financial maintenance covenant for the revolving credit facility requires us to maintain a ratio of pro forma adjusted EBITDA to cash interest expense of no less than 2.00 to 1.00, tested as of the end of each fiscal quarter, beginning with the fiscal quarter ended September 30, 2020. We were in compliance with all covenants under the credit facility as of September 30, 2020. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Extinguishment</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2020, we repaid indebtedness outstanding under our existing term loan facility. We paid $372.4 million in cash, composed of $371.4 million of principal and $1.0 million of accrued interest, resulting in a debt extinguishment loss of $0.8 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statement of operations for the nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2020, we made a repayment of principal of $100.0 million on the indebtedness outstanding under our new term loan B facility. The repayment was accounted for as a partial debt extinguishment and resulted in a debt extinguishment loss of $2.1 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statement of operations for the three and nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEU Amortizing Notes</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2020, we issued $550 million in TEUs. We offered 11 million, 5.00% TEUs at the stated amount of $50 per unit, comprised of prepaid stock purchase contracts and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $528.5 million was received, comprised of $452.4 million of prepaid stock purchase contracts and $76.1 million of senior amortizing notes, net of issuance costs. We paid $14.1 million representing partial payment of principal and interest on the TEU amortizing notes during the nine months ended September 30, 2020. See Note 9: Equity for further information.</span></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan B credit facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,175.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.912% Senior Notes due 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.272% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.900% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU amortizing notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,140.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,586.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4175000000.0 0 0 371400000 0.03912 500000000.0 500000000.0 0.04272 750000000.0 750000000.0 0.04900 750000000.0 750000000.0 66200000 0 400000 400000 101500000 16800000 6140100000 2355000000.0 553600000 24500000 5586500000 2330500000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities on long-term debt consisted of the following:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2020 and for period/years ending December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter of 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,711.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total obligations and commitments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,241.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs and other obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,140.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 16800000 567600000 68000000.0 797500000 40300000 39900000 4711100000 6241200000 101100000 6140100000 4275000000.0 4175000000.0 0.0175 750000000.0 0.0150 0.0225 200000000.0 9200000 250000000.0 90200000 13800000 2 0 7.71 2.00 372400000 371400000 1000000.0 -800000 100000000.0 -2100000 550000000 11000000 0.0500 50 528500000 452400000 76100000 14100000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. Financial Instruments and Fair Value </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large portion of our cash is held in a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019, we had $21.7 million and $18.8 million, respectively, primarily related to equity method investments included in other noncurrent assets o</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n our condensed consolidated balance sheet. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value information at September 30, 2020 and December 31, 2019 for foreign exchange contract assets (liabilities), contingent consideration liabilities, net investment hedge assets (liabilities) and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial statement line item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt - senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,186.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,186.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU amortizing note </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,175.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,068.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,068.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - cross currency interest rate contracts designated as net investment hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt - senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,120.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,120.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt - term credit facility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">We consider the carrying value to be representative of its fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities as of September 30, 2020 and December 31, 2019 related to contingent consideration associated with the acquisitions of Aratana and Prevtec during 2019. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16.3 million contingent upon the achievement of specific </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coliprotec</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility. During the nine months ended September 30, 2020, primarily as a result of a decrease in forecasted revenues related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coliprotec</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we decreased the fair value of the contingent consideration liability associated with the Prevtec acquisition by $2.1 million, and recognized the gain in other – net, (income) expense in the condensed consolidated statement of operations. See Note 6: Acquisitions and Divestitures for further discussion.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives Not Designated as Hedges</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the British pound, Canadian dollar, Euro, Japanese yen, Swiss franc (CHF), and Chinese renminbi. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other – net, (income) expense in the condensed consolidated income statement. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2020 and December 31, 2019, we had outstanding foreign exchange contracts with aggregate notional amounts of $1,496.9 million and $861.2 million, respectively. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net gain/(loss) on derivative instruments not designated as hedging instruments, recorded in other - net, (income) expense are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These amounts were substantially offset in other – net, (income) expense by the effect of changing exchange rates on the underlying foreign currency exposures.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives Designated as Hedges</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5MWRmODhmZTA3ODQ2NjJhMGVlZTRlNmVmN2VjYmZkL3NlYzo3OTFkZjg4ZmUwNzg0NjYyYTBlZWU0ZTZlZjdlY2JmZF83My9mcmFnOmMyODgwYWQyOTNiYzQyYjI5ZDVmZTUxNmQ4OGFmNGNhL3RleHRyZWdpb246YzI4ODBhZDI5M2JjNDJiMjlkNWZlNTE2ZDg4YWY0Y2FfNDc0NA_9ccf1c3f-700a-40c6-9b45-09a3c888a69f">five</span>-year cross-currency fixed interest rate swap with a 750 million CHF notional amount, which was designated as a net investment hedge (NIH) against CHF denominated assets (the fair value of which was estimated based on quoted market values of similar hedges and was classified as Level 2). During the nine months ended September 30, 2020, we fully liquidated our cross currency interest rate swaps for a cash benefit of $35.1 million (including $2.4 million in interest). Notwithstanding settlement, gains and losses within accumulated other comprehensive loss will remain in accumulated other comprehensive loss until either the sale or substantial liquidation of the hedged subsidiary.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swap contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the life of the derivative, gains or losses due to spot rate fluctuations were recorded in cumulative translation adjustment in other comprehensive income. The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swap contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in March 2020, as a means of mitigating variability in cash flows associated with the anticipated term loan B issuance, we executed forward-starting interest rate swaps with a $4.05 billion notional amount, which are designated as cash flow hedges and have settlement dates ranging between 2022 and 2025. These instruments effectively convert floating-rate debt to fixed-rate debt. The cash flow hedges are recorded at fair value on our condensed consolidated balance sheet, while changes in the fair value of the hedge are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Amounts recorded in accumulated other comprehensive income (loss) will be recognized in earnings in interest expense, net of capitalized interest when the hedged transaction affects earnings (i.e., when interest payments are accrued on the term loan B). During the three and nine months ended September 30, 2020, we recorded a loss of $7.5 million (net of tax benefit of $2.2 million) and $67.4 million (net of tax benefit of $19.6 million), respectively, on the cash flow hedges in other comprehensive income (loss). Over the next 12 months we expect to reclassify $28.0 million from accumulated other comprehensive loss to interest expense, net of capitalized interest due to the amortization of net losses on the interest rate swaps.</span></div> 21700000 18800000 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value information at September 30, 2020 and December 31, 2019 for foreign exchange contract assets (liabilities), contingent consideration liabilities, net investment hedge assets (liabilities) and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial statement line item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt - senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,186.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,186.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU amortizing note </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,175.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,068.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,068.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - cross currency interest rate contracts designated as net investment hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt - senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,120.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,120.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt - term credit facility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)We consider the carrying value to be representative of its fair value. 10700000 0 10700000 0 10700000 -7600000 0 -7600000 0 -7600000 2600000 0 0 2600000 2600000 -87000000.0 0 -87000000.0 0 -87000000.0 2000000000.0 0 2186700000 0 2186700000 66200000 0 66200000 0 66200000 4175000000.0 0 4068000000.0 0 4068000000.0 800000 0 800000 0 800000 -1100000 0 -1100000 0 -1100000 4700000 0 0 4700000 4700000 2300000 0 2300000 0 2300000 2000000000.0 0 2120600000 0 2120600000 371400000 0 371400000 0 371400000 12000000 16300000 -2100000 1496900000 861200000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net gain/(loss) on derivative instruments not designated as hedging instruments, recorded in other - net, (income) expense are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These amounts were substantially offset in other – net, (income) expense by the effect of changing exchange rates on the underlying foreign currency exposures.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swap contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swap contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -2300000 10100000 19400000 8800000 750000000 35100000 2400000 0 6200000 6200000 18400000 0 18500000 24000000.0 23900000 4050000000.00 -7500000 -2200000 -67400000 -19600000 -28000000.0 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. Leases </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Australia Sale-Leaseback</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2020, our wholly-owned subsidiary, Elanco Australasia PTY LTD, sold land and an R&amp;D facility located in New South Wales, Australia, for aggregate proceeds of $55.1 million, and leased the property back for an initial term of 15 years through a sale-leaseback transaction. Under the terms of the purchase and sale agreement, we determined that control of the assets was relinquished to the buyer-lessor. Therefore, we recognized a pre-tax gain on the sale of $45.6 million in other - net, (income) expense in the condensed consolidated statement of operations during the nine months ended September 30, 2020. Operating lease right-of-use assets and liabilities include the present value of $27.8 million for the associated lease payments, which are presented in other noncurrent assets and other noncurrent liabilities and other current liabilities on the condensed consolidated balance sheet.</span></div> 55100000 P15Y 45600000 27800000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Provision for Taxes on Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:63pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our income taxes for the nine months ended September 30, 2019 and 2020, respectively, reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return until full separation. In the jurisdictions in which we were included in a combined tax return, our income taxes were </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">determined based on the tax matters agreement between us and Lilly. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the U.S. enacted the Tax Cuts and Jobs Act (2017 Tax Act), which significantly revised U.S. tax law. Guidance related to the 2017 Tax Act, including Notices, Proposed Regulations, and Final Regulations, has been issued, and we expect additional guidance will be issued in 2020. This additional guidance could materially impact our assumptions and estimates used to record our U.S. federal and state income tax expense resulting from the 2017 Tax Act. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. During the fourth quarter of 2019, the IRS began its examination of tax years 2016 - 2018. Because the examination is still in the early stages of information gathering, the resolution of the audit will likely extend beyond the next 12 months.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, we recognized $74.0 million and $116.6 million, respectively, of income tax benefit. For the three and nine months ended September 30, 2020, our effective tax rate of 35.4% and 32.9%, respectively, differs from the statutory income tax rate primarily due to the release of foreign valuation allowances as a result of gains on divestitures. Additionally, the state tax benefit is a result of U.S. pre-tax losses and the foreign tax benefit is due to losses in jurisdictions with tax rates higher than U.S. statutory rates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2019, we recognized a tax benefit of $22.5 million and incurred $5.1 million of income tax expense, respectively. For the three and nine months ended September 30, 2019, our effective tax rate differs from the statutory income tax rate primarily due to a discrete tax benefit from the resolution of a Brazil tax audit in addition to the impact of lower pre-tax earnings largely due to restructuring charges. Tax reserves had been established in the 2015 acquisition of Novartis Animal Health (Novartis) and were partially covered by an indemnity. The favorable resolution of the Brazil tax audit resulted in an income tax benefit of approximately $14 million in the third quarter of 2019.</span></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Provision for Taxes on Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -74000000.0 -22500000 -116600000 -116600000 5100000 0.354 1.797 0.329 0.062 -74000000.0 -116600000 -116600000 0.354 0.329 -22500000 5100000 -14000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. Commitments and Contingencies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2020, a shareholder class action lawsuit captioned </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hunter v. Elanco Animal Health Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco, Jeffrey Simmons and Todd Young. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between January 10, 2020 and May 6, 2020. On September 3, 2020, the Court appointed a lead plaintiff. The deadline for the lead plaintiff to file an amended complaint is November 9, 2020. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2020, a shareholder class action lawsuit captioned </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safron Capital Corporation v. Elanco Animal Health Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3/ASR dated January 21, 2020 and accompanying prospectus on Form 424B5 issued in connection with Elanco’s secondary public offering that closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities pursuant to the secondary public offering. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.</span></div>We are party to various other legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. We accrue for certain liability claims to the extent that it is probable we will incur a loss and we can formulate a reasonable estimate of the costs. As of September 30, 2020 and December 31, 2019, we had no material liabilities established related to litigation as there were no significant claims which were probable and estimable. We have not historically had any significant litigation expense and are not currently subject to a significant claim other than the lawsuits noted above. 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15. Geographic Information </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both farm animals and pets. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant cost/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results. We are currently in the process of reviewing our operating segments as a result of potential changes to our operational structure due to the acquisition of Bayer Animal Health.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products include </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rumensin™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Optaflexx™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denagard™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tylan™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maxiban™, Baycox™, Cydectin™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other products for livestock and poultry, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trifexis™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intercepto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comfortis™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Galliprant, Seresto™, Advantage™, Advantix™, Advocate™ </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(collectively referred to as the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantage Family) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other products for pets.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a single customer that accounted for 11.7% and 15.9% of revenue for the three months ended September 30, 2020 and 2019, respectively, and for 11.9% and 13.4% of revenue for the nine months ended September 30, 2020 and 2019, respectively. The product sales resulted in accounts receivable with this customer of $78.1 million and $90.5 million as of September 30, 2020 and December 31, 2019, respectively.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected geographic area information was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue—to unaffiliated customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.3 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Revenue is attributed to the countries based on the location of the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.</span></div> 0.117 0.159 0.119 0.134 78100000 90500000 <div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected geographic area information was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue—to unaffiliated customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.3 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 421500000 388200000 969500000 1167100000 468100000 383100000 1164100000 1116900000 889600000 771300000 2133600000 2284000000.0 <div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Revenue is attributed to the countries based on the location of the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.</span></div> 942600000 709800000 243700000 39700000 206300000 192600000 273100000 205000000.0 1665700000 1147100000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16. Earnings Per Share</span></div><div><span><br/></span></div><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic Earnings Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute basic earnings (loss) per share by dividing net earnings (loss) available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. For the three and nine months ended September 30, 2020, the weighted average number of common shares outstanding used to calculate basic earnings per share includes the impact of approximately 72.9 million shares of common stock issued to Bayer and its subsidiaries for the Bayer Animal Health acquisition. In addition, basic earnings per share reflects the impacts of 25.0 million shares and 14.3 million shares, respectively, issued in connection with our common stock and TEU issuances in the first quarter of 2020. See Note 6: Acquisitions and Divestitures and Note 9: Equity for further discussion.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diluted Earnings Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts. Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average diluted shares outstanding included common stock equivalents of 1.5 million and 1.0 million for the three and nine months ended September 30, 2019, respectively. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. During the three and nine months ended September 30, 2020, we reported a net loss. Therefore, dilutive common shares are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share.</span></div>For the three and nine months ended September 30, 2019, approximately 0.1 million shares of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive. 72900000 72900000 25000000.0 25000000.0 14300000 14300000 1500000 1000000.0 100000 100000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17. Related Party Agreements and Transactions </span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elanco Shares Held by Bayer</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2020, we completed the acquisition of Bayer Animal Health, which included cash and Elanco stock consideration. Pursuant to the share and asset purchase agreement, Bayer has the right to sell such shares on or after November 1, 2020 through multiple registered offerings. Upon Bayer's written request, Elanco is obligated to use commercially reasonable efforts to file a shelf registration statement covering the resale by Bayer of its Elanco common stock. As of September 30, 2020, Bayer owns 72.9 million shares, or 15.5% of our outstanding common stock.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with Bayer Subsequent to the Acquisition of Bayer Animal Health</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various transactions between us and Bayer during the period after the acquisition of Bayer Animal Health.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total net payable due to Bayer at September 30, 2020 was $9.8 million related to these transactions. We also have $60.0 million associated with lease agreements with Bayer recorded on our condensed consolidated balance sheet as of September 30, 2020. Further details regarding our ongoing relationship with Bayer are included below. </span></div><div><span><br/></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transitional Services Agreements (TSA) and Reverse TSAs</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To ensure business continuity after the acquisition of the Bayer Animal Health business, we entered into certain TSAs and reverse TSAs with Bayer. Under the TSAs, Bayer will provide us certain specified R&amp;D services and back office support on a transitional basis, including among other things, logistical services, commercial operations support, and information systems. We will pay Bayer mutually agreed-upon fees for services provided under the TSAs, a majority of which are based on fixed hourly rates, and subject to a contractually agreed mark-up. We have recorded approximately $2.7 million of expense for the three and nine months ended September 30, 2020 related to these agreements.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reverse TSAs are primarily comprised of contracts whereby we have agreed to provide Bayer certain R&amp;D services on a transitional basis. During the three and nine months ended September 30, 2020, reverse TSA activity was immaterial. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain facilities and fleet vehicles from Bayer. Our operating lease right-of-use assets and liabilities include the present value of $60.0 million for the lease payments related to these leases, which are presented in other noncurrent assets and other noncurrent liabilities and other current liabilities on the condensed consolidated balance sheet. </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Local Country Asset Purchases</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For regulatory purposes in certain jurisdictions, consideration was required to be paid locally at closing in addition to amounts paid globally for the acquisition. Pursuant to the stock and asset purchase agreement, Bayer is to provide a refund for payment amounts duplicated in these regions. As of September 30, 2020, the local payment has not yet been made in China due to certain regulatory delays. Thus, as of September 30, 2020, we had a receivable from and payable to Bayer of $233.6 million and $233.6 million, respectively, recorded on a net basis on the condensed consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Activities</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also entered into various other agreements with Bayer, including certain supply agreements and contract manufacturing and toll manufacturing agreements. These contracts are for activities in the normal course of business and are required to maintain and establish business relationships on a long-term basis.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition, we have an obligation to reimburse Bayer for certain costs they incurred on our behalf. Accordingly, we have recorded approximately $20.4 million in other current liabilities on the condensed consolidated balance sheet as of September 30, 2020 and within asset impairment, restructuring and other special charges in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 for amounts owed to Bayer. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with Lilly Subsequent to Separation and Related to the Separation</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Local country asset purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total payable to Lilly</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 1, we completed an IPO in September 2018 and Lilly fully divested all ownership of Elanco in March 2019. In connection with the Separation, we entered into various agreements with Lilly related to the form of our separation and certain ongoing activities that will continue for a period of time. These included, among others, a master separation agreement (MSA), a TSA and a tax matters agreement. In addition, there was a portion of our operations for which the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TSA</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we are able to use Lilly Services for a fixed term established on a service-by-service basis. We pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which are based on Lilly's cost (including third-party costs) of providing the Lilly Services through March 31, 2021, and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2022. The fees under the TSA became payable for all periods beginning after October 1, 2018.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation Activities</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to our IPO, there continue to be transactions between us and Lilly related primarily to the completion of the local country asset purchases and finalization of assets and liabilities associated with the legal separation from Lilly, combined income tax returns and the impact of the tax matters agreement, historical Lilly retirement benefits, and centralized cash management. The most significant of these activities includes the finalization of the local country valuation of business and the resulting impact on deferred tax assets and the impact of combined tax returns.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Activities</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to share certain services and back office functions with Lilly, which in certain instances result in Lilly paying costs for Elanco (e.g., utilities, local country operating costs, etc.) that are then passed through to Elanco for reimbursement. These amounts are included in cash flows from operating activities in our consolidated statements of cash flows. In addition, we operate through a single treasury settlement process and prior to the local country asset purchases (as described below) continued to transact through Lilly's processes in certain instances. As a result of these activities, there were certain amounts of financing that occurred between Lilly and Elanco during the nine months ended September 30, 2019 and 2020. These amounts are included in cash flows from financing activities in our condensed consolidated statements of cash flows. </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Local Country Asset Purchases</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal transfer of certain of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. The related assets, liabilities, and results of operations have been reported in our condensed consolidated financial statements, as we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets under the terms of the MSA. We held restricted cash, and the associated payable to Lilly, at the date of Separation to fund the acquisition of these assets. As of September 30, 2020, the majority of these assets have been legally </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquired and the remainder are expected to be purchased during 2020. Restricted cash and Payable to Lilly of $10.7 million are recorded on the condensed consolidated balance sheet for the remainder of the assets expected to be purchased by the end of 2020.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with Lilly Prior to Full Separation </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, we did not operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us. The impact on our historical combined financial statements includes the following:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div>Prior to full separation, our employees participated in Lilly stock-based compensation plans, the costs of which were allocated to us and recorded in cost of sales, research and development, and marketing, selling and administrative expenses in the condensed consolidated statements of operations. The costs of such plans related to our employees were $5.1 million for the nine months ended September 30, 2019. 72900000 0.155 9800000 60000000.0 2700000 60000000.0 60000000.0 233600000 233600000 -20400000 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Local country asset purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total payable to Lilly</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1100000 10500000 -1700000 -15800000 -10700000 -11100000 -11300000 -16400000 0.07 10700000 5100000 See Note 9: Equity for further discussion. See Note 4: Implementation of New Financial Accounting Pronouncements for further discussion. See Note 6: Acquisitions and Divestitures for further discussion. See Note 6: Acquisitions and Divestitures for further discussion. See Note 17: Related Party Agreements and Transactions for further discussion. See Note 17: Related Party Agreements and Transactions for further discussion. XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover page - shares
 9 Months Ended
Sep. 30, 2020
Nov. 02, 2020
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 001-38661  
Entity Registrant Name Elanco Animal Health Inc  
Entity Incorporation, State or Country Code IN  
Entity Tax Identification Number 82-5497352  
Entity Address, Address Line One 2500 INNOVATION WAY  
Entity Address, City or Town GREENFIELD  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46140  
City Area Code 877  
Local Phone Number 352-6261  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   471,915,051
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001739104  
Current Fiscal Year End Date --12-31  
Common stock, no par value    
Document Information [Line Items]    
Title of 12(b) Security Common stock, no par value  
Trading Symbol ELAN  
Security Exchange Name NYSE  
5.00% Tangible Equity Units    
Document Information [Line Items]    
Title of 12(b) Security 5.00% Tangible Equity Units  
Trading Symbol ELAT  
Security Exchange Name NYSE  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Revenue $ 889.6 $ 771.3 $ 2,133.6 $ 2,284.0
Costs, expenses and other:        
Cost of sales 441.8 360.4 1,070.4 1,060.2
Research and development 88.1 69.9 214.3 202.8
Marketing, selling and administrative 277.7 192.3 622.5 574.3
Amortization of intangible assets 95.6 50.7 196.2 149.0
Asset impairment, restructuring and other special charges (Note 7) 262.2 77.2 456.4 133.9
Interest expense, net of capitalized interest (Note 10) 48.1 18.7 89.4 60.2
Other–net, (income) expense (114.9) 14.6 (161.7) 21.1
Costs, expenses and other 1,098.6 783.8 2,487.5 2,201.5
Income (loss) before income taxes (209.0) (12.5) (353.9) 82.5
Income tax (benefit) expense (74.0) (22.5) (116.6) 5.1
Net income (loss) $ (135.0) $ 10.0 $ (237.3) $ 77.4
Earnings (loss) per share:        
Basic (usd per share) $ (0.29) $ 0.03 $ (0.56) $ 0.21
Diluted (usd per share) $ (0.29) $ 0.03 $ (0.56) $ 0.21
Weighted average shares outstanding:        
Basic (in shares) 462.4 371.6 426.5 367.7
Diluted (in shares) 462.4 373.2 426.5 368.7
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ (135.0) $ 10.0 $ (237.3) $ 77.4
Other comprehensive income (loss):        
Unrealized loss on derivatives for cash flow hedges, net of taxes (7.5) 0.0 (67.4) 0.0
Foreign currency translation 101.2 (58.9) 121.5 (53.7)
Defined benefit pension and retiree health benefit plans, net of taxes (0.7) 21.2 (2.2) 23.4
Other comprehensive income (loss), net of tax 93.0 (37.7) 51.9 (30.3)
Comprehensive income (loss) $ (42.0) $ (27.7) $ (185.4) $ 47.1
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 659.9 $ 334.0
Accounts receivable, net of allowances of $8.8 (2020) and $6.2 (2019) 762.3 816.9
Other receivables 70.8 73.0
Inventories (Note 8) 1,597.1 1,050.7
Prepaid expenses and other 180.6 87.4
Restricted cash (Note 17) 10.7 11.1
Total current assets 3,281.4 2,373.1
Noncurrent Assets    
Goodwill 6,434.7 2,989.6
Other intangibles, net (Note 6) 5,785.6 2,482.8
Other noncurrent assets 492.8 185.0
Property and equipment, net of accumulated depreciation of $982.7 (2020) and $930.5 (2019) 1,242.5 955.3
Total assets 17,237.0 8,985.8
Current Liabilities    
Accounts payable 355.9 222.6
Employee compensation 139.9 99.6
Sales rebates and discounts 278.6 211.0
Current portion of long-term debt (Note 10) 553.6 24.5
Other current liabilities 531.9 244.4
Payable to Lilly (Note 17) 11.3 16.4
Total current liabilities 1,871.2 818.5
Noncurrent Liabilities    
Long-term debt (Note 10) 5,586.5 2,330.5
Accrued retirement benefits 299.1 82.5
Deferred taxes 823.1 100.8
Other noncurrent liabilities 312.9 106.6
Total liabilities 8,892.8 3,438.9
Commitments and Contingencies (Note 14) 0.0 0.0
Equity    
Preferred stock, no par value, 1,000,000,000 shares authorized; none issued 0.0 0.0
Common stock, no par value, 5,000,000,000 shares authorized, 471,879,904 and 373,011,513 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively 0.0 0.0
Additional paid-in capital 8,620.4 5,636.3
Retained earnings (accumulated deficit) (154.4) 84.3
Accumulated other comprehensive loss (121.8) (173.7)
Total equity 8,344.2 5,546.9
Total liabilities and equity $ 17,237.0 $ 8,985.8
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Accounts receivable, net of allowances $ 8.8 $ 6.2
Property and equipment, net of accumulated depreciation $ 982.7 $ 930.5
Preferred stock, shares authorized (in shares) 1,000,000,000 1,000,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, shares authorized (in shares) 5,000,000,000 5,000,000,000
Common stock, shares issued (in shares) 471,879,904 373,011,513
Common stock, shares outstanding (in shares) 471,879,904 373,011,513
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Aratana
Bayer Animal Business
Cumulative Effect, Period of Adoption, Adjustment
 [2]
Common Stock
Common Stock
Aratana
Common Stock
Bayer Animal Business
Additional Paid-in Capital
Additional Paid-in Capital
Aratana
Additional Paid-in Capital
Bayer Animal Business
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit)
Cumulative Effect, Period of Adoption, Adjustment
 [2]
Accumulated Other Comprehensive Income (Loss)
Cash Flow Hedge Gain (Loss)
Foreign Currency Translation
Defined Benefit Pension and Retiree Health Benefit Plans
Balance at beginning of period (in shares) at Dec. 31, 2018         365.6                      
Balance at beginning of period at Dec. 31, 2018 $ 5,197.5       $ 0.0     $ 5,403.3     $ 16.4   $ (222.2)   $ (218.2) $ (4.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income (loss) 31.5                   31.5          
Other comprehensive income (loss), net of tax (28.2)                       (28.2)   (30.2) 2.0
Separation activities [1] (7.0)             (7.0)                
Stock compensation 2.4             2.4                
Issuance of stock under employee stock plans, net (in shares)         0.1                      
Balance at end of period (in shares) at Mar. 31, 2019         365.7                      
Balance at end of period at Mar. 31, 2019 5,196.2       $ 0.0     5,398.7     47.9   (250.4)   (248.4) (2.0)
Balance at beginning of period (in shares) at Dec. 31, 2018         365.6                      
Balance at beginning of period at Dec. 31, 2018 5,197.5       $ 0.0     5,403.3     16.4   (222.2)   (218.2) (4.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income (loss) 77.4                              
Other comprehensive income (loss), net of tax (30.3)                              
Balance at end of period (in shares) at Sep. 30, 2019         373.0                      
Balance at end of period at Sep. 30, 2019 5,487.7       $ 0.0     5,646.4     93.8   (252.5)   (271.9) 19.4
Balance at beginning of period (in shares) at Dec. 31, 2018         365.6                      
Balance at beginning of period at Dec. 31, 2018 5,197.5       $ 0.0     5,403.3     16.4   (222.2)   (218.2) (4.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Accelerated vesting of equity awards (in shares)   0.1                            
Balance at end of period (in shares) at Dec. 31, 2019         373.0                      
Balance at end of period at Dec. 31, 2019 $ 5,546.9     $ (1.4) $ 0.0     5,636.3     84.3 $ (1.4) (173.7)   (198.4) 24.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201613Member                              
Balance at beginning of period (in shares) at Mar. 31, 2019         365.7                      
Balance at beginning of period at Mar. 31, 2019 $ 5,196.2       $ 0.0     5,398.7     47.9   (250.4)   (248.4) (2.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income (loss) 35.9                   35.9          
Other comprehensive income (loss), net of tax 35.6                       35.6   35.4 0.2
Separation activities [1] (18.4)             (18.4)                
Stock compensation 14.3             14.3                
Other 1.9             1.9                
Balance at end of period (in shares) at Jun. 30, 2019         365.7                      
Balance at end of period at Jun. 30, 2019 5,265.5       $ 0.0     5,396.5     83.8   (214.8)   (213.0) (1.8)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income (loss) 10.0                   10.0          
Other comprehensive income (loss), net of tax (37.7)                       (37.7)   (58.9) 21.2
Separation activities [1] (3.0)             (3.0)                
Stock compensation 11.3             11.3                
Issuance for acquisition (in shares) [3]           7.2                    
Issuance for acquisition [3]   $ 238.0             $ 238.0              
Accelerated vesting of equity awards (in shares) [3]           0.1                    
Accelerated vesting of equity awards [3]   $ 3.6             $ 3.6              
Balance at end of period (in shares) at Sep. 30, 2019         373.0                      
Balance at end of period at Sep. 30, 2019 5,487.7       $ 0.0     5,646.4     93.8   (252.5)   (271.9) 19.4
Balance at beginning of period (in shares) at Dec. 31, 2019         373.0                      
Balance at beginning of period at Dec. 31, 2019 5,546.9     (1.4) $ 0.0     5,636.3     84.3 (1.4) (173.7)   (198.4) 24.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income (loss) (49.1)                   (49.1)          
Other comprehensive income (loss), net of tax (68.9)                       (68.9) $ (39.2) (29.3) (0.4)
Separation activities [4] 15.8             15.8                
Stock compensation 11.1             11.1                
Issuance of stock under employee stock plans, net (in shares)         0.8                      
Issuance of stock under employee stock plans, net (12.8)             (12.8)                
Issuance of common stock, net of issuance costs (in shares) [5]         25.0                      
Issuance of common stock, net of issuance costs [5] 767.5             767.5                
Issuance of tangible equity units, net of issuance costs [5] 452.4             452.4                
Balance at end of period (in shares) at Mar. 31, 2020         398.8                      
Balance at end of period at Mar. 31, 2020 6,661.5       $ 0.0     6,870.3     33.8   (242.6) (39.2) (227.7) 24.3
Balance at beginning of period (in shares) at Dec. 31, 2019         373.0                      
Balance at beginning of period at Dec. 31, 2019 5,546.9     $ (1.4) $ 0.0     5,636.3     84.3 $ (1.4) (173.7)   (198.4) 24.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income (loss) (237.3)                              
Other comprehensive income (loss), net of tax 51.9                              
Balance at end of period (in shares) at Sep. 30, 2020         471.9                      
Balance at end of period at Sep. 30, 2020 8,344.2       $ 0.0     8,620.4     (154.4)   (121.8) (67.4) (76.9) 22.5
Balance at beginning of period (in shares) at Mar. 31, 2020         398.8                      
Balance at beginning of period at Mar. 31, 2020 6,661.5       $ 0.0     6,870.3     33.8   (242.6) (39.2) (227.7) 24.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income (loss) (53.2)                   (53.2)          
Other comprehensive income (loss), net of tax 27.8                       27.8 (20.7) 49.6 (1.1)
Separation activities [4] 8.8             8.8                
Stock compensation 8.3             8.3                
Issuance of stock under employee stock plans, net (in shares)         0.1                      
Issuance of stock under employee stock plans, net (1.0)             (1.0)                
Other (0.3)             (0.3)                
Balance at end of period (in shares) at Jun. 30, 2020         398.9                      
Balance at end of period at Jun. 30, 2020 6,651.9       $ 0.0     6,886.1     (19.4)   (214.8) (59.9) (178.1) 23.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income (loss) (135.0)                   (135.0)          
Other comprehensive income (loss), net of tax 93.0                       93.0 (7.5) 101.2 (0.7)
Stock compensation 11.7             11.7                
Issuance of stock under employee stock plans, net (in shares)         0.1                      
Issuance of stock under employee stock plans, net (0.2)             (0.2)                
Issuance for acquisition (in shares) [6]             72.9                  
Issuance for acquisition [6]     $ 1,722.8             $ 1,722.8            
Balance at end of period (in shares) at Sep. 30, 2020         471.9                      
Balance at end of period at Sep. 30, 2020 $ 8,344.2       $ 0.0     $ 8,620.4     $ (154.4)   $ (121.8) $ (67.4) $ (76.9) $ 22.5
[1] See Note 17: Related Party Agreements and Transactions for further discussion.
[2] See Note 4: Implementation of New Financial Accounting Pronouncements for further discussion.
[3] See Note 6: Acquisitions and Divestitures for further discussion.
[4] See Note 17: Related Party Agreements and Transactions for further discussion.
[5] See Note 9: Equity for further discussion.
[6] See Note 6: Acquisitions and Divestitures for further discussion.
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash Flows from Operating Activities    
Net income (loss) $ (237.3) $ 77.4
Adjustments to reconcile net income (loss) to cash flows from operating activities:    
Depreciation and amortization 294.7 231.1
Change in deferred income taxes (159.8) 14.9
Stock-based compensation expense 31.1 36.7
Asset impairment charges 4.7 24.7
Gain on sale of assets (51.3) 0.0
Gain on divestitures (Note 6) (169.7) 0.0
Changes in operating assets and liabilities, net of acquisitions 290.9 (267.0)
Other non-cash operating activities, net 48.6 (20.0)
Net Cash Provided by Operating Activities 51.9 97.8
Cash Flows from Investing Activities    
Net proceeds from sale (purchases) of property and equipment (16.2) (49.8)
Cash paid for acquisitions, net of cash acquired (Note 6) (5,001.3) (32.8)
Proceeds from settlement of net investment hedges (Note 11) 32.7 0.0
Divestiture proceeds (Note 6) 434.7 0.0
Purchases of software (147.8) (36.2)
Other investing activities, net (8.0) (41.7)
Net Cash Used for Investing Activities (4,705.9) (160.5)
Cash Flows from Financing Activities    
Repayments of borrowings (Note 10) (684.2) (115.0)
Proceeds from issuance of long-term debt (Note 10) 4,554.2 0.0
Proceeds from issuance of common stock and tangible equity units (Note 9) 1,219.9 0.0
Debt issuance costs (102.5) 0.0
Consideration paid to Lilly in connection with the Separation (Note 1) 0.0 (191.6)
Other net financing transactions with Lilly 0.0 6.3
Other financing activities, net (15.2) 1.7
Net Cash Provided by (Used for) Financing Activities 4,972.2 (298.6)
Effect of exchange rate changes on cash and cash equivalents 7.3 4.1
Net increase (decrease) in cash, cash equivalents and restricted cash 325.5 (357.2)
Cash, cash equivalents and restricted cash at beginning of period 345.1 677.5
Cash, cash equivalents and restricted cash at end of period 670.6 320.3
Cash, cash equivalents and restricted cash $ 670.6 $ 320.3
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Nature of Business and Organization
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Organization
Note 1. Nature of Business and Organization

Nature of Business

Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us or our) was formed as a wholly-owned subsidiary of Eli Lilly and Company (Lilly). Elanco is a global animal health company that innovates, develops, manufactures and markets products for pets and farm animals. We offer a diverse portfolio of approximately 190 brands to veterinarians and farm animal producers in more than 90 countries.

Organization

Elanco Parent was formed in May 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.

On September 24, 2018, Elanco Parent completed an initial public offering (IPO) resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares), which represented 19.8% of the outstanding shares, at $24 per share resulting in total net proceeds, after underwriting discounts and commissions, of $1.7 billion.  In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business. In exchange, Elanco Parent has paid to Lilly approximately $4.2 billion, which included the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 10: Debt). These transactions are collectively referred to herein as the Separation.

On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. The disposition of Elanco shares was completed on March 11, 2019, and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco.

On August 1, 2020, we completed the previously announced acquisition of Bayer Animal Health, for payment of $5.2 billion in cash, subject to customary post-closing adjustments, and approximately 72.9 million shares of Elanco common stock. See Note 6: Acquisitions and Divestitures for additional information.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
Note 2. Basis of Presentation and Summary of Significant Accounting Policies

We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The accounts of all wholly owned and controlled subsidiaries are included in the condensed consolidated financial statements and all intercompany balances and transactions have been eliminated.

Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with current presentation.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020.
Our income taxes in 2019 and thereafter reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return with Lilly until full separation. The income tax amounts in the financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions.

The significant accounting policies set forth in Note 4 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to the adoption of the standards that were effective January 1, 2020 as described in Note 4: Implementation of New Financial Accounting Pronouncements.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Impact of Separation
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Impact of Separation
Note 3. Impact of Separation

In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement, a tax matters agreement and the transitional services agreement (TSA).

In addition to the agreements referenced above, we entered into several other related party transactions with Lilly before and at the time of the Separation. For additional information regarding our ongoing agreements, as well as certain activities while Lilly was a related party, see Note 17: Related Party Agreements and Transactions.
Note 9. Equity

Common Stock Offering

On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 22.7 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2.3 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25.0 million shares of our common stock for $767.5 million, after issuance costs.

Tangible Equity Unit (TEU) Offering

On January 22, 2020, we also completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528.5 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification.
The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in long-term debt on the consolidated balance sheet, with payments expected in the next twelve months reflected in current portion of long-term debt. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.

The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$470.8 $79.2 $550.0 
Less: Issuance costs18.4 3.1 21.5 
Net proceeds$452.4 $76.1 $528.5 

The senior amortizing notes have an aggregate principal amount of $79.2 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we will pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate will be equivalent to 5.00% per year with respect to the $50 stated amount per TEU.

Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)

The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14.3 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Implementation of New Financial Accounting Pronouncements
 9 Months Ended
Sep. 30, 2020
Accounting Changes and Error Corrections [Abstract]  
Implementation of New Financial Accounting Pronouncements
Note 4. Implementation of New Financial Accounting Pronouncements

The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables.
We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements.
Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract
This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements.
The following table provides a brief description of accounting standards applicable to us that have not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.We are currently evaluating the effect of this standard on our consolidated financial statements.
Accounting Standards Update 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting
This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Revenue
Note 5. Revenue

Our sales rebates are based on specific agreements and the majority relate to sales in the U.S. As of September 30, 2020 and 2019, the liability for sales rebates in the U.S. represents approximately 54% and 71%, respectively, of our total liability with the next largest country representing approximately 12% and 6%, respectively, of our total liability.

The following table summarizes the activity in the sales rebates liability in the U.S.:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Beginning balance$122.0 $132.1 $150.4 $118.5 
Bayer Animal Health at acquisition20.8 — 20.8 — 
Reduction of revenue86.4 75.9 212.0 222.2 
Payments(78.6)(78.9)(232.6)(211.6)
Ending balance$150.6 $129.1 $150.6 $129.1 

Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2020 and 2019 for product shipped in previous periods were not material.

Product returns in the U.S. were approximately 0.1% and less than 0.1% of net revenue for the three months ended September 30, 2020 and 2019, respectively and approximately 1.2% and 0.1% of net revenue for the nine months ended September 30, 2020 and 2019, respectively.
Disaggregation of Revenue

The following table summarizes our revenue disaggregated by product category:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Pet Health Disease Prevention$297.0 $207.6 $613.6 $616.9 
Pet Health Therapeutics103.3 87.6 247.1 252.4 
Farm Animal Future Protein & Health180.9 191.5 518.8 534.5 
Farm Animal Ruminants & Swine292.3 266.2 703.1 811.8 
Contract Manufacturing (1)
16.1 18.4 51.0 68.4 
Revenue$889.6 $771.3 $2,133.6 $2,284.0 
(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. This category was previously called Strategic Exits.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures
 9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Acquisitions and Divestitures
Note 6. Acquisitions and Divestitures

During 2020, we completed the acquisition of Bayer Animal Health. During 2019, we completed the acquisitions of all outstanding shares of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec). These transactions were accounted for as business combinations under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our condensed consolidated financial statements from the dates of acquisition.

Bayer Animal Health Acquisition

On August 1, 2020, we completed our previously announced acquisition of Bayer Animal Health in a cash and stock transaction. Bayer Animal Health is a provider of products intended to improve the health and well-being of pets and farm animals. The acquisition expands our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our existing product portfolio and pipeline are enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure while expanding our direct to retailer/e-commerce presence.

Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows:

Cash consideration$5,170.1 
Fair value of Elanco common stock (1)
1,723.7 
Fair value of total consideration transferred (2)
$6,893.8 

(1)Represents the acquisition date fair value of 72.9 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).
(2)The purchase price is preliminary and subject to working capital and customary purchase price adjustments.

We recognized transaction costs related to the acquisition of Bayer Animal Health of $90.7 million and $17.4 million for the three months ended September 30, 2020 and 2019, respectively, and $212.3 million and $21.4 million for the nine months ended September 30, 2020 and 2019, respectively. These costs were associated with legal and professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.
The amount of revenues attributable to Bayer Animal Health included in our condensed consolidated statements of operations since the date of acquisition for the three and nine months ended September 30, 2020 is $195.6 million. Based on our current operational structure, we did not record standalone costs for Bayer Animal Health after the date of the acquisition. As a result, we are unable to accurately determine earnings or loss attributable to Bayer Animal Health since the date of acquisition.

The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2020. The purchase price allocation is preliminary and subject to change, including the valuation of inventories, property and equipment, intangible assets, income taxes and goodwill, among other items. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. Finalization of the valuation during the measurement period could result in a change in the amounts recorded for the acquisition date fair value.

The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 1, 2020
Cash and cash equivalents$168.8 
Accounts receivable9.7 
Inventories513.9 
Prepaid expenses and other current assets57.9 
Property and equipment299.6 
Intangible assets:
Acquired in-process research and development 240.0 
Marketed products3,220.0 
Assets held for sale146.9 
Accounts payable and accrued liabilities(172.8)
Accrued retirement benefits(209.6)
Other noncurrent assets and liabilities - net (707.9)
Total identifiable net assets3,566.5 
Goodwill3,327.3 
Total consideration transferred$6,893.8 

Inventories comprised of $359.6 million, $28.2 million, $126.1 million in finished products, work in process, and raw materials, respectively. The preliminary estimate of fair value of finished products was determined based on net realizable value adjusted for the costs to complete the sales process, a reasonable profit allowance from the sales process, and estimated holding costs. The preliminary estimate of fair value of work in process was determined based on net realizable value adjusted for costs to complete the manufacturing process, costs of the sales process, a reasonable profit allowance for the remaining manufacturing and sales process effort, and an estimate of holding costs. The fair value of raw materials was determined to approximate book value. The fair value step-up adjustment to inventories of $166.8 million is being amortized to cost of sales when the inventory is sold to customers, which is expected to be within less than one year from the acquisition date.

Property and equipment is mostly composed of land, buildings, equipment (including machinery, furniture and fixtures, and computer equipment), and construction in progress. The fair value of property and equipment was determined to approximate net book value at the time of the acquisition based on the information currently available and pending finalization of our fair value assessment.

Intangible assets relate to $240.0 million of in-process research and development (IPR&D) and $3,220.0 million of marketed products. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 12 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the "income approach," which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would
generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors. The fair value of intangible assets as of September 30, 2020 is based on preliminary assumptions which are subject to change as we complete our valuation procedures.
    
Assets held for sale include $135.0 million of marketed products rights, $7.3 million of IPR&D and $4.6 million of inventory related to the divestitures of Drontal™, Profender™ and other products. See the Divestitures section below for more information.

Accrued retirement benefits primarily relate to certain Bayer Animal Health international subsidiaries that have underfunded defined benefit pension plans. We have recorded the fair value of these plans using assumptions and accounting policies similar to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019. Upon acquisition, the excess of projected benefit obligation over the plan assets was recognized as a liability and previously existing deferred actuarial gains and losses and unrecognized service costs or benefits were eliminated. The resulting incremental net pension expense from the acquired plans was immaterial for the three months ended September 30, 2020.

The goodwill recognized from this acquisition represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies and cost savings from the creation of a single combined global organization. The majority of goodwill associated with this acquisition is not deductible for tax purposes.

The following table summarizes the changes in the carrying amount of goodwill during the period:

Balance as of December 31, 2019$2,989.6 
Aratana measurement period adjustments19.9 
Additions related to the Bayer Animal Health acquisition3,327.3 
Foreign currency translation adjustments97.9 
Balance as of September 30, 2020$6,434.7 

Goodwill is reviewed for impairment at least annually and when certain impairment indicators are present. As of September 30, 2020, there were no goodwill impairment losses.

Pro forma financial information (unaudited)

The following table presents the estimated unaudited pro forma combined results of Elanco, Bayer Animal Health and Aratana for the three and nine months ended September 30, 2020 and 2019 as if the acquisitions had occurred on January 1, 2019:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenues$1,072.6 $1,111.2 $3,318.3 $3,553.7 
Loss before income taxes
(222.8)(144.0)(382.1)(29.2)

The supplemental pro forma financial information has been prepared using the acquisition method of accounting and is based on the historical financial information of Elanco, Bayer Animal Health and Aratana. The supplemental pro forma financial information does not necessarily represent what the combined companies' revenue or results of operations would have been had the acquisitions been completed on January 1, 2019, nor is it intended to be a projection of future operating results of the combined company. It also does not reflect any operating efficiencies or potential cost savings that might be achieved from synergies of combining Elanco, Bayer Animal Health and Aratana.
The unaudited supplemental pro forma financial information reflects primarily pro forma adjustments related to divestitures, fair value estimates for intangibles and inventory, and interest expense and amortization of debt issuance costs for the debt issuance to finance the acquisition of Bayer Animal Health. The unaudited supplemental pro forma financial information includes transaction charges associated with the acquisition. There are no material, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported pro forma revenue and loss before income taxes.

Divestitures

In order to secure the necessary regulatory clearances for the acquisition of Bayer Animal Health, we signed agreements to divest the rights to manufacture and commercialize certain products. The following table summarizes the financial impact of the material divestitures completed during the third quarter of 2020, the pre-tax gains and losses on which are included in other - net, (income) expense in the condensed consolidated statement of operations.

Three and Nine Months Ended September 30, 2020
Gross Cash ProceedsPre-tax Gain
Osurnia™ $140.5 $93.1 
Vecoxan™ 55.1 37.1 
Capstar™ 95.9 25.5 
Drontal and Profender™
140.6 — 
Other immaterial divestitures2.6 0.7 
Total (1)
$434.7 $156.4 
(1) Pre-tax gain is net of transaction costs of $13.3 million.

We determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results.

Elanco product divestitures

In January 2020, we signed agreements to divest the worldwide rights to Osurnia and the U.S. rights to Capstar, and in February 2020, we signed an agreement to divest the worldwide rights to Vecoxan. The carrying value of the divested assets consisted of $114.1 million of marketed product rights and $7.9 million of inventory. In July 2020, we completed these sales, along with certain other immaterial divestitures. The transactions were accounted for as asset divestitures.

Bayer Animal Health product divestitures

To allow the Bayer Animal Health acquisition to close on a timely basis, we signed agreements to divest the rights to the Drontal and Profender product families within the United Kingdom and European Economic Area as well as other IPR&D. We completed the transactions, which were accounted for as asset divestitures, on August 3, 2020. Drontal, Profender, and the IPR&D were acquired as part of the Bayer Animal Health acquisition. The related assets were classified as held for sale on the balance sheet as of the acquisition date and measured at fair value at the time of the acquisition; therefore, no gains were recognized on the sales. A loss of $7.3 million was recorded on the sale of IPR&D as recognition of the potential income from the divestiture was constrained by revenue accounting standards. The estimated fair value of the divested assets consisted of $135.0 million of marketed product rights, $7.3 million of IPR&D, and $3.6 million of inventory.

There are additional marketed and pipeline products that we are required to dispose of in order to comply with regulatory requirements. These divestitures are not expected to have a material effect on our operations, cash flows or financial position.
Assets Held For Sale

The related assets for the Osurnia and Capstar divestitures met the assets held for sale criteria as of December 31, 2019. No adjustments were required to record the assets at the lower of their carrying amounts or fair values less costs to sell on the consolidated balance sheet. Assets and liabilities considered held for sale in connection with the divestitures were included in the respective line items on the consolidated balance sheet as follows:
December 31, 2019
Inventories$10.6 
Other intangibles, net61.2 
Property and equipment, net0.2 
Total assets held for sale$72.0 
Deferred taxes$(1.4)
Total liabilities held for sale$(1.4)

Other intangibles, net classified as held for sale primarily consisted of marketed products.

2019 Acquisitions

Aratana Therapeutics, Inc.

On July 18, 2019, we acquired Aratana, a pet therapeutics company focused on innovative therapies for dogs and cats, for stock and cash-based contingent value rights. Aratana is the creator of the canine osteoarthritis medicine, Galliprant™, the rights to which we acquired in 2016. The acquisition enhances our presence in the areas of appetite stimulants in dogs, pain relief in dogs and cats, and treatments of other conditions in the U.S. and internationally. In connection with the acquisition, we issued approximately 7.2 million shares with a value of $238.0 million to Aratana shareholders, based on our stock price on the last trading day immediately prior to the closing date. The purchase consideration also included up to $12 million in contingent value rights, which represent the rights of Aratana shareholders to receive a contingent payment of $0.25 per share in cash upon the achievement of a specified milestone as outlined in the merger agreement. We calculated an immaterial fair value for the contingent value rights using the Monte Carlo simulation model.

Contingent consideration liabilities that we previously recorded for future royalty and milestone payments in relation to the 2016 acquisition of rights to Galliprant were settled upon the closing of our acquisition of Aratana. The liabilities were valued at $84.7 million as of the acquisition date using the Monte Carlo simulation model. The resulting $7.5 million loss upon settlement was recorded in other - net, (income) expense in the consolidated and combined statement of operations for the year ended December 31, 2019.
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 18, 2019
Cash and cash equivalents$26.4 
Inventories10.3 
Acquired in-process research and development 31.9 
Marketed products (1)
36.7 
Other intangible assets (1)
13.2 
Other assets and liabilities - net 4.1 
Total identifiable net assets122.6 
Goodwill (2)
30.7 
Settlement of existing contingent consideration liabilities84.7 
Total consideration transferred$238.0 
(1)These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.
(2)The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.

The accounting for this acquisition is complete. A $19.1 million measurement period adjustment was recorded to establish a deferred tax liability for the preexisting Galliprant contingent consideration liability during the nine months ended September 30, 2020.

We issued 0.1 million shares and recorded $3.6 million of stock-based compensation expense for the vesting of Aratana equity awards that was accelerated upon the closing of the acquisition during 2019.

Prevtec Microbia Inc.

On July 31, 2019, we acquired Prevtec in a cash transaction for approximately $60.3 million, inclusive of certain post-closing adjustments. Prevtec is a Canadian biotechnology company specializing in the development of vaccines intended to help prevent bacterial diseases in farm animals. The acquisition allows us to expand on our previous distribution arrangement for Coliprotec™ and is consistent with our efforts to explore innovative antibiotic alternatives.

The purchase consideration included up to $16.3 million in additional cash consideration, contingent upon the achievement of specific sales milestones by December 31, 2021. We recorded a $4.7 million liability on the condensed consolidated balance sheet as of the acquisition date based on the fair value of the contingent consideration as calculated using the Monte Carlo simulation model.

A previously existing $0.7 million receivable owed from Prevtec to Elanco Animal Health UK Limited was settled upon the closing of our acquisition of Prevtec. The resulting immaterial gain upon settlement was recorded in other - net, (income) expense in the consolidated and combined statement of operations for the year ended December 31, 2019.
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 31, 2019
Cash and cash equivalents$0.9 
Property and equipment0.5 
Acquired in-process research and development 2.8 
Marketed products (1)
58.9 
Other intangible assets1.1 
Other assets and liabilities - net(9.3)
Total identifiable net assets54.9 
Goodwill (2)
10.1 
Total consideration transferred$65.0 
(1)These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.
(2)The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.
The accounting for this acquisition is complete. An immaterial measurement period adjustment to deferred taxes was recorded during the nine months ended September 30, 2020.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Asset Impairment, Restructuring and Other Special Charges
 9 Months Ended
Sep. 30, 2020
Restructuring and Related Activities [Abstract]  
Asset Impairment, Restructuring and Other Special Charges
Note 7. Asset Impairment, Restructuring and Other Special Charges

In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.

For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.
Components of asset impairment, restructuring and other special charges are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Restructuring charges:
Severance and other costs (1) (2)
$130.2 $10.4 $131.2 $9.6 
Facility exit costs— — 0.7 — 
Acquisition related charges:
Transaction and integration costs (3)
131.1 46.1 318.5 99.6 
Non-cash and other items:
Asset impairment (4) (5)
— 10.2 3.5 14.2 
Asset write-down (6)
0.9 10.5 3.2 10.5 
Gain on sale of fixed assets (7)
— — (3.8)— 
Settlements and other (8)
— — 3.1 
Total expense$262.2 $77.2 $456.4 $133.9 

(1)For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program initiated following the acquisition of Bayer Animal Health. See below for further details.
(2)For the three and nine months ended September 30, 2019, these charges primarily related to a restructuring program initiated in 2019 to reduce costs and support margin expansion by eliminating certain positions across multiple locations and functions, including exiting research and development (R&D) operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England.
(3)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisition of Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly.
(4)Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an in-process research and development asset resulting from a reassessment of geographic viability.
(5)Asset impairment charges for the three and nine months ended September 30, 2019 related to an adjustment to fair value of intangible assets that were subject to product rationalization.
(6)Asset write-down expenses for the three and nine months ended September 30, 2020 and 2019 resulted from adjustments recorded to write assets classified as held and used down to their current fair value. Included are charges related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.
(7)Represents a gain on the disposal from the sale of an R&D facility in Prince Edward Island, Canada, which was written down during the three months ended September 30, 2019 as part of the announced 2019 program to streamline operations.
(8)Charge primarily relates to a non-recurring litigation settlement for a matter that originated prior to the Separation.

Following the closing of the Bayer Animal Health acquisition, we implemented a restructuring program designed to reduce duplication, drive efficiency and optimize our footprint in key geographies. As part of the restructuring plan, we intend to eliminate approximately 900 positions across 40 countries, primarily in the commercial and marketing functions, but also in the R&D, manufacturing and quality, and back office support functions. The proposed initiative is expected to lead to total restructuring charges of approximately $190 million to $210 million through 2021, consisting primarily of severance.
The following table summarizes the activity in our reserves established in connection with restructuring activities:
Facility exit costs SeveranceTotal
Balance at December 31, 2018$9.3 $35.1 $44.4 
Charges20.7 20.0 40.7 
Reserve adjustments— (10.2)(10.2)
Cash paid(2.0)(18.8)(20.8)
Balance at September 30, 2019$28.0 $26.1 $54.1 
Balance at December 31, 2019$5.4 $15.5 $20.9 
Charges0.7 131.9 132.6 
Reserve adjustments— (0.8)(0.8)
Cash paid(1.2)(15.0)(16.2)
Balance at September 30, 2020$4.9 $131.6 $136.5 

These reserves are included in other current liabilities on the consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories
 9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Inventories
Note 8. Inventories

We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method.

Inventories consisted of the following:
September 30, 2020December 31, 2019
Finished products$797.1 $402.9 
Work in process664.1 603.2 
Raw materials and supplies167.0 83.9 
Total1,628.2 1,090.0 
Decrease to LIFO cost(31.1)(39.3)
Inventories$1,597.1 $1,050.7 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Equity
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Equity
Note 3. Impact of Separation

In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement, a tax matters agreement and the transitional services agreement (TSA).

In addition to the agreements referenced above, we entered into several other related party transactions with Lilly before and at the time of the Separation. For additional information regarding our ongoing agreements, as well as certain activities while Lilly was a related party, see Note 17: Related Party Agreements and Transactions.
Note 9. Equity

Common Stock Offering

On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 22.7 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2.3 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25.0 million shares of our common stock for $767.5 million, after issuance costs.

Tangible Equity Unit (TEU) Offering

On January 22, 2020, we also completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528.5 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification.
The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in long-term debt on the consolidated balance sheet, with payments expected in the next twelve months reflected in current portion of long-term debt. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.

The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$470.8 $79.2 $550.0 
Less: Issuance costs18.4 3.1 21.5 
Net proceeds$452.4 $76.1 $528.5 

The senior amortizing notes have an aggregate principal amount of $79.2 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we will pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate will be equivalent to 5.00% per year with respect to the $50 stated amount per TEU.

Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)

The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14.3 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Debt
 9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Debt
Note 10. Debt

Long-term debt consisted of the following:
September 30, 2020December 31, 2019
Term loan B credit facility$4,175.0 $— 
Term credit facility— 371.4 
3.912% Senior Notes due 2021
500.0 500.0 
4.272% Senior Notes due 2023
750.0 750.0 
4.900% Senior Notes due 2028
750.0 750.0 
TEU amortizing notes66.2 — 
Other obligations0.4 0.4 
Unamortized debt issuance costs(101.5)(16.8)
Total debt6,140.1 2,355.0 
Less current portion of long-term debt553.6 24.5 
Total long-term debt$5,586.5 $2,330.5 
Maturities on long-term debt consisted of the following:

As of September 30, 2020 and for period/years ending December 31
Fourth quarter of 2020$16.8 
2021567.6 
202268.0 
2023797.5 
202440.3 
202539.9 
Thereafter4,711.1 
Total obligations and commitments6,241.2 
Unamortized debt issuance costs and other obligations(101.1)
Total debt$6,140.1 

New Credit Facility

In connection with the acquisition of Bayer Animal Health, on August 1, 2020, we executed our previously announced borrowing of $4,275.0 million under a term loan B credit facility, of which $4,175.0 million was outstanding as of September 30, 2020. The term loan B facility bears interest at a floating rate of LIBOR plus 175 basis points over a seven-year term.

Simultaneously, we entered into a revolving credit facility providing up to $750.0 million and maturing over a five-year term. The revolving credit facility bears interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on our corporate family rating or corporate credit rating. On August 1, 2020, we drew down $200.0 million on the revolving credit facility to fund local country asset purchases in connection with our acquisition of Bayer Animal Health subsidiaries and subsequently repaid the amount in full later that month. As a result, we capitalized approximately $9.2 million of debt issuance costs in other noncurrent assets on the condensed consolidated balance sheet. In October 2020, we drew down $250.0 million on the revolving credit facility to fund local country asset purchases in connection with our acquisition of Bayer Animal Health subsidiaries. Pursuant to the stock and asset purchase agreement, Bayer is to reimburse us for these purchases. See Note 17: Related Party Agreements and Transactions for further discussion.

We have capitalized deferred financing costs of approximately $90.2 million, consisting of legal, accounting and other fees relating to our new credit facility. Deferred financing costs are recorded as a contra-liability and presented
net against long-term debt on the condensed consolidated balance sheet. Upon closing the acquisition of Bayer Animal Health on August 1, 2020, we terminated our unused commitments and incurred approximately $13.8 million in fees, which are included in other - net, (income) expense in the condensed consolidated statement of operations.

Proceeds from the equity and debt activities were used to finance the cash portion of our acquisition of Bayer Animal Health and to pay related fees and expenses (see Note 6: Acquisitions and Divestitures for further discussion). Subsequent to these borrowings, we have terminated all unused commitments to our lenders.

These senior secured first lien credit facilities are secured by a significant portion of our assets. They include two financial maintenance covenants which are solely for the benefit of lenders under the revolving credit facility. There are no financial maintenance covenants for the benefit of the term loan B facility. The lenders under the term loan B facility have no enforcement rights with respect to the financial maintenance covenants for the revolving credit facility.

The first financial maintenance covenant for the revolving credit facility requires us to maintain a net total leverage ratio level (which is not subject to step-downs) as of the end of each quarter, beginning with the fiscal quarter ending September 30, 2020. The required level of this covenant is based on closing date pro forma net leverage and pro forma adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) not exceeding 7.71 to 1.00 of our pro forma adjusted EBITDA for the four fiscal quarters ended September 30, 2020.

The second financial maintenance covenant for the revolving credit facility requires us to maintain a ratio of pro forma adjusted EBITDA to cash interest expense of no less than 2.00 to 1.00, tested as of the end of each fiscal quarter, beginning with the fiscal quarter ended September 30, 2020. We were in compliance with all covenants under the credit facility as of September 30, 2020.

Debt Extinguishment

On January 31, 2020, we repaid indebtedness outstanding under our existing term loan facility. We paid $372.4 million in cash, composed of $371.4 million of principal and $1.0 million of accrued interest, resulting in a debt extinguishment loss of $0.8 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statement of operations for the nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs.

On September 25, 2020, we made a repayment of principal of $100.0 million on the indebtedness outstanding under our new term loan B facility. The repayment was accounted for as a partial debt extinguishment and resulted in a debt extinguishment loss of $2.1 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statement of operations for the three and nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs.

TEU Amortizing Notes

On January 22, 2020, we issued $550 million in TEUs. We offered 11 million, 5.00% TEUs at the stated amount of $50 per unit, comprised of prepaid stock purchase contracts and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $528.5 million was received, comprised of $452.4 million of prepaid stock purchase contracts and $76.1 million of senior amortizing notes, net of issuance costs. We paid $14.1 million representing partial payment of principal and interest on the TEU amortizing notes during the nine months ended September 30, 2020. See Note 9: Equity for further information.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments and Fair Value
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value
Note 11. Financial Instruments and Fair Value

Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.

A large portion of our cash is held in a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.
As of September 30, 2020 and December 31, 2019, we had $21.7 million and $18.8 million, respectively, primarily related to equity method investments included in other noncurrent assets on our condensed consolidated balance sheet.

The following table summarizes the fair value information at September 30, 2020 and December 31, 2019 for foreign exchange contract assets (liabilities), contingent consideration liabilities, net investment hedge assets (liabilities) and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2020
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$10.7 $— $10.7 $— $10.7 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(7.6)— (7.6)— (7.6)
Other noncurrent liabilities - contingent consideration(2.6)— — (2.6)(2.6)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges(87.0)— (87.0)— (87.0)
Long-term debt - senior notes(2,000.0)— (2,186.7)— (2,186.7)
TEU amortizing note (1)
(66.2)— (66.2)— (66.2)
Term loan B(4,175.0)— (4,068.0)— (4,068.0)
December 31, 2019
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$0.8 $— $0.8 $— $0.8 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(1.1)— (1.1)— (1.1)
Other noncurrent liabilities - contingent consideration(4.7)— — (4.7)(4.7)
Other noncurrent assets - cross currency interest rate contracts designated as net investment hedges2.3 — 2.3 — 2.3 
Long-term debt - senior notes(2,000.0)— (2,120.6)— (2,120.6)
Long-term debt - term credit facility (1)
(371.4)— (371.4)— (371.4)

(1)We consider the carrying value to be representative of its fair value.

We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities.
Contingent consideration liabilities as of September 30, 2020 and December 31, 2019 related to contingent consideration associated with the acquisitions of Aratana and Prevtec during 2019. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16.3 million contingent upon the achievement of specific Coliprotec sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility. During the nine months ended September 30, 2020, primarily as a result of a decrease in forecasted revenues related to Coliprotec, we decreased the fair value of the contingent consideration liability associated with the Prevtec acquisition by $2.1 million, and recognized the gain in other – net, (income) expense in the condensed consolidated statement of operations. See Note 6: Acquisitions and Divestitures for further discussion.

Derivative Instruments and Hedging Activities

We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures.

Derivatives Not Designated as Hedges

We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the British pound, Canadian dollar, Euro, Japanese yen, Swiss franc (CHF), and Chinese renminbi. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other – net, (income) expense in the condensed consolidated income statement. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2020 and December 31, 2019, we had outstanding foreign exchange contracts with aggregate notional amounts of $1,496.9 million and $861.2 million, respectively.

The amount of net gain/(loss) on derivative instruments not designated as hedging instruments, recorded in other - net, (income) expense are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Foreign exchange forward contracts (1)
$(2.3)$10.1 $19.4 $8.8 

(1)These amounts were substantially offset in other – net, (income) expense by the effect of changing exchange rates on the underlying foreign currency exposures.

Derivatives Designated as Hedges

In October 2018, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a five-year cross-currency fixed interest rate swap with a 750 million CHF notional amount, which was designated as a net investment hedge (NIH) against CHF denominated assets (the fair value of which was estimated based on quoted market values of similar hedges and was classified as Level 2). During the nine months ended September 30, 2020, we fully liquidated our cross currency interest rate swaps for a cash benefit of $35.1 million (including $2.4 million in interest). Notwithstanding settlement, gains and losses within accumulated other comprehensive loss will remain in accumulated other comprehensive loss until either the sale or substantial liquidation of the hedged subsidiary.
Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cross-currency interest rate swap contracts$— $6.2 $6.2 $18.4 

Over the life of the derivative, gains or losses due to spot rate fluctuations were recorded in cumulative translation adjustment in other comprehensive income. The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cross-currency interest rate swap contracts$— $18.5 $24.0 $23.9 


Separately, in March 2020, as a means of mitigating variability in cash flows associated with the anticipated term loan B issuance, we executed forward-starting interest rate swaps with a $4.05 billion notional amount, which are designated as cash flow hedges and have settlement dates ranging between 2022 and 2025. These instruments effectively convert floating-rate debt to fixed-rate debt. The cash flow hedges are recorded at fair value on our condensed consolidated balance sheet, while changes in the fair value of the hedge are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Amounts recorded in accumulated other comprehensive income (loss) will be recognized in earnings in interest expense, net of capitalized interest when the hedged transaction affects earnings (i.e., when interest payments are accrued on the term loan B). During the three and nine months ended September 30, 2020, we recorded a loss of $7.5 million (net of tax benefit of $2.2 million) and $67.4 million (net of tax benefit of $19.6 million), respectively, on the cash flow hedges in other comprehensive income (loss). Over the next 12 months we expect to reclassify $28.0 million from accumulated other comprehensive loss to interest expense, net of capitalized interest due to the amortization of net losses on the interest rate swaps.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Leases
 9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Leases
Note 12. Leases

Australia Sale-Leaseback

On June 26, 2020, our wholly-owned subsidiary, Elanco Australasia PTY LTD, sold land and an R&D facility located in New South Wales, Australia, for aggregate proceeds of $55.1 million, and leased the property back for an initial term of 15 years through a sale-leaseback transaction. Under the terms of the purchase and sale agreement, we determined that control of the assets was relinquished to the buyer-lessor. Therefore, we recognized a pre-tax gain on the sale of $45.6 million in other - net, (income) expense in the condensed consolidated statement of operations during the nine months ended September 30, 2020. Operating lease right-of-use assets and liabilities include the present value of $27.8 million for the associated lease payments, which are presented in other noncurrent assets and other noncurrent liabilities and other current liabilities on the condensed consolidated balance sheet.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes
 9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
Income Taxes
Note 13. Income Taxes


Provision for Taxes on IncomeThree Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Income tax (benefit) expense$(74.0)$(22.5)$(116.6)$5.1 
Effective tax rate35.4 %179.7 %32.9 %6.2 %

Our income taxes for the nine months ended September 30, 2019 and 2020, respectively, reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return until full separation. In the jurisdictions in which we were included in a combined tax return, our income taxes were
determined based on the tax matters agreement between us and Lilly. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns.

In 2017, the U.S. enacted the Tax Cuts and Jobs Act (2017 Tax Act), which significantly revised U.S. tax law. Guidance related to the 2017 Tax Act, including Notices, Proposed Regulations, and Final Regulations, has been issued, and we expect additional guidance will be issued in 2020. This additional guidance could materially impact our assumptions and estimates used to record our U.S. federal and state income tax expense resulting from the 2017 Tax Act.

We are included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. During the fourth quarter of 2019, the IRS began its examination of tax years 2016 - 2018. Because the examination is still in the early stages of information gathering, the resolution of the audit will likely extend beyond the next 12 months.

For the three and nine months ended September 30, 2020, we recognized $74.0 million and $116.6 million, respectively, of income tax benefit. For the three and nine months ended September 30, 2020, our effective tax rate of 35.4% and 32.9%, respectively, differs from the statutory income tax rate primarily due to the release of foreign valuation allowances as a result of gains on divestitures. Additionally, the state tax benefit is a result of U.S. pre-tax losses and the foreign tax benefit is due to losses in jurisdictions with tax rates higher than U.S. statutory rates.

For the three and nine months ended September 30, 2019, we recognized a tax benefit of $22.5 million and incurred $5.1 million of income tax expense, respectively. For the three and nine months ended September 30, 2019, our effective tax rate differs from the statutory income tax rate primarily due to a discrete tax benefit from the resolution of a Brazil tax audit in addition to the impact of lower pre-tax earnings largely due to restructuring charges. Tax reserves had been established in the 2015 acquisition of Novartis Animal Health (Novartis) and were partially covered by an indemnity. The favorable resolution of the Brazil tax audit resulted in an income tax benefit of approximately $14 million in the third quarter of 2019.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 14. Commitments and Contingencies

Legal Matters

On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco, Jeffrey Simmons and Todd Young. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between January 10, 2020 and May 6, 2020. On September 3, 2020, the Court appointed a lead plaintiff. The deadline for the lead plaintiff to file an amended complaint is November 9, 2020. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

On October 16, 2020, a shareholder class action lawsuit captioned Safron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3/ASR dated January 21, 2020 and accompanying prospectus on Form 424B5 issued in connection with Elanco’s secondary public offering that closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities pursuant to the secondary public offering. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.
We are party to various other legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. We accrue for certain liability claims to the extent that it is probable we will incur a loss and we can formulate a reasonable estimate of the costs. As of September 30, 2020 and December 31, 2019, we had no material liabilities established related to litigation as there were no significant claims which were probable and estimable. We have not historically had any significant litigation expense and are not currently subject to a significant claim other than the lawsuits noted above.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Geographic Information
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Geographic Information
Note 15. Geographic Information

We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both farm animals and pets. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant cost/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results. We are currently in the process of reviewing our operating segments as a result of potential changes to our operational structure due to the acquisition of Bayer Animal Health.

Our products include Rumensin™, Optaflexx™, Denagard™, Tylan™, Maxiban™, Baycox™, Cydectin™ and other products for livestock and poultry, as well as Trifexis™, Interceptor™, Comfortis™, Galliprant, Seresto™, Advantage™, Advantix™, Advocate™ (collectively referred to as the Advantage Family) and other products for pets.

We have a single customer that accounted for 11.7% and 15.9% of revenue for the three months ended September 30, 2020 and 2019, respectively, and for 11.9% and 13.4% of revenue for the nine months ended September 30, 2020 and 2019, respectively. The product sales resulted in accounts receivable with this customer of $78.1 million and $90.5 million as of September 30, 2020 and December 31, 2019, respectively.

We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

Selected geographic area information was as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenue—to unaffiliated customers (1)
United States$421.5 $388.2 $969.5 $1,167.1 
International468.1 383.1 1,164.1 1,116.9 
Revenue$889.6 $771.3 $2,133.6 $2,284.0 
September 30, 2020December 31, 2019
Long-lived assets (2)
United States$942.6 $709.8 
Germany243.7 39.7 
United Kingdom206.3 192.6 
Other foreign countries273.1 205.0 
Long-lived assets$1,665.7 $1,147.1 
(1)Revenue is attributed to the countries based on the location of the customer.
(2)Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Earnings Per Share
Note 16. Earnings Per Share

Basic Earnings Per Share

We compute basic earnings (loss) per share by dividing net earnings (loss) available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. For the three and nine months ended September 30, 2020, the weighted average number of common shares outstanding used to calculate basic earnings per share includes the impact of approximately 72.9 million shares of common stock issued to Bayer and its subsidiaries for the Bayer Animal Health acquisition. In addition, basic earnings per share reflects the impacts of 25.0 million shares and 14.3 million shares, respectively, issued in connection with our common stock and TEU issuances in the first quarter of 2020. See Note 6: Acquisitions and Divestitures and Note 9: Equity for further discussion.

Diluted Earnings Per Share

Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts. Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method.

Weighted average diluted shares outstanding included common stock equivalents of 1.5 million and 1.0 million for the three and nine months ended September 30, 2019, respectively.
Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. During the three and nine months ended September 30, 2020, we reported a net loss. Therefore, dilutive common shares are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share.
For the three and nine months ended September 30, 2019, approximately 0.1 million shares of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Agreements and Transactions
 9 Months Ended
Sep. 30, 2020
Related Party Transactions [Abstract]  
Related Party Agreements and Transactions
Note 17. Related Party Agreements and Transactions

Elanco Shares Held by Bayer

On August 1, 2020, we completed the acquisition of Bayer Animal Health, which included cash and Elanco stock consideration. Pursuant to the share and asset purchase agreement, Bayer has the right to sell such shares on or after November 1, 2020 through multiple registered offerings. Upon Bayer's written request, Elanco is obligated to use commercially reasonable efforts to file a shelf registration statement covering the resale by Bayer of its Elanco common stock. As of September 30, 2020, Bayer owns 72.9 million shares, or 15.5% of our outstanding common stock.
Transactions with Bayer Subsequent to the Acquisition of Bayer Animal Health

There were various transactions between us and Bayer during the period after the acquisition of Bayer Animal Health. The total net payable due to Bayer at September 30, 2020 was $9.8 million related to these transactions. We also have $60.0 million associated with lease agreements with Bayer recorded on our condensed consolidated balance sheet as of September 30, 2020. Further details regarding our ongoing relationship with Bayer are included below.

Transitional Services Agreements (TSA) and Reverse TSAs

To ensure business continuity after the acquisition of the Bayer Animal Health business, we entered into certain TSAs and reverse TSAs with Bayer. Under the TSAs, Bayer will provide us certain specified R&D services and back office support on a transitional basis, including among other things, logistical services, commercial operations support, and information systems. We will pay Bayer mutually agreed-upon fees for services provided under the TSAs, a majority of which are based on fixed hourly rates, and subject to a contractually agreed mark-up. We have recorded approximately $2.7 million of expense for the three and nine months ended September 30, 2020 related to these agreements.

The reverse TSAs are primarily comprised of contracts whereby we have agreed to provide Bayer certain R&D services on a transitional basis. During the three and nine months ended September 30, 2020, reverse TSA activity was immaterial.

Leases

We lease certain facilities and fleet vehicles from Bayer. Our operating lease right-of-use assets and liabilities include the present value of $60.0 million for the lease payments related to these leases, which are presented in other noncurrent assets and other noncurrent liabilities and other current liabilities on the condensed consolidated balance sheet.

Local Country Asset Purchases

For regulatory purposes in certain jurisdictions, consideration was required to be paid locally at closing in addition to amounts paid globally for the acquisition. Pursuant to the stock and asset purchase agreement, Bayer is to provide a refund for payment amounts duplicated in these regions. As of September 30, 2020, the local payment has not yet been made in China due to certain regulatory delays. Thus, as of September 30, 2020, we had a receivable from and payable to Bayer of $233.6 million and $233.6 million, respectively, recorded on a net basis on the condensed consolidated balance sheet.

Other Activities

We also entered into various other agreements with Bayer, including certain supply agreements and contract manufacturing and toll manufacturing agreements. These contracts are for activities in the normal course of business and are required to maintain and establish business relationships on a long-term basis.

In connection with the acquisition, we have an obligation to reimburse Bayer for certain costs they incurred on our behalf. Accordingly, we have recorded approximately $20.4 million in other current liabilities on the condensed consolidated balance sheet as of September 30, 2020 and within asset impairment, restructuring and other special charges in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 for amounts owed to Bayer.
Transactions with Lilly Subsequent to Separation and Related to the Separation

Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services were as follows:
September 30, 2020December 31, 2019
TSA$1.1 $10.5 
Other activities(1.7)(15.8)
Local country asset purchases(10.7)(11.1)
Total payable to Lilly$(11.3)$(16.4)

As described in Note 1, we completed an IPO in September 2018 and Lilly fully divested all ownership of Elanco in March 2019. In connection with the Separation, we entered into various agreements with Lilly related to the form of our separation and certain ongoing activities that will continue for a period of time. These included, among others, a master separation agreement (MSA), a TSA and a tax matters agreement. In addition, there was a portion of our operations for which the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries.

TSA

Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we are able to use Lilly Services for a fixed term established on a service-by-service basis. We pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which are based on Lilly's cost (including third-party costs) of providing the Lilly Services through March 31, 2021, and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2022. The fees under the TSA became payable for all periods beginning after October 1, 2018.

Separation Activities

Subsequent to our IPO, there continue to be transactions between us and Lilly related primarily to the completion of the local country asset purchases and finalization of assets and liabilities associated with the legal separation from Lilly, combined income tax returns and the impact of the tax matters agreement, historical Lilly retirement benefits, and centralized cash management. The most significant of these activities includes the finalization of the local country valuation of business and the resulting impact on deferred tax assets and the impact of combined tax returns.

Other Activities

We continue to share certain services and back office functions with Lilly, which in certain instances result in Lilly paying costs for Elanco (e.g., utilities, local country operating costs, etc.) that are then passed through to Elanco for reimbursement. These amounts are included in cash flows from operating activities in our consolidated statements of cash flows. In addition, we operate through a single treasury settlement process and prior to the local country asset purchases (as described below) continued to transact through Lilly's processes in certain instances. As a result of these activities, there were certain amounts of financing that occurred between Lilly and Elanco during the nine months ended September 30, 2019 and 2020. These amounts are included in cash flows from financing activities in our condensed consolidated statements of cash flows.

Local Country Asset Purchases

The legal transfer of certain of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. The related assets, liabilities, and results of operations have been reported in our condensed consolidated financial statements, as we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets under the terms of the MSA. We held restricted cash, and the associated payable to Lilly, at the date of Separation to fund the acquisition of these assets. As of September 30, 2020, the majority of these assets have been legally
acquired and the remainder are expected to be purchased during 2020. Restricted cash and Payable to Lilly of $10.7 million are recorded on the condensed consolidated balance sheet for the remainder of the assets expected to be purchased by the end of 2020.

Transactions with Lilly Prior to Full Separation

Prior to the IPO, we did not operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us. The impact on our historical combined financial statements includes the following:

Stock-based Compensation
Prior to full separation, our employees participated in Lilly stock-based compensation plans, the costs of which were allocated to us and recorded in cost of sales, research and development, and marketing, selling and administrative expenses in the condensed consolidated statements of operations. The costs of such plans related to our employees were $5.1 million for the nine months ended September 30, 2019.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The accounts of all wholly owned and controlled subsidiaries are included in the condensed consolidated financial statements and all intercompany balances and transactions have been eliminated.
Reclassifications Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with current presentation.
Consolidation The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020.
Income Tax Our income taxes in 2019 and thereafter reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return with Lilly until full separation. The income tax amounts in the financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions.
Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables.
We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements.
Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract
This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements.
The following table provides a brief description of accounting standards applicable to us that have not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.We are currently evaluating the effect of this standard on our consolidated financial statements.
Accounting Standards Update 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting
This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Implementation of New Financial Accounting Pronouncements (Tables)
 9 Months Ended
Sep. 30, 2020
Accounting Changes and Error Corrections [Abstract]  
Description of Accounting Standards Adopted and Not Yet Adopted
The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables.
We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements.
Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract
This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements.
The following table provides a brief description of accounting standards applicable to us that have not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.We are currently evaluating the effect of this standard on our consolidated financial statements.
Accounting Standards Update 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting
This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue (Tables)
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Summary of Activity in Sales Rebates and Discounts Liability
The following table summarizes the activity in the sales rebates liability in the U.S.:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Beginning balance$122.0 $132.1 $150.4 $118.5 
Bayer Animal Health at acquisition20.8 — 20.8 — 
Reduction of revenue86.4 75.9 212.0 222.2 
Payments(78.6)(78.9)(232.6)(211.6)
Ending balance$150.6 $129.1 $150.6 $129.1 
Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Pet Health Disease Prevention$297.0 $207.6 $613.6 $616.9 
Pet Health Therapeutics103.3 87.6 247.1 252.4 
Farm Animal Future Protein & Health180.9 191.5 518.8 534.5 
Farm Animal Ruminants & Swine292.3 266.2 703.1 811.8 
Contract Manufacturing (1)
16.1 18.4 51.0 68.4 
Revenue$889.6 $771.3 $2,133.6 $2,284.0 
(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. This category was previously called Strategic Exits.
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures (Tables)
 9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Purchase Consideration
Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows:

Cash consideration$5,170.1 
Fair value of Elanco common stock (1)
1,723.7 
Fair value of total consideration transferred (2)
$6,893.8 

(1)Represents the acquisition date fair value of 72.9 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).
(2)The purchase price is preliminary and subject to working capital and customary purchase price adjustments.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 1, 2020
Cash and cash equivalents$168.8 
Accounts receivable9.7 
Inventories513.9 
Prepaid expenses and other current assets57.9 
Property and equipment299.6 
Intangible assets:
Acquired in-process research and development 240.0 
Marketed products3,220.0 
Assets held for sale146.9 
Accounts payable and accrued liabilities(172.8)
Accrued retirement benefits(209.6)
Other noncurrent assets and liabilities - net (707.9)
Total identifiable net assets3,566.5 
Goodwill3,327.3 
Total consideration transferred$6,893.8 
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 18, 2019
Cash and cash equivalents$26.4 
Inventories10.3 
Acquired in-process research and development 31.9 
Marketed products (1)
36.7 
Other intangible assets (1)
13.2 
Other assets and liabilities - net 4.1 
Total identifiable net assets122.6 
Goodwill (2)
30.7 
Settlement of existing contingent consideration liabilities84.7 
Total consideration transferred$238.0 
(1)These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.
(2)The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 31, 2019
Cash and cash equivalents$0.9 
Property and equipment0.5 
Acquired in-process research and development 2.8 
Marketed products (1)
58.9 
Other intangible assets1.1 
Other assets and liabilities - net(9.3)
Total identifiable net assets54.9 
Goodwill (2)
10.1 
Total consideration transferred$65.0 
(1)These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.
(2)The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.
Schedule of Goodwill
The following table summarizes the changes in the carrying amount of goodwill during the period:

Balance as of December 31, 2019$2,989.6 
Aratana measurement period adjustments19.9 
Additions related to the Bayer Animal Health acquisition3,327.3 
Foreign currency translation adjustments97.9 
Balance as of September 30, 2020$6,434.7 
Pro Forma Information
The following table presents the estimated unaudited pro forma combined results of Elanco, Bayer Animal Health and Aratana for the three and nine months ended September 30, 2020 and 2019 as if the acquisitions had occurred on January 1, 2019:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenues$1,072.6 $1,111.2 $3,318.3 $3,553.7 
Loss before income taxes
(222.8)(144.0)(382.1)(29.2)
Divestitures Activities The following table summarizes the financial impact of the material divestitures completed during the third quarter of 2020, the pre-tax gains and losses on which are included in other - net, (income) expense in the condensed consolidated statement of operations.
Three and Nine Months Ended September 30, 2020
Gross Cash ProceedsPre-tax Gain
Osurnia™ $140.5 $93.1 
Vecoxan™ 55.1 37.1 
Capstar™ 95.9 25.5 
Drontal and Profender™
140.6 — 
Other immaterial divestitures2.6 0.7 
Total (1)
$434.7 $156.4 
(1) Pre-tax gain is net of transaction costs of $13.3 million.
Assets and liabilities considered held for sale in connection with the divestitures were included in the respective line items on the consolidated balance sheet as follows:
December 31, 2019
Inventories$10.6 
Other intangibles, net61.2 
Property and equipment, net0.2 
Total assets held for sale$72.0 
Deferred taxes$(1.4)
Total liabilities held for sale$(1.4)
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Asset Impairment, Restructuring and Other Special Charges (Tables)
 9 Months Ended
Sep. 30, 2020
Restructuring and Related Activities [Abstract]  
Total Charges Related to Asset Impairment, Restructuring and Other Special Charges
Components of asset impairment, restructuring and other special charges are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Restructuring charges:
Severance and other costs (1) (2)
$130.2 $10.4 $131.2 $9.6 
Facility exit costs— — 0.7 — 
Acquisition related charges:
Transaction and integration costs (3)
131.1 46.1 318.5 99.6 
Non-cash and other items:
Asset impairment (4) (5)
— 10.2 3.5 14.2 
Asset write-down (6)
0.9 10.5 3.2 10.5 
Gain on sale of fixed assets (7)
— — (3.8)— 
Settlements and other (8)
— — 3.1 
Total expense$262.2 $77.2 $456.4 $133.9 

(1)For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program initiated following the acquisition of Bayer Animal Health. See below for further details.
(2)For the three and nine months ended September 30, 2019, these charges primarily related to a restructuring program initiated in 2019 to reduce costs and support margin expansion by eliminating certain positions across multiple locations and functions, including exiting research and development (R&D) operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England.
(3)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisition of Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly.
(4)Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an in-process research and development asset resulting from a reassessment of geographic viability.
(5)Asset impairment charges for the three and nine months ended September 30, 2019 related to an adjustment to fair value of intangible assets that were subject to product rationalization.
(6)Asset write-down expenses for the three and nine months ended September 30, 2020 and 2019 resulted from adjustments recorded to write assets classified as held and used down to their current fair value. Included are charges related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.
(7)Represents a gain on the disposal from the sale of an R&D facility in Prince Edward Island, Canada, which was written down during the three months ended September 30, 2019 as part of the announced 2019 program to streamline operations.
(8)Charge primarily relates to a non-recurring litigation settlement for a matter that originated prior to the Separation.
Summary of Activity in Reserves
The following table summarizes the activity in our reserves established in connection with restructuring activities:
Facility exit costs SeveranceTotal
Balance at December 31, 2018$9.3 $35.1 $44.4 
Charges20.7 20.0 40.7 
Reserve adjustments— (10.2)(10.2)
Cash paid(2.0)(18.8)(20.8)
Balance at September 30, 2019$28.0 $26.1 $54.1 
Balance at December 31, 2019$5.4 $15.5 $20.9 
Charges0.7 131.9 132.6 
Reserve adjustments— (0.8)(0.8)
Cash paid(1.2)(15.0)(16.2)
Balance at September 30, 2020$4.9 $131.6 $136.5 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories consisted of the following:
September 30, 2020December 31, 2019
Finished products$797.1 $402.9 
Work in process664.1 603.2 
Raw materials and supplies167.0 83.9 
Total1,628.2 1,090.0 
Decrease to LIFO cost(31.1)(39.3)
Inventories$1,597.1 $1,050.7 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Equity (Tables)
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Schedule of Stockholders Equity
The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$470.8 $79.2 $550.0 
Less: Issuance costs18.4 3.1 21.5 
Net proceeds$452.4 $76.1 $528.5 
Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Long-term debt consisted of the following:
September 30, 2020December 31, 2019
Term loan B credit facility$4,175.0 $— 
Term credit facility— 371.4 
3.912% Senior Notes due 2021
500.0 500.0 
4.272% Senior Notes due 2023
750.0 750.0 
4.900% Senior Notes due 2028
750.0 750.0 
TEU amortizing notes66.2 — 
Other obligations0.4 0.4 
Unamortized debt issuance costs(101.5)(16.8)
Total debt6,140.1 2,355.0 
Less current portion of long-term debt553.6 24.5 
Total long-term debt$5,586.5 $2,330.5 
Schedule of Maturities of Long-term Debt
Maturities on long-term debt consisted of the following:

As of September 30, 2020 and for period/years ending December 31
Fourth quarter of 2020$16.8 
2021567.6 
202268.0 
2023797.5 
202440.3 
202539.9 
Thereafter4,711.1 
Total obligations and commitments6,241.2 
Unamortized debt issuance costs and other obligations(101.1)
Total debt$6,140.1 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments and Fair Value (Tables)
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Summary of Fair Value Information
The following table summarizes the fair value information at September 30, 2020 and December 31, 2019 for foreign exchange contract assets (liabilities), contingent consideration liabilities, net investment hedge assets (liabilities) and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2020
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$10.7 $— $10.7 $— $10.7 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(7.6)— (7.6)— (7.6)
Other noncurrent liabilities - contingent consideration(2.6)— — (2.6)(2.6)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges(87.0)— (87.0)— (87.0)
Long-term debt - senior notes(2,000.0)— (2,186.7)— (2,186.7)
TEU amortizing note (1)
(66.2)— (66.2)— (66.2)
Term loan B(4,175.0)— (4,068.0)— (4,068.0)
December 31, 2019
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$0.8 $— $0.8 $— $0.8 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(1.1)— (1.1)— (1.1)
Other noncurrent liabilities - contingent consideration(4.7)— — (4.7)(4.7)
Other noncurrent assets - cross currency interest rate contracts designated as net investment hedges2.3 — 2.3 — 2.3 
Long-term debt - senior notes(2,000.0)— (2,120.6)— (2,120.6)
Long-term debt - term credit facility (1)
(371.4)— (371.4)— (371.4)
(1)We consider the carrying value to be representative of its fair value.
Net Gain/Loss on Derivative Instruments
The amount of net gain/(loss) on derivative instruments not designated as hedging instruments, recorded in other - net, (income) expense are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Foreign exchange forward contracts (1)
$(2.3)$10.1 $19.4 $8.8 

(1)These amounts were substantially offset in other – net, (income) expense by the effect of changing exchange rates on the underlying foreign currency exposures.
Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cross-currency interest rate swap contracts$— $6.2 $6.2 $18.4 
The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cross-currency interest rate swap contracts$— $18.5 $24.0 $23.9 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
Provision for Taxes on Income
Provision for Taxes on IncomeThree Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Income tax (benefit) expense$(74.0)$(22.5)$(116.6)$5.1 
Effective tax rate35.4 %179.7 %32.9 %6.2 %
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Geographic Information (Tables)
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Revenue by Selected Geographic Area Information
Selected geographic area information was as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenue—to unaffiliated customers (1)
United States$421.5 $388.2 $969.5 $1,167.1 
International468.1 383.1 1,164.1 1,116.9 
Revenue$889.6 $771.3 $2,133.6 $2,284.0 
Long-lived Assets by Selected Geographic Area Information
September 30, 2020December 31, 2019
Long-lived assets (2)
United States$942.6 $709.8 
Germany243.7 39.7 
United Kingdom206.3 192.6 
Other foreign countries273.1 205.0 
Long-lived assets$1,665.7 $1,147.1 
(1)Revenue is attributed to the countries based on the location of the customer.
(2)Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Agreements and Transactions (Tables)
 9 Months Ended
Sep. 30, 2020
Related Party Transactions [Abstract]  
Amounts Due From/(Due To) Lilly and Allocations of Services
Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services were as follows:
September 30, 2020December 31, 2019
TSA$1.1 $10.5 
Other activities(1.7)(15.8)
Local country asset purchases(10.7)(11.1)
Total payable to Lilly$(11.3)$(16.4)
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Nature of Business and Organization (Details)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Aug. 01, 2020
USD ($)
shares
Jan. 23, 2020
USD ($)
shares
Sep. 24, 2018
USD ($)
$ / shares
shares
Sep. 30, 2020
brand
country
shares
Sep. 30, 2020
brand
country
shares
Subsidiary, Sale of Stock [Line Items]          
Number of brands in diverse portfolio | brand       190 190
Number of countries in which entity operates (more than) | country       90 90
Number of shares issued (in shares) | shares   25.0      
Total net proceeds, after underwriting discounts and commissions   $ 767.5      
Bayer Animal Business          
Subsidiary, Sale of Stock [Line Items]          
Cash paid in acquisition $ 5,170.1        
Shares issued to previous shareholders upon closing (in shares) | shares 72.9     72.9 72.9
IPO          
Subsidiary, Sale of Stock [Line Items]          
Number of shares issued (in shares) | shares     72.3    
Percentage of total outstanding shares     19.80%    
Price per share (usd per share) | $ / shares     $ 24    
Total net proceeds, after underwriting discounts and commissions     $ 1,700.0    
Payments made to date     $ 4,200.0    
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Impact of Separation (Details) - USD ($)
Aug. 01, 2020
Sep. 24, 2018
Senior Notes    
Debt Instrument [Line Items]    
Debt instrument, face amount   $ 2,000,000,000.0
Credit Facility | Senior Unsecured Revolving Credit Facility    
Debt Instrument [Line Items]    
Credit facility, maximum borrowing capacity $ 750,000,000.0 750,000,000.0
Credit Facility | Senior Unsecured Term Credit Facility    
Debt Instrument [Line Items]    
Credit facility, maximum borrowing capacity   $ 500,000,000.0
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Implementation of New Financial Accounting Pronouncements (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Sep. 30, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201613Member  
Decrease due to adoption $ (84.3) $ 154.4
Cumulative Effect, Period of Adoption, Adjustment    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Decrease due to adoption $ 1.4  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Geographic Concentration Risk | Contract With Customer Liability | United States        
Concentration Risk [Line Items]        
Concentration risk (less than 0.1%)     54.00% 71.00%
Geographic Concentration Risk | Contract With Customer Liability | Next Largest Country        
Concentration Risk [Line Items]        
Concentration risk (less than 0.1%)     12.00% 6.00%
Product Return Concentration Risk | Net Revenue        
Concentration Risk [Line Items]        
Concentration risk (less than 0.1%) 0.10% 0.10% 1.20% 0.10%
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Change In Contract With Customer, Liability [Roll Forward]        
Beginning balance $ 122.0 $ 132.1 $ 150.4 $ 118.5
Bayer Animal Health at acquisition 20.8 0.0 20.8 0.0
Reduction of revenue 86.4 75.9 212.0 222.2
Payments (78.6) (78.9) (232.6) (211.6)
Ending balance $ 150.6 $ 129.1 $ 150.6 $ 129.1
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Disaggregation of Revenue [Line Items]        
Revenue $ 889.6 $ 771.3 $ 2,133.6 $ 2,284.0
Pet Health Disease Prevention        
Disaggregation of Revenue [Line Items]        
Revenue 297.0 207.6 613.6 616.9
Pet Health Therapeutics        
Disaggregation of Revenue [Line Items]        
Revenue 103.3 87.6 247.1 252.4
Farm Animal Future Protein & Health        
Disaggregation of Revenue [Line Items]        
Revenue 180.9 191.5 518.8 534.5
Farm Animal Ruminants & Swine        
Disaggregation of Revenue [Line Items]        
Revenue 292.3 266.2 703.1 811.8
Contract Manufacturing        
Disaggregation of Revenue [Line Items]        
Revenue $ 16.1 $ 18.4 $ 51.0 $ 68.4
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures - Purchase Consideration (Details) - Bayer Animal Business - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Aug. 01, 2020
Sep. 30, 2020
Sep. 30, 2020
Business Acquisition [Line Items]      
Cash consideration $ 5,170.1    
Fair value of Elanco common stock 1,723.7    
Fair value of total consideration transferred (2) $ 6,893.8    
Shares issued to previous shareholders upon closing (in shares) 72.9 72.9 72.9
Common stock price (in dollars per share) $ 23.64    
Fair value used in estimate $ 2,300.0    
Volume weighted average stock price as of the last day of trading before the closing of the acquisition duration 20 days    
Symmetrical collar (as a percent) 7.50%    
Volume weighted average price for thirty trading days (usd per share) $ 33.60    
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Aug. 01, 2020
Jul. 31, 2019
Jul. 18, 2019
Sep. 30, 2020
Dec. 31, 2019
Intangible assets:          
Goodwill       $ 6,434.7 $ 2,989.6
Bayer Animal Business          
Business Acquisition [Line Items]          
Cash and cash equivalents $ 168.8        
Accounts receivable 9.7        
Inventories 513.9        
Prepaid expenses and other current assets 57.9        
Property and equipment 299.6        
Intangible assets:          
Assets held for sale 146.9        
Accounts payable and accrued liabilities (172.8)        
Accrued retirement benefits (209.6)        
Other noncurrent assets and liabilities - net (707.9)        
Total identifiable net assets 3,566.5        
Goodwill 3,327.3        
Total consideration transferred $ 6,893.8        
Average useful life 12 years        
Bayer Animal Business | Marketed products          
Intangible assets:          
Finite lived intangible assets $ 3,220.0        
Bayer Animal Business | In-Process Research and Development          
Intangible assets:          
Acquired in-process research and development $ 240.0        
Aratana          
Business Acquisition [Line Items]          
Cash and cash equivalents     $ 26.4    
Inventories     10.3    
Intangible assets:          
Other assets and liabilities - net     4.1    
Total identifiable net assets     122.6    
Goodwill     30.7    
Settlement of existing contingent consideration liabilities     84.7    
Total consideration transferred     $ 238.0    
Average useful life     12 years 6 months    
Aratana | Marketed products          
Intangible assets:          
Finite lived intangible assets     $ 36.7    
Aratana | Other intangible assets          
Intangible assets:          
Finite lived intangible assets     13.2    
Aratana | In-Process Research and Development          
Intangible assets:          
Acquired in-process research and development     $ 31.9    
Prevtec          
Business Acquisition [Line Items]          
Cash and cash equivalents   $ 0.9      
Property and equipment   0.5      
Intangible assets:          
Other assets and liabilities - net   (9.3)      
Total identifiable net assets   54.9      
Goodwill   10.1      
Total consideration transferred   $ 65.0      
Average useful life   10 years      
Prevtec | Marketed products          
Intangible assets:          
Finite lived intangible assets   $ 58.9      
Prevtec | Other intangible assets          
Intangible assets:          
Finite lived intangible assets   1.1      
Prevtec | In-Process Research and Development          
Intangible assets:          
Acquired in-process research and development   $ 2.8      
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures - Narrative (Details) - USD ($)
$ / shares in Units, shares in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 03, 2020
Aug. 01, 2020
Jul. 31, 2019
Jul. 18, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Jul. 31, 2020
Business Acquisition [Line Items]                    
Revenue         $ 889,600,000 $ 771,300,000 $ 2,133,600,000 $ 2,284,000,000.0    
Goodwill impairment             0      
Gain (loss) on disposition of business             169,700,000 0    
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations                    
Business Acquisition [Line Items]                    
Gain (loss) on disposition of business         156,400,000   156,400,000      
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan | Inventories                    
Business Acquisition [Line Items]                    
Divested assets, fair value                   $ 7,900,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan | Marketed products                    
Business Acquisition [Line Items]                    
Divested assets, fair value                   $ 114,100,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Rights To The Profender And Drontal                    
Business Acquisition [Line Items]                    
Gain (loss) on disposition of business $ 0                  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Rights To The Profender And Drontal | Inventories                    
Business Acquisition [Line Items]                    
Assets held for sale   $ 4,600,000                
Divested assets, fair value 3,600,000                  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Rights To The Profender And Drontal | Marketed products                    
Business Acquisition [Line Items]                    
Assets held for sale   135,000,000.0                
Divested assets, fair value 135,000,000.0                  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Rights To The Profender And Drontal | In-Process Research and Development                    
Business Acquisition [Line Items]                    
Assets held for sale   7,300,000                
Divested assets, fair value 7,300,000                  
Gain (loss) on disposition of business $ 7,300,000                  
Bayer Animal Business                    
Business Acquisition [Line Items]                    
Transaction costs         90,700,000 $ 17,400,000 212,300,000 $ 21,400,000    
Revenue         $ 195,600,000   $ 195,600,000      
Inventories   513,900,000                
Business combination, inventories, step-up fair value adjustment   $ 166,800,000                
Average useful life   12 years                
Assets held for sale   $ 146,900,000                
Shares issued to previous shareholders upon closing (in shares)   72.9     72.9   72.9      
Value of shares issued as consideration   $ 1,723,700,000                
Consideration paid for acquisition   6,893,800,000                
Bayer Animal Business | In-Process Research and Development                    
Business Acquisition [Line Items]                    
Acquired in-process research and development   240,000,000.0                
Bayer Animal Business | Marketed products                    
Business Acquisition [Line Items]                    
Finite lived intangible assets   3,220,000,000.0                
Bayer Animal Business | Finished Products                    
Business Acquisition [Line Items]                    
Inventories   359,600,000                
Bayer Animal Business | in Process                    
Business Acquisition [Line Items]                    
Inventories   28,200,000                
Bayer Animal Business | Raw Materials                    
Business Acquisition [Line Items]                    
Inventories   $ 126,100,000                
Aratana                    
Business Acquisition [Line Items]                    
Inventories       $ 10,300,000            
Average useful life       12 years 6 months            
Shares issued to previous shareholders upon closing (in shares)       7.2            
Value of shares issued as consideration       $ 238,000,000.0            
Contingent value rights included in purchase consideration       $ 12,000,000            
Contingent payment (usd per share)       $ 0.25            
Measurement period adjustment             $ 19,100,000      
Accelerated vesting of equity awards (in shares)                 0.1  
Accelerated stock based compensation expense                 $ 3,600,000  
Aratana | In-Process Research and Development                    
Business Acquisition [Line Items]                    
Acquired in-process research and development       $ 31,900,000            
Aratana | Marketed products                    
Business Acquisition [Line Items]                    
Finite lived intangible assets       36,700,000            
Galliprant                    
Business Acquisition [Line Items]                    
Contingent consideration liability       $ 84,700,000            
Loss upon settlement of contingent consideration liability                 $ 7,500,000  
Prevtec                    
Business Acquisition [Line Items]                    
Average useful life     10 years              
Contingent value rights included in purchase consideration     $ 16,300,000              
Contingent consideration liability     4,700,000              
Loss upon settlement of contingent consideration liability             $ 2,100,000      
Consideration paid for acquisition     60,300,000              
Settlement of accounts receivable     700,000              
Prevtec | In-Process Research and Development                    
Business Acquisition [Line Items]                    
Acquired in-process research and development     2,800,000              
Prevtec | Marketed products                    
Business Acquisition [Line Items]                    
Finite lived intangible assets     $ 58,900,000              
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures - Carrying Goodwill (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2020
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning balance $ 2,989.6
Aratana measurement period adjustments 19.9
Additions related to the Bayer Animal Health acquisition 3,327.3
Foreign currency translation adjustments 97.9
Goodwill, ending balance $ 6,434.7
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures - Pro Forma Information (Details) - Bayer Animal Business - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Business Acquisition [Line Items]        
Revenues $ 1,072.6 $ 1,111.2 $ 3,318.3 $ 3,553.7
Loss before income taxes $ (222.8) $ (144.0) $ (382.1) $ (29.2)
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures - Divestitures (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Gross Cash Proceeds   $ 434.7 $ 0.0
Pre-tax Gain   169.7 $ 0.0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Gross Cash Proceeds $ 434.7 434.7  
Pre-tax Gain 156.4 156.4  
Divestiture transaction costs 13.3 13.3  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Osurnia      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Gross Cash Proceeds 140.5 140.5  
Pre-tax Gain 93.1 93.1  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Vecoxan      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Gross Cash Proceeds 55.1 55.1  
Pre-tax Gain 37.1 37.1  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Capstar      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Gross Cash Proceeds 95.9 95.9  
Pre-tax Gain 25.5 25.5  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Drontal and Profender      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Gross Cash Proceeds 140.6 140.6  
Pre-tax Gain 0.0 0.0  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Other Immaterial Divestitures      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Gross Cash Proceeds 2.6 2.6  
Pre-tax Gain $ 0.7 $ 0.7  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details) - Worldwide rights to Osurnia and U.S. rights to Capstar - Held for Sale
$ in Millions
Dec. 31, 2019
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Inventories $ 10.6
Other intangibles, net 61.2
Property and equipment, net 0.2
Total assets held for sale 72.0
Deferred taxes (1.4)
Total liabilities held for sale $ (1.4)
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Restructuring charges:        
Severance and other costs $ 130.2 $ 10.4 $ 131.2 $ 9.6
Facility exit costs 0.0 0.0 0.7 0.0
Acquisition related charges:        
Transaction and integration costs 131.1 46.1 318.5 99.6
Non-cash and other items:        
Asset impairment 0.0 10.2 3.5 14.2
Asset write-down 0.9 10.5 3.2 10.5
Gain on sale of fixed assets 0.0 0.0 (3.8) 0.0
Settlements and other 0.0 0.0 3.1
Total expense $ 262.2 $ 77.2 $ 456.4 $ 133.9
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) - Bayer Animal Business
$ in Millions
 9 Months Ended
Sep. 30, 2020
USD ($)
position
country
Restructuring Cost and Reserve [Line Items]  
Expected number of positions eliminated | position 900
Number of countries expected to eliminate positions | country 40
Minimum  
Restructuring and Related Activities [Abstract]  
Expected total restructuring charges $ 190
Restructuring Cost and Reserve [Line Items]  
Expected total restructuring charges 190
Maximum  
Restructuring and Related Activities [Abstract]  
Expected total restructuring charges 210
Restructuring Cost and Reserve [Line Items]  
Expected total restructuring charges $ 210
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Restructuring Reserve [Roll Forward]    
Balance at beginning of period $ 20.9 $ 44.4
Charges 132.6 40.7
Reserve adjustments (0.8) (10.2)
Cash paid (16.2) (20.8)
Balance at end of period 136.5 54.1
Facility exit costs    
Restructuring Reserve [Roll Forward]    
Balance at beginning of period 5.4 9.3
Charges 0.7 20.7
Reserve adjustments 0.0 0.0
Cash paid (1.2) (2.0)
Balance at end of period 4.9 28.0
Severance    
Restructuring Reserve [Roll Forward]    
Balance at beginning of period 15.5 35.1
Charges 131.9 20.0
Reserve adjustments (0.8) (10.2)
Cash paid (15.0) (18.8)
Balance at end of period $ 131.6 $ 26.1
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Finished products $ 797.1 $ 402.9
Work in process 664.1 603.2
Raw materials and supplies 167.0 83.9
Total 1,628.2 1,090.0
Decrease to LIFO cost (31.1) (39.3)
Inventories $ 1,597.1 $ 1,050.7
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Equity - Narrative (Details)
Jan. 23, 2020
USD ($)
shares
Jan. 22, 2020
USD ($)
trading_day
$ / shares
shares
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Class of Stock [Line Items]        
Number of shares sold in public offering | shares 25,000,000.0      
Proceeds after underwriting discounts and commissions $ 767,500,000      
Net proceeds     $ 6,140,100,000 $ 2,355,000,000.0
Tangible Equity Unit (TEU)        
Class of Stock [Line Items]        
Number of shares sold in public offering | shares   11,000,000    
Offering price (usd per share) | $ / shares   $ 50    
Proceeds after underwriting discounts and commissions   $ 528,500,000    
Tangible Equity Unit (TEU) | Minimum        
Class of Stock [Line Items]        
Shares issued upon conversion of prepaid stock purchase contracts (in shares) | shares   14,300,000    
Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) | $ / shares   $ 32.00    
Tangible Equity Unit (TEU) | Maximum        
Class of Stock [Line Items]        
Shares issued upon conversion of prepaid stock purchase contracts (in shares) | shares   17,200,000    
Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) | $ / shares   $ 38.40    
5.00% Tangible Equity Units | Senior Notes        
Class of Stock [Line Items]        
Interest rate on debt component   5.00%    
Number of consecutive trading days | trading_day   20    
2.75% Senior Amortizing Notes | Senior Notes        
Class of Stock [Line Items]        
Interest rate on debt component   2.75%    
Net proceeds   $ 79,200,000    
Quarterly cash installment per amortizing note   0.6250    
Initial principal amount   7.2007    
First installment payment per amortizing note   $ 0.6528    
Common Stock Offering        
Class of Stock [Line Items]        
Number of shares sold in public offering | shares   22,700,000    
Offering price (usd per share) | $ / shares   $ 32.00    
Over-Allotment Option        
Class of Stock [Line Items]        
Number of shares sold in public offering | shares   2,300,000    
Tangible Equity Unit (TEU)        
Class of Stock [Line Items]        
Offering price (usd per share) | $ / shares   $ 50    
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Equity - Schedule of Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Jan. 23, 2020
Jan. 22, 2020
Sep. 30, 2020
Sep. 30, 2019
Class of Stock [Line Items]        
Gross proceeds     $ 1,219.9 $ 0.0
Net proceeds $ 767.5      
Equity Component        
Class of Stock [Line Items]        
Price per share (usd per share)   $ 42.80    
Gross proceeds   $ 470.8    
Less: Issuance costs   18.4    
Net proceeds   $ 452.4    
Debt Component        
Class of Stock [Line Items]        
Price per share (usd per share)   $ 7.20    
Gross proceeds   $ 79.2    
Less: Issuance costs   3.1    
Net proceeds   $ 76.1    
Tangible Equity Unit (TEU)        
Class of Stock [Line Items]        
Price per share (usd per share)   $ 50    
Gross proceeds   $ 550.0    
Less: Issuance costs   21.5    
Net proceeds   $ 528.5    
Tangible Equity Unit (TEU) | Minimum        
Class of Stock [Line Items]        
Applicable Market Value (usd per share)   $ 32.00    
Settlement rate   130.21%    
Tangible Equity Unit (TEU) | Maximum        
Class of Stock [Line Items]        
Applicable Market Value (usd per share)   $ 38.40    
Settlement rate   156.25%    
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Jan. 22, 2020
Dec. 31, 2019
Debt Instrument [Line Items]      
Long-term debt, gross $ 6,241.2    
Unamortized debt issuance costs (101.5)   $ (16.8)
Total debt 6,140.1   2,355.0
Less current portion of long-term debt 553.6   24.5
Total long-term debt 5,586.5   2,330.5
Credit facility | Term loan B credit facility      
Debt Instrument [Line Items]      
Long-term debt, gross 4,175.0   0.0
Credit facility | Term credit facility      
Debt Instrument [Line Items]      
Long-term debt, gross $ 0.0   371.4
Senior Notes | 3.912% Senior Notes due 2021      
Debt Instrument [Line Items]      
Interest rate 3.912%    
Long-term debt, gross $ 500.0   500.0
Senior Notes | 4.272% Senior Notes due 2023      
Debt Instrument [Line Items]      
Interest rate 4.272%    
Long-term debt, gross $ 750.0   750.0
Senior Notes | 4.900% Senior Notes due 2028      
Debt Instrument [Line Items]      
Interest rate 4.90%    
Long-term debt, gross $ 750.0   750.0
Senior Notes | TEU amortizing notes      
Debt Instrument [Line Items]      
Interest rate   5.00%  
Long-term debt, gross 66.2   0.0
Other obligations      
Debt Instrument [Line Items]      
Long-term debt, gross $ 0.4   $ 0.4
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Debt - Narrative (Details)
 1 Months Ended 9 Months Ended
Sep. 25, 2020
USD ($)
Aug. 01, 2020
USD ($)
Jan. 31, 2020
USD ($)
Jan. 23, 2020
USD ($)
shares
Jan. 22, 2020
USD ($)
$ / shares
shares
Oct. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
numberOfCovenants
Sep. 24, 2018
USD ($)
Debt Instrument [Line Items]                
Debt financing costs             $ 90,200,000  
Unused commitment fee   $ 13,800,000            
Number of shares issued (in shares) | shares       25,000,000.0        
Proceeds after underwriting discounts and commissions       $ 767,500,000        
Tangible Equity Unit (TEU)                
Debt Instrument [Line Items]                
Number of shares issued (in shares) | shares         11,000,000      
Price per share (usd per share) | $ / shares         $ 50      
Proceeds after underwriting discounts and commissions         $ 528,500,000      
Equity Component                
Debt Instrument [Line Items]                
Price per share (usd per share) | $ / shares         $ 42.80      
Proceeds after underwriting discounts and commissions         $ 452,400,000      
Debt Component                
Debt Instrument [Line Items]                
Price per share (usd per share) | $ / shares         $ 7.20      
Proceeds after underwriting discounts and commissions         $ 76,100,000      
Credit Facility | Term loan B credit facility                
Debt Instrument [Line Items]                
Number of financial covenants | numberOfCovenants             0  
Debt repaid, principal $ 100,000,000.0              
Debt extinguishment loss $ 2,100,000              
Credit Facility | Term loan B credit facility | Bayer Animal Business                
Debt Instrument [Line Items]                
Credit facility, maximum borrowing capacity   4,275,000,000.0            
Outstanding debt   $ 4,175,000,000.0            
Debt maturity term   7 years            
Credit Facility | Term loan B credit facility | LIBOR | Bayer Animal Business                
Debt Instrument [Line Items]                
Basis spread on variable rate   1.75%            
Credit Facility | Revolving credit facility                
Debt Instrument [Line Items]                
Credit facility, maximum borrowing capacity   $ 750,000,000.0           $ 750,000,000.0
Debt maturity term   5 years            
Drawdown   $ 200,000,000.0            
Debt issuance costs   $ 9,200,000            
Number of financial covenants | numberOfCovenants             2  
Required ratio of pro forma net leverage and pro forma adjusted EBITDA             7.71  
Required ratio of pro forma adjusted EBITDA to cash interest expense (no less than)             2.00  
Credit Facility | Revolving credit facility | Subsequent Event                
Debt Instrument [Line Items]                
Drawdown           $ 250,000,000.0    
Credit Facility | Revolving credit facility | LIBOR | Minimum                
Debt Instrument [Line Items]                
Basis spread on variable rate   1.50%            
Credit Facility | Revolving credit facility | LIBOR | Maximum                
Debt Instrument [Line Items]                
Basis spread on variable rate   2.25%            
Credit Facility | Term Loan Facility                
Debt Instrument [Line Items]                
Credit facility, maximum borrowing capacity               500,000,000.0
Debt repaid     $ 372,400,000          
Debt repaid, principal     371,400,000          
Debt repaid, interest     1,000,000.0          
Debt extinguishment loss     $ 800,000          
Senior Notes                
Debt Instrument [Line Items]                
Debt instrument, face amount               $ 2,000,000,000.0
Senior Notes | TEUs                
Debt Instrument [Line Items]                
Debt instrument, face amount         $ 550,000,000      
Interest rate         5.00%      
Partial payment on principal and interest             $ 14,100,000  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Debt - Maturity of Long-Term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
Fourth quarter of 2020 $ 16.8  
2021 567.6  
2022 68.0  
2023 797.5  
2024 40.3  
2025 39.9  
Thereafter 4,711.1  
Total obligations and commitments 6,241.2  
Unamortized debt issuance costs and other obligations (101.1)  
Total debt $ 6,140.1 $ 2,355.0
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments and Fair Value - Narrative (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2018
CHF (SFr)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jul. 31, 2019
USD ($)
Jul. 18, 2019
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                  
Equity method investments   $ 21,700,000   $ 21,700,000     $ 18,800,000    
Loss on cash flow hedge, net of tax benefit   7,500,000 $ 0 67,400,000 $ 0        
Tax benefit on loss on cash flow hedge   2,200,000   19,600,000          
Expected reclassification from accumulated other comprehensive loss   28,000,000.0   28,000,000.0          
Aratana                  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                  
Maximum aggregate contingent payment                 $ 12,000,000
Prevtec                  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                  
Maximum aggregate contingent payment               $ 16,300,000  
Decrease of fair value of contingent consideration liability       2,100,000          
Cross-currency fixed interest rate swap | Not Designated as Hedging Instrument                  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                  
Notional amount (USD, CHF)   $ 1,496,900,000   1,496,900,000     $ 861,200,000    
Cross-currency fixed interest rate swap | Net Investment Hedging | Designated as Hedging Instrument                  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                  
Notional amount (USD, CHF) | SFr SFr 750,000,000                
Term of contract 5 years                
Cash benefit for liquidation       35,100,000          
Interest included in cash benefit       $ 2,400,000          
Forward-starting interest rate contracts designated as cash flow hedges | Cash Flow Hedging | Designated as Hedging Instrument                  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                  
Notional amount (USD, CHF)           $ 4,050,000,000.00      
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments and Fair Value - Summary of Fair Value Information (Details) - Recurring - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes $ 0.0 $ 0.0
TEU amortizing note 0.0  
Term loan B 0.0  
Long-term debt - term credit facility   0.0
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes (2,186.7) (2,120.6)
TEU amortizing note (66.2)  
Term loan B (4,068.0)  
Long-term debt - term credit facility   (371.4)
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes 0.0 0.0
TEU amortizing note 0.0  
Term loan B 0.0  
Long-term debt - term credit facility   0.0
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes (2,000.0) (2,000.0)
TEU amortizing note (66.2)  
Term loan B (4,175.0)  
Long-term debt - term credit facility   (371.4)
Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes (2,186.7) (2,120.6)
TEU amortizing note (66.2)  
Term loan B (4,068.0)  
Long-term debt - term credit facility   (371.4)
Prepaid expenses and other | Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0.0 0.0
Prepaid expenses and other | Significant Other Observable Inputs (Level 2) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 10.7 0.8
Prepaid expenses and other | Significant Unobservable Inputs (Level 3) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0.0 0.0
Prepaid expenses and other | Carrying Amount | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 10.7 0.8
Prepaid expenses and other | Fair Value | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 10.7 0.8
Other current liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0.0 0.0
Other current liabilities | Significant Other Observable Inputs (Level 2) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (7.6) (1.1)
Other current liabilities | Significant Unobservable Inputs (Level 3) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0.0 0.0
Other current liabilities | Carrying Amount | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (7.6) (1.1)
Other current liabilities | Fair Value | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (7.6) (1.1)
Other noncurrent liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0.0 0.0
Other noncurrent liabilities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0.0 0.0
Other noncurrent liabilities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (2.6) (4.7)
Other noncurrent liabilities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (2.6) (4.7)
Other noncurrent liabilities | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (2.6) (4.7)
Other noncurrent assets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0.0  
Other noncurrent assets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross currency interest rate contracts designated as net investment hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   0.0
Other noncurrent assets | Significant Other Observable Inputs (Level 2) | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (87.0)  
Other noncurrent assets | Significant Other Observable Inputs (Level 2) | Cross currency interest rate contracts designated as net investment hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   2.3
Other noncurrent assets | Significant Unobservable Inputs (Level 3) | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0.0  
Other noncurrent assets | Significant Unobservable Inputs (Level 3) | Cross currency interest rate contracts designated as net investment hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   0.0
Other noncurrent assets | Carrying Amount | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (87.0)  
Other noncurrent assets | Carrying Amount | Cross currency interest rate contracts designated as net investment hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   2.3
Other noncurrent assets | Fair Value | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) $ (87.0)  
Other noncurrent assets | Fair Value | Cross currency interest rate contracts designated as net investment hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   $ 2.3
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details) - Cross-currency fixed interest rate swap - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Not Designated as Hedging Instrument | Other Operating Income (Expense)        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Net gain (loss) on derivative instruments $ (2.3) $ 10.1 $ 19.4 $ 8.8
Designated as Hedging Instrument | Net Investment Hedging        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Gain, net of tax 0.0 18.5 24.0 23.9
Designated as Hedging Instrument | Interest Expense | Net Investment Hedging        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Amount offsetting interest expense $ 0.0 $ 6.2 $ 6.2 $ 18.4
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Jun. 26, 2020
Sep. 30, 2020
Leases [Abstract]    
Sale leaseback proceeds $ 55.1  
Sale leaseback initial lease term 15 years  
Sale leaseback gain   $ 45.6
Sale leaseback lease payments   $ 27.8
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes - Provision for Taxes on Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ (74.0) $ (22.5) $ (116.6) $ 5.1
Effective tax rate 35.40% 179.70% 32.90% 6.20%
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ (74.0) $ (22.5) $ (116.6) $ 5.1
Effective tax rate 35.40% 179.70% 32.90% 6.20%
Income Tax Contingency [Line Items]        
Income tax (benefit) expense $ (74.0) $ (22.5) $ (116.6) $ 5.1
Novartis Animal Health        
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense (14.0)      
Income Tax Contingency [Line Items]        
Income tax (benefit) expense $ (14.0)      
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - Narrative (Details) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]    
Liabilities related to litigation $ 0 $ 0
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Geographic Information - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
Sep. 30, 2020
USD ($)
segment
Sep. 30, 2019
Dec. 31, 2019
USD ($)
Segment Reporting [Abstract]          
Number of operating segments | segment     1    
Concentration Risk [Line Items]          
Accounts receivable $ 762.3   $ 762.3   $ 816.9
Product Sales          
Concentration Risk [Line Items]          
Accounts receivable $ 78.1   $ 78.1   $ 90.5
Customer Concentration Risk | Revenue | Single Customer          
Concentration Risk [Line Items]          
Concentration risk (as a percent) 11.70% 15.90% 11.90% 13.40%  
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Geographic Information - Revenue by Selected Geographic Area Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue $ 889.6 $ 771.3 $ 2,133.6 $ 2,284.0
United States        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue 421.5 388.2 969.5 1,167.1
International        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue $ 468.1 $ 383.1 $ 1,164.1 $ 1,116.9
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets $ 1,665.7 $ 1,147.1
United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets 942.6 709.8
Germany    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets 243.7 39.7
United Kingdom    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets 206.3 192.6
Other foreign countries    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets $ 273.1 $ 205.0
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share (Details) - shares
shares in Millions
 3 Months Ended 9 Months Ended
Aug. 01, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Subsidiary, Sale of Stock [Line Items]          
Common stock equivalents included in weighted average diluted shares outstanding (in shares)     1.5   1.0
Antidilutive shares not included in calculating diluted earnings per share (in shares)     0.1   0.1
Bayer Animal Business          
Subsidiary, Sale of Stock [Line Items]          
Shares issued to previous shareholders upon closing (in shares) 72.9 72.9   72.9  
Common Stock Offering          
Subsidiary, Sale of Stock [Line Items]          
Weighted average commons shares included in calculation of basic earnings per share (in shares)   25.0   25.0  
Tangible Equity Unit (TEU)          
Subsidiary, Sale of Stock [Line Items]          
Weighted average commons shares included in calculation of basic earnings per share (in shares)   14.3   14.3  
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details) - Lilly - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Related Party Transaction [Line Items]    
Total payable to Lilly $ (11.3) $ (16.4)
TSA    
Related Party Transaction [Line Items]    
Total payable to Lilly 1.1 10.5
Other activities    
Related Party Transaction [Line Items]    
Total payable to Lilly (1.7) (15.8)
Local country asset purchases    
Related Party Transaction [Line Items]    
Total payable to Lilly $ (10.7) $ (11.1)
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Agreements and Transactions - Narrative (Details) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Aug. 01, 2020
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Related Party Transaction [Line Items]          
Restricted cash and payable   $ 10.7 $ 10.7 $ 11.1 $ 11.1
Bayer Animal Business          
Related Party Transaction [Line Items]          
Interest percentage   15.50% 15.50%    
Bayer Animal Business          
Related Party Transaction [Line Items]          
Shares issued to previous shareholders upon closing (in shares) 72.9 72.9 72.9    
Bayer          
Related Party Transaction [Line Items]          
Related party, accounts payable   $ 9.8 $ 9.8    
Bayer | Leases          
Related Party Transaction [Line Items]          
Operating lease liabilities   60.0 60.0    
Operating lease, right-of-use asset   60.0 60.0    
Bayer | TSA          
Related Party Transaction [Line Items]          
Other liabilities due to affiliate   2.7 2.7    
Bayer | Local country asset purchases          
Related Party Transaction [Line Items]          
Due from related party   233.6 233.6    
Due to related party   233.6 233.6    
Bayer | Other activities          
Related Party Transaction [Line Items]          
Receivable from, payable (to) related party   (20.4) (20.4)    
Lilly          
Related Party Transaction [Line Items]          
Receivable from, payable (to) related party   (11.3) (11.3)   (16.4)
Cost of stock-based compensation plans       $ 5.1  
Lilly | TSA          
Related Party Transaction [Line Items]          
Receivable from, payable (to) related party   1.1 $ 1.1   10.5
Mark-up rate     7.00%    
Lilly | Local country asset purchases          
Related Party Transaction [Line Items]          
Receivable from, payable (to) related party   (10.7) $ (10.7)   (11.1)
Lilly | Other activities          
Related Party Transaction [Line Items]          
Receivable from, payable (to) related party   $ (1.7) $ (1.7)   $ (15.8)
EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 83 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 368 390 1 true 103 0 false 11 false false R1.htm 0001001 - Document - Cover page Sheet http://www.elanco.com/role/Coverpage Cover page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.elanco.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited Condensed Consolidated Statements of Equity (Unaudited) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 2101101 - Disclosure - Nature of Business and Organization Sheet http://www.elanco.com/role/NatureofBusinessandOrganization Nature of Business and Organization Notes 8 false false R9.htm 2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 9 false false R10.htm 2105103 - Disclosure - Impact of Separation Sheet http://www.elanco.com/role/ImpactofSeparation Impact of Separation Notes 10 false false R11.htm 2107104 - Disclosure - Implementation of New Financial Accounting Pronouncements Sheet http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements Implementation of New Financial Accounting Pronouncements Notes 11 false false R12.htm 2110105 - Disclosure - Revenue Sheet http://www.elanco.com/role/Revenue Revenue Notes 12 false false R13.htm 2115106 - Disclosure - Acquisitions and Divestitures Sheet http://www.elanco.com/role/AcquisitionsandDivestitures Acquisitions and Divestitures Notes 13 false false R14.htm 2124107 - Disclosure - Asset Impairment, Restructuring and Other Special Charges Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges Asset Impairment, Restructuring and Other Special Charges Notes 14 false false R15.htm 2129108 - Disclosure - Inventories Sheet http://www.elanco.com/role/Inventories Inventories Notes 15 false false R16.htm 2132109 - Disclosure - Equity Sheet http://www.elanco.com/role/Equity Equity Notes 16 false false R17.htm 2136110 - Disclosure - Debt Sheet http://www.elanco.com/role/Debt Debt Notes 17 false false R18.htm 2141111 - Disclosure - Financial Instruments and Fair Value Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValue Financial Instruments and Fair Value Notes 18 false false R19.htm 2146112 - Disclosure - Leases Sheet http://www.elanco.com/role/Leases Leases Notes 19 false false R20.htm 2148113 - Disclosure - Income Taxes Sheet http://www.elanco.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2152114 - Disclosure - Commitments and Contingencies Sheet http://www.elanco.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 2154115 - Disclosure - Geographic Information Sheet http://www.elanco.com/role/GeographicInformation Geographic Information Notes 22 false false R23.htm 2159116 - Disclosure - Earnings Per Share Sheet http://www.elanco.com/role/EarningsPerShare Earnings Per Share Notes 23 false false R24.htm 2161117 - Disclosure - Related Party Agreements and Transactions Sheet http://www.elanco.com/role/RelatedPartyAgreementsandTransactions Related Party Agreements and Transactions Notes 24 false false R25.htm 2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 25 false false R26.htm 2308301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) Sheet http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables Implementation of New Financial Accounting Pronouncements (Tables) Tables http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements 26 false false R27.htm 2311302 - Disclosure - Revenue (Tables) Sheet http://www.elanco.com/role/RevenueTables Revenue (Tables) Tables http://www.elanco.com/role/Revenue 27 false false R28.htm 2316303 - Disclosure - Acquisitions and Divestitures (Tables) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresTables Acquisitions and Divestitures (Tables) Tables http://www.elanco.com/role/AcquisitionsandDivestitures 28 false false R29.htm 2325304 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables Asset Impairment, Restructuring and Other Special Charges (Tables) Tables http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges 29 false false R30.htm 2330305 - Disclosure - Inventories (Tables) Sheet http://www.elanco.com/role/InventoriesTables Inventories (Tables) Tables http://www.elanco.com/role/Inventories 30 false false R31.htm 2333306 - Disclosure - Equity (Tables) Sheet http://www.elanco.com/role/EquityTables Equity (Tables) Tables http://www.elanco.com/role/Equity 31 false false R32.htm 2337307 - Disclosure - Debt (Tables) Sheet http://www.elanco.com/role/DebtTables Debt (Tables) Tables http://www.elanco.com/role/Debt 32 false false R33.htm 2342308 - Disclosure - Financial Instruments and Fair Value (Tables) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueTables Financial Instruments and Fair Value (Tables) Tables http://www.elanco.com/role/FinancialInstrumentsandFairValue 33 false false R34.htm 2349309 - Disclosure - Income Taxes (Tables) Sheet http://www.elanco.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.elanco.com/role/IncomeTaxes 34 false false R35.htm 2355310 - Disclosure - Geographic Information (Tables) Sheet http://www.elanco.com/role/GeographicInformationTables Geographic Information (Tables) Tables http://www.elanco.com/role/GeographicInformation 35 false false R36.htm 2362311 - Disclosure - Related Party Agreements and Transactions (Tables) Sheet http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsTables Related Party Agreements and Transactions (Tables) Tables http://www.elanco.com/role/RelatedPartyAgreementsandTransactions 36 false false R37.htm 2402401 - Disclosure - Nature of Business and Organization (Details) Sheet http://www.elanco.com/role/NatureofBusinessandOrganizationDetails Nature of Business and Organization (Details) Details http://www.elanco.com/role/NatureofBusinessandOrganization 37 false false R38.htm 2406402 - Disclosure - Impact of Separation (Details) Sheet http://www.elanco.com/role/ImpactofSeparationDetails Impact of Separation (Details) Details http://www.elanco.com/role/ImpactofSeparation 38 false false R39.htm 2409403 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details) Sheet http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsDetails Implementation of New Financial Accounting Pronouncements (Details) Details http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables 39 false false R40.htm 2412404 - Disclosure - Revenue - Narrative (Details) Sheet http://www.elanco.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 40 false false R41.htm 2413405 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) Sheet http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) Details 41 false false R42.htm 2414406 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 42 false false R43.htm 2417407 - Disclosure - Acquisitions and Divestitures - Purchase Consideration (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails Acquisitions and Divestitures - Purchase Consideration (Details) Details 43 false false R44.htm 2418408 - Disclosure - Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Details 44 false false R45.htm 2419409 - Disclosure - Acquisitions and Divestitures - Narrative (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails Acquisitions and Divestitures - Narrative (Details) Details 45 false false R46.htm 2420410 - Disclosure - Acquisitions and Divestitures - Carrying Goodwill (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresCarryingGoodwillDetails Acquisitions and Divestitures - Carrying Goodwill (Details) Details 46 false false R47.htm 2421411 - Disclosure - Acquisitions and Divestitures - Pro Forma Information (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails Acquisitions and Divestitures - Pro Forma Information (Details) Details 47 false false R48.htm 2422412 - Disclosure - Acquisitions and Divestitures - Divestitures (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails Acquisitions and Divestitures - Divestitures (Details) Details 48 false false R49.htm 2423413 - Disclosure - Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details) Details 49 false false R50.htm 2426414 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) Details 50 false false R51.htm 2427415 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) Details http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables 51 false false R52.htm 2428416 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) Details 52 false false R53.htm 2431417 - Disclosure - Inventories (Details) Sheet http://www.elanco.com/role/InventoriesDetails Inventories (Details) Details http://www.elanco.com/role/InventoriesTables 53 false false R54.htm 2434418 - Disclosure - Equity - Narrative (Details) Sheet http://www.elanco.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 54 false false R55.htm 2435419 - Disclosure - Equity - Schedule of Stockholders' Equity (Details) Sheet http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails Equity - Schedule of Stockholders' Equity (Details) Details 55 false false R56.htm 2438420 - Disclosure - Debt - Schedule of Long-term Debt (Details) Sheet http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails Debt - Schedule of Long-term Debt (Details) Details 56 false false R57.htm 2439421 - Disclosure - Debt - Narrative (Details) Sheet http://www.elanco.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 57 false false R58.htm 2440422 - Disclosure - Debt - Maturity of Long-Term Debt (Details) Sheet http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails Debt - Maturity of Long-Term Debt (Details) Details 58 false false R59.htm 2443423 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails Financial Instruments and Fair Value - Narrative (Details) Details 59 false false R60.htm 2444424 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails Financial Instruments and Fair Value - Summary of Fair Value Information (Details) Details 60 false false R61.htm 2445425 - Disclosure - Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details) Details 61 false false R62.htm 2447426 - Disclosure - Leases - Narrative (Details) Sheet http://www.elanco.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 62 false false R63.htm 2450427 - Disclosure - Income Taxes - Provision for Taxes on Income (Details) Sheet http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails Income Taxes - Provision for Taxes on Income (Details) Details 63 false false R64.htm 2451428 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.elanco.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 64 false false R65.htm 2453429 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 65 false false R66.htm 2456430 - Disclosure - Geographic Information - Narrative (Details) Sheet http://www.elanco.com/role/GeographicInformationNarrativeDetails Geographic Information - Narrative (Details) Details 66 false false R67.htm 2457431 - Disclosure - Geographic Information - Revenue by Selected Geographic Area Information (Details) Sheet http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails Geographic Information - Revenue by Selected Geographic Area Information (Details) Details 67 false false R68.htm 2458432 - Disclosure - Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details) Sheet http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details) Details 68 false false R69.htm 2460433 - Disclosure - Earnings Per Share (Details) Sheet http://www.elanco.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.elanco.com/role/EarningsPerShare 69 false false R70.htm 2463434 - Disclosure - Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details) Sheet http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details) Details 70 false false R71.htm 2464435 - Disclosure - Related Party Agreements and Transactions - Narrative (Details) Sheet http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails Related Party Agreements and Transactions - Narrative (Details) Details 71 false false All Reports Book All Reports elan-20200930.htm elan-20200930.xsd elan-20200930_cal.xml elan-20200930_def.xml elan-20200930_lab.xml elan-20200930_pre.xml ex311elanco-20200930xceoce.htm ex312elanco-20200930xcfoce.htm ex32elanco-20200930xsectio.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "elan-20200930.htm": { "axisCustom": 0, "axisStandard": 35, "contextCount": 368, "dts": { "calculationLink": { "local": [ "elan-20200930_cal.xml" ] }, "definitionLink": { "local": [ "elan-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "elan-20200930.htm" ] }, "labelLink": { "local": [ "elan-20200930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "elan-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "elan-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 567, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 6, "http://www.elanco.com/20200930": 1, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 12 }, "keyCustom": 42, "keyStandard": 348, "memberCustom": 40, "memberStandard": 57, "nsprefix": "elan", "nsuri": "http://www.elanco.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover page", "role": "http://www.elanco.com/role/Coverpage", "shortName": "Cover page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Impact of Separation", "role": "http://www.elanco.com/role/ImpactofSeparation", "shortName": "Impact of Separation", "subGroupType": "", "uniqueAnchor": null }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107104 - Disclosure - Implementation of New Financial Accounting Pronouncements", "role": "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements", "shortName": "Implementation of New Financial Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110105 - Disclosure - Revenue", "role": "http://www.elanco.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115106 - Disclosure - Acquisitions and Divestitures", "role": "http://www.elanco.com/role/AcquisitionsandDivestitures", "shortName": "Acquisitions and Divestitures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124107 - Disclosure - Asset Impairment, Restructuring and Other Special Charges", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges", "shortName": "Asset Impairment, Restructuring and Other Special Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129108 - Disclosure - Inventories", "role": "http://www.elanco.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132109 - Disclosure - Equity", "role": "http://www.elanco.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": null }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136110 - Disclosure - Debt", "role": "http://www.elanco.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141111 - Disclosure - Financial Instruments and Fair Value", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValue", "shortName": "Financial Instruments and Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146112 - Disclosure - Leases", "role": "http://www.elanco.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148113 - Disclosure - Income Taxes", "role": "http://www.elanco.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152114 - Disclosure - Commitments and Contingencies", "role": "http://www.elanco.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2154115 - Disclosure - Geographic Information", "role": "http://www.elanco.com/role/GeographicInformation", "shortName": "Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159116 - Disclosure - Earnings Per Share", "role": "http://www.elanco.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2161117 - Disclosure - Related Party Agreements and Transactions", "role": "http://www.elanco.com/role/RelatedPartyAgreementsandTransactions", "shortName": "Related Party Agreements and Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables)", "role": "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables", "shortName": "Implementation of New Financial Accounting Pronouncements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Revenue (Tables)", "role": "http://www.elanco.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316303 - Disclosure - Acquisitions and Divestitures (Tables)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresTables", "shortName": "Acquisitions and Divestitures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325304 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables", "shortName": "Asset Impairment, Restructuring and Other Special Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330305 - Disclosure - Inventories (Tables)", "role": "http://www.elanco.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2333306 - Disclosure - Equity (Tables)", "role": "http://www.elanco.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337307 - Disclosure - Debt (Tables)", "role": "http://www.elanco.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342308 - Disclosure - Financial Instruments and Fair Value (Tables)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables", "shortName": "Financial Instruments and Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2349309 - Disclosure - Income Taxes (Tables)", "role": "http://www.elanco.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2355310 - Disclosure - Geographic Information (Tables)", "role": "http://www.elanco.com/role/GeographicInformationTables", "shortName": "Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2362311 - Disclosure - Related Party Agreements and Transactions (Tables)", "role": "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsTables", "shortName": "Related Party Agreements and Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "elan:NumberOfBrandsInEntitysPortfolio", "reportCount": 1, "unitRef": "brand", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Nature of Business and Organization (Details)", "role": "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "shortName": "Nature of Business and Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ib1fad5c2454f4b37b852ac834c303011_D20180924-20180924", "decimals": "-5", "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i8e6415f0ae034467bb8cf5ab9f6fac93_I20180924", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Impact of Separation (Details)", "role": "http://www.elanco.com/role/ImpactofSeparationDetails", "shortName": "Impact of Separation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ia1c79f2f8bb84e61a94fd01e54581aaf_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details)", "role": "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsDetails", "shortName": "Implementation of New Financial Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ib7f352672c2b4f508bd43f075ea206ab_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i4dd04702dd8f4900be9a0dd5a4d98580_D20200101-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Revenue - Narrative (Details)", "role": "http://www.elanco.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i4dd04702dd8f4900be9a0dd5a4d98580_D20200101-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ief42934d7bd14ed7b4ad165560a05963_I20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details)", "role": "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails", "shortName": "Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ief42934d7bd14ed7b4ad165560a05963_I20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "role": "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails", "shortName": "Revenue - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "iad253700e6db4d398334d118f9dbc4c3_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i25b7890e6bfa49df8f1086906c0fa041_D20200801-20200801", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - Acquisitions and Divestitures - Purchase Consideration (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "shortName": "Acquisitions and Divestitures - Purchase Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "iede99f0f4e5e49bd8413d33f462fa62e_I20200801", "decimals": "INF", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "iede99f0f4e5e49bd8413d33f462fa62e_I20200801", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Acquisitions and Divestitures - Narrative (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "shortName": "Acquisitions and Divestitures - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ia1c79f2f8bb84e61a94fd01e54581aaf_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Acquisitions and Divestitures - Carrying Goodwill (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresCarryingGoodwillDetails", "shortName": "Acquisitions and Divestitures - Carrying Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "iac088c39cb9944728d330619116462c0_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Acquisitions and Divestitures - Pro Forma Information (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "shortName": "Acquisitions and Divestitures - Pro Forma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "iac088c39cb9944728d330619116462c0_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Acquisitions and Divestitures - Divestitures (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails", "shortName": "Acquisitions and Divestitures - Divestitures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ief6d50c8215b49ad933adf23c5858bf2_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i66f45cf20551419dbc4e3b04f9866b4f_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "shortName": "Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i66f45cf20551419dbc4e3b04f9866b4f_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ic866ac664f3d4d72a09f3b4d31268e6b_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "reportCount": 1, "unique": true, "unitRef": "position", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427415 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ic866ac664f3d4d72a09f3b4d31268e6b_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "reportCount": 1, "unique": true, "unitRef": "position", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ia1c79f2f8bb84e61a94fd01e54581aaf_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ia1c79f2f8bb84e61a94fd01e54581aaf_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431417 - Disclosure - Inventories (Details)", "role": "http://www.elanco.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7bface71d06c483b8b694903b41c3c65_D20200123-20200123", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434418 - Disclosure - Equity - Narrative (Details)", "role": "http://www.elanco.com/role/EquityNarrativeDetails", "shortName": "Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i3e70495b571949ceb4a607fc5531432f_I20200122", "decimals": "-5", "lang": "en-US", "name": "elan:TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435419 - Disclosure - Equity - Schedule of Stockholders' Equity (Details)", "role": "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails", "shortName": "Equity - Schedule of Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i65179ffe7cef435f9680cf44aa27a257_D20200122-20200122", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438420 - Disclosure - Debt - Schedule of Long-term Debt (Details)", "role": "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "shortName": "Debt - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Debt - Narrative (Details)", "role": "http://www.elanco.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440422 - Disclosure - Debt - Maturity of Long-Term Debt (Details)", "role": "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails", "shortName": "Debt - Maturity of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443423 - Disclosure - Financial Instruments and Fair Value - Narrative (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "shortName": "Financial Instruments and Fair Value - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ia1c79f2f8bb84e61a94fd01e54581aaf_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ia00e02df70fd4a70ba65e8b6ed0145a3_I20181231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Equity (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "shortName": "Condensed Consolidated Statements of Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i73e41d249f404567890566d71875d3f5_D20190101-20190331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i41d5b01eaab449db8227d1fff0fa6227_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444424 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails", "shortName": "Financial Instruments and Fair Value - Summary of Fair Value Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i41d5b01eaab449db8227d1fff0fa6227_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "idd1fdd9cc79d427488937dfd064fca55_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445425 - Disclosure - Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails", "shortName": "Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "idd1fdd9cc79d427488937dfd064fca55_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i64cfd4516b704695b974040ec77d8083_D20200626-20200626", "decimals": "-5", "first": true, "lang": "en-US", "name": "elan:SaleLeasebackTransactionNetProceeds", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447426 - Disclosure - Leases - Narrative (Details)", "role": "http://www.elanco.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i64cfd4516b704695b974040ec77d8083_D20200626-20200626", "decimals": "-5", "first": true, "lang": "en-US", "name": "elan:SaleLeasebackTransactionNetProceeds", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450427 - Disclosure - Income Taxes - Provision for Taxes on Income (Details)", "role": "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails", "shortName": "Income Taxes - Provision for Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451428 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R65": { "firstAnchor": { "ancestors": [ "us-gaap:LitigationReserve", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453429 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:LitigationReserve", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456430 - Disclosure - Geographic Information - Narrative (Details)", "role": "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "shortName": "Geographic Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ia4aec7ab28b74ca5b9fa780d300ae4cb_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i9ea0366f86644e4f8ecc21f61da8acec_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457431 - Disclosure - Geographic Information - Revenue by Selected Geographic Area Information (Details)", "role": "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "shortName": "Geographic Information - Revenue by Selected Geographic Area Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "idbd5e6bf50c946e0bf50ef3c5d184e9d_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458432 - Disclosure - Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details)", "role": "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails", "shortName": "Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ie376a41728c3436cb2b8394d8f9a632a_D20190701-20190930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460433 - Disclosure - Earnings Per Share (Details)", "role": "http://www.elanco.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "ie376a41728c3436cb2b8394d8f9a632a_D20190701-20190930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i10871a6fbaef442abea84c189abf8d2b_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463434 - Disclosure - Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details)", "role": "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "shortName": "Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "if1d13c7b50824f138fd931c08c53e448_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464435 - Disclosure - Related Party Agreements and Transactions - Narrative (Details)", "role": "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails", "shortName": "Related Party Agreements and Transactions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i3ad6e60e0b7f41ce97cd8de8fe7fc519_D20190101-20190930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Nature of Business and Organization", "role": "http://www.elanco.com/role/NatureofBusinessandOrganization", "shortName": "Nature of Business and Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20200930.htm", "contextRef": "i7db465da7266457897db37cbe216bd6e_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 103, "tag": { "country_DE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "GERMANY", "terseLabel": "Germany" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails" ], "xbrltype": "domainItemType" }, "country_GB": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED KINGDOM", "terseLabel": "United Kingdom" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States", "verboseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r582" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r583" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r584" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r584" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r584" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r585" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r584" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r584" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r584" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r584" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r580" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r581" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "tradingSymbolItemType" }, "elan_A275SeniorAmortizingNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.75% Senior Amortizing Notes", "label": "2.75% Senior Amortizing Notes [Member]", "terseLabel": "2.75% Senior Amortizing Notes" } } }, "localname": "A275SeniorAmortizingNotesMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_A3.912SeniorNotesDue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.912% Senior Notes Due 2021 [Member]", "label": "3.912% Senior Notes Due 2021 [Member]", "terseLabel": "3.912% Senior Notes due 2021" } } }, "localname": "A3.912SeniorNotesDue2021Member", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A4.272SeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.272% Senior Notes Due 2023 [Member]", "label": "4.272% Senior Notes Due 2023 [Member]", "terseLabel": "4.272% Senior Notes due 2023" } } }, "localname": "A4.272SeniorNotesDue2023Member", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A4.9SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.9% Senior Notes Due 2028 [Member]", "label": "4.9% Senior Notes Due 2028 [Member]", "terseLabel": "4.900% Senior Notes due 2028" } } }, "localname": "A4.9SeniorNotesDue2028Member", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A500TangibleEquityUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "5.00% Tangible Equity Units", "label": "5.00% Tangible Equity Units [Member]", "netLabel": "TEUs", "terseLabel": "5.00% Tangible Equity Units", "verboseLabel": "TEU amortizing notes" } } }, "localname": "A500TangibleEquityUnitsMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/Coverpage", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_APICShareBasedPaymentArrangementIncreaseForCostRecognitionAcceleratedVesting": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Accelerated Vesting", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Accelerated Vesting", "terseLabel": "Accelerated vesting of equity awards" } } }, "localname": "APICShareBasedPaymentArrangementIncreaseForCostRecognitionAcceleratedVesting", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_AratanaTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aratana Therapeutics, Inc. [Member]", "label": "Aratana Therapeutics, Inc. [Member]", "verboseLabel": "Aratana" } } }, "localname": "AratanaTherapeuticsInc.Member", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_AssetImpairmentChargesIncludingInventoryWriteDown": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Impairment Charges, Including Inventory Write-Down", "label": "Asset Impairment Charges, Including Inventory Write-Down", "verboseLabel": "Asset impairment charges" } } }, "localname": "AssetImpairmentChargesIncludingInventoryWriteDown", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_BayerAnimalBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bayer Animal Business", "label": "Bayer Animal Business [Member]", "terseLabel": "Bayer Animal Business" } } }, "localname": "BayerAnimalBusinessMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableUsedInEstimate": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Used In Estimate", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Used In Estimate", "terseLabel": "Fair value used in estimate" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableUsedInEstimate", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationConsiderationTransferredSettlementOfAccountsReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Settlement Of Accounts Receivable", "label": "Business Combination, Consideration Transferred, Settlement Of Accounts Receivable", "terseLabel": "Settlement of accounts receivable" } } }, "localname": "BusinessCombinationConsiderationTransferredSettlementOfAccountsReceivable", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationConsiderationTransferredSymmetricalCollar": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Symmetrical Collar", "label": "Business Combination, Consideration Transferred, Symmetrical Collar", "terseLabel": "Symmetrical collar (as a percent)" } } }, "localname": "BusinessCombinationConsiderationTransferredSymmetricalCollar", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "percentItemType" }, "elan_BusinessCombinationContingentConsiderationAmountPerSharePaidUponSpecifiedMergerAgreementMilestones": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration, Amount Per Share Paid Upon Specified Merger Agreement Milestones", "label": "Business Combination, Contingent Consideration, Amount Per Share Paid Upon Specified Merger Agreement Milestones", "terseLabel": "Contingent payment (usd per share)" } } }, "localname": "BusinessCombinationContingentConsiderationAmountPerSharePaidUponSpecifiedMergerAgreementMilestones", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "perShareItemType" }, "elan_BusinessCombinationInventoriesStepUpFairValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Inventories, Step-Up Fair Value Adjustment", "label": "Business Combination, Inventories, Step-Up Fair Value Adjustment", "terseLabel": "Business combination, inventories, step-up fair value adjustment" } } }, "localname": "BusinessCombinationInventoriesStepUpFairValueAdjustment", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Other Current Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Other Current Assets", "negatedTerseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherCurrentAssets", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Held For Sale", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Held For Sale", "terseLabel": "Assets held for sale" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsHeldForSale", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Employee-Related Liabilities, Current", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Employee-Related Liabilities, Current", "negatedTerseLabel": "Accrued retirement benefits" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsAndOtherLiabilitiesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets And Other Liabilities, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets And Other Liabilities, Net", "terseLabel": "Other assets and liabilities - net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsAndOtherLiabilitiesNet", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssetsAndOtherLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Noncurrent Assets And Other Liabilities, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Noncurrent Assets And Other Liabilities, Net", "negatedTerseLabel": "Other noncurrent assets and liabilities - net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssetsAndOtherLiabilitiesNet", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationVolumeWeightedAveragePriceFor30TradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Volume Weighted Average Price For 30 Trading Days", "label": "Business Combination, Volume Weighted Average Price For 30 Trading Days", "terseLabel": "Volume weighted average price for thirty trading days (usd per share)" } } }, "localname": "BusinessCombinationVolumeWeightedAveragePriceFor30TradingDays", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "perShareItemType" }, "elan_BusinessCombinationVolumeWeightedAverageStockPriceAsOfLastDayOfTradingBeforeClosingAcquisitionDuration": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Volume Weighted Average Stock Price As Of Last Day Of Trading Before Closing Acquisition Duration", "label": "Business Combination, Volume Weighted Average Stock Price As Of Last Day Of Trading Before Closing Acquisition Duration", "terseLabel": "Volume weighted average stock price as of the last day of trading before the closing of the acquisition duration" } } }, "localname": "BusinessCombinationVolumeWeightedAverageStockPriceAsOfLastDayOfTradingBeforeClosingAcquisitionDuration", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "durationItemType" }, "elan_CapstarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capstar", "label": "Capstar [Member]", "terseLabel": "Capstar" } } }, "localname": "CapstarMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails" ], "xbrltype": "domainItemType" }, "elan_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Change In Contract With Customer, Liability [Roll Forward]", "label": "Change In Contract With Customer, Liability [Roll Forward]", "terseLabel": "Change In Contract With Customer, Liability [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "stringItemType" }, "elan_CommonStockNoParValueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, No Par Value", "label": "Common Stock, No Par Value [Member]", "terseLabel": "Common stock, no par value" } } }, "localname": "CommonStockNoParValueMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/Coverpage" ], "xbrltype": "domainItemType" }, "elan_CommonStockOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock Offering", "label": "Common Stock Offering [Member]", "terseLabel": "Common Stock Offering" } } }, "localname": "CommonStockOfferingMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_ContractManufacturingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract Manufacturing [Member]", "label": "Contract Manufacturing [Member]", "verboseLabel": "Contract Manufacturing" } } }, "localname": "ContractManufacturingMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_ContractWithCustomerLiabilityIncreaseFromCashReceipts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability, Increase From Cash Receipts", "label": "Contract With Customer, Liability, Increase From Cash Receipts", "negatedTerseLabel": "Payments" } } }, "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "elan_ContractWithCustomerLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability [Member]", "label": "Contract With Customer, Liability [Member]", "terseLabel": "Contract With Customer Liability" } } }, "localname": "ContractWithCustomerLiabilityMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_CustomerAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "terseLabel": "Single Customer" } } }, "localname": "CustomerAMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_DebtInstrumentFirstPeriodicPaymentPerAmortizingNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, First Periodic Payment Per Amortizing Note", "label": "Debt Instrument, First Periodic Payment Per Amortizing Note", "terseLabel": "First installment payment per amortizing note" } } }, "localname": "DebtInstrumentFirstPeriodicPaymentPerAmortizingNote", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DebtInstrumentInitialPrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Initial Principal Amount", "label": "Debt Instrument, Initial Principal Amount", "terseLabel": "Initial principal amount" } } }, "localname": "DebtInstrumentInitialPrincipalAmount", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DebtInstrumentNumberOfFinancialCovenants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Number Of Financial Covenants", "label": "Debt Instrument, Number Of Financial Covenants", "terseLabel": "Number of financial covenants" } } }, "localname": "DebtInstrumentNumberOfFinancialCovenants", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "elan_DebtInstrumentPaymentPrincipalAndInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Payment, Principal And Interest", "label": "Debt Instrument, Payment, Principal And Interest", "terseLabel": "Partial payment on principal and interest" } } }, "localname": "DebtInstrumentPaymentPrincipalAndInterest", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DebtInstrumentPeriodicPaymentPerAmortizingNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Periodic Payment Per Amortizing Note", "label": "Debt Instrument, Periodic Payment Per Amortizing Note", "terseLabel": "Quarterly cash installment per amortizing note" } } }, "localname": "DebtInstrumentPeriodicPaymentPerAmortizingNote", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DerivativeInstrumentsLiquidatedForCashBenefitAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Derivative Instruments, Liquidated For Cash Benefit, Amount", "label": "Derivative Instruments, Liquidated For Cash Benefit, Amount", "terseLabel": "Cash benefit for liquidation" } } }, "localname": "DerivativeInstrumentsLiquidatedForCashBenefitAmount", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DerivativeInstrumentsLiquidatedForCashBenefitInterestAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Derivative Instruments, Liquidated For Cash Benefit, Interest, Amount", "label": "Derivative Instruments, Liquidated For Cash Benefit, Interest, Amount", "terseLabel": "Interest included in cash benefit" } } }, "localname": "DerivativeInstrumentsLiquidatedForCashBenefitInterestAmount", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DisposalGroupIncludingDiscontinuedOperationTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Transaction Costs", "label": "Disposal Group, Including Discontinued Operation, Transaction Costs", "terseLabel": "Divestiture transaction costs" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionCosts", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "elan_DivestedAssetsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Divested Assets, Fair Value", "label": "Divested Assets, Fair Value", "terseLabel": "Divested assets, fair value" } } }, "localname": "DivestedAssetsFairValue", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DrontalAndProfenderMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Drontal and Profender", "label": "Drontal and Profender [Member]", "terseLabel": "Drontal and Profender" } } }, "localname": "DrontalAndProfenderMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails" ], "xbrltype": "domainItemType" }, "elan_DueToAffiliateOtherLiabilitiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Due To Affiliate, Other Liabilities, Current", "label": "Due To Affiliate, Other Liabilities, Current", "terseLabel": "Other liabilities due to affiliate" } } }, "localname": "DueToAffiliateOtherLiabilitiesCurrent", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_FarmAnimalFutureProteinAndHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Farm Animal Future Protein And Health [Member]", "label": "Farm Animal Future Protein And Health [Member]", "terseLabel": "Farm Animal Future Protein & Health" } } }, "localname": "FarmAnimalFutureProteinAndHealthMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_FarmAnimalRuminantsAndSwineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Farm Animal Ruminants And Swine [Member]", "label": "Farm Animal Ruminants And Swine [Member]", "terseLabel": "Farm Animal Ruminants & Swine" } } }, "localname": "FarmAnimalRuminantsAndSwineMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_FinishedGoodsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finished Goods", "label": "Finished Goods [Member]", "terseLabel": "Finished Products" } } }, "localname": "FinishedGoodsMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_GalliprantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Galliprant", "label": "Galliprant [Member]", "terseLabel": "Galliprant" } } }, "localname": "GalliprantMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_InProcessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "in Process", "label": "in Process [Member]", "terseLabel": "in Process" } } }, "localname": "InProcessMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_LeasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leases", "label": "Leases [Member]", "terseLabel": "Leases" } } }, "localname": "LeasesMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_LocalCountryAssetPurchasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local Country Asset Purchases [Member]", "label": "Local Country Asset Purchases [Member]", "terseLabel": "Local country asset purchases" } } }, "localname": "LocalCountryAssetPurchasesMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_NovartisAnimalHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Novartis Animal Health", "label": "Novartis Animal Health [Member]", "terseLabel": "Novartis Animal Health" } } }, "localname": "NovartisAnimalHealthMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_NumberOfBrandsInEntitysPortfolio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Brands In Entity's Portfolio", "label": "Number Of Brands In Entity's Portfolio", "terseLabel": "Number of brands in diverse portfolio" } } }, "localname": "NumberOfBrandsInEntitysPortfolio", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "integerItemType" }, "elan_OsurniaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Osurnia", "label": "Osurnia [Member]", "terseLabel": "Osurnia" } } }, "localname": "OsurniaMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails" ], "xbrltype": "domainItemType" }, "elan_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax", "terseLabel": "Gain, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "elan_OtherForeignCountriesNotSeparatelyDisclosedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Foreign Countries Not Separately Disclosed [Member]", "label": "Other Foreign Countries Not Separately Disclosed [Member]", "terseLabel": "Other foreign countries" } } }, "localname": "OtherForeignCountriesNotSeparatelyDisclosedMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails" ], "xbrltype": "domainItemType" }, "elan_OtherImmaterialDivestituresMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Immaterial Divestitures", "label": "Other Immaterial Divestitures [Member]", "terseLabel": "Other Immaterial Divestitures" } } }, "localname": "OtherImmaterialDivestituresMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails" ], "xbrltype": "domainItemType" }, "elan_OtherRelatedPartyActivitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Related Party Activities [Member]", "label": "Other Related Party Activities [Member]", "terseLabel": "Other activities" } } }, "localname": "OtherRelatedPartyActivitiesMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_PaymentsOfSeparationRelatedCostsFinancingActivities": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments Of Separation Related Costs, Financing Activities", "label": "Payments Of Separation Related Costs, Financing Activities", "negatedLabel": "Consideration paid to Lilly in connection with the Separation (Note 1)" } } }, "localname": "PaymentsOfSeparationRelatedCostsFinancingActivities", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_PetHealthDiseasePreventionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pet Health Disease Prevention [Member]", "label": "Pet Health Disease Prevention [Member]", "terseLabel": "Pet Health Disease Prevention" } } }, "localname": "PetHealthDiseasePreventionMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_PetHealthTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pet Health Therapeutics [Member]", "label": "Pet Health Therapeutics [Member]", "terseLabel": "Pet Health Therapeutics" } } }, "localname": "PetHealthTherapeuticsMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_PrevtecMicrobiaInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prevtec Microbia, Inc. [Member]", "label": "Prevtec Microbia, Inc. [Member]", "terseLabel": "Prevtec" } } }, "localname": "PrevtecMicrobiaInc.Member", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_ProceedsFromPaymentsToTransactionsWithParent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From (Payments To) Transactions With Parent", "label": "Proceeds From (Payments To) Transactions With Parent", "terseLabel": "Other net financing transactions with Lilly" } } }, "localname": "ProceedsFromPaymentsToTransactionsWithParent", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_ProductReturnConcentrationRiskMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product Return Concentration Risk [Member]", "label": "Product Return Concentration Risk [Member]", "terseLabel": "Product Return Concentration Risk" } } }, "localname": "ProductReturnConcentrationRiskMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_RelatedPartyTransactionMarkUpRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related Party Transaction, Mark-Up Rate", "label": "Related Party Transaction, Mark-Up Rate", "terseLabel": "Mark-up rate" } } }, "localname": "RelatedPartyTransactionMarkUpRate", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "elan_RepaymentsOfLongTermDebtAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Repayments Of Long Term Debt, Accrued Interest", "label": "Repayments Of Long Term Debt, Accrued Interest", "terseLabel": "Debt repaid, interest" } } }, "localname": "RepaymentsOfLongTermDebtAccruedInterest", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_RequiredRatioOfProFormaAdjustedEBITDAToCashInterestExpense": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Required Ratio Of Pro Forma Adjusted EBITDA To Cash Interest Expense", "label": "Required Ratio Of Pro Forma Adjusted EBITDA To Cash Interest Expense", "terseLabel": "Required ratio of pro forma adjusted EBITDA to cash interest expense (no less than)" } } }, "localname": "RequiredRatioOfProFormaAdjustedEBITDAToCashInterestExpense", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "elan_RequiredRatioOfProFormaNetLeverageAndProFormaAdjustedEBITDA": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Required Ratio Of Pro Forma Net Leverage And Pro Forma Adjusted EBITDA", "label": "Required Ratio Of Pro Forma Net Leverage And Pro Forma Adjusted EBITDA", "terseLabel": "Required ratio of pro forma net leverage and pro forma adjusted EBITDA" } } }, "localname": "RequiredRatioOfProFormaNetLeverageAndProFormaAdjustedEBITDA", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "elan_RestructuringAndRelatedCostNumberOfCountriesExpectedToEliminatePositions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring And Related Cost, Number Of Countries Expected to Eliminate Positions", "label": "Restructuring And Related Cost, Number Of Countries Expected to Eliminate Positions", "terseLabel": "Number of countries expected to eliminate positions" } } }, "localname": "RestructuringAndRelatedCostNumberOfCountriesExpectedToEliminatePositions", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "integerItemType" }, "elan_RightsToTheProfenderAndDrontalProductFamiliesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rights To The Profender And Drontal Product Families", "label": "Rights To The Profender And Drontal Product Families [Member]", "terseLabel": "Rights To The Profender And Drontal" } } }, "localname": "RightsToTheProfenderAndDrontalProductFamiliesMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_SaleLeasebackTransactionNetProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sale Leaseback Transaction, Net Proceeds", "label": "Sale Leaseback Transaction, Net Proceeds", "terseLabel": "Sale leaseback proceeds" } } }, "localname": "SaleLeasebackTransactionNetProceeds", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_SeparationRelatedCostsFinancingActivitiesPaymentsMadeToDate": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Separation Related Costs, Financing Activities, Payments Made To Date", "label": "Separation Related Costs, Financing Activities, Payments Made To Date", "terseLabel": "Payments made to date" } } }, "localname": "SeparationRelatedCostsFinancingActivitiesPaymentsMadeToDate", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "elan_SharesIssuedSharesShareBasedPaymentArrangementAfterForfeitureAcceleratedVesting": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Accelerated Vesting", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Accelerated Vesting", "terseLabel": "Accelerated vesting of equity awards (in shares)" } } }, "localname": "SharesIssuedSharesShareBasedPaymentArrangementAfterForfeitureAcceleratedVesting", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "elan_StockholdersEquitySeparationAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stockholders' Equity, Separation Adjustments", "label": "Stockholders' Equity, Separation Adjustments", "verboseLabel": "Separation activities" } } }, "localname": "StockholdersEquitySeparationAdjustments", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_TangibleEquityUnitAverageApplicableMarketValueTriggeringInclusionInCalculationOfDilutedSharesOutstandingPerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share", "label": "Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share", "terseLabel": "Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share)", "verboseLabel": "Applicable Market Value (usd per share)" } } }, "localname": "TangibleEquityUnitAverageApplicableMarketValueTriggeringInclusionInCalculationOfDilutedSharesOutstandingPerShare", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "elan_TangibleEquityUnitDebtComponentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible Equity Unit, Debt Component", "label": "Tangible Equity Unit, Debt Component [Member]", "terseLabel": "Debt Component" } } }, "localname": "TangibleEquityUnitDebtComponentMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitEquityComponentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible Equity Unit, Equity Component", "label": "Tangible Equity Unit, Equity Component [Member]", "terseLabel": "Equity Component" } } }, "localname": "TangibleEquityUnitEquityComponentMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible Equity Unit", "label": "Tangible Equity Unit [Member]", "terseLabel": "Tangible Equity Unit (TEU)" } } }, "localname": "TangibleEquityUnitMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion", "label": "Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion", "terseLabel": "Shares issued upon conversion of prepaid stock purchase contracts (in shares)" } } }, "localname": "TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "elan_TangibleEquityUnitSettlementRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible Equity Unit, Settlement Rate", "label": "Tangible Equity Unit, Settlement Rate", "terseLabel": "Settlement rate" } } }, "localname": "TangibleEquityUnitSettlementRate", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "elan_TangibleEquityUnitsIssuedDuringPeriodValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Tangible Equity Units Issued During Period, Value", "label": "Tangible Equity Units Issued During Period, Value", "terseLabel": "Issuance of tangible equity units, net of issuance costs" } } }, "localname": "TangibleEquityUnitsIssuedDuringPeriodValue", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_TermBLoanFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term B Loan Facility", "label": "Term B Loan Facility [Member]", "terseLabel": "Term loan B credit facility" } } }, "localname": "TermBLoanFacilityMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_TermCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Credit Facility [Member]", "label": "Term Credit Facility [Member]", "netLabel": "Term Loan Facility", "terseLabel": "Senior Unsecured Term Credit Facility", "verboseLabel": "Term credit facility" } } }, "localname": "TermCreditFacilityMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "domainItemType" }, "elan_TransitionalServicesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transitional Services Agreement [Member]", "label": "Transitional Services Agreement [Member]", "netLabel": "TSA", "terseLabel": "TSA" } } }, "localname": "TransitionalServicesAgreementMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_VecoxanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vecoxan", "label": "Vecoxan [Member]", "terseLabel": "Vecoxan" } } }, "localname": "VecoxanMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails" ], "xbrltype": "domainItemType" }, "elan_WorldwideRightsToOsurniaAndUSRightsToCapstarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Worldwide Rights To Osurnia And U.S. Rights To Capstar", "label": "Worldwide Rights To Osurnia And U.S. Rights To Capstar [Member]", "terseLabel": "Worldwide rights to Osurnia and U.S. rights to Capstar" } } }, "localname": "WorldwideRightsToOsurniaAndUSRightsToCapstarMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_WorldwideRightsToOsurniaUSRightsToCapstarAndWorldwideRightsToVecoxanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan", "label": "Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan [Member]", "terseLabel": "Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan" } } }, "localname": "WorldwideRightsToOsurniaUSRightsToCapstarAndWorldwideRightsToVecoxanMember", "nsuri": "http://www.elanco.com/20200930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r336", "r480", "r481", "r483", "r578" ], "lang": { "en-US": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Bayer" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r142", "r150", "r228", "r349", "r350", "r351", "r375", "r376" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r142", "r150", "r228", "r349", "r350", "r351", "r375", "r376" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r142", "r150", "r228", "r349", "r350", "r351", "r375", "r376" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r217", "r313", "r319", "r552" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r339", "r341", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r549", "r553" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r339", "r341", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r549", "r553" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r217", "r313", "r319", "r552" ], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r211", "r313", "r317", "r497", "r548", "r550" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r211", "r313", "r317", "r497", "r548", "r550" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r328", "r339", "r341", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r549", "r553" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r328", "r339", "r341", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r549", "r553" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r212", "r213", "r313", "r318", "r551", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r212", "r213", "r313", "r318", "r551", "r567", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]", "terseLabel": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsTextBlock": { "auth_ref": [ "r154", "r157" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.", "label": "Accounting Changes and Error Corrections [Text Block]", "terseLabel": "Implementation of New Financial Accounting Pronouncements" } } }, "localname": "AccountingChangesAndErrorCorrectionsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r143", "r144", "r145", "r146", "r225", "r226", "r227", "r228", "r229", "r230", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r375", "r376", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565" ], "lang": { "en-US": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r53", "r135", "r482", "r483" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Related party, accounts payable" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r19", "r35", "r219", "r220" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowances of $8.8 (2020) and $6.2 (2019)", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r78", "r84", "r85", "r413" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Benefit Pension and Retiree Health Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r51", "r258" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "verboseLabel": "Property and equipment, net of accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r84", "r93", "r412" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Cash Flow Hedge Gain (Loss)" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r38", "r81", "r83", "r84", "r535", "r561", "r565" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r80", "r84", "r85", "r139", "r140", "r141", "r413", "r556", "r557" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r76", "r84", "r85", "r413", "r458", "r459", "r460", "r461", "r463" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Average useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r36", "r352" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r139", "r140", "r141", "r349", "r350", "r351" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Issuance of stock under employee stock plans, net" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r342", "r343", "r354", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r343", "r344", "r353" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Cost of stock-based compensation plans" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r42", "r221", "r231" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, net of allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r123", "r244", "r252" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive shares not included in calculating diluted earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentChargesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asset Impairment Charges [Abstract]", "terseLabel": "Acquisition related charges:" } } }, "localname": "AssetImpairmentChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r130", "r196", "r201", "r207", "r224", "r409", "r415", "r455", "r517", "r533" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r20", "r21", "r72", "r130", "r224", "r409", "r415", "r455" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Noncurrent Assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r1", "r2", "r9", "r11", "r14", "r262" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r424", "r428" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r338", "r340" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r338", "r340", "r391", "r392" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r404" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Shares issued to previous shareholders upon closing (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r389", "r390" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Common stock price (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r389", "r390" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Loss before income taxes" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r389", "r390" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r388" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r399", "r400", "r402" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration paid for acquisition", "totalLabel": "Fair value of total consideration transferred (2)" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Value of shares issued as consideration", "verboseLabel": "Fair value of Elanco common stock" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r122", "r407" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedLabel": "Decrease of fair value of contingent consideration liability", "negatedTerseLabel": "Loss upon settlement of contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r406" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Maximum aggregate contingent payment", "verboseLabel": "Contingent value rights included in purchase consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r398", "r401", "r405" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Transaction and integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "auth_ref": [ "r396" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "terseLabel": "Measurement period adjustment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r394" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r394" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r394" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r394" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Acquired in-process research and development" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r393", "r394" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Finite lived intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r393", "r394" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r393", "r394" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r393", "r394" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r394" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r123", "r265", "r271", "r277" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Facility exit costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r450", "r451" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r17", "r49", "r125" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r119", "r125", "r126" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r119", "r456" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r128", "r130", "r161", "r162", "r163", "r165", "r167", "r178", "r179", "r180", "r224", "r455" ], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r64", "r279", "r523", "r539" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r139", "r140" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r34", "r292" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r34" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, no par value, 5,000,000,000 shares authorized, 471,879,904 and 373,011,513 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r88", "r90", "r91", "r99", "r527", "r544" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r184", "r185", "r217", "r452", "r453" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r184", "r185", "r217", "r452", "r453", "r566" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r184", "r185", "r217", "r452", "r453", "r566" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r184", "r185", "r217", "r452", "r453" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as a percent)", "verboseLabel": "Concentration risk (less than 0.1%)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r181", "r184", "r185", "r186", "r452", "r454" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r184", "r185", "r217", "r452", "r453" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r127", "r411" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Summary of Activity in Sales Rebates and Discounts Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r301", "r302", "r314" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r301", "r302", "r314" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Sales rebates and discounts" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "auth_ref": [ "r303" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "terseLabel": "Bayer Animal Health at acquisition" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Reduction of revenue" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "negatedLabel": "TEU amortizing note" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r102", "r497" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r101" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Costs, expenses and other" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, expenses and other:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r329", "r433" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross currency interest rate contracts designated as net investment hedges" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r182", "r217" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r28", "r29", "r30", "r518", "r519", "r532" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r30", "r283", "r519", "r532" ], "calculation": { "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross", "totalLabel": "Total obligations and commitments" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Number of consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r467", "r469" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "verboseLabel": "Interest rate on debt component" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r62" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r62", "r133", "r293", "r296", "r297", "r298", "r466", "r467", "r469", "r531" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt maturity term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r284", "r468" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized debt issuance costs and other obligations" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityFee": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of commitment fees for the unused borrowing capacity under the long-term financing arrangement that is available to the entity.", "label": "Debt Instrument, Unused Borrowing Capacity, Fee", "terseLabel": "Unused commitment fee" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityFee", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r468" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt financing costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r52", "r468" ], "calculation": { "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r52", "r468" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r131", "r370", "r379", "r380", "r381" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Change in deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r359", "r360" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r123", "r194" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Derivative assets (liabilities)" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "auth_ref": [ "r429", "r437" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "terseLabel": "Amount offsetting interest expense" } } }, "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r426" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Net gain (loss) on derivative instruments" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r425", "r427", "r430", "r435" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r423", "r425", "r430" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r419", "r420" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount (USD, CHF)" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r313", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r255", "r257", "r263" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r11", "r255", "r263" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Held for Sale" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract]", "terseLabel": "Non-cash and other items:" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": { "auth_ref": [ "r1", "r2", "r9", "r262" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities", "negatedLabel": "Deferred taxes" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "auth_ref": [ "r1", "r2", "r9", "r262" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Other intangibles, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r1", "r2", "r9", "r262" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r1", "r2", "r9", "r262" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r123", "r257", "r260" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 7.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedLabel": "Settlements and other" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r123", "r257", "r260" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 5.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "terseLabel": "Asset write-down" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r338", "r340" ], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r135", "r481", "r521", "r541" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Due from related party" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r53", "r135", "r481" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Payable to Lilly (Note 17)" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r135", "r481", "r522", "r540" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Earnings (loss) per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r100", "r148", "r149", "r150", "r151", "r152", "r158", "r161", "r165", "r166", "r167", "r171", "r172", "r528", "r545" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r100", "r148", "r149", "r150", "r151", "r152", "r161", "r165", "r166", "r167", "r171", "r172", "r528", "r545" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r168", "r169", "r170", "r173" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r456" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r139", "r140", "r141", "r144", "r153", "r156", "r177", "r228", "r292", "r299", "r349", "r350", "r351", "r375", "r376", "r457", "r458", "r459", "r460", "r461", "r463", "r556", "r557", "r558" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r50", "r197", "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r449" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Facility exit costs" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r439", "r440", "r441", "r445" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r439", "r450", "r451" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r440", "r487", "r488", "r489" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r439", "r446" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r439", "r440", "r442", "r443", "r447" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial Instruments and Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r329", "r330", "r335", "r337", "r440", "r487" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r329", "r330", "r335", "r337", "r440", "r488" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r440", "r489" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r439", "r440" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value Information" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r487", "r488", "r489" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r444", "r447" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r245", "r248", "r251", "r254", "r498", "r502" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r245", "r250" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r329", "r432" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Cross-currency fixed interest rate swap", "verboseLabel": "Foreign exchange contracts not designated as hedging instruments" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r123", "r257", "r260" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 6.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "Gain on sale of fixed assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r123", "r414" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedLabel": "Gain on divestitures (Note 6)", "terseLabel": "Pre-tax Gain", "verboseLabel": "Gain (loss) on disposition of business" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r123" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedLabel": "Gain on sale of assets" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r123", "r286", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Debt extinguishment loss" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r233", "r235", "r516" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresCarryingGoodwillDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Additions related to the Bayer Animal Health acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresCarryingGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r238" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresCarryingGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r123", "r234", "r237", "r241" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r239", "r387" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Aratana measurement period adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresCarryingGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresCarryingGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r423", "r436" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r123", "r256" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 4.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Asset impairment" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r96", "r196", "r200", "r203", "r206", "r209", "r515", "r524", "r530", "r546" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r338", "r340" ], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r12", "r13", "r14", "r263", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r364", "r365", "r367", "r372" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r363", "r366", "r369", "r377", "r382", "r384", "r385", "r386" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r131", "r155", "r156", "r195", "r361", "r378", "r383", "r547" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax (benefit) expense", "verboseLabel": "Income tax (benefit) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r92", "r127", "r357", "r358", "r366", "r367", "r368", "r371", "r568" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Tax" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r122" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedTerseLabel": "Changes in operating assets and liabilities, net of acquisitions" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r247", "r253" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r247", "r253" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Intangible Assets, Gross (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible assets:" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r243", "r249" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangibles, net (Note 6)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r94", "r193", "r465", "r468", "r529" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense, net of capitalized interest (Note 10)" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "negatedTerseLabel": "Expected reclassification from accumulated other comprehensive loss" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r329", "r431" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Forward-starting interest rate contracts designated as cash flow hedges" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Inventories" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r67" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r70" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r71" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedTerseLabel": "Decrease to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r18", "r70" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories (Note 8)", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r69" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials and supplies" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r68" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r474" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorSalesTypeLeaseTermOfContract1": { "auth_ref": [ "r475" ], "lang": { "en-US": { "role": { "documentation": "Term of lessor's sales-type lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Sales-type Lease, Term of Contract", "terseLabel": "Sale leaseback initial lease term" } } }, "localname": "LessorSalesTypeLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r57", "r130", "r202", "r224", "r410", "r415", "r416", "r455" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r41", "r130", "r224", "r455", "r520", "r537" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r59", "r130", "r224", "r410", "r415", "r416", "r455" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r1", "r2", "r9", "r11", "r14", "r262" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "negatedTotalLabel": "Total liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r30", "r519", "r532" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding debt" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Credit Facility", "verboseLabel": "Credit facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LinesOfCreditFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time.", "label": "Lines of Credit, Fair Value Disclosure", "negatedLabel": "Long-term debt - term credit facility" } } }, "localname": "LinesOfCreditFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r64", "r279" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Liabilities related to litigation" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of contractual obligation to pay money on demand or on fixed or determinable dates.", "label": "Loans Payable, Fair Value Disclosure", "negatedTerseLabel": "Term loan B" } } }, "localname": "LoansPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Long-lived Assets by Selected Geographic Area Information" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Represents the assets held for sale.", "label": "Long Lived Assets Held-for-sale by Asset Type [Axis]", "terseLabel": "Long Lived Assets Held-for-sale by Asset Type [Axis]" } } }, "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongLivedAssetsHeldForSaleNameDomain": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "A name of the assets to be disposed.", "label": "Long Lived Assets Held-for-sale, Name [Domain]", "terseLabel": "Long Lived Assets Held-for-sale, Name [Domain]" } } }, "localname": "LongLivedAssetsHeldForSaleNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r30", "r285", "r519", "r534" ], "calculation": { "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Net proceeds", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Less current portion of long-term debt", "verboseLabel": "Current portion of long-term debt (Note 10)" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r137", "r281" ], "calculation": { "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r137", "r281" ], "calculation": { "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r137", "r281" ], "calculation": { "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r137", "r281" ], "calculation": { "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r137", "r281" ], "calculation": { "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r137", "r281" ], "calculation": { "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r137" ], "calculation": { "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails": { "order": 7.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Fourth quarter of 2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtMaturityofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt (Note 10)", "verboseLabel": "Total long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r62" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r62", "r282" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MajorityShareholderMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.", "label": "Majority Shareholder [Member]", "terseLabel": "Lilly" } } }, "localname": "MajorityShareholderMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketingRelatedIntangibleAssetsMember": { "auth_ref": [ "r397" ], "lang": { "en-US": { "role": { "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.", "label": "Marketing-Related Intangible Assets [Member]", "terseLabel": "Marketed products" } } }, "localname": "MarketingRelatedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r15", "r408" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Acquisitions and Divestitures" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestitures" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Interest percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r119" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by (Used for) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r119" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used for Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r119", "r120", "r124" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r14", "r86", "r89", "r97", "r124", "r130", "r143", "r148", "r149", "r150", "r151", "r155", "r156", "r164", "r196", "r200", "r203", "r206", "r209", "r224", "r455", "r525", "r542" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r147", "r150", "r171", "r225", "r226", "r227", "r228", "r229", "r230", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r373", "r374", "r375", "r376", "r499", "r500", "r501", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Implementation of New Financial Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Next Largest Country", "verboseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.", "label": "Nonfinancial Liabilities Fair Value Disclosure", "negatedLabel": "Contingent consideration" } } }, "localname": "NonfinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r105" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Other\u2013net, (income) expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "negatedTerseLabel": "Long-term debt - senior notes" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Other obligations" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfCountriesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of countries in which the entity operates as of balance sheet date.", "label": "Number of Countries in which Entity Operates", "terseLabel": "Number of countries in which entity operates (more than)" } } }, "localname": "NumberOfCountriesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "auth_ref": [ "r73", "r74" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Liabilities [Table Text Block]", "terseLabel": "Net Gain/Loss on Derivative Instruments" } } }, "localname": "OffsettingLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "auth_ref": [ "r176", "r476" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income, Lease Payments", "terseLabel": "Sale leaseback lease payments" } } }, "localname": "OperatingLeaseLeaseIncomeLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r471" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r470" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease, right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r16", "r417" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business and Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r77", "r81" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "negatedLabel": "Loss on cash flow hedge, net of tax benefit", "terseLabel": "Unrealized loss on derivatives for cash flow hedges, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "negatedLabel": "Tax benefit on loss on cash flow hedge" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r75" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r87", "r90", "r93", "r98", "r292", "r457", "r462", "r463", "r526", "r543" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r79", "r81" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Defined benefit pension and retiree health benefit plans, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r22", "r23", "r58" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other non-cash operating activities, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other operating income (expense).", "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other Operating Income (Expense)" } } }, "localname": "OtherOperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": { "auth_ref": [ "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.", "label": "Payment for Contingent Consideration Liability, Investing Activities", "terseLabel": "Settlement of existing contingent consideration liabilities" } } }, "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r117" ], "calculation": { "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Payment of Financing and Stock Issuance Costs", "terseLabel": "Less: Issuance costs" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r107", "r111", "r136" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r118", "r267" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash paid" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r109" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedLabel": "Purchases of software" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r116" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r108", "r403" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid in acquisition", "verboseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r108" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions, net of cash acquired (Note 6)" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r109" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Net proceeds from sale (purchases) of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r31", "r325", "r326", "r327", "r337" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "terseLabel": "Accrued retirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r33" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, no par value, 1,000,000,000 shares authorized; none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r20", "r47", "r48" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r106" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "terseLabel": "Divestiture proceeds (Note 6)", "verboseLabel": "Gross Cash Proceeds" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresDivestituresDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromHedgeInvestingActivities": { "auth_ref": [ "r107", "r121" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.", "label": "Proceeds from Hedge, Investing Activities", "terseLabel": "Proceeds from settlement of net investment hedges (Note 11)" } } }, "localname": "ProceedsFromHedgeInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-term Debt", "terseLabel": "Proceeds from issuance of long-term debt (Note 10)" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r112" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from issuance of common stock and tangible equity units (Note 9)", "verboseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r113", "r134" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Drawdown" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r114", "r117", "r136" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r26", "r27", "r259", "r538" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net of accumulated depreciation of $982.7 (2020) and $930.5 (2019)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryRawMaterialsMember": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Basic goods that are to be consumed directly or indirectly in the production of finished goods or services.", "label": "Raw Materials [Member]", "terseLabel": "Raw Materials" } } }, "localname": "PublicUtilitiesInventoryRawMaterialsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r336", "r480", "r481" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r336", "r480", "r481", "r483" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r135", "r481" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Total payable to Lilly", "verboseLabel": "Receivable from, payable (to) related party" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r336", "r480", "r483", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r478", "r479", "r481", "r484", "r485" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Agreements and Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r115" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Debt repaid" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r115" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "terseLabel": "Debt repaid, principal" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r115" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedTerseLabel": "Repayments of borrowings (Note 10)" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r356", "r579" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r17", "r25", "r126" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "netLabel": "Restricted cash and payable", "terseLabel": "Restricted cash (Note 17)", "verboseLabel": "Restricted cash (Note 17)" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r266", "r268", "r275", "r278" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected total restructuring charges" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "terseLabel": "Expected number of positions eliminated" } } }, "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r123", "r265", "r271", "r277" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "Asset Impairment, Restructuring and Other Special Charges" } } }, "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r267", "r273" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r265", "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Reserve adjustments" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "auth_ref": [ "r103" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.", "label": "Restructuring, Settlement and Impairment Provisions", "terseLabel": "Asset impairment, restructuring and other special charges (Note 7)", "totalLabel": "Total expense" } } }, "localname": "RestructuringSettlementAndImpairmentProvisions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring, Settlement and Impairment Provisions [Abstract]", "terseLabel": "Restructuring charges:" } } }, "localname": "RestructuringSettlementAndImpairmentProvisionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r299", "r352", "r536", "r560", "r565" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Decrease due to adoption", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r139", "r140", "r141", "r144", "r153", "r156", "r228", "r349", "r350", "r351", "r375", "r376", "r556", "r558" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r191", "r192", "r199", "r204", "r205", "r211", "r212", "r217", "r312", "r313", "r497" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Revenue", "terseLabel": "Revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r184", "r217" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Net Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r316", "r324" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue by Selected Geographic Area Information" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Senior Unsecured Revolving Credit Facility", "verboseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleAndLeasebackTransactionGainLossNet": { "auth_ref": [ "r472", "r473", "r477" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.", "label": "Sale and Leaseback Transaction, Gain (Loss), Net", "terseLabel": "Sale leaseback gain" } } }, "localname": "SaleAndLeasebackTransactionGainLossNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Total net proceeds, after underwriting discounts and commissions", "totalLabel": "Net proceeds", "verboseLabel": "Proceeds after underwriting discounts and commissions" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued (in shares)", "verboseLabel": "Number of shares sold in public offering" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.", "label": "Sale of Stock, Percentage of Ownership before Transaction", "terseLabel": "Percentage of total outstanding shares" } } }, "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share (usd per share)", "verboseLabel": "Offering price (usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r184", "r217" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r391", "r392" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r391", "r392" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Purchase Consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Provision for Taxes on Income" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r62", "r133", "r293", "r296", "r297", "r298", "r466", "r467", "r469", "r531" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r12", "r13", "r14", "r263", "r264" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Divestitures Activities" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r240", "r242" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r24", "r44", "r45", "r46" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r147", "r150", "r174", "r175" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Description of Accounting Standards Adopted and Not Yet Adopted" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "verboseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r132", "r482", "r483" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Amounts Due From/(Due To) Lilly and Allocations of Services" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r269", "r270", "r274" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r269", "r270", "r274" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Total Charges Related to Asset Impairment, Restructuring and Other Special Charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r267", "r276" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Summary of Activity in Reserves" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r95", "r216" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r65", "r128", "r178", "r179", "r289", "r290", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Stockholders Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r187", "r189", "r190", "r196", "r198", "r203", "r207", "r208", "r209", "r210", "r211", "r216", "r217", "r218" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r104" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Marketing, selling and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r123", "r265", "r271", "r277" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and other costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r122" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-based Payment Arrangement, Accelerated Cost", "terseLabel": "Accelerated stock based compensation expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r32", "r33", "r34", "r128", "r130", "r161", "r162", "r163", "r165", "r167", "r178", "r179", "r180", "r224", "r292", "r455" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/Coverpage", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r66", "r139", "r140", "r141", "r144", "r153", "r156", "r177", "r228", "r292", "r299", "r349", "r350", "r351", "r375", "r376", "r457", "r458", "r459", "r460", "r461", "r463", "r556", "r557", "r558" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r139", "r140", "r141", "r177", "r497" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r33", "r34", "r299" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance for acquisition (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r33", "r34", "r292", "r299" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of stock under employee stock plans, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited", "terseLabel": "Issuance of common stock, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r66", "r292", "r299" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance for acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r33", "r34", "r292", "r299" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r34", "r39", "r40", "r130", "r222", "r224", "r455" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r129", "r299", "r300" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Impact of Separation", "verboseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/Equity", "http://www.elanco.com/role/ImpactofSeparation" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r464", "r486" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r464", "r486" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r464", "r486" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Common stock equivalents included in weighted average diluted shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r160", "r167" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r158", "r159" ], "lang": { "en-US": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "terseLabel": "Weighted average commons shares included in calculation of basic earnings per share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r158", "r167" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3581-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r15": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256" }, "r16": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=SL65897772-128472" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r408": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r417": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r474": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121606570&loc=SL77919786-209982" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r485": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r581": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r582": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r583": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r584": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r585": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 89 0001739104-20-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739104-20-000023-xbrl.zip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�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

HF342['>%GTRCR=NJ$D^9=2WQEA:P[L]\M)\XKQT%W2*XW0R,RDC#$8PQ>4D>X M2*GXFFR)FG6?&NLZ"XHB"]YCYKBQPA@/=6<&?,%"D%Y9 MQ&*1"F*:B'0A),(*^)8741'J7KP61&VIFG6?&NNFW'Q-++<&V!53;HPG@FKL M"\-$D*XVX#>/=6<&/*>Q (79(2P#R%H9@765],A+#HHT"%UK-+ NXQLE=9_% M@?N\ ?]QW&WW3"J(6-KNG\[@\OKH?4F)"(R#F6>L]IHS41A/.29,.*I-E)C7 MIONF(=%\+Q;BBH($[A"G@#\<5#\$(H4A00&*#)5&Y%, 3>NC]Z?'NEH$+](! M'O-@_3%F96%2(3;C<:JC*&O3??-8=RX!@S!)P'1#T7H,!CLKD/&:KUEWTUB7A2B)\5J2H#E13EDP P*H^\*+R)FJ3??-8]V9Z1ZE MH;[P!?+.F-0!32*+)4,.ME!$B@L2\8O7!6;UV?O38]W 5,2,%F"K4]"QHI). M,BEBB,#+GN':=-\\UITSW7D(CCB+%,V!](0B4U"&C)6NL*HH1#KK4H36?O-[;7YTK%54.@=/VK:2/XA^/,"4LTFJ8WCO!+VO?R.]+!2IK%VCE>' VV!"Y"5CQ:+ I' %.!$!5@*>> MU(Z'34I1P5W"T2"0=E0A+D(@/@@%BNR+UT2NK65-?7BQ,9QK M!-%14!6X=*D0;FK,(0OJO LX,%Z'_&\@YU[,U;/!3&O"$58Z(@[,FCHW!R1@ M&YWS#!0CEZ)][A]\6'/NIG&N3KUS' \L&/AIG=7&TP P+BQAA:E#_C>0<^?< M#EBJ2+5')OA4BY\Z\#L)RZZ,1*&JA$3<6(V4I1EY@S8U@PJ0:G+J/KL_>UD>.4CK8#"3,BHI.0\\JN!2)K0DWBCC@JM= M&IL&TO-E# Q1WE+.$'6@67$7/5*&:A0\ARW%DM,42Z&47ELR]*]OP[NF,Z$- M1$X8JH;-7[48MSI.*Z3AI*#*,;DTT19+X1&AEF/.!4"V4(7B 9) MG$PR,377I2\)6T,)TUH/K6&UAM5Y;92""FHHL=H(KD$S]9B2HM#*!V!*SF_@ M9JUA=7-@=>:!E3YJJCQ!1EN!.+,$8%7"GU*8H+F).MH$JU3Q^Q^?; RL9A?N MOW)+SM=7M-'^UU*SX1]U-EZ(!2-J$?Q6M=A%Z:+U\+K8HC=HH'I5E!;=4C^* MTEK==K=C8%9^L+8A.W6AS%NB';,DRF'#EHMQU,:]? MG(_A=!"&(>4%3KO5 P8WS&!@>D>AF[]I]QIGQVUWW#@+C11]:(8-D['TV:_C3.8(KS8 MMW9_/(0Y )EW4F=*F#!:L+38! @$)PH;B4 MU. 0 @\RQ"(X&_VA$"]>/T@[[V88'(7!<'NV:O!R?FZRUTSF&<YYZ_W'=NO]G\<'%P[O?7X+<_X3- "0T?O'<6_' MT>;1822Z*(S5B,?4WYMYB;3P&*5BSP)6G?$0EQ&/<,:)405A7'&FF?'!4$,T MIXH&BO6J_MX_1\->W2^1\7IYY:"YH?O.7RZW?#Z+CO\RN4P\#L M\Z-6734(\!&\U\N&Z?;A+?LP6AH2[H'/1LX_E$/MAON'Z4IMP>-:.#'-],9YT'2A)=?Q8,(*:?N M89\&W25_ *G M>4G+AX7O+KU"-:'3\< =ISZ;IX#@H='_5JWYW'/GIYZ6J!-X[2A(?3RH@Q2&V?XX*C?]V?M3J>< ;S#N#/*4^B? I5-J7*4*6:! M5H$L*TV@W(3^>)!0#)@4;+?T6U;ORZ5*90E *^@ R\('I::0=9 T?9]7)-/- M=/BMS1'):X.9/,ZK]@@>ZFZ L2NP9!YOG^ "787#1,!R[/4:V^,CF$B#O%R% MQHG\YM1!T^L!!KE$Y-="= DAS@R/,U\.1Z"KS*/CUNJ;DH8,ZNRW=D+#>=6V M#1":VZ0#!K2[Z9*0"?VXO#$]XRQT.LB&!/#IS@QTO80I ]#+\V.&E[$S?(?5 M]L/R58'5J_&JYTXU8\!4_RWQ6QH\7=J!Q8#9G/8'HP@\"<#4_EZ^7^F[26.G MI[M!, FU$YZ&$0!?PQJX%\ '_CQ+R)&&FYMCONOJF0!*;S7VX);PO3W, T\N MF$TEC] ^S79IAI30.S9YW^QY"6Y@0OU@[UY69DM)""6RE$C4!=4W8\X9WNC_.YOYZK'M^Z> OS.3IO[1_@YL[7 ML^;9H758$E$4R$;B4U:E0TIJC8Q1P6)/F1&7O!@^>BX8[! H_9P*JKAUK%!@ M'3 3-':K=/K-P^(LFO;[(,2RB$_85P)(B2=A,"AQKV35S&_ D<.QA4O;)D%" MUBV7-:YVNJ;;A0LN2KT$T*'3/QN^N@5/W4RL52Z^RDDI5_KT8*3L0YQZ/$N_ M)2QJQYP.PZO)+__V8/%VS/FK=B\O4KYIQ6'ZO\_:?G2CP7R2"Z0FPA)^N?-1UU_F/*LB M^_WMTC:;"-?[?[ZV+K[B@Y,/9\V+#[Q% M_SQI[:=YO>LV=XY@SO]\73[7:GU^>]8Z^7KVY?,'F"_(WIWMBQ9<>]!MDM;G M W;P^>!L;\?QUN>/L3FKW7W1O#BZ."1*6<,<02F; '$F U),"00[JC@6,>#D M]A8O28$W*AWWH1,,?II3\*I2A/..B;?)?3>S OI_9G"^18P=G2^FPR[,!P-=X?#I'3W?/HEJ60UW-X&;C\M MP6U4AG+.9:K45B!N%0.DM1()7V =G&4\A1*0EP5E6\7S+B+SZ^!V=(U)]FB@ MEUX!O=?MV@^#3ZZ./'FZNOM:%J265S]#7I%:(-U&(+67!!(3$5ME4SJQ9XA[ M)I#%W" J%<8D$A>D>/%:OE2:K:V7P#JX:8U1;3_%$?9DP]WF]/E?&_HU%XJU MZLQYZ6SW2J K8P(V .OF3@=6ZN![@XD*WAIW;1CLQ4]YZN6WCQT%UW:BT/IP MJ&*AB6$&,<93.^*46"8X1R$8XPJ#B18IL8Q>V9(,Z+:3B&06+[+* C>CQG_] M2'[^%09YAY;#Q'W0.N+(@PA<6Z\X89ZQR"6-1M)PN+N*I'9;[VY ./EY?Z48 MARD]X.=-#]_W/AQJF6+[#$6$!(H&4 7RH;=.'\+?\-:[O;=5!,^45/7S)M7SUMDA M9LS32 QRF!6@CE&*+#$1418+X7602J;VKE=FQ-H*N4 W:?O9P?^/#K[O1$!S M) ,RW;WRXX$WY]?1RS_]#LS@%>_(\9CG;,^5X$ M8/RUZ[0H@$'#A2PSLDA,)#0Q.TJ9.2=#:WE9RTO23/3G@J))7@:=2@DS4/4CX2AJ M:T".$@X(>$MY"39M&\@G1]AFJJMBAN,#:OOT3I(T"]%W_0'#E? $03JL#8&2 M6BB@%3%$X,)(Q$*J."*%1DKAB$3!0DK0$V /O'B=DN,OIW'^OA1&O9P+^3R] M0:OSZ*X/SUL,YXM2" [JBW7.<*<+&U@(1#K@81LIGAQE/*84Q.M?:?]R7D([ M9^%UVBE)8G!>!E#/=*:S_N!K4J^<.4V![V68<4[X3A)LKR\T+ZREP\.E#B\"X9E-?*@^6ZYPXKY9AV5FO."ZI "&!)-"$21('# M-RCO=Y_3DSG+Z6/YJF_2>S];KV%S?UOL[?_]O;GOOL/U#%0)0QQ55$HDE0/A MX A#*DB.A,/<:.F(+\R+UQI?>2X_\1HFOKP-:7C.O#:N\$P3'G4P',<(+Q05 MM0++FY3$KTGCIY$&;QT=@C+I?5 "6:4"XL0:9(5RR!:%EAK$G-'^Q6M27%F" M=T(:DW#MT?$@A$87J.!XV"CS6SZ%TU'(Y@W#95).)J0RTQ',@E.0 B"5.RDE MY98$%JT2@E"O&0$]M "BX X5DNB)/7J)I7;:P+[603FSI(/QSN%"VX1+X(" M[,$.&4\)*C 5#.Q4HECR4).K#9F[@@^#QW!F'.5>\,B"9*HDV;@P^O>10N1OV M3-*=2Z6IS'->*E+1"4>39+9!/\)NE[EAH+=] [WTAYI6/D09)$TM=N")U8@I MH3"?K+2[IZ8]*$]4DI^DS#/+.79P8YGUG*::+'=0A0='87A-+NU;I4JN=21,6= M-??]=A#V8]YXX"LH-@OB(31V'PRG3.DAOD M7XMK *^[M.;7+->*Q2F]E;>*$+ERE+N1S1I'G29(7K9EKZ^@L53+B"LP^EF, M7)O4;P(T#5"GE?%2%-88M=GY> F4NJGF0L*$JLC/L&%&HT';CLM4MFE.WG+J M\XTR^*]"G09(1Q>F:?Q+6?Q+NF."O!L!>7NXL;KB8RYB]TL5@WVX]NB02"=5 MT!05!?6I?K)%QFJ#-'!=X4.A,0ZWZ\WV@#Z*>N_OM?>%* !B-4.6.HFX#!09 M8B,B!'MI '<+3D!B:K&BSNN/U<14H*$*2LD8-AX,4@F6*4SEPB-5BG\N&^'; M@$3]454)I9&+[9A.OS?1$A-NK4+++)T7T&Y)']QJ;*>R$&4=E?RHI!R.>Q,( M-LZE((!T #@I+1,:P0QZJ?!- Y[:Z0]O!MP_!-ZG6#[E6@F8XB:G=7IN6CTH M%<5)E' .RGHNCI-JU70F6>@PT&7Q5!;F6/9==SI]9R:Y[#_PB,--O:,P7T1O MM#SW=@]P9I3K9[Q,%@F0\:@<)]49.BVMB78/B/:HG2AD4O('A@0<:HS,]ZK" MT*2XSV*5I3:\SZ2Z2%8:AO-^YG1]JIRTL YIBNW>K%I(+Z1*1>GM1OUI#9:2 M%^"N\R$L ?S7MR,#.^5?-E(D1:_?2%948A^@BL1KYT#XBR&M*DNP%)3[ MD]CJH2I\?)SN\FZ:53NV0?G-M%-E*:?S^__,F&2[Y)']!$-U\8]\(LM20;\@ M"P:6!>+4P0_L'3*P18@Z!C:'#*!]VF7S GOF&''2*LI 2\FGZHX[&HI"4RK% M8RK^D6J0Y>HJZ;+>I"'(O [6N$++>"B&; M7PCD[;2V7\ZM_"<3K1DMU1U;SASZP:LNE.N_:SKJC7.+-G!%WTQJJN7B:DE[ M 21(7H0[IE\]P_S-)YZA>;=8L\M=L%:MC-^.K M/@2[9\TNF.0G7UGKHM-MPGR:]&_Q9>>?KRD?\\N.HP?TR_'!B6.7^A"<;)]_ MV7][OK?OV-[G@^^M]W]??-GOP'T?",SU:^OBR\F7[KMVZ\+/%Q @K7VP^Q4) MT06+L$L'A59;I$3A$+.%PM0&R:P$NU^J=2=K_LQTS"?9)W:[+-R;C:( M _L MZ854#82KTI_5WGEQ^G6U:AU*]2:RS)O[>S20\>D9,XK)*E,KNK40<6F M@VR/HY,A>(+YB]?Z69<\>3@6W9WYQ.X$23>MU%=#TEH@:;)=YS4&W0V#LN;$ ME+.J, 8)(BQ 4!&183*=EOG(!?-!IH-I0=B56>'/HNWN6K"A^C0_#AYC**H3_M+^E/R=,4IL%M_=LG"]Z-K3#A?9$(DD&34"KQJL[NC$R7HE4KXP8@K1D%'%<1*2 M!)#0RC!JHXN2O'C-7E*Z!L2J'1DW4;?*2,+CT"E#=X?FCH?53UFKNJ<;XZI* M3G>&H_*2_X$]>]&\2CPJ!1 MQ8@8]32":"H,TRD+5=8G1 \;07-JSG-\<,X/=VXP#@N!SL]"K?KM44-5M9-_ ME1LY.1):.#6JT>M6Z/5A&;VB%HX2%I$E$M"+*XH,*RQB+GH*QG? Q*0:-71% M9.#OM3JU9N#*(HW:52&5#+\3V'4W QZ95/6JL>ML][?3/0ZC*T3];T^VL[JBTK;G+6Z%&L5MYL)9B M";F5E#$=4/06="U!%5+./\LN4W!L@>!LE_BBJ\![+9JF%M6PX+FV&"'$0X%!GLQ.&04!C4L>J$Y MB<2([(4'56U%]X8ZE^PA&?E]57OD66A@FX5:DZ6OX>86<+/W9CE"@=%@A46X MX QQ94%?BLH"X.AT!AA,<"%A#:/%E05N:[5I_6K3E2VN?TE_Y"=8<.!9-XS> M7)UR NJU;KD6W?+K)=W2FN@9U8@)+! W&O!> MX+2520131"FR?>5/KZ]D K MBO;>JN?TAI6RFDLJSE7L!NU<1?)V75(TI4HH4Y "!XX)MIXP#+BA''S&,-LP M,_3)9.:NKZ3;V:$+'C9(!%2PU$=%R@(9IRE2P+K>*F>#2TVVQ-5)(%4ETI>W MZZ)22$L(8=([QHTR0#)&""L4X2)J2VK2V6S2X$ B+F/*' M*. M&!25$<0S:12V+UY3M47723E"%#(259BH&:=*:F>4L,0+9PAW!:TI9\,I9^_# MH53>2T$L"I848&$J"<8E$4C$6+C(O>$%>_&:4+E%KNF2TY M]UKZJDI&*7OP#,Q9(]6X2\)SN*)1QD+MQE 5Q$LB<;&.XZ7'Y=;@TY+&?M8E M/'FV!R&7<4V:33E"V>EMKNAJ679YN9ALBND.]BC7W3TS MJ11R'/2[*^]*B:[3RG['_4XNNIL?>)LW7EK->[SOZG?MFMXXFDEWD.GLRXLG M?=MOM1[5T@Y"U[13?>FE1^2ZQ/,#-D E[0]&Y8J!"C:_%BN6;7%Y%NAJ>7%2 MX>M9\]N&[?>_5@5UET>"13I%X].Y5H#IYKF"R+?5SN[;.OB<>OD) MWNOOTU16,E>5W)Z^7@V()2"*UMFA#Q)T9QT0=19,,&P9F& <(UQ@)P5L'"6I M99F45QI@4T <-FS(1-X%BB[[)_8S\2;Z*:G^[#CTJL+6E7!*MX&555Y;%?5/ M.'K<=L?INU3VPU5]@&R8-/KI)-99K&D]A:)+):V?6UWVU>4&TF)V83,ZYQD# M^Y75!6R4:X6W,]; RL]N^&U6+KUK'"Q[&)R_;,3Q #A_/"C#;",P*/Q>07X: M>)Q*BT\'^7WR1:]L!E!)3L"E([AK):JM+KY^#;PE"3"#N%1 -K= :7=7-0R8 M"8[E&NM50 2LD?EFVIUI-/%IZ.5UB$O%T5/G@[G9F]R$(DUWJW%-Z]1'3F.7 MLI>K?EUI7VXC*NZ>@_J+=.HGG9ZZALXC!Z*U<_0=S'M"HC?&,V2QH(@7& 1+ MI!Y%CT,1->;!R1]GFTX$2^[.<'UZ]V^[?WW\7Z9[^N^=WV_=W;#.,'QT)+>@ MR^QOGX$N U#%-5$8%09CQ$5AD<&2HAB9UE[RZ)([^<<)@W-$UUW.RZWZ=TQJ M#DR@ '42%EQN#I+;T"RK1/UO(!Y-HP37X)&!O\U1F+.6QL,0QYU&IQW+ZOTS M*0=BZ4=]*^ZD=L_1+\@"]\J/!TF=6J;>"3F^NQK\/E>OM%V^T=_Y-?X#;_&\ M"?.\]0&P4#EAN4"1I=:<@CJD&(Z BK0 '=OZZ&/R.BR?!F3-=I@4%9.:*9FT MP"@)XZ3!M"MZG%'.3!/))MM"L-MEZLQ=.>7%U53FTQZH/F]?#'3 MQ\U<,YA1<,>]]O\;)V,:-"ZX^!L\<[ALQXXNJ7AFTJISJHB5O-8X->GTI UJ MS*C2_*N6=]4PN:1]!&M[.!OC+#>=N=R)4'9=@Y@'U;^/0B^%8X12GK2S_CUQ.>NP0HT9\P\G72SS M'3,,2H;8')-2KN;5@)]6:$& MW/2R,0P@MRL/F_'=Y"H=#3([SUU?F:)EH[?D?"CG434!!ELU&XH)]4X'J55Q MP[>'.2.Q,2B-S+D.7%7[J]+=UQY^75C%_))QG,WDZ6HD" ^F6SXEBW=W[CIY M=V:+4GY[VA\E[#8=6(VC,%3/ M#W,O9#>: 'OYNMFN3@^\/#.3Q$*GDUL!Y9R/Y+KL#U;:Z2OTG2N:MV77T 3I M%]JTS1%A*6&2RG2I<5LYK9GK-EG=,RF4#0.?G!!K\/0\#/>6JN;EGX]@_D1< M40=BB@>WL;L*%F5!J'/<6VX=-HI2R@(3I(BVP/H.(8Q)QK )HN$$@YXRPF$4NK 4-EXD5AE?C1S97(X?5#&]W4FNI-)SH0HM" M<.^C-B#P=;+HB0:S\#YG_#59/43[VK/F2?-B[\.AQI$4'BPE&0Q%J=$?4C1H MQ'6TLN!6D4*]>'UU,/ <94V]0[=V#D4G&&-8&.PT3,%K&V B!$79H8+>8+22B,C61-)8#2.F(,)"2YB: PD]?O.;7Q1O-MXL]K_S>^4 B MZ\Z@?(& SH_#KQ+8<"46VY!LDJ18 M=ON#A0.ZK6M.U9[>8>X/:H2D+MBI VSG?.[P[?]G[\V;VDJ2M?&OHN#WQOUU M1[B8VI>>^Q)!-[:'OH-HM_$X['\>0M,1Q5DP5)6:S]>$DYU:G)\-E]!U_%(%U>19]7)8? MU"LP<" :U?GOMVJ(=GZZ25;5SDWVMCEC6E,DE"$\!,#?.H/3$6Q;_-$9%0^> M>7>&Q6Q>/SZU66I:A["+%E2L-IX)1I':K,!MN MOHS>R['<^=L@4BM%";XFYVOJ7:T2)1=**?)ME?N7GZW3JRN.)NL\/AH"AO5 ME(]&U7HO&N#^TC0WKWD]#'Y6)*K5[8SF2A*&\22?;&8:LWKB>IDJ#Z%3*>SA M/1X, ML\3#QR:+ "HR\)WB-G(=S^5%@'_V!V/0AFP;B\Q2(6/V1^OD=)A+5A:D>!Y_ MQ'O=)=2,:R_2 6QO^TO25 ?#&>@338A3JY#5 2/EJ%>"ND2T?%[CU\M,Y:A. MH7L[')Y5)[^G91I]H@:AK 4M+ ? M[^&]XT^D?;QWOG?P=V_O^-V/O8-NY]/QF\[^VW<_V@>>?:*O\>?CK_QB9VS1 MX7K\@<(G?[3??CIK[[S^L?_QS\[>QUW^>>+P MTGC/M$V\#(;A98[W;N-F_VS43 TO?YT.P>$:Q>U)[F#:W?'D2R(?%GNFL]GX MWKD77YQFD01!$8Y8(NY%YJR+!@5C?UAU<> .T4T^5=ABQKDNQWRU5X7%L5\+&\21UP' MA;05!F'X==)28,[XRMBG&J_K!BKX9C"$?]9M6?ZLI)[JE@G)QN]Z>+^KVI _ MJOTXF&['6]OI_WLP:IROI2"H5.BER$TBWK.@INB[K\9N;=\""P MQ+F+HNANJ([Y-UO;5QB5H@8%WE@4<3R\//TV N7VUZ?%KL7^P?0; F !?[_[XJGU6A.&/(T>97(#9"-C*&&I5(C8 MA"0VMOJ#R_7PDY/B&2DJBX"6Z7!95_6[>4UBS692BF5!OM$O6I]F*3M^.>W; MT] 9Q_#K:A;G?LM&ZF+O[6DV#9XP%Z_9W>E3-:4D52G)NR_8,J*QXTCI8P3]<1+2>8JOV:( &K!SF6(E0Y,*J_*:K["A+S.0*D M+1BF^NQJOEXOO]+/K>37%.X5;\SGPCD*ZESBTAFUCFQH#7R1HBD:_/ZT8!2' M9ZVJDN"1BULFWJOO['C\L/"NS;*R'O]67(NS*3_&Q7I)UM MP T7Y*XG#5!L%GEFKI[\D-Q.Z M5*ZL 8EL00(KFD'E?I#K6*LI8%>9%1G1BIQ/-YG%[T]L0>;??:.Z&[O_-[ M9^_\[^,]^J;3/GC'V^?;Y^WST-O["/?WVR"NLZ,I*BI>Q!KG)3( MV$B1\(E*J9@GV9MCKX1@JZZXNS^8>^AVC0E'RKVK:L'BE?5%&R-M58A M%Y5&W"6--*,*48W!0[,Z#YC=V**4+IB?]NMC=&NL^NCVI2KN"K)&C>(^K.+. M98HB\=8FR5#042%.8T(:$U!<(Z*EWE!!]<86X7P!8W6CN$]8<5>0!VD4]V$5 M=S[W81TS6@0473%"R4%0( *!H$!0SF%'O MH83.W0>SXX/RAXXZHSSAVV<.XH7?>/.FB)*M=JG'"8-8TM36XZ!* NZJB:/U M_:@:/CQIU"8)2QT7Q2CT- M:5'/Q2NXOV%>MLZX(/TNRGK+ =JVYK2NUJD:4E7=0C%^:W)?"Y[B;+.UFP?> MCP;3=1C&U,WSFN#5F>O$E#*7=[_@\\Z3OB8CK>:(A@OB\5X6K^+N_%$G?JM) MDJ?\Q' SY8WD*]]T:Y<8";@J56U&"[Z(T8+7C@J\,%K0*8V;IQV8'J+R:'290-\:50P6G MT^=*]O+)0)97U3]AL^$3$T[[@BN]G,([L1$A.L#'T>BT(/DH:?3K)KGYU^"^ MRB>,EZP67&<#@ONZ<6[$#KPCG%N9Q^7(Q*+EKF*$FZ.I[V\P5"S70^+*0QSC8JU MI:L'&"PZ$EC!O+ZU?-:6)6R41;-4KNF4 MS9G9E[X;[3#KWU1#KU?"5WEJ9 [Y\F"-PV&,I9A/0*::W9GGRQ43/<&)RO,N M\XW,S]J$AYHP.TPG]SS8@(&=S@C< MM]"Y'.R6BWGI2ZDX>35F9F?^)"EL'J M^S$H?G[GG*B2!:_I-J^ZS0^_"!*5",FAJ )'8.(E M=86C]+X0%\)'\^0FW2([#4!ZJ<6G$#&C2= SK M+,B70ZM0GA;SJIC5"R+VZ\2VUC,/!AE'1D6LT"_.S0LK-:I%<3[4V;P43-\+ M_"WTWZ[?L?D=YB (WC.;%9IKI[77X+C%:+A3@.MJH7_\Q(8M*+*IL&K:IK%H MVJ:O:)O.2'%-N_!E6KR'Z!E^ZEV'8-C!0_XCC^/^*T^SCN%J2M.F:?/2\OU5 MV;/,0?HLFS>O#"H6K\<^>'7]CJVG3C9=G4V![$QH0@-+X.)&GH+A(7AGL3+& M!J&9E"+*&U2(((H_=*B,# 1TZ9)Q-\ M:GSQM8.PLPN^.&'8F,0E"D*"Z<)*(3!:%CEN#%@;2BWE2XF&T80RD3@E/G"N M&!@_:9+@V$G*I.)-!/]41$,I1VVFM&8FSTE7*2$K2$ RV$ ]\93DDE@A[L&Z M-07NZX;X*U?KQB-=C<[.>Z3*6*$\T0A"1 ^1"/-(NSSA01G%%:%>)_>XEK[9 M]_O8=\M83 93Y+0#,VX%0RY!3$*5ASC2$Q(#1"),K3=6O] CL3_LR6ALAW<* M-I[Q %LO16!4$V<9YQYC+9BWP4IED_(T-A[ENJ)4^X\+'B5LCF>F(OW*U;IS.U>CL MO--)%?;$,(TB]@IQ82BR@QU!_/T%AULZ@:TG',7$ <0]YL@Q*5%427(A":9L.>--?> J>AX-@1T>-JWX_JGRQ,HTJ[ES(),4!<<95GO,M$6,0 M486(J8G^H5&^D8;'D@8(IW54' 3!DH0XMQAIS3W"'%N3=)(XZ U ;$U)=H#7 M%]J?RT'1SSNEBK[F3F]A7W5S2'2!\58H)KT1,E?-1I8L$4IY[Q+XLUSJIB)M M;4%JVATBVCN'] LQ40HM/(K22 IB$XT9Q09*@0-%*(3DI;+*EJ,'79&&$(Y M9MXX0FRB5@1F/>.N"4R>BFBPI(7TT2+&,1@Q[6R>$TA12H81Z;GC(6YL+9H1 MN$9YQ^:,:#55 :O6ZL;E7(W*GL^H+/_BDV4Z) /:ZBWB-#AD"85_&F^#UT1# M)/FXAK[9]_O8]RBPEB:HG$^,$&]X X%G2HA!C,%L,($*N;&%%TS&62.H?MY' M1#\G51FL^#A(;HH;?/$"5M+F+ZV9',5]@8^L7\NOB\YKK=JKJGZKH MD!C(21B<9NJC_'Q7=U<]P];:52[($WM$(0'4ADC&,H6D,388'[);V/F&2 BVI*A.,&[!@# M8Y8H\Q"Q:I=H$TL^&=%PUFD+#@J-@2(NI4762HTP_)*9J(A1X*!PQN_!15DA MUC[RX5AC7QO[NK1]73F(-B'<:D.XZNS042TI(2A@D1"//%=C,X-$8)X:AW&4 MXG']JF;?[V/?50H*E!(VP3+PG'Q2R$3N$?/*>.=AIXS?V")";O+G:!D73-9Y M!)IRL4EOP%-^5;A,-_4UX7(K_V^%X;V^$:OZ7S/DSGD$3#^6[-&SHP2*20?P MR__SL!;EVKG:L,#]W^;8SG].=GXP?:@_\C,]=5"Z-9/YWL$G *]=VC[_<+:_ MLTOWM[\PPYTA!6$2SX1)1B!G5 #3$I-.#.,0Z$.;ED8 'E '/5"N-Q"X"SX M%M1SI#TWR%*)#0Z.I031%V&;[*8F!B"JFT>,W&FPTI,<5?$Q#X09QV&O&(4U MKD=\A4I2:WK^>HQ-QEP[&L4\4Z6>DO6_I_ XZ:P87U'.2RG&FXU:-E]F(MI3 MAOR6B]Z>9GK]\>RLK7K.F(4GAS?&PXYOC8XZ:5S>5AZV!M_P';:J'"-F6SU[ M#+^)*>4A77E8QNEP=N189O6>SANHQG^]J-$LB_>\'#-6S_M87!GT?!;GNDDM M]82Y:J?!\,N^%[)\Q.6'GD+A0Z0X[]H%TXQ1<7BI97YL/F^\TU6Y2* M'N'A%Z6>UM5Z$]UPL8#UIS+V1$2L8K9[^-7<;!5CQ[P=#L^R=2D'IU7&J5RX MO**E90TW;X-5;3VPI35VE3ULQEY"))R[614G ($(37FG'-L').1P6^ MC&GDXE[E0NR!S\\AN,-)(69S";KD"CG'.#)1>^P)9H:8C2VU@.'ADE1,!BIN MMK+Y/^W.0/-TX!0 "WBHX +'T:MU@-Z'[:XMOM)V!P"UQ2S&>D;5H MR)E\S B6-(^<*X<>Y^&WX*[;48G3%S[Z##W/)7=XT=3?QD?/U40MFV?*%;9^ MX6CDF7F)X"CEX7\QAX.V->[T(JBWL^ /+#DS,?]K'?2^:JY_)*]^'59@TES_ M"!!8ZU]QR3RO.Z-A-17P0[\8@/L_X(^&0:]8KM>GP\%)A)M[#?[#H-?QK>UA MM!GROL=N-_]= NCN7W__E^V=_'-GL_7Q@M&9P\]7U=3"F\+HJRSVVZ>'H+4M M5HXLVUR+/:RD^-64*>%^C.K-XM3)\J_#TCR"5%?B!*@Y+**FUHD=3B9Q7H.P MI9&O\X%5Q%5%H/R]"8H?J'65]_M_UFSMF'G?'9X8= /HQB?^FS9_S"//Z]X]=B M_V#[;.]\[T?[^#5M?_\2@XZ::H\8=AIQ1A(R05 4(!*+PGMJ_69KNYS=O62" "1#)&$8]4Y",$HLS6%?E-&K:/'D MJ/ J*;E11/CO!/M\P]D?V?W![R7[WW_P@AC3!N,@@-!X5$1Y#(C MB1(RF:@2"][FJ/#R0=!\5/@=H"B+RC#,"TJ6CXFQ:%5O GFJ1W,7,X<'8W D MRTGWQ03X- 1O8)J7*BQS\0TY+P76O3AI<6?30?*E7<]IK=$8@,\"9)0HFS_= M*W!V!O]6G?3"SH):.665-9S":AJC86T$%519IV.5W+B-*#?)C6N3&Z^_M[>_ M1.-$3)$@*J1$7,6 C'(1<9EX;DN*W.299DQLXELGO5XM)11$)\R,L5)JGBN? M#==2&>$$%QY+FAJAN%>A. -L$]SKP+1$DA4UZ((CARD8%F8"=0[DPOJ;8-LL MA+U:/O49"0X2*R^%X%P UOHDX>NQ\20XUJ##_0H"WGOW)<2HH]4&1:ED+J6D MR$7'D8V66$O ^\!Q8XLM:%S^2>KSQ261CHJ8)_\70F&_P6!/H#)KQ4GGI*AP MJW%S5)8=?"\_-8Q5M%3DBW)Q1"P7M%74$Q9YIQS&GY7YTF$\/(4("5:Z_F21 M;2K,^FC.,Q@5E\\5$/''2?3C\BLF!0Y5FO6J&H=7+9]G:Z?NX'M1'3$M=ZB+ M^Y:I:8'U..STB]I(.5\QOU2)2[7PG);D*)?+#*N9]&7I]\P'JY)-//V(=:-! M]W1\^2-7W\CLGT?#:4OD841N&.U79!,LZF^V^]V>C3;^,;\ \/07[OZJ>[UZ MKW/=K8#G!G+5:*$,\]Q%(YK8@FST1.26!(;ZYJN5PL1I;18K7_E/,<;4+T< MI=T[JE8[6RG*8B5];)R]F!S*2:!UR:97-3*/<9BV)MGT1RN(F3=ZO5BF\2H9 MF<\6^F&GL'M5AG G^MAS8&09R3EM8C9;[0'8\2SOY2%.E>N9FN@RF)_]ABIM M"(82+E3&T!!23PI*;"_'X*4-G<3:HU8WCD9553E<=923^%5Z(,?;N7>@D/2Y MO.9F:S%> U#&:+A3 #'J(EX21T)VOD/ FFO-K0H96@$V M+2.*T D$9='J=JSK=,%HQBH5 $X)W-C\NG9RA7R_'TNOOW!4+N0IJJ7L%+7) ML:A?*LL_1]DW@?>U"A<)MJ!36(O]4__#.[=%U[]ENG7PAN\:&++1!@3J?>P"8N/8**X*&Z M?O7R9O'2A7Z5\C4M-H415[Z,-\F5K_WLLH1N4GRSRU[#2W$M9=#EMR[HL*S\ MC,?O++R$'7/=1"NB ES#WM+=*M+K7&;[N^[A7E)C[7*/_,1;9Z5,7/@$0"$( M)R8XSR-SF">CI72\2.H10^CE,K;YDXDEVEAJ,3PC3SVC4[55?CK__'9/?/[X M9[=-/YVUC]_]:!^\Z>SO[ IX_X_/;^']!_ZL??!G]U);Y7$;OJ_;_=3[P#X? M[]+VSFNR]W&7[QU_A6>$>Z'O2/M\E^SU_I/VYEBUO_[X(@4X45(EY(WFB'N1 MD*'YM ,[$S"/RF?R5;*(5'O%L\&?)#?2@_.N]L>V?]AQN7@P]\PT(\#7 (GJ M+2F]Y@:/EL&CS@4\L@R+$(E'1'&+.'$"V40CHMIPZ7,M!0<\DF23/C_BYS5$ MG;]RV=EP?%:$@CD,/LEQ\>VAYQE3?SX"]-2[\Q>$QN/M?GA=;U"#0XRP$M9D M.B=)]B);T<++/U\CLA-3'!9' M./;'$HG+FT;*:_*42YN'M3<"OZRW UZ+U8']\>_I.5EC$Y:Q"?,9@/,OB5.; M4J1(*ZW!YPX$V6 -4D302'V(T>6,Y *:MU^;V'_UCO?L^>_MO.]Y8]20KJYT M01K0+D%[!GX;__W>L/KL E9K2A2)2B :,ZF&B@II+D,F-H\D$>H2-W?%ZA5J MRVK(-R^7F]RHSN3IE38O/G+Z:3OFR1 T= @W,-\V=+%UY(71,BRN\\S UMJ> M=I@^1_Z%)6L(MP&4;=_F8O:A/8FGH)(@=(#@U\G+^J_$5<]-=6RK9.RNG&R.$5O@.UGCD1_.BI[##O]_N!;40]?O36[;EE# MP^"PK.GS-K=M%4H['OBOU>]&1RB3\8:J6O PLX>5G8%EH]=F?2.9([>HSQO& MW(E0-PYZV\\E? -0^H$=CH^&(-6Y'C-T//Q^I6WY='GY*M;YL0MEBYMX:[O= MSLG0]L?_]?]IKND_'[1DMKB%5QF^ID7UI4CSKS'(6& M=4:CS!\*-SL<_"@:8D$'KW1>1T?P>*,+_BM+TBF) Y[QW(/Q]E]L?4PS@4G*)%"_:'ZE$5B:!%*4X,JRU5"RW/UYUNE=WO97B M4 J7G;90+],#^1C"\\>@YSJEKOQ1E7-/>:'+;-9"HLD2A/???7&& M*!Z21][+G*&*&&FJ&1(DCWR,"21(@WO']+5=U0"]M4TMQ.EHT(7] ! L#7'5 ME5<::7"M_83O!%SP<2;TR:%-*]BSS)P&AK9$,'CG8%A33672JO)-XUBB^4T*TDD$([4,(E'-ORTC^ MD@S+.\MPY:O,2?/V$,3YL.R-_#O_M)_V3\>916%4M '_"TS?"Q;C3S_V#K^D M/#?%1X^" 33D6GH(WI5!*3(JG">\3H *A>) M?M5C$SM%F^K,A4_L6<%G>QW$_A6'A;5;B706[#LS3>5+"]E/?S%^V$SZ< M#/KO3^#2.7+>B\/#.-RNV>+V.A!=CP?]^(*)>@[\&6"KECHQ[Q+B3%H0RAB1 M=MZB@ D7F%OJB2UJ;\1E>IX3\!(+62ID,K&G]42=^B[4$@X-0NR^I&[Z(C"9:M,%ZS1[#%&WSP.J?.L,3D?= MLRG'3E[W=%HPXPP'9[9;E2Y.-[G"D2*(*/O&2SNW&+[\SNU:RD M%BM6Z'U!-K<4/XIS(F+%C?*,:QNU8D$*8KA+41,IKW"G[AX2++)F]>G*VREQ2>,F=,7 M?KKW .6/H_SC;N4S[J?KE/#)M[S=10LY.(F" 1;BD!!5)J=P%$>&BCRWRP5B ME280U>04SF4?<5X)"Z;&PI"55JUP#^I'++"0@YG--^%WM=\[,$*H=Q+-HAZU,7!L6T!$L0;'3<.,\-VZ<57G[ MBSDCKN/,N< 9P9P)P@AAN J3*9TFC*N*#<. M,)A[&I4RE,I+WZ.5]U0J[K4@' MJK:=Y(H8EPD=7$"\\-=::DJBBL.DE9<1I M+Y^1G\?R%*TF")EAE"UIN$L*C@F9\@4N#GC]M%<>P5_A2/QV)[*?-62XX)M: M\OM@N#!,KI+A8GUKU%Y/>%\S(6+K/S7O]=SA\Y6-?==P>=RV$O+&M3MKN*!_ MY"Q3?7Q>-$A"M)=]NH8;H^'&N,NQR*4"QP6AQ=\3B[&;C5LG=>RD"WV[LAO; M_3!3&KE=&HTLM56[:"6N3SVBJ,H@_W.\MW/X_7/OSZ^?#T)G?^?OH\]P;VV( M+#X=[Y'/QW"MG:_G[>.CKY?*(#_N?=_?^;WWJ0?/0'=Y^^V;WEXO4Z9V.WOG M_^E!=,+A/NC^V[]G232^?]%>:DZ"04%3B$6PH\@DZ\#AE=0([;#T9F.++AI+ MWA!HK EQT4MGS5A'C)H0_#30M PT=6:@B5*A7&02I4SPP[7*7!J.(Q(U1">. M0(2E"FZ?JYB^FWZ:52KD]K2V#IT,!SXS0.9S<3OTI0\9XK?8'10$#JU;0=0S M9M=0DD2E'4GP?ZZ4MP1;)E@D#!M!E'H1HD-\4-;F)!4CM[P8@5G[ZX3G94L.YO;/U"?KV07FWH$ES% M/ =9<\$]DTP%*O'C8.JDVZC!SR7PE?5O-\:EXH]K-[7+_\U\Z9V?"[$E0^$5K/)/J$PC\0P ME(C)U?,X(DNI0\YI"YZ]]CJ"%>>;Y 6[? _-G=.9T8X"H$KTNDMN[P[GQ"\0 MP.[#MVI0:DF4FLWL>8F3DC0B3R-%/%F#;#(8*14CH)7,S9.YYXPV\P;6(6A] M.QB$[YUN]^E$J;3)]=TKDM82T4#@$A"X/YN<$][@((E&6": 0&XXTA1P4&M- M$R>YDSQM;#'\HI-S#Z=#[Z>5_X/4BC\ZHZ+59*9O\\I&Q.:,=N5T%O-@\U?9 MJ_EF,+RN)297BQ0;MYV'"3XG%M8'0JCWUI4NR!.'[D<.M&NOL@FX5U%*<[ ] MGI0H;W_!(H;W>CL6A*R*8NI%P='L6B2 MO7#J73,#9:X6%ZLQV? LYR7IE84;'MI\;51,A88'ZXQ: WC<:KIVG/0QG8YB M.LTLY=\R/6V^7N[,]>-R6O>1+6B$ROO.S7)P"7L8IY]*L6(KO$P V ;L&7;\ M"ES)BS>H0_< MT_;V%^Z95\[RW/@M$0^8(4=E1%P;GJ+3/'&>LXG31O!J4[>*MNO1U?0Z+P8H MZ/H 1>NPSC;.ML(.!SU0^LYHKKTU_W,\'G;<:=FC.J6=!J6? ,#HK!]A&S/[ M;;Y*V9)?#"$:#-_8G*S@&@# MWRG J"(:O7RS_0'8P)C+)@L0+'K_[8_,Q ?;%B_*X<(^_Z?(YE1RQ_KWM /]]F[7=?'!4VB"AS,QWXJB$%I)D/*#A!@S+8FLS-2LR5I]@ULT$.S: M).E9"WR=&G$+=O >?.1H5!&>O(\GXXKQ!.?>"7U'_,\L=7?Y<_/E[9JBM$K0S9$;; MF>?ES6"88B>3\ $,QFZ6BAC^4R9H7S#$[1* .$53TC9F3',><7!4D34F(>^M M\0!PEEB1"2ZO0[B*?CH7PDV@;"E^N0>0G]IX3@4&S&?F3;I(@?7[V669^FZ' M849\9C_YQV#TY%-"=Y$CMK_]!6RCB+ I2 EK$?=!(Q>-0REJ!\X/3@F\G2UV M91U%+4?@RA;\TI/9#]-EGI!LGFW:F9.FSV\R<8M9(J\ MQ%=3FHD%I%?/P@(L.0;EKV'\-HZ^M=?QPX'KV)M,0'F2Z_+S\4/54)2:#6U^ M*$J]1IV<+BK85XHSD0KX"@:EN:S.,M@8C.32,.J4D]P*:9DV*G*OI @L"E%G M>1A!]0\/P-+7EU M0WL%>J]*GOM1)AD',/)Q.,XC22 6'Z,:I*;A @3_$V$#9&O] ;@7.J %KC. M7Q[U00L.SR:3> IF:="B\WR5BAYPMK,;OO ;P&/>]&)P2;\*0HYB]Z2@-,YO MVTIVV .+7XC9YUX$)IJ=,ZW2VFHYV]A?C(-XPZ#,)3T MSB@6DK6.XQBL##PYZH07U&KKZ[/4E1N-9A#&DF:EO?,:YV,$H0W16"',.48\ M0C3F>&*(2,&DL"Q%2C:VB+S.K!2^2"B'5.6*C>R4S$G5J]F,R56S":K)!+X8 MJ#B:,M>/6N[L(D4L)<5 @DD :)^NH#84X^V=(K"SDAJ37$ :$X4XQ1(9Z0/" MN86;&A&3M+F1YSJ&\6D.;C#A* XYG OS;,7.=O- M];H*!8=*E?RDD]F$N57 M9T9=U./_KDH&PB5G)F8T@R\6YE*W9Z=93#+,ZQ:T_&0(SL*(95I!K [5"(5B0\II!13R*G ZS1].%G1 MUN![?69:ARS@O+S."CYH;1>!0^M?$7R^H]:'_VG]N]/K%,>6H*%+CO6HKOZ" MQGI,IQ#,#/PYS&%C0R#?$,B_/ +Y:PGA+Q"[&TV#BTSHA",GQ&DE&+5<^M_/N1YM^/H+_OK;?OCENG__Y=>_ \T_';[H7.RX^G;_I?3Z& M6.[M+F\?''YO[[QFGWOYOW#ZYU?M39^_B?>4+X%!VFF!ND'26(FT3@ M)YL0.$DRR<@5PSI'=:OB+GU>! F=.42N<=Q4:+"'#V&(CU,ICB'PBW9OFDM(O&RYP] M=QBCW ^&G-(:>QH1!X\=V8 3LM1)H90.VN>!97?G,'["WMPZ$:Z_B&39+P^2 M+1O!T\%/#?/ZTT"MSAQJ.4833\AP[1"73B,(1@FBS$7N!<8^T^69!=7#OS;N M4T.ZOG;NU3JF_!N 6A*@9I-D$:O 52(H:, F'FU 6AJ"K%3>,>6U-1JB//X\ MCB3K\B-XC+BQ0-]__LYGGIQK"-T;E'[6A.X/ Z_[%^:$P2I3 ZX?@"K'C(#_ MYS@RABOG&8N,BV+,=C-ZYRG1)<_;LH8N>:4+TH!O0Y>\)EA^@2Z9^51-JPX^\ M\@;3@]??VX=??)262@ ORT1$W$F);-0 0!([:I/#JN!'Q@T[B-F0[-ZQ_@X,P!-TJ-F.W=V([PX*!LSHGG([4VNF,,BT ;/M\'A_]S=.X:0X6#O^][QN^]@"#O[']^=?_[X6K1W_@1C^8ZW MW[X^OVA8]^CG7KOWX0RN<+1WOGW6WOG]:/_MKOB\ _=S\!7O]7;QYYU#_.F@ MG?;.O_XH!@]P$X2-R'EK$"=,(VUY0 D+B5/4 C-SL0$ZZ2 \X"JK)PISM]?UJ@W^C4 MC<:9>*U(3HW&HTN&;SBWEF M#X>V-ZK(($9C-"P-8,$SE3GF"\XV@-=<.E Z M\!63%/CPJ1M_E!%$O^)T'7<*ZK=\I5;]/0#F%S9PHNHS3D-%A=;RU5Y>O.]D M?HIA);($SEH\".9Y$J..KR\@V&A[8_6?S\#*VL#OF.2E:F@J 2 MU!B\KNHQLL$_[5?/[#.G)7P+O*WP$-U97O%1;%6+\L_\SV&$QXJOP"7KH[+' MN20RN;RR^9:FD6RYGO.![>0;Z^?*-UTQK>3-S8Q(F7-JAFRJ\BCK/?H'+'$ MKV38J])GQ:KT!ZWNH'\("PL["^(8)Q2?U?=6I"L3_[405OCS<)!7I B@7Q(# M50%A;V IRQX5E/,#E[=K1E[SZE;OFJ8H8C_FG$-G8AZR]$%<-1X,1T6NX23W M,&6K ?(\800K-N(4WC@J% .N.&$5J_8Z5LWTJ: WO1PN5+?W"N2_E3-L)\5( MI^JV:OS+W]\I_-&";<<.AV=5(@6^%-0M+?I]]GL/AS&[NL5-EWYKH5?3AP2' M:$K&$W\4S5IP VXP^%H_2EZ6J0QOMG;F)1;>/2/A62[[&%N%%:>_ 606^:$BK,O[,07K M]P4123'>YCV(968A!(O5FLXR:?TUZ'9\I\*VO&>GHU%)075HAP5&7WT3EX.T MF93#?2A8PVCTW!B-%H:XUSO6\XXX,S1@*5)B@7&MF',I8>4(=2PE8^7&?<=; M[_T1^$+=N)_FO"^(M_Z.W7+6 9CW%QUBO?M"B+7148='V0!6I%*C MJSF>%B'#FA$Z<;8I;\B\M"2A$\6WXXGZ^6N"7?VESY6:9OA=>+XKU*GF] MYMBN9M]J;D(!5MG QR]\.#@:QI*.]VC4>GTY]WI;_J^GNR+MG(R^X8+<559F MBJZN.NM?<-R_ELN6'9X;",N-GO-EK-?MR?6>[9(T(G0G$7H.A9V73B&*1YU/ M55?N[V]7\]_0"ZI>5(+)( CTHLKS/V=QB M,L0T]BS/'9Y,[PCYM75E_\B=>T:>7/WVH@=[XG78)EK,I$Q:2LXC3SIZ3TF2 M).0J[.BK9)SZR03P"ZFY6NB+%-SZ#-R[91*N+*0^]OS3^=[9YX]_?FV?MWOM M@WU<+'VP3?8/#O'%0NKV^='QWOF?W4^]=VR/?B+M';BW M7'1X<'BV?P K\!'N9>>#V-_Y>YZ8"[8%FY@8HH%ZQ+&4R&B/D9&<<&$)9<)N M;!&&-^D:=<7<$N4OVJ0&6YX!MD2FI.5$4>T99]([ZC0S/.A\1L"HK4N9JP') M#;;<,[:<3[$% -YP8U%(2B&NHT%.!(V")U1A3I71M&BXXPVT--"RAM!RJS/$ M!EKN#5K(!%I$HE8'C9$EDB(N+?PDC4*! [90ABU6,;LMI'%;&FQ92VR)%'P5 M2XDS5G #+DS E"@PB2$&(3BOW!;2N"T/@RUL@BU2J(0E$<@S[Q"GA"*+C4<2 M:VFF�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`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�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end